Details of Disease

General Information of Disease (ID: DISJC981)

• Disease Name: Pancreatic cancer
• Synonyms: pancreatic carcinoma, familial; exocrine cancer; cancer of the pancreas; cancer of pancreas; pancreas cancer; pancreatic cancer; pancreatic cancer (not islets); carcinoma of exocrine pancreas; carcinoma of pancreas; carcinoma of the pancreas; exocrine pancreas carcinoma; pancreas carcinoma; pancreatic carcinoma
• Disease Class: 2C10: Pancreatic cancer
• Definition: A carcinoma that arises from epithelial cells of the exocrine pancreas
• Disease Hierarchy:
  DISFC6MM: Digestive system carcinoma
  DISIA6JF: Malignant exocrine pancreas neoplasm
  DISH9F1N: Carcinoma
  DISJC981: Pancreatic cancer
• ICD Code:
  ICD-11: ICD-11: 2C10
  ICD-9: ICD-9: 157
  Expand ICD-9: 157
• Disease Identifiers:
  MONDO ID: MONDO_0005192
  UMLS CUI: C0235974
  OMIM ID: 260350
  MedGen ID: 65917
  Orphanet ID: 217074
  SNOMED CT ID: 372142002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 14 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[1]
Bentiromide	DMDFDW0	Approved	Small molecular drug	[2]
Erlotinib	DMCMBHA	Approved	Small molecular drug	[3]
Ibrutinib	DMHZCPO	Approved	Small molecular drug	[1]
Motixafortide	DMW34B1	Approved	Peptide	[1]
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[1]
Olaparib	DM8QB1D	Approved	Small molecular drug	[1]
Plazomicin	DMKMBES	Approved	Small molecular drug	[4]
Ruxolitinib	DM7Q98D	Approved	Small molecular drug	[5]
Streptozocin	DMOF7AT	Approved	Small molecular drug	[6]
Sunitinib	DMCBJSR	Approved	Small molecular drug	[7]
Taxol	DMUOT9V	Approved	Small molecular drug	[1]
Trimethadione	DM0Q8MZ	Approved	Small molecular drug	[8]
Uridine triacetate	DM1WYDU	Approved	Small molecular drug	[9]

This Disease is Treated as An Indication in 143 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AC-1204	DM3J99W	Phase 3	Small molecular drug	[10]
Aglatimagene besadenovec	DMACVU8	Phase 3	Gene therapy	[1]
Algenpantucel-L	DMBQK0X	Phase 3	Vaccine	[11]
AM0010	DMGMNUE	Phase 3	NA	[12]
ANX-510	DMTN4TK	Phase 3	Small molecular drug	[13]
Civacir	DMKUQU3	Phase 3	NA	[14]
CPI-613	DM5XUQL	Phase 3	Small molecular drug	[15]
Glufosfamide	DMEFCTP	Phase 3	Small molecular drug	[1]
Glufosfomide	DMABFRQ	Phase 3	NA	[16]
GRASPA	DM4Y7WV	Phase 3	Protein	[17]
GV1001	DMHULRK	Phase 3	Vaccine	[18]
Marimastat	DM6V34C	Phase 3	Small molecular drug	[19]
Masitinib	DMRSNEU	Phase 3	Small molecular drug	[1]
MM-398	DMIE3DX	Phase 3	NA	[20]
Napabucasin	DMDZ6Q3	Phase 3	NA	[1]
Pamrevlumab	DMKTR0A	Phase 3	NA	[21]
Pancreas algenpantucel-L	DMSEVHK	Phase 3	NA	[22]
Pelareorep	DM4WCF9	Phase 3	NA	[23]
Radiosensitizer gene therapy	DMN1ZEU	Phase 3	NA	[24]
Sapacitabine	DM704AN	Phase 3	Small molecular drug	[1]
Y-90 Clivatuzumab	DM0Z1L7	Phase 3	Monoclonal antibody	[25]
Yttrium (90Y) clivatuzumab tetraxetan	DMOLR5W	Phase 3	Antibody	[26]
Zarnestra	DMF30HL	Phase 3	Small molecular drug	[27]
Zolbetuximab	DM5ST9Z	Phase 3	Antibody	[28]
LY2157299	DMP8HW1	Phase 2/3	Small molecular drug	[1]
NLG8189	DM0798Z	Phase 2/3	Small molecular drug	[1]
OT-101	DMCTRLN	Phase 2/3	Antisense oligonucleotide	[1]
RP101	DMNIYSZ	Phase 2/3	Small molecular drug	[29]
SM-88	DMD9ISG	Phase 2/3	NA	[30]
ALT-803	DMK3U1X	Phase 2	NA	[23]
Anti-PSCA mab	DMJPZDC	Phase 2	Monoclonal antibody	[31]
Antroquinonol	DMRGQVZ	Phase 2	NA	[1]
ARQ 761	DMH5CAL	Phase 2	NA	[1]
BC-819	DMY9U56	Phase 2	NA	[32]
BNT141	DM9XRBT	Phase 2	Antibody	[33]
BNT321	DMRWG8B	Phase 2	Antibody	[34]
BPM 31510	DMIW5P1	Phase 2	Lipid-drug conjugate	[35]
BVD-523	DMNB4XK	Phase 2	NA	[1]
Cabiralizumab	DMGE058	Phase 2	NA	[1]
CAP1-6D	DMEYIVW	Phase 2	Small molecular drug	[36]
CART 19	DMTBFXW	Phase 2	CAR T Cell Therapy	[37]
CO-101	DMH5GQU	Phase 2	Small molecular drug	[38]
CP-613	DMZ5I80	Phase 2	NA	[39]
CRS-207	DMXU5LZ	Phase 2	Vaccine	[40]
CYTO-401	DMRFYYK	Phase 2	NA	[41]
Demcizumab	DM5W0NT	Phase 2	NA	[16]
Encapsulated live cells converting ifosfamide	DMLRLZG	Phase 2	NA	[1]
Ensitiximab	DMA9FH0	Phase 2	NA	[16]
Ficlatuzumab	DMG65WH	Phase 2	Monoclonal antibody	[1]
GC4419	DM4KLCS	Phase 2	NA	[1]
GC4711	DM77C1R	Phase 2	Small molecular drug	[42]
GI-4000	DMTY4PG	Phase 2	Vaccine	[43]
IRT-102	DMCAFVN	Phase 2	Small molecular drug	[44]
Istiratumab	DMGTZ64	Phase 2	NA	[23]
LE-DT	DM68LCD	Phase 2	NA	[45]
LY2603618	DMCXRZF	Phase 2	Small molecular drug	[46]
MENK	DM2WONM	Phase 2	NA	[16]
MM-141	DM2RJ4D	Phase 2	NA	[1]
Necuparanib	DMOIS62	Phase 2	NA	[47]
NPC-1C	DM9VEAL	Phase 2	Antibody	[23]
Ocaperidone	DMP6B59	Phase 2	Small molecular drug	[23]
OCV-101	DMT9QI2	Phase 2	NA	[48]
PBI-05204	DM05WIU	Phase 2	NA	[1]
PCI-27483	DMUJ52O	Phase 2	NA	[49]
PEGPH20	DM26YJ1	Phase 2	NA	[50]
PX-12	DMLVHAJ	Phase 2	Small molecular drug	[51]
Reolysinpelareorep	DM9R6G1	Phase 2	NA	[1]
RX-0201	DMTBAV3	Phase 2	NA	[16]
RX-3117	DME8ARP	Phase 2	NA	[1]
Salirasib	DMRSU4X	Phase 2	Small molecular drug	[52]
SGT-53	DMLYIPA	Phase 2	Gene therapy	[1]
SiG12D-LODER	DM39RXO	Phase 2	Small interfering RNA	[1]
Tarextumab	DM95FR3	Phase 2	Monoclonal antibody	[53]
TH-302	DMFU0JY	Phase 2	Small molecular drug	[1]
Tigatuzumab	DMKYJJC	Phase 2	Monoclonal antibody	[54]
TL-118	DMOW3SA	Phase 2	NA	[55]
VS-6063	DMGBLI3	Phase 2	Small molecular drug	[1]
VT-122	DMUY20Y	Phase 2	NA	[16]
Zenocutuzumab	DM1FLHH	Phase 2	Monoclonal antibody	[56]
ABTL0812	DMM1W9R	Phase 1/2	Small molecule	[57]
Anti-HER2 CAR-T	DMQD6B9	Phase 1/2	CAR T Cell Therapy	[58]
Anti-mesothelin CAR transduced PBL	DMXI03L	Phase 1/2	CAR T Cell Therapy	[59]
Anti-Mesothelin CAR-T cells	DM4NMBW	Phase 1/2	CAR T Cell Therapy	[60]
Anti-MUC1 AR20.5	DM8ITPL	Phase 1/2	NA	[23]
Anti-MUC1 CAR T Cells	DM0C1IX	Phase 1/2	CAR T Cell Therapy	[61]
AR20.5	DMJUJW9	Phase 1/2	NA	[1]
BPX-601	DMV9QGW	Phase 1/2	CAR T Cell Therapy	[62]
BrevaRex	DMCEGP2	Phase 1/2	Monoclonal antibody	[63]
CAR-T cells targeting CEA	DM6VCPX	Phase 1/2	CAR T Cell Therapy	[64]
CAR-T Cells targeting EpCAM	DMREQCF	Phase 1/2	CAR T Cell Therapy	[65]
CAR-T cells targeting mesothelin	DMPK35H	Phase 1/2	CAR T Cell Therapy	[66]
CAR-T cells targeting MucI	DMBPN4K	Phase 1/2	CAR T Cell Therapy	[64]
DCVax-Pancreas	DMAUQ62	Phase 1/2	NA	[67]
Delolimogene mupadenorepvec	DM4RCZ7	Phase 1/2	Oncolytic virus	[68]
Encapsulated cell therapy	DMC0A4W	Phase 1/2	NA	[69]
ETBX-011 cancer vaccine	DMQFDMH	Phase 1/2	NA	[43]
G0-203-2c	DMG48WN	Phase 1/2	NA	[70]
GB1275	DMCT9NG	Phase 1/2	NA	[71]
GP-2250	DMGVWKC	Phase 1/2	Small molecular drug	[72]
GSK3145095	DM059OH	Phase 1/2	Small molecular drug	[73]
LOAd703	DMC81RD	Phase 1/2	NA	[1]
MALP-2S	DMBZ68C	Phase 1/2	NA	[74]
NANT	DMG4JFY	Phase 1/2	NA	[1]
PEGylated hyaluronidase (human recombinant)	DM1D6BT	Phase 1/2	NA	[75]
AB680	DMGONUE	Phase 1	Small molecular drug	[76]
AbGn-107	DMRZMPB	Phase 1	NA	[1]
Anti-CD133-CAR vector-transduced T cells	DMGUM90	Phase 1	CAR T Cell Therapy	[77]
Anti-CEA CAR-T cells	DMA7L3O	Phase 1	CAR T Cell Therapy	[78]
Anti-CEA-CAR T	DMJA3H1	Phase 1	CAR T Cell Therapy	[79]
Anti-hCD70 CAR transduced PBL	DMK4GIS	Phase 1	CAR T Cell Therapy	[80]
Anti-meso-CAR vector transduced T cells	DM5UQA9	Phase 1	CAR T Cell Therapy	[81]
Anti-MUC1 AR20.5 mab	DMSYNHI	Phase 1	Monoclonal antibody	[82]
Anti-MUC1 mab	DMQ5ZND	Phase 1	Monoclonal antibody	[83]
ASG-5ME	DMD0BMN	Phase 1	Antibody	[84]
Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	DMTLU37	Phase 1	CAR T Cell Therapy	[85]
CAR-20/19-T Cells	DM4CXE2	Phase 1	CAR T Cell Therapy	[86]
CAR-T cells targeting EGFRviii	DMRSG04	Phase 1	CAR T Cell Therapy	[64]
CAR-T cells targeting HER2	DMLI5VG	Phase 1	CAR T Cell Therapy	[64]
CAR-T Cells targeting Mesothelin	DM6DULC	Phase 1	CAR T Cell Therapy	[64]
CAR-T cells targeting PSCA	DMU4G9J	Phase 1	CAR T Cell Therapy	[64]
CART-meso cells	DM90QPK	Phase 1	CAR T Cell Therapy	[87]
CART-meso-19 T cells	DMZ4I03	Phase 1	CAR T Cell Therapy	[88]
CARTmeso/19	DMV84ZR	Phase 1	CAR T Cell Therapy	[89]
CEND-1	DMQSH9J	Phase 1	Peptide	[90]
CRS-207 + GVAX	DMBP89G	Phase 1	NA	[16]
HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	DMUMXWW	Phase 1	NA	[91]
HuCART-meso cells	DM4F8AU	Phase 1	CAR T Cell Therapy	[92]
IRX4204	DM9SCME	Phase 1	Small molecular drug	[1]
LMB-100	DMXVR46	Phase 1	NA	[1]
M9241	DMZUM67	Phase 1	NA	[93]
Meso-CART	DMQSJ9T	Phase 1	CAR T Cell Therapy	[94]
MORAb-066	DMTUKW9	Phase 1	Antibody	[95]
MOv19-BBz CAR T cells	DMYH98H	Phase 1	CAR T Cell Therapy	[96]
MVT-1075	DM8X0L6	Phase 1	NA	[1]
MVT-5873	DMEJ4C1	Phase 1	NA	[23]
NBF-006	DMG0SWE	Phase 1	Small interfering RNA	[97]
OCV-105	DMYJ8S6	Phase 1	NA	[98]
PLX7486	DM0IVGU	Phase 1	NA	[99]
RG7882	DM2E5Z7	Phase 1	Antibody	[23]
SBP-101	DMESA9F	Phase 1	NA	[16]
SEL-403	DM57JZS	Phase 1	NA	[1]
STAT400	DMDULL2	Phase 1	NA	[100]
CAR-CLD18 T cell	DM6ZHTV	Clinical trial	CAR T Cell Therapy	[101]

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID28460551-Compound-1	DMHV75N	Patented	Small molecular drug	[102]

This Disease is Treated as An Indication in 9 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Larotaxel	DMCM239	Discontinued in Phase 3	Small molecular drug	[103]
Tanomastat	DMVB9XC	Discontinued in Phase 3	Small molecular drug	[104]
Apricoxib	DMR3Q82	Discontinued in Phase 2	Small molecular drug	[105]
Lintitript	DMS5X94	Discontinued in Phase 2	Small molecular drug	[106]
LY293111	DM03FHA	Discontinued in Phase 2	Small molecular drug	[107]
Merbarone	DMMZ4E9	Discontinued in Phase 2	Small molecular drug	[108]
HMN-214	DMH4ANG	Discontinued in Phase 1	Small molecular drug	[109]
RG7600	DMVVBET	Discontinued in Phase 1	NA	[110]
IPH-4201	DMRVZMX	Terminated	Antibody	[113]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ANAVEX 1007	DM2U16Z	Preclinical	NA	[111]
IC261	DMXB95R	Preclinical	Small molecular drug	[112]

This Disease is Treated as An Indication in 9 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Gastrin 17C diphtheria toxoid conjugate	DMKKMS8	Investigative	NA	[114]
GS-326	DMXGAWD	Investigative	Small molecular drug	[114]
HS-P1	DMEZKLI	Investigative	Small molecular drug	[114]
MesoTarg	DMHY8UF	Investigative	NA	[114]
OP-04	DMZMQGF	Investigative	NA	[114]
PAT-PM-1	DMGGUWD	Investigative	NA	[114]
Pbi-shPDX-1 LP	DMP0T2Q	Investigative	NA	[114]
Prodigiosin	DM5B0UT	Investigative	Small molecular drug	[114]
VLI-27	DM95KRY	Investigative	NA	[115]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 735 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCC4	TTUEAFL	Limited	Biomarker	[117]
ACVR1	TTJNBQA	Limited	Altered Expression	[118]
ADAM8	TTQWYMD	Limited	Altered Expression	[119]
ADAMTS1	TTS2TEI	Limited	Biomarker	[120]
ADH1A	TT5AHZ0	Limited	Altered Expression	[121]
ADRA1A	TTNGILX	Limited	Biomarker	[122]
ADRA2B	TTWM4TY	Limited	Biomarker	[122]
AGR2	TT9K86S	Limited	Biomarker	[123]
AGTR1	TT8DBY3	Limited	Biomarker	[124]
AKR1B1	TTFBNVI	Limited	Biomarker	[125]
AKT3	TTO6SGY	Limited	Altered Expression	[126]
ALOX12B	TTQ4QQH	Limited	Biomarker	[127]
ANG	TTURHFP	Limited	Biomarker	[128]
ANGPT1	TTWNQ1T	Limited	Altered Expression	[129]
ANGPTL4	TTWALY5	Limited	Biomarker	[130]
ANXA1	TTUCK4B	Limited	Altered Expression	[131]
ANXA8	TTSW16P	Limited	Altered Expression	[132]
APOA2	TTGQA9W	Limited	Biomarker	[133]
AQP3	TTLDNMQ	Limited	Biomarker	[134]
ARG2	TTV1AG6	Limited	Biomarker	[135]
ASPH	TT2KHP7	Limited	Biomarker	[136]
ATG7	TTLVB9Z	Limited	Biomarker	[137]
ATR	TT8ZYBQ	Limited	Biomarker	[138]
BRS3	TTKYEPM	Limited	Biomarker	[122]
BTK	TTGM6VW	Limited	Biomarker	[139]
CA9	TT2LVK8	Limited	Biomarker	[140]
CASP9	TTB6T7O	Limited	Altered Expression	[141]
CCKAR	TTCG0AL	Limited	Altered Expression	[142]
CCL21	TTLZK1U	Limited	Biomarker	[143]
CCN2	TTIL516	Limited	Biomarker	[144]
CCR6	TTFDB30	Limited	Altered Expression	[145]
CCR7	TT2GIDQ	Limited	Biomarker	[146]
CD24	TTCTYNP	Limited	Altered Expression	[147]
CD276	TT6CQUM	Limited	Biomarker	[148]
CD47	TT28S46	Limited	Biomarker	[149]
CDA	TTQ12RK	Limited	Altered Expression	[150]
CDC20	TTBKFDV	Limited	Biomarker	[151]
CDK1	TTH6V3D	Limited	Biomarker	[152]
CDK5R1	TTBYM6V	Limited	Altered Expression	[153]
CDK8	TTBJR4L	Limited	Biomarker	[154]
CDK9	TT1LVF2	Limited	Genetic Variation	[155]
CEACAM1	TTA9CK4	Limited	Biomarker	[156]
CEACAM6	TTIGH2W	Limited	Biomarker	[157]
CES1	TTMF541	Limited	Biomarker	[158]
CFB	TTA0P7K	Limited	Biomarker	[159]
CHST15	TTFK7E1	Limited	Genetic Variation	[160]
CLCA1	TT3AF4R	Limited	Altered Expression	[161]
CLDN18	TT6PKBX	Limited	Altered Expression	[162]
CLIC1	TT8KZG6	Limited	Biomarker	[163]
COL1A2	TTUABC1	Limited	Altered Expression	[164]
CRY2	TTAO58M	Limited	Altered Expression	[165]
CRYZ	TTP6UO8	Limited	Biomarker	[166]
CYP24A1	TT82UI1	Limited	Genetic Variation	[167]
DCK	TTJOCE4	Limited	Biomarker	[168]
DDR1	TTI1FPZ	Limited	Biomarker	[169]
DHCR24	TTTK0NH	Limited	Biomarker	[170]
DIABLO	TTN74LE	Limited	Biomarker	[171]
DKK1	TTE3RAC	Limited	Altered Expression	[172]
DUSP1	TTG8HIM	Limited	Biomarker	[173]
DYRK1B	TTYGQ8A	Limited	Biomarker	[174]
E2F3	TTWIJYH	Limited	Altered Expression	[175]
EEF2K	TT1QFLA	Limited	Biomarker	[176]
EPAS1	TTWPA54	Limited	Altered Expression	[177]
EPHA2	TTRJB2G	Limited	Biomarker	[178]
EPHB4	TTI4ZX2	Limited	Biomarker	[179]
EPHX2	TT7WVHI	Limited	Biomarker	[158]
ESRRB	TTKF0XS	Limited	Biomarker	[180]
EZR	TTE47YC	Limited	Biomarker	[181]
FAP	TTGPQ0F	Limited	Biomarker	[182]
FDPS	TTIKWV4	Limited	Biomarker	[183]
FGF10	TTNPEFX	Limited	Biomarker	[184]
FGFR4	TT1KX2S	Limited	Biomarker	[185]
FKBP5	TT0J5KQ	Limited	Altered Expression	[186]
FLT3	TTGJCWZ	Limited	Biomarker	[187]
FOSL1	TTY8LZG	Limited	Altered Expression	[188]
FOXC1	TTNT3YA	Limited	Biomarker	[189]
GATA4	TT1VDN2	Limited	Biomarker	[190]
GJB2	TTRGZX3	Limited	Biomarker	[191]
GLP1R	TTVIMDE	Limited	Biomarker	[192]
GOT1	TTU507L	Limited	Biomarker	[193]
GPRC6A	TTI1PRE	Limited	Biomarker	[194]
GRHL2	TTUGH4C	Limited	Biomarker	[195]
GRM1	TTVBPDM	Limited	Biomarker	[196]
GSK3A	TTQWAU1	Limited	Biomarker	[197]
HMGA2	TTSTVM0	Limited	Altered Expression	[198]
HMGB2	TTA78JQ	Limited	Biomarker	[199]
HNF1A	TT01M3K	Limited	Altered Expression	[200]
HSF1	TTN6STZ	Limited	Altered Expression	[201]
HSP90AA1	TT78R5H	Limited	Biomarker	[202]
HSPA9	TTMTPG3	Limited	Altered Expression	[203]
IDO2	TTALN9W	Limited	Altered Expression	[204]
IL12A	TTRTK6Y	Limited	Altered Expression	[153]
IL13RA2	TTMPZ7V	Limited	Altered Expression	[205]
IL17D	TTC5LTG	Limited	Biomarker	[206]
IL21	TT9QEJ6	Limited	Biomarker	[207]
IL23A	TTC1GLB	Limited	Altered Expression	[208]
IL9	TT0JTFD	Limited	Biomarker	[209]
ITGA2	TTSJ542	Limited	Biomarker	[210]
ITGAM	TTB69FJ	Limited	Biomarker	[211]
ITGB2	TTIJWR7	Limited	Biomarker	[212]
ITGB6	TTKQSXZ	Limited	Biomarker	[213]
ITK	TT3C80U	Limited	Biomarker	[214]
KDM1A	TTNR0UQ	Limited	Biomarker	[215]
KDM1B	TT8VP2T	Limited	Altered Expression	[215]
KDM5A	TTIG67W	Limited	Biomarker	[216]
KISS1	TTU2O6T	Limited	Altered Expression	[217]
KISS1R	TT3KBZY	Limited	Biomarker	[218]
KLK6	TTLPF4X	Limited	Altered Expression	[219]
KLK7	TTE6GTB	Limited	Biomarker	[220]
KSR1	TTHL1TV	Limited	Genetic Variation	[221]
L1CAM	TTC9D3K	Limited	Biomarker	[222]
LASP1	TTZJA87	Limited	Altered Expression	[223]
LGMN	TTPTWV5	Limited	Biomarker	[224]
LPAR1	TTQ6S1K	Limited	Biomarker	[225]
LPAR3	TTE2YJR	Limited	Biomarker	[194]
LRP2	TTPH1AJ	Limited	Genetic Variation	[167]
LTA	TTP73TM	Limited	Altered Expression	[141]
LTB4R	TTN53ZF	Limited	Biomarker	[226]
MAGEA3	TTWSKHD	Limited	Altered Expression	[227]
MALT1	TTCI81G	Limited	Biomarker	[228]
MAP2K2	TT8H9GB	Limited	Biomarker	[229]
MAP3K10	TT9FN4J	Limited	Biomarker	[230]
MAP3K5	TTOQCD8	Limited	Biomarker	[231]
MAP3K7	TTJQT60	Limited	Altered Expression	[232]
MLH1	TTISG27	Limited	Altered Expression	[233]
MMP11	TTZW4MV	Limited	Altered Expression	[234]
MMP16	TTNP4CU	Limited	Altered Expression	[235]
MPL	TTIHYA4	Limited	Altered Expression	[236]
MRGPRX1	TTIX6PK	Limited	Biomarker	[194]
MTDH	TTH6SA5	Limited	Biomarker	[237]
MYB	TT8V13P	Limited	Biomarker	[238]
NAMPT	TTD1WIG	Limited	Biomarker	[239]
NCL	TTK1V5Q	Limited	Biomarker	[240]
NCOA3	TT124R0	Limited	Biomarker	[241]
NEDD9	TT1UREA	Limited	Biomarker	[242]
NLRP1	TTQX29T	Limited	Biomarker	[243]
NRG1	TTEH395	Limited	Biomarker	[244]
NRP1	TTIPJCB	Limited	Biomarker	[245]
NTN1	TT0AH4L	Limited	Biomarker	[246]
NUAK1	TT65FL0	Limited	Biomarker	[247]
NUF2	TTIXBFP	Limited	Biomarker	[248]
OLR1	TTKSND3	Limited	Biomarker	[249]
OXER1	TT7WBSV	Limited	Biomarker	[194]
PADI4	TTQHAXM	Limited	Biomarker	[250]
PAWR	TT3I4WV	Limited	Altered Expression	[251]
PBK	TTMY6BZ	Limited	Biomarker	[252]
PDGFRB	TTI7421	Limited	Biomarker	[253]
PDK1	TTCZOF2	Limited	Biomarker	[254]
PDZK1	TTDTBLM	Limited	Biomarker	[255]
PEBP1	TT1BGU8	Limited	Biomarker	[256]
PHB	TT6U071	Limited	Biomarker	[257]
PIK3CB	TT9H4P3	Limited	Biomarker	[258]
PKLR	TT31N4S	Limited	Altered Expression	[259]
PLAUR	TTNOSTX	Limited	Biomarker	[260]
PRMT1	TTVOJAI	Limited	Biomarker	[261]
PRMT5	TTR1D7X	Limited	Biomarker	[262]
PROKR2	TTM67AX	Limited	Altered Expression	[263]
PTBP1	TTWMX0U	Limited	Biomarker	[264]
PTK6	TT6TH8V	Limited	Biomarker	[265]
PTPN1	TTELIN2	Limited	Biomarker	[266]
PTPN14	TTNIR6C	Limited	Biomarker	[267]
PTPRC	TTUS45N	Limited	Biomarker	[268]
RASA1	TTPNZ1F	Limited	Biomarker	[269]
RICTOR	TT143WL	Limited	Biomarker	[270]
ROBO1	TTND1YP	Limited	Biomarker	[271]
ROR2	TTUDPCI	Limited	Biomarker	[272]
RPS6KA2	TT0ZW9O	Limited	Biomarker	[273]
RPS6KB1	TTG0U4H	Limited	Biomarker	[274]
RPSA	TTLUW5B	Limited	Biomarker	[275]
S100A6	TT716MY	Limited	Biomarker	[276]
S100A8	TT4AF6N	Limited	Altered Expression	[277]
S100A9	TT0TMQG	Limited	Altered Expression	[277]
SATB1	TTLFRIC	Limited	Biomarker	[278]
SEMA4D	TT5UT28	Limited	Biomarker	[279]
SERPINF1	TTR59S1	Limited	Biomarker	[280]
SLC16A1	TTN1J82	Limited	Altered Expression	[281]
SLC16A3	TTG6VD5	Limited	Biomarker	[282]
SLC6A14	TTB6H2S	Limited	Biomarker	[283]
SLC8A1	TTCF82X	Limited	Biomarker	[284]
SLCO1B3	TTU86P0	Limited	Biomarker	[285]
SMYD3	TTKLJYX	Limited	Biomarker	[286]
SOX2	TTCNOT6	Limited	Altered Expression	[287]
SP1	TTZEP6S	Limited	Altered Expression	[288]
SSTR2	TTZ6T9E	Limited	Biomarker	[289]
SSTR3	TTJX3UE	Limited	Altered Expression	[290]
SSTR4	TTAE1BR	Limited	Biomarker	[122]
STK33	TTP34DQ	Limited	Biomarker	[291]
STK4	TTCPLVN	Limited	Altered Expression	[230]
TACR1	TTZPO1L	Limited	Biomarker	[292]
TGFBR1	TTP4520	Limited	Biomarker	[293]
TGM2	TT2F4OL	Limited	Biomarker	[294]
TICAM1	TT2GQT6	Limited	Biomarker	[295]
TLR1	TTW14D0	Limited	Altered Expression	[296]
TNFSF13	TTOI1RM	Limited	Altered Expression	[297]
TNIK	TTPB1W3	Limited	Altered Expression	[298]
TNS4	TT1K65C	Limited	Biomarker	[283]
TP53BP1	TTX4UE9	Limited	Biomarker	[299]
TPT1	TT3PTB6	Limited	Biomarker	[300]
TPX2	TT0PHL4	Limited	Biomarker	[301]
TRAF6	TTCDR6M	Limited	Biomarker	[302]
TRIM59	TT613U4	Limited	Biomarker	[303]
TRPM7	TTFPVZO	Limited	Biomarker	[163]
TXN	TTZJ5U9	Limited	Biomarker	[304]
TXNIP	TTTLDZK	Limited	Altered Expression	[305]
UBC	TTBP3XA	Limited	Biomarker	[306]
USP5	TTGYTMA	Limited	Biomarker	[307]
UTRN	TTNO1VA	Limited	Altered Expression	[308]
VHL	TTEMWSD	Limited	Biomarker	[309]
VTCN1	TTCK85E	Limited	Altered Expression	[310]
WDR5	TT7OFWB	Limited	Genetic Variation	[311]
XPO1	TTCJUR4	Limited	Biomarker	[312]
CCKBR	TTVFO0U	Disputed	Biomarker	[313]
CEACAM3	TTPX7I5	Disputed	Biomarker	[314]
CS	TTZA6B3	Disputed	Biomarker	[315]
FOXM1	TTD3KOX	Disputed	Biomarker	[316]
KDM3A	TTKXS4A	Disputed	Biomarker	[317]
SLC1A2	TT2F078	Disputed	Biomarker	[318]
SLCO3A1	TT5CE6L	Disputed	Altered Expression	[319]
SLCO4A1	TTV1YIE	Disputed	Altered Expression	[319]
TWIST1	TTX1MY7	Disputed	Biomarker	[320]
ABCA4	TTLB52K	moderate	Biomarker	[321]
AGER	TTMO9HF	moderate	Biomarker	[322]
AIMP2	TTXWHGF	moderate	Biomarker	[323]
ALKBH5	TTOHB1M	moderate	Biomarker	[324]
ANO1	TTOJI4S	moderate	Biomarker	[325]
ATAD2	TT9A0HI	moderate	Biomarker	[326]
AURKA	TTPS3C0	moderate	Altered Expression	[327]
AZGP1	TTUPYLV	moderate	Biomarker	[328]
BAK1	TTFM7V0	moderate	Altered Expression	[329]
CA2	TTANPDJ	moderate	Biomarker	[330]
CAD	TT2YT1K	moderate	Biomarker	[331]
CASP2	TT12VNG	moderate	Biomarker	[332]
CD86	TT53XHB	moderate	Altered Expression	[333]
CDH11	TTRGWZC	moderate	Biomarker	[334]
CDK2	TT7HF4W	moderate	Biomarker	[335]
CLDN4	TTMTS9H	moderate	Biomarker	[336]
COL18A1	TT63DI9	moderate	Biomarker	[337]
CPN1	TT8V2KD	moderate	Biomarker	[338]
CRK	TTFEUYR	moderate	Biomarker	[323]
CXCR1	TTMWT8Z	moderate	Biomarker	[339]
CYP1A2	TTS1DTU	moderate	Genetic Variation	[340]
CYP2B6	TTMH124	moderate	Biomarker	[341]
CYP51A1	TT67TDP	moderate	Biomarker	[342]
DCLK1	TTOHTCY	moderate	Altered Expression	[343]
DDX58	TTVB0O3	moderate	Biomarker	[344]
DEPTOR	TTLYP6D	moderate	Altered Expression	[345]
DGKA	TTGL8F0	moderate	Altered Expression	[346]
DPEP1	TTYUENF	moderate	Biomarker	[347]
DPYD	TTZPS91	moderate	Altered Expression	[348]
E2F2	TT5FYX0	moderate	Altered Expression	[349]
EGF	TTED8JB	moderate	Biomarker	[350]
EGLN2	TTMHFRY	moderate	Biomarker	[351]
EHMT2	TTS6RZT	moderate	Biomarker	[352]
EPCAM	TTZ8WH4	moderate	Biomarker	[353]
EPHA1	TTLFZVU	moderate	Genetic Variation	[354]
EPHA4	TTG84D3	moderate	Biomarker	[355]
EPHB1	TT8MDAC	moderate	Biomarker	[182]
EPHB3	TT5LM7U	moderate	Biomarker	[182]
F10	TTCIHJA	moderate	Biomarker	[356]
F2RL3	TTD0652	moderate	Altered Expression	[251]
FGF21	TTQ916P	moderate	Biomarker	[357]
FGF7	TTFY134	moderate	Altered Expression	[358]
FKBP4	TTHY0FT	moderate	Altered Expression	[186]
FOLR1	TTVC37M	moderate	Altered Expression	[359]
FUT3	TTUPAD7	moderate	Genetic Variation	[360]
GHR	TTHJWYD	moderate	Biomarker	[361]
GLUL	TTURQ2G	moderate	Biomarker	[362]
GPR87	TTO897C	moderate	Altered Expression	[363]
GSTO1	TTWO3SH	moderate	Biomarker	[364]
HIPK2	TTOB49C	moderate	Biomarker	[365]
HPSE	TTR7GJO	moderate	Altered Expression	[366]
HSP90B1	TTFPKXQ	moderate	Biomarker	[367]
HSPA5	TTW26OG	moderate	Biomarker	[368]
HSPE1	TTWYMFE	moderate	Genetic Variation	[369]
HTR1B	TTK8CXU	moderate	Biomarker	[370]
HTR1D	TT6MSOK	moderate	Biomarker	[370]
HTRA1	TT8POQR	moderate	Altered Expression	[371]
IL24	TT1EPXZ	moderate	Biomarker	[372]
IRF8	TTHUBNK	moderate	Biomarker	[373]
ITCH	TT5SEWD	moderate	Biomarker	[374]
ITGA6	TT165T3	moderate	Biomarker	[275]
KCNH2	TTQ6VDM	moderate	Altered Expression	[375]
KCNQ1	TT846HF	moderate	Altered Expression	[375]
KDM4C	TTV8CRH	moderate	Biomarker	[376]
KMT5C	TT7H3YM	moderate	Altered Expression	[377]
LAG3	TTNVXAW	moderate	Altered Expression	[378]
LGALS3	TTFPQV7	moderate	Biomarker	[379]
MANF	TT56RYE	moderate	Genetic Variation	[380]
MAP3K1	TTW8TJI	moderate	Genetic Variation	[381]
MAP3K14	TT4LIAC	moderate	Biomarker	[252]
MAP3K3	TTJZNIG	moderate	Biomarker	[382]
MAP3K4	TT1RSX7	moderate	Biomarker	[383]
MAP3K9	TTUNSIX	moderate	Biomarker	[384]
MAPK9	TT3IVG2	moderate	Altered Expression	[173]
MERTK	TTO7LKR	moderate	Biomarker	[385]
MMP7	TTMTWOS	moderate	Altered Expression	[386]
MRC1	TTKV8W5	moderate	Genetic Variation	[387]
MSI2	TTTXQF6	moderate	Biomarker	[388]
MST1R	TTBQ3OC	moderate	Biomarker	[389]
NEDD8	TTNDC4K	moderate	Altered Expression	[390]
NME1	TTDY8JH	moderate	Biomarker	[391]
NRP2	TTRXUVC	moderate	Biomarker	[392]
PIP5K1A	TTA7DU1	moderate	Biomarker	[393]
PKN1	TTSL41O	moderate	Genetic Variation	[394]
PLK4	TTGPNZQ	moderate	Biomarker	[395]
PNLIP	TTXMY0J	moderate	Biomarker	[396]
PNP	TTMCF1Y	moderate	Genetic Variation	[397]
PPIA	TTL2ADK	moderate	Biomarker	[398]
PRTN3	TT5MLC4	moderate	Altered Expression	[399]
PTAFR	TTQL5VC	moderate	Biomarker	[400]
PTGES	TTYLQ8V	moderate	Biomarker	[401]
RAC1	TT2M9CG	moderate	Biomarker	[402]
RIPK4	TTB4S01	moderate	Altered Expression	[256]
ROR1	TTDEJAU	moderate	Altered Expression	[403]
SCGB1D2	TT5D314	moderate	Biomarker	[404]
SCN10A	TT90XZ8	moderate	Biomarker	[405]
SERPINB5	TT1KW50	moderate	Biomarker	[283]
SERPING1	TTVQ6R9	moderate	Altered Expression	[406]
SLC5A1	TT2UE56	moderate	Biomarker	[407]
SLC6A8	TTYUHB5	moderate	Biomarker	[408]
SLCO1B1	TTFGXEB	moderate	Genetic Variation	[409]
SMAD7	TT0J32Z	moderate	Biomarker	[410]
SREBF2	TTRQ4AP	moderate	Biomarker	[411]
TACC3	TTQ4UFD	moderate	Altered Expression	[412]
TMPRSS2	TT1GM2Z	moderate	Genetic Variation	[413]
TRPV6	TTBK14N	moderate	Biomarker	[414]
TYMP	TTO0IB8	moderate	Altered Expression	[415]
UCHL3	TT23UD6	moderate	Biomarker	[416]
ABCG2	TTIMJ02	Strong	Posttranslational Modification	[417]
ACVR1B	TTPKHTZ	Strong	Biomarker	[418]
ACVRL1	TTGYPTC	Strong	Altered Expression	[419]
ADIPOQ	TTXKA7D	Strong	Biomarker	[420]
ADM	TTV14YH	Strong	Biomarker	[421]
ADRB2	TTG8ZWP	Strong	Biomarker	[125]
ADRB3	TTMXGCW	Strong	Genetic Variation	[422]
AGPAT1	TTPL1TK	Strong	Altered Expression	[423]
AKT2	TTH24WI	Strong	Biomarker	[424]
ANXA10	TT0NL6U	Strong	Altered Expression	[425]
ANXA2	TT4YANI	Strong	Biomarker	[426]
APEX1	TTHGL48	Strong	Biomarker	[427]
APOL1	TTDB8PW	Strong	Biomarker	[428]
AREG	TT76B3W	Strong	Altered Expression	[429]
AURKB	TT9RTBL	Strong	Genetic Variation	[430]
BACH1	TT2ME4S	Strong	Genetic Variation	[431]
BBC3	TT7JUKC	Strong	Altered Expression	[432]
BGN	TT0JPVF	Strong	Biomarker	[433]
BIRC2	TTQ5LRD	Strong	Biomarker	[434]
BMI1	TTIPNSR	Strong	Altered Expression	[435]
BPHL	TTTZ3EU	Strong	Biomarker	[436]
BRAF	TT0EOB8	Strong	Altered Expression	[437]
BRD7	TT07ZS1	Strong	Genetic Variation	[438]
BRSK2	TTHZN4X	Strong	Altered Expression	[439]
BSG	TT5UJWD	Strong	Biomarker	[440]
BUB1	TT78309	Strong	Genetic Variation	[441]
C1QBP	TTWTD7F	Strong	Biomarker	[442]
CAPN1	TT1WBIJ	Strong	Altered Expression	[443]
CARM1	TTIZQFJ	Strong	Biomarker	[444]
CASP7	TTM7Y45	Strong	Altered Expression	[445]
CBL	TT7QT13	Strong	Altered Expression	[446]
CBR1	TTVG0SN	Strong	Altered Expression	[447]
CBX7	TTBN3HC	Strong	Biomarker	[448]
CCK	TT90CMU	Strong	Biomarker	[449]
CCN1	TTPK79J	Strong	Biomarker	[450]
CCNA2	TTAMQ62	Strong	Biomarker	[451]
CCND3	TT1JXNR	Strong	Altered Expression	[452]
CCNE2	TTLDRGX	Strong	Altered Expression	[453]
CD248	TTYJWT7	Strong	Biomarker	[454]
CD274	TT8ZLTI	Strong	Altered Expression	[169]
CD74	TTCMYP9	Strong	Biomarker	[455]
CDC25A	TTLZS4Q	Strong	Biomarker	[456]
CDC25B	TTR0SWN	Strong	Biomarker	[457]
CDC25C	TTESBNC	Strong	Altered Expression	[458]
CDC7	TTSMTDI	Strong	Biomarker	[459]
CDH3	TTARMD9	Strong	Altered Expression	[460]
CDH5	TTXLCFO	Strong	Biomarker	[461]
CDK5	TTL4Q97	Strong	Altered Expression	[462]
CDK6	TTO0FDJ	Strong	Biomarker	[463]
CDK7	TTQYF7G	Strong	Altered Expression	[464]
CEACAM5	TTY6DTE	Strong	Biomarker	[465]
CHEK1	TTTU902	Strong	Genetic Variation	[466]
CHKA	TT10AWB	Strong	Altered Expression	[467]
CHRNA7	TTLA931	Strong	Biomarker	[468]
CMA1	TT8VUE0	Strong	Altered Expression	[281]
COL6A3	TT5WCAH	Strong	Posttranslational Modification	[469]
CPE	TTXPWO6	Strong	Altered Expression	[470]
CRY1	TT5MLZR	Strong	Biomarker	[471]
CSNK2A2	TT7GR5W	Strong	Altered Expression	[472]
CTDSP1	TTHZAF0	Strong	Biomarker	[473]
CTPS1	TTN12BZ	Strong	Altered Expression	[474]
CTSH	TT3G406	Strong	Altered Expression	[475]
CUBN	TT9YLCR	Strong	Genetic Variation	[167]
CXCR5	TTIW59R	Strong	Biomarker	[476]
CYP2A6	TTAQ6ZW	Strong	Genetic Variation	[477]
DAPK3	TTERVQN	Strong	Altered Expression	[375]
DEFB4A	TTIVY12	Strong	Biomarker	[478]
DKK2	TTST5KX	Strong	Altered Expression	[479]
DKK3	TTY2ZV6	Strong	Biomarker	[480]
DLL3	TT1C9K6	Strong	Biomarker	[481]
DNASE1	TTYWGOJ	Strong	Biomarker	[482]
DNM2	TTVRA5G	Strong	Biomarker	[483]
DYRK1A	TTSBVFO	Strong	Biomarker	[484]
EGFL7	TT7WD0H	Strong	Biomarker	[485]
EHMT1	TTOFXD7	Strong	Genetic Variation	[486]
EIF4E	TTZGCP6	Strong	Biomarker	[487]
EIF5A	TTIVCNR	Strong	Biomarker	[488]
EIF5A2	TTH53G9	Strong	Biomarker	[489]
ELAVL1	TTPC9D0	Strong	Altered Expression	[490]
ENTPD1	TTYM8DJ	Strong	Biomarker	[491]
EPHB2	TTKPV6O	Strong	Biomarker	[492]
ERBB3	TTSINU2	Strong	Biomarker	[493]
EREG	TTYSB89	Strong	Biomarker	[494]
EZH2	TT9MZCQ	Strong	Altered Expression	[223]
F11R	TT3C8EG	Strong	Altered Expression	[495]
F2RL1	TTQR74A	Strong	Genetic Variation	[496]
F3	TT38MDJ	Strong	Altered Expression	[497]
FAT1	TTGUJYV	Strong	Biomarker	[498]
FBXW7	TT29KY7	Strong	Biomarker	[499]
FER	TTRA9G0	Strong	Biomarker	[500]
FLT1	TT1VAUK	Strong	Biomarker	[501]
FOXQ1	TTEJZOL	Strong	Biomarker	[502]
FPR2	TTOJ1NF	Strong	Altered Expression	[503]
FUT4	TTNV1KZ	Strong	Biomarker	[504]
G3BP1	TTG0R8Z	Strong	Biomarker	[505]
GABRA3	TT37EDJ	Strong	Biomarker	[506]
GABRP	TT3E0DI	Strong	Biomarker	[507]
GAD2	TT7UY6K	Strong	Biomarker	[508]
GAST	TT4LRVO	Strong	Biomarker	[509]
GCK	TTDLNGZ	Strong	Biomarker	[510]
GDF2	TTAP4T1	Strong	Biomarker	[511]
GDNF	TTF23ML	Strong	Biomarker	[512]
GGT1	TTZVT7O	Strong	Genetic Variation	[513]
GLI1	TTJOMH6	Strong	Biomarker	[287]
GLO1	TTV9A7R	Strong	Biomarker	[514]
GMNN	TT390KA	Strong	Altered Expression	[515]
GNE	TT4DP5S	Strong	Biomarker	[516]
GPI	TT19JIZ	Strong	Biomarker	[510]
GPNMB	TT7315J	Strong	Biomarker	[517]
GPR137	TTATO6X	Strong	Biomarker	[518]
GPR182	TTT23CG	Strong	Altered Expression	[519]
GRB2	TTEYRJ9	Strong	Biomarker	[520]
GRIA3	TT82EZV	Strong	Biomarker	[521]
GSN	TTUH7OM	Strong	Altered Expression	[522]
GUSB	TTHS7CM	Strong	Biomarker	[523]
HBEGF	TT15SL0	Strong	Altered Expression	[524]
HCAR1	TTVK4ZO	Strong	Altered Expression	[525]
HCRTR1	TT60Q8D	Strong	Biomarker	[526]
HDAC1	TT6R7JZ	Strong	Biomarker	[527]
HDAC2	TTSHTOI	Strong	Biomarker	[528]
HDAC3	TT4YWTO	Strong	Biomarker	[529]
HDAC9	TT8M4E1	Strong	Biomarker	[530]
HDGF	TTKGV26	Strong	Biomarker	[531]
HEXIM1	TTFOKAH	Strong	Biomarker	[532]
HGF	TT4V2JM	Strong	Biomarker	[533]
HGFAC	TTD96RW	Strong	Altered Expression	[534]
HHAT	TT1VNCG	Strong	Biomarker	[535]
HMGA1	TTBA219	Strong	Altered Expression	[536]
HNRNPA2B1	TT8UPW6	Strong	Biomarker	[537]
HP	TTLC8E1	Strong	Biomarker	[314]
HPD	TT8DSFC	Strong	Biomarker	[538]
HSP90AB1	TTH5YN2	Strong	Biomarker	[456]
HSPB1	TT9AZWY	Strong	Altered Expression	[539]
HSPB3	TTLH8WG	Strong	Altered Expression	[539]
HTATIP2	TTC6IX5	Strong	Altered Expression	[540]
IAPP	TTHN8EM	Strong	Biomarker	[541]
ID2	TTW8A5N	Strong	Altered Expression	[542]
IFNAR1	TTSYFMA	Strong	Biomarker	[543]
IGF2R	TTPNE41	Strong	Genetic Variation	[544]
IKBKB	TTJ3E9X	Strong	Biomarker	[545]
IL17F	TT2B6PS	Strong	Genetic Variation	[546]
IL20	TTNZMY2	Strong	Biomarker	[547]
IL21R	TTZO9B0	Strong	Biomarker	[548]
IL22	TTLDX4N	Strong	Biomarker	[549]
IL32	TTD4G7L	Strong	Altered Expression	[550]
ILK	TT7ALZG	Strong	Biomarker	[551]
IRAK4	TTILUKB	Strong	Biomarker	[552]
IRS2	TTF95B8	Strong	Altered Expression	[553]
ITGA1	TTPERWV	Strong	Altered Expression	[554]
ITGA11	TTANXZ7	Strong	Biomarker	[555]
ITGA5	TTHIZP9	Strong	Altered Expression	[556]
JAG2	TTOJY1B	Strong	Biomarker	[557]
KCNJ11	TT329V4	Strong	Genetic Variation	[422]
KCNN4	TT7M9I6	Strong	Biomarker	[507]
KDM5B	TTCLI75	Strong	Biomarker	[558]
KDM6B	TTDIJUQ	Strong	Altered Expression	[559]
KDR	TTUTJGQ	Strong	Biomarker	[560]
KRT17	TTKV0EC	Strong	Biomarker	[561]
LAMB3	TT2WOUQ	Strong	Biomarker	[562]
LAMP1	TTC214J	Strong	Altered Expression	[563]
LAPTM4B	TTEJQT0	Strong	Genetic Variation	[564]
LGALS1	TTO3NYT	Strong	Altered Expression	[565]
LIF	TTGZ5WN	Strong	Biomarker	[566]
LIFR	TTID542	Strong	Biomarker	[567]
LIMK1	TTWL9TY	Strong	Biomarker	[568]
LIMK2	TTASMD8	Strong	Biomarker	[568]
LIN28A	TTO50LN	Strong	Biomarker	[569]
LIPE	TTLUQ8E	Strong	Biomarker	[570]
LMO2	TTFX379	Strong	Biomarker	[571]
LONP1	TTM1VPZ	Strong	Biomarker	[572]
LOXL2	TTFSUHX	Strong	Altered Expression	[573]
LRP6	TTSXOWE	Strong	Biomarker	[574]
LSM1	TT2KHSC	Strong	Biomarker	[575]
LTA4H	TTXZEAJ	Strong	Biomarker	[576]
LTB	TTHQ6US	Strong	Altered Expression	[576]
LTB4R2	TTVJX54	Strong	Biomarker	[577]
MAP2K1	TTIDAPM	Strong	Biomarker	[578]
MAP3K20	TTTUZ3O	Strong	Biomarker	[579]
MAP4K1	TTSHWUP	Strong	Genetic Variation	[580]
MAP4K4	TT6NI13	Strong	Altered Expression	[581]
MAPK8	TT0K6EO	Strong	Biomarker	[582]
MAPKAPK2	TTMUG9D	Strong	Altered Expression	[583]
MCHR2	TTS17MG	Strong	Biomarker	[584]
MCL1	TTL53M6	Strong	Biomarker	[585]
MDK	TTV8UE7	Strong	Biomarker	[586]
MDM2	TT9TE0O	Strong	Biomarker	[587]
MIA	TT5HNVS	Strong	Biomarker	[588]
MMP1	TTMX39J	Strong	Altered Expression	[589]
MMP14	TTJ4QE7	Strong	Biomarker	[590]
MSH2	TTCAWRT	Strong	Altered Expression	[591]
MSMB	TTYH1ZK	Strong	Posttranslational Modification	[592]
MTAP	TTDBX7N	Strong	Biomarker	[593]
MUC1	TTBHFYQ	Strong	Biomarker	[594]
MUC16	TTC1PS3	Strong	Biomarker	[595]
MUC17	TTVO0JU	Strong	Altered Expression	[596]
MUC5AC	TTEL90S	Strong	Biomarker	[597]
MYC	TTNQ5ZP	Strong	Biomarker	[573]
NECTIN4	TTPO9EG	Strong	Altered Expression	[598]
NEK2	TT3VZ24	Strong	Biomarker	[599]
NELL1	TT7H4BF	Strong	Biomarker	[600]
NGF	TTDN3LF	Strong	Biomarker	[601]
NOP2	TTBLG3H	Strong	Biomarker	[602]
NOX4	TTQRBSJ	Strong	Altered Expression	[603]
NPTX2	TTNJ5A6	Strong	Posttranslational Modification	[604]
NPY2R	TTJ6WK9	Strong	Altered Expression	[605]
NR1H2	TTXA6PH	Strong	Genetic Variation	[606]
NR1I2	TT7LCTF	Strong	Biomarker	[607]
NR4A1	TTMXE2Q	Strong	Altered Expression	[608]
NR5A2	TTAU3SY	Strong	Genetic Variation	[609]
NTSR1	TTTUMEP	Strong	Biomarker	[610]
OGFR	TT6IEYX	Strong	Altered Expression	[611]
OLFM4	TTK1CX7	Strong	Altered Expression	[612]
OSM	TTIVXSE	Strong	Biomarker	[613]
P2RX7	TT473XN	Strong	Biomarker	[614]
P2RY2	TTOZHQC	Strong	Biomarker	[491]
P2RY6	TTNVSKA	Strong	Biomarker	[491]
PAK1	TTFN95D	Strong	Altered Expression	[615]
PAK2	TT279WO	Strong	Biomarker	[616]
PAK4	TT7Y3BZ	Strong	Biomarker	[617]
PARG	TT39J16	Strong	Biomarker	[436]
PARP1	TTVDSZ0	Strong	Genetic Variation	[618]
PBRM1	TTH8ZRL	Strong	Altered Expression	[619]
PCSK6	TT75LN9	Strong	Biomarker	[620]
PDE8A	TTIS4OW	Strong	Biomarker	[621]
PDGFA	TTSM78N	Strong	Biomarker	[622]
PGGT1B	TTX20QP	Strong	Altered Expression	[623]
PHGDH	TT8DRCK	Strong	Biomarker	[487]
PIM1	TTTN5QW	Strong	Biomarker	[624]
PIM3	TTCGOIN	Strong	Biomarker	[624]
PLK1	TTH4IP0	Strong	Biomarker	[625]
PLK2	TT976FS	Strong	Biomarker	[185]
PLOD2	TT8MEUD	Strong	Altered Expression	[626]
PMS1	TTX1ISF	Strong	Biomarker	[627]
PNMT	TT0NZIC	Strong	Genetic Variation	[628]
POSTN	TT8ALTZ	Strong	Biomarker	[629]
PPIB	TT6ZFQ4	Strong	Altered Expression	[630]
PPID	TTNAFOU	Strong	Biomarker	[631]
PPIF	TTRFQTB	Strong	Biomarker	[631]
PPP5C	TTTW7FJ	Strong	Biomarker	[632]
PRKCA	TTFJ8Q1	Strong	Biomarker	[633]
PRKCZ	TTBSN0L	Strong	Biomarker	[634]
PRKD1	TTSLUMT	Strong	Altered Expression	[635]
PRKDC	TTK3PY9	Strong	Genetic Variation	[636]
PRMT3	TTL4XSQ	Strong	Biomarker	[637]
PRNP	TTY5F9C	Strong	Altered Expression	[638]
PROM1	TTXMZ81	Strong	Altered Expression	[639]
PSCA	TT9T4AV	Strong	Biomarker	[640]
PSMD10	TT2H4LN	Strong	Biomarker	[641]
PTGER4	TT79WV3	Strong	Biomarker	[642]
PTK2	TTON5IT	Strong	Altered Expression	[643]
PTN	TTA9EJK	Strong	Altered Expression	[644]
PTPN13	TT405FP	Strong	Biomarker	[645]
PYY	TTVFJLX	Strong	Biomarker	[605]
RAF1	TTAN5W2	Strong	Genetic Variation	[646]
RALBP1	TTVSRUA	Strong	Biomarker	[647]
RBPJ	TT72D4Z	Strong	Biomarker	[648]
REG3A	TTL4H8N	Strong	Altered Expression	[649]
REG4	TTVZEHU	Strong	Biomarker	[650]
RGS16	TTFRES8	Strong	Biomarker	[651]
RHOB	TT6LPFO	Strong	Altered Expression	[337]
RIPK1	TTVJHX8	Strong	Biomarker	[647]
RNASEL	TT7V0K4	Strong	Genetic Variation	[652]
ROCK2	TTGWKQJ	Strong	Biomarker	[653]
RORA	TT1TYN7	Strong	Genetic Variation	[654]
RORB	TTGB2LZ	Strong	Genetic Variation	[654]
RPS6KA1	TTIXKA4	Strong	Biomarker	[273]
RPS6KA3	TTUM2ZR	Strong	Biomarker	[273]
RRM1	TTWP0NS	Strong	Altered Expression	[655]
RUNX2	TTD6SZ8	Strong	Biomarker	[656]
RUNX3	TTKCVO7	Strong	Biomarker	[657]
RXRA	TT6PEUO	Strong	Genetic Variation	[658]
S100A4	TTPR5SX	Strong	Biomarker	[659]
S1PR1	TT9JZCK	Strong	Biomarker	[532]
SCN9A	TT4G2JS	Strong	Biomarker	[660]
SCT	TTOBVIN	Strong	Biomarker	[661]
SDC1	TTYDSVG	Strong	Biomarker	[662]
SERPINH1	TTPSWQG	Strong	Biomarker	[663]
SFRP4	TTX8I1Y	Strong	Biomarker	[664]
SFTPD	TTGLMU7	Strong	Biomarker	[665]
SIK1	TT1H6LC	Strong	Biomarker	[666]
SIRT2	TTLKF5M	Strong	Biomarker	[667]
SIRT3	TTVZLIJ	Strong	Biomarker	[668]
SKP2	TT5B2EO	Strong	Altered Expression	[669]
SLC38A7	TTEARWC	Strong	Biomarker	[670]
SLC44A4	TT0NYDG	Strong	Biomarker	[671]
SLC5A5	TTW7HI9	Strong	Biomarker	[672]
SLC7A5	TTPH2JB	Strong	Altered Expression	[673]
SLC9A1	TTGSEFH	Strong	Altered Expression	[674]
SLCO2B1	TTDL3UZ	Strong	Biomarker	[675]
SLIT2	TTDWK85	Strong	Biomarker	[676]
SMAD1	TT9GR53	Strong	Biomarker	[677]
SMAD6	TTON5JB	Strong	Biomarker	[678]
SMC2	TTS8D17	Strong	Genetic Variation	[679]
SMYD2	TT7YJFO	Strong	Biomarker	[680]
SNCG	TT5TQNZ	Strong	Genetic Variation	[681]
SOCS1	TT8COJM	Strong	Posttranslational Modification	[682]
SOCS3	TTI0ME6	Strong	Altered Expression	[683]
SOD2	TT9O4C5	Strong	Biomarker	[684]
SPAG6	TTDAKTW	Strong	Biomarker	[685]
SPARC	TTBQFM7	Strong	Biomarker	[686]
SPHK2	TTCN0M9	Strong	Biomarker	[687]
SPOCK1	TTF23RE	Strong	Biomarker	[688]
SRC	TT6PKBN	Strong	Biomarker	[689]
SRPK2	TTCZEJ9	Strong	Biomarker	[690]
SST	TTWF7UG	Strong	Biomarker	[691]
SSTR1	TTIND6G	Strong	Biomarker	[692]
SSTR5	TT2BC4G	Strong	Altered Expression	[290]
STK38L	TTNM4ZH	Strong	Biomarker	[693]
STMN1	TT7W5OT	Strong	Altered Expression	[694]
STYK1	TTRMCYJ	Strong	Biomarker	[323]
TACSTD2	TTP2HE5	Strong	Biomarker	[695]
TAGLN	TTDRZ9H	Strong	Biomarker	[696]
TAGLN2	TTP6BIJ	Strong	Biomarker	[697]
TDG	TTEXRQD	Strong	Biomarker	[698]
TF	TT8WXAV	Strong	Genetic Variation	[699]
TFAP2A	TTDY4BS	Strong	Altered Expression	[700]
TFF1	TTNOJIZ	Strong	Altered Expression	[701]
TGFA	TTTLQFR	Strong	Biomarker	[702]
THBS1	TTKI0H1	Strong	Biomarker	[699]
TK1	TTP3QRF	Strong	Altered Expression	[703]
TLR6	TTWRI8V	Strong	Genetic Variation	[704]
TLR7	TTRJ1K4	Strong	Biomarker	[705]
TLR8	TT8CWFK	Strong	Altered Expression	[706]
TMEM97	TT9NXW4	Strong	Altered Expression	[707]
TMSB4X	TTMVAIU	Strong	Biomarker	[708]
TNC	TTUCPMY	Strong	Biomarker	[426]
TNFRSF10A	TT5WLRX	Strong	Altered Expression	[709]
TNFRSF10B	TTW20TU	Strong	Biomarker	[710]
TNFSF10	TTA5MS9	Strong	Biomarker	[711]
TNK1	TTWS7I3	Strong	Biomarker	[712]
TOP1	TTGTQHC	Strong	Biomarker	[713]
TPSD1	TTNWD8O	Strong	Biomarker	[714]
TREM1	TTHZQP0	Strong	Biomarker	[715]
TRH	TT2Z39D	Strong	Posttranslational Modification	[716]
TRIM27	TTTO3QN	Strong	Altered Expression	[503]
TRIM28	TTQ2BKV	Strong	Biomarker	[717]
TRIM37	TTAMCSL	Strong	Biomarker	[718]
TTK	TTP7EGM	Strong	Biomarker	[719]
TUSC2	TTJ8O14	Strong	Biomarker	[720]
TYMS	TTP1UKZ	Strong	Biomarker	[721]
TYRO3	TTIEMFN	Strong	Biomarker	[722]
UMPS	TTAFJUD	Strong	Altered Expression	[723]
USP44	TTJLTNM	Strong	Biomarker	[724]
VANGL1	TT18WJB	Strong	Altered Expression	[725]
VEGFD	TTOM5H4	Strong	Biomarker	[726]
WEE1	TTJFOAL	Strong	Biomarker	[169]
WNT5A	TTKG7F8	Strong	Biomarker	[727]
XIAP	TTK3WBU	Strong	Biomarker	[728]
XPA	TTGT87E	Strong	Biomarker	[729]
YAP1	TT8UN2D	Strong	Biomarker	[730]
YES1	TT0SQ8J	Strong	Biomarker	[731]
ABCC3	TTVLG21	Definitive	Biomarker	[732]
ALDH2	TTFLN4T	Definitive	Genetic Variation	[733]
ALPI	TTHYMUV	Definitive	Biomarker	[541]
CALR	TTUZ7OA	Definitive	Biomarker	[408]
CCL20	TT2XAZY	Definitive	Biomarker	[734]
CD80	TT89Z17	Definitive	Biomarker	[735]
CEBPB	TTUI35N	Definitive	Biomarker	[736]
CFLAR	TTJZQYH	Definitive	Biomarker	[737]
COPS5	TTSTNJR	Definitive	Biomarker	[738]
CTSE	TTLXC4Q	Definitive	Altered Expression	[739]
CXCR6	TT2BVUA	Definitive	Biomarker	[122]
DCN	TTB3XAN	Definitive	Altered Expression	[740]
DEK	TT1NMGV	Definitive	Altered Expression	[741]
DLL4	TTV23LH	Definitive	Biomarker	[481]
EBI3	TTJF68X	Definitive	Biomarker	[153]
EIF4EBP1	TTKGEBL	Definitive	Biomarker	[742]
EYA2	TTUY9C6	Definitive	Biomarker	[743]
F2R	TTL935N	Definitive	Biomarker	[607]
FOXO1	TTLRVIA	Definitive	Biomarker	[744]
FSCN1	TTTRS9B	Definitive	Biomarker	[745]
GCG	TT6Y4PN	Definitive	Biomarker	[746]
GEM	TTAZF9M	Definitive	Biomarker	[747]
HK2	TTK02H8	Definitive	Altered Expression	[748]
IDO1	TTZJYKH	Definitive	Biomarker	[657]
IKZF3	TTCZVFZ	Definitive	Genetic Variation	[749]
IL4R	TTDWHC3	Definitive	Biomarker	[750]
ISG15	TTVOH3T	Definitive	Biomarker	[751]
ITGAV	TTT1R2L	Definitive	Altered Expression	[752]
JUN	TTS7IR5	Definitive	Biomarker	[753]
KEAP1	TT3Z6Y9	Definitive	Biomarker	[754]
LILRB1	TTC0QRJ	Definitive	Biomarker	[384]
LPAR2	TTB7Y8I	Definitive	Biomarker	[122]
MARK2	TTAJ45Y	Definitive	Biomarker	[607]
MCAM	TTHRE05	Definitive	Biomarker	[755]
MMP15	TTNSTO3	Definitive	Altered Expression	[756]
MTA1	TTO4HUS	Definitive	Altered Expression	[757]
NEDD4	TT1QU6G	Definitive	Altered Expression	[758]
NF2	TTZIK7P	Definitive	Biomarker	[390]
NOTCH3	TTVX7IA	Definitive	Altered Expression	[759]
NTF3	TTZHKV9	Definitive	Biomarker	[760]
PDPK1	TTYMGWX	Definitive	Biomarker	[761]
RACK1	TTJ10AL	Definitive	Altered Expression	[762]
RAD51	TTC0G1L	Definitive	Biomarker	[763]
ROCK1	TTZN7RP	Definitive	Biomarker	[764]
RRM2	TT1S4LJ	Definitive	Biomarker	[765]
SHH	TTIENCJ	Definitive	Biomarker	[766]
SLC22A3	TTG2UMS	Definitive	Biomarker	[767]
SLC29A1	TTLXAKE	Definitive	Altered Expression	[768]
SLC52A2	TT6TKEN	Definitive	Biomarker	[607]
TIAM1	TTNU6I5	Definitive	Altered Expression	[769]
TNFRSF9	TTPW9LJ	Definitive	Biomarker	[770]
TOP2A	TTCGY2K	Definitive	Biomarker	[629]
TRPM8	TTXDKTO	Definitive	Biomarker	[163]
VEGFC	TT0QUFV	Definitive	Biomarker	[771]
VSIR	TT51SK8	Definitive	Biomarker	[772]
ZEB2	TTT2WK4	Definitive	Biomarker	[773]

This Disease Is Related to 14 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC25A3	DTCRIWV	Limited	Biomarker	[774]
SLC31A1	DTP8L4F	Limited	Altered Expression	[775]
SLC39A3	DTH08M7	Limited	Biomarker	[776]
SLC7A8	DTJF3DX	Limited	Biomarker	[249]
ANXA11	DTGQ2CF	moderate	Altered Expression	[777]
SLC25A16	DTNU9EW	moderate	Biomarker	[778]
SLC25A37	DTLBGTZ	moderate	Altered Expression	[779]
KCNK2	DTENHUP	Strong	Biomarker	[780]
SLC32A1	DTXQYLR	Strong	Posttranslational Modification	[716]
SLC35F6	DTJ7R5M	Strong	Biomarker	[781]
SLC39A4	DTEZCUM	Strong	Biomarker	[768]
SLC52A1	DT7NOKR	Strong	Biomarker	[782]
SLC5A8	DTE3TAW	Strong	Biomarker	[783]
ABCC5	DTYVM24	Definitive	Biomarker	[784]

This Disease Is Related to 39 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AKR1A1	DED2FW3	Limited	Biomarker	[785]
ALDH1B1	DEXI4UQ	Limited	Altered Expression	[786]
CES2	DETHCPD	Limited	Altered Expression	[787]
CRMP1	DE0EUXB	Limited	Altered Expression	[308]
EGLN3	DEMQTKH	Limited	Biomarker	[788]
NNMT	DECVGJ3	Limited	Altered Expression	[789]
PER1	DE9HF0I	Limited	Biomarker	[471]
ADH1B	DEEN9RD	moderate	Genetic Variation	[790]
ADH4	DEOCWU3	moderate	Altered Expression	[121]
ADH6	DE017IC	moderate	Altered Expression	[121]
AKR7A2	DE4G629	moderate	Biomarker	[121]
FADS1	DE05S8C	moderate	Biomarker	[791]
INPP4A	DEBJ2NL	moderate	Biomarker	[792]
P4HA2	DE5EGK0	moderate	Altered Expression	[399]
PCYT1A	DEQYXD4	moderate	Biomarker	[793]
UCK2	DETN1O0	moderate	Biomarker	[794]
UPRT	DE20ETR	moderate	Biomarker	[795]
ACP3	DEDW5H6	Strong	Biomarker	[720]
ALDH1A1	DE2JP1Y	Strong	Biomarker	[796]
ASNS	DEXISVQ	Strong	Biomarker	[797]
CMPK1	DEMPH4I	Strong	Biomarker	[798]
CYP2A13	DEXZA9U	Strong	Genetic Variation	[790]
CYP2R1	DEBIHM3	Strong	Genetic Variation	[658]
GGCT	DEKW6PB	Strong	Biomarker	[799]
HPGD	DEHKSC6	Strong	Altered Expression	[447]
MAT1A	DEQ6NC9	Strong	Genetic Variation	[800]
MTRR	DE6NIY9	Strong	Genetic Variation	[801]
PON2	DEHJU7E	Strong	Biomarker	[802]
SULT1A1	DEYWLRK	Strong	Genetic Variation	[340]
UGP2	DE4U39Y	Strong	Altered Expression	[803]
UGT1A3	DEF2WXN	Strong	Biomarker	[804]
WARS1	DEPVE0M	Strong	Altered Expression	[805]
WARS2	DEPTKBQ	Strong	Altered Expression	[805]
ADH1C	DEM1HNL	Definitive	Genetic Variation	[790]
AKR1B10	DEP6GT1	Definitive	Biomarker	[806]
GLS	DE3E0VT	Definitive	Biomarker	[807]
NAT1	DE7OAB3	Definitive	Genetic Variation	[340]
NAT2	DER7TA0	Definitive	Genetic Variation	[808]
UGT1A7	DEZO4N3	Definitive	Genetic Variation	[809]

This Disease Is Related to 966 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADA2	OTGCV24S	Limited	Biomarker	[810]
AFAP1	OTR473H8	Limited	Biomarker	[118]
AIP	OTDJ3OSV	Limited	Biomarker	[811]
ALDOA	OTWRFTIB	Limited	Altered Expression	[812]
ANGPTL2	OTB6JG41	Limited	Altered Expression	[813]
ANKRD1	OTHJ7JV9	Limited	Biomarker	[130]
ANLN	OTXJY54C	Limited	Altered Expression	[223]
ANP32B	OT3SQMLU	Limited	Altered Expression	[297]
APLP2	OTTFE53M	Limited	Biomarker	[814]
ARF6	OTVV7KJO	Limited	Biomarker	[815]
ARHGAP24	OTCQCEZS	Limited	Altered Expression	[816]
ARHGAP4	OTXV053R	Limited	Biomarker	[817]
ARHGEF15	OTGHDJFP	Limited	Altered Expression	[818]
ARTN	OTWIWGL6	Limited	Altered Expression	[512]
ASS1	OT4ZMG0Q	Limited	Biomarker	[819]
ATAD1	OTJ02XFL	Limited	Posttranslational Modification	[820]
AZIN2	OT8OB7CG	Limited	Biomarker	[821]
B3GALT5	OTWXPEMU	Limited	Posttranslational Modification	[822]
BAG1	OTRQNIA4	Limited	Biomarker	[823]
BHLHE22	OTZUQY5L	Limited	Biomarker	[824]
BHLHE40	OTITX14U	Limited	Altered Expression	[165]
BNC1	OTGJ5WUF	Limited	Biomarker	[120]
BNIP3	OT4SO7J4	Limited	Biomarker	[825]
BRCA1	OT5BN6VH	Limited	Genetic Variation	[826]
BTF3	OT5ZZFJL	Limited	Posttranslational Modification	[827]
BTG2	OTZF6K1H	Limited	Altered Expression	[828]
BUB3	OTU91HAU	Limited	Biomarker	[829]
CCL14	OT8QETQU	Limited	Biomarker	[830]
CCL28	OTY6XNQ7	Limited	Biomarker	[831]
CCN5	OTADU8JJ	Limited	Biomarker	[450]
CCNG1	OT17IA9L	Limited	Biomarker	[832]
CD68	OTOYEY3J	Limited	Biomarker	[833]
CDC42	OT5QBC5M	Limited	Altered Expression	[834]
CDCA5	OTZLCQ5U	Limited	Altered Expression	[153]
CDCP1	OTD7RRWK	Limited	Altered Expression	[835]
CDH17	OT9EV2XK	Limited	Biomarker	[836]
CDKN2B	OTAG24N1	Limited	Genetic Variation	[837]
CELF2	OTLJJ4VT	Limited	Altered Expression	[838]
CEMIP	OTK80FYN	Limited	Biomarker	[839]
CHI3L1	OT2Z7VJH	Limited	Biomarker	[840]
CHPT1	OT4FJ0K3	Limited	Biomarker	[841]
CILK1	OTWOYEYP	Limited	Biomarker	[252]
CISD2	OTVS7S2H	Limited	Biomarker	[842]
CLEC7A	OTRTBH27	Limited	Biomarker	[843]
CLIC4	OT6KTPKD	Limited	Altered Expression	[844]
CLOCK	OTNEOJY7	Limited	Altered Expression	[845]
COL11A1	OTB0DRMS	Limited	Biomarker	[191]
COMP	OTS2FPMI	Limited	Altered Expression	[846]
COPS6	OTG9AAG0	Limited	Altered Expression	[847]
CUL4B	OT2QX4DO	Limited	Altered Expression	[848]
DAPK2	OTWODUQG	Limited	Altered Expression	[308]
DENR	OTXP9HOY	Limited	Altered Expression	[308]
DESI2	OTHUOKOC	Limited	Biomarker	[849]
DHDDS	OTVLYBUS	Limited	Biomarker	[841]
DMAP1	OT1ZMQTU	Limited	Biomarker	[829]
DPYSL3	OTINJV20	Limited	Biomarker	[850]
DUSP28	OTDYDBN7	Limited	Biomarker	[851]
ECT2	OTQDUCT6	Limited	Biomarker	[392]
EEF1A2	OT9Z23K5	Limited	Altered Expression	[852]
EFEMP1	OTZVUOOB	Limited	Biomarker	[853]
EI24	OTD4NOYS	Limited	Biomarker	[854]
EIF6	OTEXMUED	Limited	Biomarker	[855]
EMB	OT67E3Q1	Limited	Biomarker	[856]
ENO1	OTB1KWJS	Limited	Altered Expression	[857]
EPS8	OTZ6ES6V	Limited	Biomarker	[858]
ERO1A	OTVKOQWM	Limited	Biomarker	[859]
FBN2	OT3KYJQL	Limited	Biomarker	[860]
FCGR3B	OTSLSPZG	Limited	Genetic Variation	[861]
FCN2	OTTHJBKZ	Limited	Altered Expression	[153]
FGF13	OTHNNVSG	Limited	Biomarker	[862]
FHL2	OT0OAYWT	Limited	Biomarker	[863]
FOSB	OTW6C05J	Limited	Biomarker	[753]
FOXA1	OTEBY0TD	Limited	Biomarker	[864]
FSTL1	OT6KEZUD	Limited	Altered Expression	[865]
FUNDC2	OTY3TQM5	Limited	Biomarker	[830]
GADL1	OTJM4A0R	Limited	Biomarker	[821]
GATA1	OTX1R7O1	Limited	Altered Expression	[866]
GATA6	OTO2BC0F	Limited	Biomarker	[867]
GCHFR	OTEOT8GI	Limited	Altered Expression	[153]
GDE1	OTU6FSBF	Limited	Biomarker	[868]
GFRA2	OT34CXNN	Limited	Biomarker	[869]
GLUD1	OTXKOCUH	Limited	Altered Expression	[870]
GPC1	OTQKRSSV	Limited	Biomarker	[871]
GPR151	OT7EACU6	Limited	Biomarker	[194]
GPR42	OTEB0ROY	Limited	Biomarker	[122]
GPRC5A	OTPOCWR7	Limited	Biomarker	[872]
GRB10	OTCKXGRC	Limited	Biomarker	[873]
HAP1	OT6SG0JQ	Limited	Biomarker	[874]
HAVCR2	OTOL603T	Limited	Biomarker	[875]
HEATR1	OTOWIB9Z	Limited	Biomarker	[876]
HHLA2	OTYBTVQS	Limited	Biomarker	[877]
HIC1	OTI9TWY4	Limited	Biomarker	[878]
HNRNPK	OTNPRM8U	Limited	Altered Expression	[879]
HOXD13	OTWSC8TF	Limited	Biomarker	[880]
HSPA14	OTZCA5LK	Limited	Altered Expression	[881]
HSPA2	OTSDET7B	Limited	Altered Expression	[882]
IGF2BP2	OT4ZSEEE	Limited	Biomarker	[883]
IGF2BP3	OTB97VIK	Limited	Altered Expression	[884]
IL18R1	OT83XMPQ	Limited	Biomarker	[885]
IL6ST	OT1N9C70	Limited	Biomarker	[886]
IMMP2L	OT9WGAFD	Limited	Biomarker	[883]
ING4	OT0VVG4V	Limited	Biomarker	[887]
INPP4B	OTLROA7G	Limited	Biomarker	[888]
IQGAP1	OTZRWTGA	Limited	Biomarker	[889]
IQSEC1	OTK1PBFD	Limited	Altered Expression	[890]
IRF2	OTAZRUW3	Limited	Biomarker	[891]
ISOC1	OTAO7Z87	Limited	Biomarker	[892]
ITGA3	OTBCH21D	Limited	Altered Expression	[893]
ITGB4	OT28UK84	Limited	Altered Expression	[578]
ITIH5	OTP46PZM	Limited	Biomarker	[894]
JDP2	OTW35WKX	Limited	Biomarker	[753]
JUNB	OTG2JXV5	Limited	Biomarker	[753]
JUND	OTNKACJD	Limited	Biomarker	[753]
KANK2	OT3SZIWM	Limited	Biomarker	[895]
KLF10	OT4F4UGS	Limited	Biomarker	[896]
KLF5	OT1ABI9N	Limited	Biomarker	[897]
KLK10	OTD573EL	Limited	Altered Expression	[219]
LAT2	OTWJDKIH	Limited	Biomarker	[249]
LDHB	OT9B1CT3	Limited	Altered Expression	[362]
LDLRAD3	OTYAKC55	Limited	Biomarker	[898]
LGR6	OTPZ1PWR	Limited	Biomarker	[194]
LTBP2	OTS88GSD	Limited	Biomarker	[899]
LUM	OTSRC874	Limited	Biomarker	[900]
MAK16	OTD546E5	Limited	Biomarker	[264]
MAP4K5	OTUFGLXE	Limited	Biomarker	[901]
MCAT	OTH07FIW	Limited	Altered Expression	[281]
MDC1	OTEUQH4J	Limited	Altered Expression	[902]
MED12	OTQZ4D2X	Limited	Biomarker	[903]
METTL3	OTSXP1M3	Limited	Biomarker	[904]
MFN2	OTPYN8A3	Limited	Biomarker	[905]
MNAT1	OTXLOYCB	Limited	Altered Expression	[153]
MR1	OTZU3XX7	Limited	Altered Expression	[906]
MRGPRX3	OTRKCCDS	Limited	Biomarker	[194]
MRGPRX4	OTOBHZVA	Limited	Biomarker	[194]
MSH6	OT46FP09	Limited	Genetic Variation	[907]
MSN	OTZJ4J6G	Limited	Altered Expression	[386]
MTA2	OTCCYIQJ	Limited	Altered Expression	[908]
MTSS1	OT5DTDO2	Limited	Biomarker	[909]
MUC2	OT3X4QVX	Limited	Posttranslational Modification	[820]
MUC5B	OTPW6K5C	Limited	Altered Expression	[910]
MYDGF	OT9HRPL6	Limited	Biomarker	[206]
MYOF	OTRFC3IJ	Limited	Biomarker	[911]
NBDY	OTV8WY4S	Limited	Biomarker	[912]
NBL1	OTT37U4O	Limited	Altered Expression	[913]
NBN	OT73B5MD	Limited	Genetic Variation	[914]
NEU2	OTW76T35	Limited	Biomarker	[915]
NEUROG1	OTMJZP9G	Limited	Biomarker	[327]
NFATC1	OT4TMERS	Limited	Altered Expression	[916]
NFYA	OTWFFOVH	Limited	Genetic Variation	[820]
NLRP2	OTJA81JU	Limited	Genetic Variation	[914]
NOC2L	OTNT7R33	Limited	Biomarker	[917]
NTS	OTPGDNQS	Limited	Biomarker	[918]
OCIAD1	OTJBY7PV	Limited	Altered Expression	[919]
ORM1	OTZKSBRE	Limited	Biomarker	[920]
OSBPL5	OTI1UJXT	Limited	Biomarker	[921]
PAF1	OTDDGUBQ	Limited	Posttranslational Modification	[922]
PAFAH1B2	OTRDWN2V	Limited	Biomarker	[923]
PARN	OTTG4PE3	Limited	Altered Expression	[913]
PAX8	OTRPD9MI	Limited	Altered Expression	[924]
PDCD4	OTZ6NXUX	Limited	Altered Expression	[925]
PDIK1L	OTISF4KG	Limited	Biomarker	[137]
PEG10	OTWD2278	Limited	Biomarker	[926]
PER2	OTU2B1DJ	Limited	Biomarker	[471]
PIMREG	OTKC8T3E	Limited	Altered Expression	[927]
PKD1	OT5ALRZ5	Limited	Altered Expression	[635]
PNO1	OT010GIS	Limited	Biomarker	[264]
PRDM14	OTWZKY4L	Limited	Altered Expression	[928]
PRDX1	OTZ3BEC4	Limited	Biomarker	[929]
PRKAR2A	OTZ7P17Z	Limited	Altered Expression	[263]
PRPF31	OTSJ0Z1Y	Limited	Biomarker	[930]
PRRT2	OTCJUBDO	Limited	Biomarker	[931]
PRSS2	OTOMVUWL	Limited	Biomarker	[932]
PSME3	OTSTC4YY	Limited	Biomarker	[933]
PTPRU	OTHDO0QG	Limited	Biomarker	[774]
RAB27A	OT9SQRWY	Limited	Biomarker	[934]
RAB27B	OTPF9D0K	Limited	Biomarker	[934]
RAB5A	OTFR2KM4	Limited	Biomarker	[935]
RASAL2	OTGMMX6W	Limited	Biomarker	[936]
RBM14	OTO9GMBD	Limited	Biomarker	[895]
RBM5	OTCBWHHV	Limited	Biomarker	[937]
RBMS3	OTFSC9MR	Limited	Biomarker	[264]
REG1A	OTMHUH1D	Limited	Biomarker	[774]
REG3G	OTLIUY8Z	Limited	Biomarker	[938]
RGCC	OTYJMLWM	Limited	Biomarker	[939]
RMDN1	OTE1NB6U	Limited	Altered Expression	[940]
RMDN2	OTK5WSFI	Limited	Altered Expression	[940]
RMDN3	OTKO7AUM	Limited	Altered Expression	[940]
ROBO3	OTPVG40S	Limited	Biomarker	[344]
RPL10	OTBHOZGC	Limited	Biomarker	[941]
RPS15A	OT0BUA12	Limited	Biomarker	[942]
RPS27A	OTIIGGZ2	Limited	Biomarker	[306]
S100A10	OTI71243	Limited	Biomarker	[943]
S100A11	OTI57KDN	Limited	Biomarker	[944]
S100A2	OTTGHJ1H	Limited	Altered Expression	[945]
SARDH	OTQ49Q27	Limited	Altered Expression	[946]
SAV1	OTSAEV92	Limited	Biomarker	[947]
SCAMP1	OTFS4IKJ	Limited	Altered Expression	[948]
SEMA3D	OTD5TJV1	Limited	Biomarker	[949]
SEMA7A	OT0ZJK64	Limited	Altered Expression	[950]
SERPINB2	OT72QLZB	Limited	Biomarker	[951]
SET	OTGYYQJO	Limited	Biomarker	[952]
SFRP1	OT0U9G41	Limited	Altered Expression	[953]
SGSM3	OTIB1P8A	Limited	Biomarker	[954]
SHC1	OT1J5IRN	Limited	Biomarker	[955]
SIX1	OT70YYWM	Limited	Biomarker	[956]
SLC16A4	OT1YXBKC	Limited	Biomarker	[282]
SMAD4	OTWQWCKG	Limited	Biomarker	[957]
SMARCA2	OTSGJ8SV	Limited	Biomarker	[958]
SMG1	OTTS3SXE	Limited	Biomarker	[959]
SMURF1	OT5UIZR8	Limited	Biomarker	[960]
SOX4	OTSS40SS	Limited	Genetic Variation	[961]
SOX9	OTVDJFGN	Limited	Altered Expression	[902]
SPINT2	OTQV7BKQ	Limited	Altered Expression	[962]
SPPL3	OT2HLJF6	Limited	Biomarker	[883]
SRF	OTW18FQN	Limited	Biomarker	[963]
SRRM2	OTSIMMC9	Limited	Biomarker	[264]
SRY	OT516T6D	Limited	Biomarker	[964]
STING1	OTDAP4G0	Limited	Biomarker	[965]
STK11	OT1YZSP3	Limited	Genetic Variation	[966]
SULF1	OTJCNCO0	Limited	Altered Expression	[967]
SYBU	OT3FQV7N	Limited	Altered Expression	[940]
TAS2R10	OT4RWZZD	Limited	Biomarker	[968]
TFIP11	OT7NVSWU	Limited	Altered Expression	[969]
TGFB1I1	OTIK337D	Limited	Altered Expression	[970]
TGIF1	OTN9VHAG	Limited	Altered Expression	[971]
TM7SF2	OTILU5S7	Limited	Altered Expression	[129]
TNFRSF10C	OTVHOL9B	Limited	Biomarker	[972]
TPD52	OTPKSK43	Limited	Biomarker	[973]
TPM3	OT5RU5G6	Limited	Biomarker	[974]
TRIM69	OTTEGTRD	Limited	Biomarker	[295]
TSACC	OT3QW6PH	Limited	Biomarker	[895]
TSPAN8	OT1F68WQ	Limited	Altered Expression	[975]
ALPG	OTCIM29R	Disputed	Biomarker	[976]
APIP	OT8ZABOU	Disputed	Biomarker	[318]
CEACAM7	OTKFDTZY	Disputed	Biomarker	[314]
CEP85L	OTSHJFOT	Disputed	Biomarker	[318]
CLTC	OTBFASMA	Disputed	Biomarker	[318]
CREM	OTJIJ5AL	Disputed	Biomarker	[318]
FAM133B	OTQH2A95	Disputed	Biomarker	[318]
FOXB2	OTJE3RRR	Disputed	Biomarker	[977]
GOLGA6A	OTHU9MRX	Disputed	Genetic Variation	[486]
PSG2	OT2EIXAI	Disputed	Biomarker	[314]
RCBTB1	OTAYELI8	Disputed	Genetic Variation	[486]
ACADS	OTGFANYQ	moderate	Genetic Variation	[978]
AHSA1	OTC7AFHT	moderate	Biomarker	[323]
AIM2	OT86QUI8	moderate	Altered Expression	[779]
ANKRD36B	OT3MW415	moderate	Altered Expression	[227]
AP2A1	OTEFZB21	moderate	Altered Expression	[700]
ARHGEF2	OTBQTFRT	moderate	Biomarker	[979]
ARHGEF4	OTR2VG0W	moderate	Biomarker	[197]
ARL2BP	OT7REEDA	moderate	Biomarker	[980]
ASPN	OTYJM80N	moderate	Biomarker	[981]
ASTL	OTB9KA3F	moderate	Biomarker	[982]
ASTN2	OTF0W2FJ	moderate	Genetic Variation	[546]
ATP6V0D1	OT9GU2NW	moderate	Biomarker	[462]
BAD	OT63ERYM	moderate	Altered Expression	[983]
BASP1	OTF4VS5G	moderate	Biomarker	[984]
BHLHA15	OTY7IER8	moderate	Altered Expression	[985]
BICD2	OTVJ03NZ	moderate	Biomarker	[986]
BOK	OTDQPDIX	moderate	Biomarker	[987]
BSND	OTYWZWPD	moderate	Biomarker	[980]
CAB39	OT2CL9ST	moderate	Biomarker	[988]
CACUL1	OT6P1ZVP	moderate	Biomarker	[390]
CAP1	OTYM8A2N	moderate	Biomarker	[989]
CAV2	OT1FGRQX	moderate	Altered Expression	[990]
CBX3	OTOP9RLD	moderate	Biomarker	[991]
CC2D1A	OTVPU04K	moderate	Altered Expression	[992]
CCT4	OT5D452X	moderate	Biomarker	[993]
CCT8	OTA7GQN9	moderate	Biomarker	[994]
CDK15	OT8S67QS	moderate	Biomarker	[252]
CDK16	OTUBXIIT	moderate	Biomarker	[252]
CDK5R2	OTNUTLPU	moderate	Biomarker	[462]
CDKN2D	OT2TTZPZ	moderate	Altered Expression	[995]
CFAP97	OT0RSQO4	moderate	Biomarker	[996]
CLDN1	OT27KV99	moderate	Altered Expression	[997]
CLIC3	OT5KUZ3A	moderate	Biomarker	[163]
CLPTM1L	OTDJWQXI	moderate	Biomarker	[998]
CNBP	OTTGM9NK	moderate	Altered Expression	[999]
COL17A1	OTID5AH2	moderate	Altered Expression	[1000]
COL4A2	OTJK1LKN	moderate	Biomarker	[1001]
COL5A2	OT5VOSQE	moderate	Biomarker	[1002]
COL6A1	OTYKSCOB	moderate	Biomarker	[1003]
CPQ	OTTNZNLD	moderate	Biomarker	[1004]
CTCF	OT8ZB70U	moderate	Genetic Variation	[1005]
CTNND1	OTUMPSHR	moderate	Biomarker	[1006]
CTRL	OTB6NA5O	moderate	Biomarker	[191]
DCC	OT2C1SHW	moderate	Genetic Variation	[1007]
DDT	OTF5HTYL	moderate	Biomarker	[1008]
DDX17	OTXRMMBP	moderate	Biomarker	[1009]
DESI1	OTFNIW98	moderate	Biomarker	[849]
DLC1	OTP8LMCR	moderate	Altered Expression	[1010]
DLD	OT378CU9	moderate	Altered Expression	[1011]
DLEC1	OTMKKBUW	moderate	Altered Expression	[1010]
DNA2	OT4DJFFU	moderate	Biomarker	[629]
DST	OTHZBM4X	moderate	Biomarker	[1012]
DVL2	OTMNYNCM	moderate	Altered Expression	[1013]
DYNLL1	OTR69LHT	moderate	Altered Expression	[1010]
EFNB2	OT0DCUOM	moderate	Biomarker	[1014]
ENTPD8	OTB9GJ1V	moderate	Biomarker	[1015]
ETV4	OT8C98UZ	moderate	Biomarker	[1016]
EXO1	OTI87RS5	moderate	Biomarker	[1017]
FAM83A	OTBI16V7	moderate	Biomarker	[1018]
FANCG	OT7MC8TZ	moderate	Genetic Variation	[1019]
FATE1	OTPYXV64	moderate	Posttranslational Modification	[1020]
FBXL14	OTBTN6WS	moderate	Biomarker	[1021]
FBXO32	OTUE978R	moderate	Biomarker	[138]
FH	OTEQWU6Q	moderate	Altered Expression	[1022]
FOXD1	OT80PRHS	moderate	Biomarker	[1023]
FOXK1	OTLZGS7J	moderate	Biomarker	[1024]
FOXL1	OT89XFPN	moderate	Altered Expression	[1025]
FUBP1	OT77SC9N	moderate	Altered Expression	[1026]
FZD6	OTBCPII8	moderate	Biomarker	[1027]
GALNT5	OTCV61V1	moderate	Altered Expression	[1028]
GDF11	OTOSNMND	moderate	Altered Expression	[1029]
GPC5	OT8NR7GC	moderate	Biomarker	[1030]
GPX2	OTXI2NTI	moderate	Altered Expression	[1031]
GRAP2	OTS5NIZ3	moderate	Biomarker	[323]
GSTM3	OTLA2WJT	moderate	Altered Expression	[249]
H4C1	OTB71W46	moderate	Biomarker	[1032]
HASPIN	OTI0SMF2	moderate	Biomarker	[1033]
HIF3A	OTPWAAMC	moderate	Biomarker	[177]
HOXB8	OTKHOD17	moderate	Biomarker	[1034]
HYAL1	OT2SJN0X	moderate	Biomarker	[996]
IFNA1	OTPMKY0L	moderate	Biomarker	[1035]
IFNLR1	OTWWWK45	moderate	Altered Expression	[1036]
IGF2BP1	OT9G360P	moderate	Altered Expression	[1037]
IGSF21	OTUFCXBS	moderate	Genetic Variation	[546]
IL18BP	OTW0LRYZ	moderate	Biomarker	[1038]
IL22RA1	OTGVKLBR	moderate	Biomarker	[1039]
ILF2	OTWWVM9X	moderate	Biomarker	[1040]
INTS11	OTOFT19G	moderate	Biomarker	[1041]
JADE1	OTBPJIRI	moderate	Biomarker	[1014]
KLF12	OTVH4KD4	moderate	Biomarker	[1013]
KLF8	OTUC5CDB	moderate	Biomarker	[863]
KLF9	OTBFEJRQ	moderate	Altered Expression	[1042]
LDLRAD4	OTQUX50Z	moderate	Genetic Variation	[546]
LIN7C	OTB3015O	moderate	Genetic Variation	[546]
LRPPRC	OTXSK5LP	moderate	Biomarker	[886]
MACROD1	OTWFEVRW	moderate	Biomarker	[1043]
MAP2	OT6UYT3X	moderate	Genetic Variation	[966]
MAP2K4	OTZPZX11	moderate	Biomarker	[383]
MBD3	OTRL76H5	moderate	Biomarker	[1044]
MEF2A	OTV2SF6E	moderate	Genetic Variation	[1045]
MFAP5	OT46VXSG	moderate	Biomarker	[1046]
MFSD13A	OTP306N2	moderate	Genetic Variation	[1005]
MIIP	OT79EXZ7	moderate	Altered Expression	[1047]
MOB4	OTOQRMAS	moderate	Biomarker	[230]
MPST	OTCDPH5D	moderate	Biomarker	[230]
MRGBP	OTXBPDMS	moderate	Biomarker	[1048]
MST1	OTOC4UNG	moderate	Biomarker	[533]
MSTO1	OT37XCNP	moderate	Biomarker	[230]
MT1M	OTVT8PLU	moderate	Altered Expression	[1049]
MYH14	OT1TZEJK	moderate	Altered Expression	[823]
MYH9	OT94Z706	moderate	Altered Expression	[823]
MYRIP	OTH2TFYH	moderate	Biomarker	[1014]
NANOG	OTUEY1FM	moderate	Biomarker	[1050]
NCAPH	OTXOS97C	moderate	Altered Expression	[1051]
NCSTN	OT5QBTA4	moderate	Biomarker	[1052]
NEBL	OT2WH1NC	moderate	Altered Expression	[1053]
NELFE	OTL4E94L	moderate	Altered Expression	[1054]
NETO2	OT0YAMC0	moderate	Biomarker	[1055]
NIBAN2	OTVDQSPI	moderate	Biomarker	[1056]
NKAIN2	OTI4H30Z	moderate	Biomarker	[1057]
NMU	OTW9X7BQ	moderate	Altered Expression	[1058]
NUMB	OTMB586Q	moderate	Altered Expression	[1059]
OTUD7B	OTMVM8R7	moderate	Biomarker	[1060]
PARP10	OTILI1DU	moderate	Biomarker	[1061]
PARP14	OTFXJAKK	moderate	Altered Expression	[1062]
PARP4	OTXBK59G	moderate	Biomarker	[1017]
PBX3	OT8WMVM4	moderate	Biomarker	[1063]
PCBP3	OT6EX9N6	moderate	Biomarker	[187]
PDK4	OTCMHMBZ	moderate	Altered Expression	[1064]
PDS5B	OT3U3X8Z	moderate	Altered Expression	[1065]
PENK	OT8P3HMP	moderate	Posttranslational Modification	[1066]
PFKM	OT1QY9JM	moderate	Biomarker	[1067]
PFKP	OTFP7AA8	moderate	Biomarker	[1067]
PHB2	OTCAX3AW	moderate	Biomarker	[1068]
PINK1	OT50NR57	moderate	Biomarker	[1069]
PIP4K2B	OTF1VGJ9	moderate	Biomarker	[1070]
PIWIL1	OT7CRGZ3	moderate	Altered Expression	[1071]
PIWIL2	OT1PXQIF	moderate	Altered Expression	[1071]
POLD1	OTWO4UCJ	moderate	Biomarker	[824]
POLDIP2	OT8SZSJ6	moderate	Biomarker	[323]
POLE	OTFM3MMU	moderate	Genetic Variation	[1072]
POU5F1	OTDHHN7O	moderate	Biomarker	[767]
PPP1R1A	OTGTAGCV	moderate	Biomarker	[1073]
PRB1	OTV0SYMD	moderate	Genetic Variation	[546]
PRB2	OTAD4JZ0	moderate	Genetic Variation	[546]
PRDX6	OTS8KC8A	moderate	Biomarker	[1074]
PRKACG	OTKOQYF8	moderate	Biomarker	[252]
PRKAG2	OTHTAM54	moderate	Genetic Variation	[966]
PROK1	OT8S7RUG	moderate	Posttranslational Modification	[1075]
PRPF40A	OT6EXJZN	moderate	Biomarker	[449]
PRPF40B	OTBPUXVD	moderate	Biomarker	[1076]
PSD4	OTEFB87Z	moderate	Biomarker	[1077]
PSENEN	OTJ7M7G9	moderate	Biomarker	[1052]
PTCH2	OTOQ0K9V	moderate	Biomarker	[1065]
QKI	OTTAUGLB	moderate	Biomarker	[1078]
RAB14	OTF1J0TB	moderate	Altered Expression	[1079]
RAB20	OTP9OOVS	moderate	Altered Expression	[1080]
RAB2B	OTEIYK4O	moderate	Biomarker	[1081]
RAB38	OTU0NZU0	moderate	Biomarker	[1082]
RBM3	OTAJ7R31	moderate	Biomarker	[1083]
RBM6	OTI99KAZ	moderate	Biomarker	[1084]
RER1	OTTBAUBP	moderate	Biomarker	[1085]
REST	OTLL92LQ	moderate	Biomarker	[1086]
RNF19A	OTKWCV80	moderate	Biomarker	[323]
RPTOR	OT4TQZ9F	moderate	Genetic Variation	[966]
RTN3	OTGZ51QF	moderate	Biomarker	[823]
S100A7	OTJFVJRF	moderate	Altered Expression	[1087]
SAFB	OTGRV2LW	moderate	Biomarker	[823]
SARS1	OTFKXQ1O	moderate	Biomarker	[1088]
SARS2	OTU4T99W	moderate	Biomarker	[1088]
SCO2	OTJQQDRS	moderate	Altered Expression	[415]
SCTR	OTC80IMR	moderate	Genetic Variation	[1089]
SDF4	OTQ7WFYW	moderate	Altered Expression	[945]
SERBP1	OTZVSU0X	moderate	Altered Expression	[1090]
SETD1A	OTVVWRIC	moderate	Genetic Variation	[1005]
SF3A1	OTI733D7	moderate	Genetic Variation	[1076]
SF3B4	OTGB9OR9	moderate	Biomarker	[1091]
SGMS1	OTZQE7PW	moderate	Biomarker	[230]
SH3D21	OTNK2Q4M	moderate	Biomarker	[1092]
SIM2	OT0QWHK4	moderate	Altered Expression	[1093]
SIRT4	OT5S0J23	moderate	Biomarker	[1094]
SLC12A9	OTR7VRAK	moderate	Altered Expression	[1095]
SLC25A45	OTP7EAUM	moderate	Biomarker	[1096]
SLFN5	OTT1AESL	moderate	Biomarker	[1097]
SMARCAD1	OT90AZTX	moderate	Biomarker	[1098]
SNX6	OTLKQYJU	moderate	Biomarker	[1099]
SOAT1	OTB4Y5RJ	moderate	Biomarker	[1100]
SOCS5	OTN1ABYR	moderate	Biomarker	[1101]
SOX12	OT93P8C9	moderate	Biomarker	[1102]
SOX6	OTT0W0LE	moderate	Altered Expression	[1103]
SOX7	OTOZOFAG	moderate	Altered Expression	[1104]
SPINK4	OTHTCW94	moderate	Biomarker	[509]
SPNS2	OTPODAPU	moderate	Biomarker	[1009]
SRCIN1	OTQZNQQ5	moderate	Biomarker	[1105]
ST7L	OT0I8XNI	moderate	Biomarker	[1106]
STAT2	OTO9G2RZ	moderate	Biomarker	[1107]
STIP1	OT7TXLOX	moderate	Biomarker	[1108]
STK31	OT3ZLRH0	moderate	Altered Expression	[1109]
STRN4	OTHK2ZN6	moderate	Biomarker	[1110]
TFF2	OTRXB19X	moderate	Altered Expression	[701]
TFF3	OTJJDRTU	moderate	Altered Expression	[701]
TLE1	OT50MRZ1	moderate	Biomarker	[1111]
TLK1	OTICTXI8	moderate	Biomarker	[252]
TMEFF2	OT1WZ2QO	moderate	Biomarker	[1112]
TMEM158	OT0KUBBI	moderate	Altered Expression	[258]
TMEM37	OT317PEL	moderate	Biomarker	[399]
TMSB10	OTLVZ13T	moderate	Altered Expression	[1113]
TNFRSF6B	OTKAN9G7	moderate	Biomarker	[1114]
TNIP1	OTRAOTEW	moderate	Biomarker	[842]
TRIM21	OTA4UJCF	moderate	Altered Expression	[1115]
TRIM29	OT2DNESG	moderate	Biomarker	[1116]
TRIM31	OT7VW6RP	moderate	Biomarker	[1117]
TRIM63	OTUSWA74	moderate	Biomarker	[295]
TTLL4	OTHEIBQG	moderate	Altered Expression	[1118]
A4GNT	OT8GOL3T	Strong	Altered Expression	[1119]
ACO1	OT2VUR7L	Strong	Genetic Variation	[1120]
ACTR2	OT3C8U5T	Strong	Biomarker	[1121]
ADAM12	OTZKOTDB	Strong	Biomarker	[1122]
ADAM15	OTZ7VLTP	Strong	Altered Expression	[1123]
ADAM28	OT3GBVHL	Strong	Biomarker	[1124]
ADAMTS8	OT2KFY1S	Strong	Altered Expression	[1125]
ADAT2	OT8AG6ZN	Strong	Genetic Variation	[267]
ADGRG1	OTQBB8NT	Strong	Biomarker	[1126]
AGFG1	OTI8ZKC4	Strong	Biomarker	[1127]
AGO2	OT4JY32Q	Strong	Biomarker	[538]
AIMP1	OTTA5C3U	Strong	Altered Expression	[1128]
ALDH1A3	OT1C9NKQ	Strong	Altered Expression	[1129]
ALKBH3	OTS1CD9Z	Strong	Biomarker	[1130]
ANO9	OTQ2UM3M	Strong	Biomarker	[1131]
ANP32A	OTRHPFO2	Strong	Altered Expression	[1132]
ANXA6	OT9KIQ0Y	Strong	Biomarker	[1133]
APC	OTKV0TIK	Strong	Biomarker	[1134]
APOBEC3B	OTHLNI51	Strong	Genetic Variation	[1135]
APOC1	OTA58CED	Strong	Biomarker	[1136]
ARFRP1	OTP1OV78	Strong	Genetic Variation	[380]
ARHGDIB	OT9PD6CS	Strong	Biomarker	[1137]
ARHGEF7	OT9BPJCL	Strong	Biomarker	[1138]
ARID1B	OTILK3Q7	Strong	Biomarker	[1139]
ARID2	OTIRJXWM	Strong	Genetic Variation	[438]
ARPC1A	OTAEEXGQ	Strong	Biomarker	[1140]
ARPC4	OT0ZE01B	Strong	Biomarker	[1121]
ART1	OT7FBG5W	Strong	Altered Expression	[1141]
ASAH1	OT1DNGXL	Strong	Biomarker	[1142]
ASAP1	OT4DLRYY	Strong	Genetic Variation	[1143]
ASAP2	OTGEXULW	Strong	Biomarker	[720]
ASCC1	OTH4VAP9	Strong	Biomarker	[1138]
ASPG	OT5E2EKR	Strong	Biomarker	[1144]
ASPM	OTKXQMNA	Strong	Biomarker	[1145]
ATF2	OTNIZPEA	Strong	Biomarker	[1146]
ATG12	OTJRO09Y	Strong	Altered Expression	[1147]
ATN1	OTNZFLKY	Strong	Genetic Variation	[1148]
B3GNT6	OTAX8BNJ	Strong	Altered Expression	[1149]
BAG3	OTVXYUDQ	Strong	Biomarker	[1150]
BAG5	OT0J97C6	Strong	Altered Expression	[1151]
BCAR1	OTKT2C2N	Strong	Genetic Variation	[609]
BCKDHB	OT8OSVYU	Strong	Biomarker	[1152]
BCL2L11	OTNQQWFJ	Strong	Biomarker	[1153]
BCL9L	OTTWI90E	Strong	Biomarker	[1154]
BEST1	OTWHE1ZC	Strong	Biomarker	[1155]
BICD1	OT78IYPF	Strong	Genetic Variation	[1156]
BMP3	OTCTI0UW	Strong	Genetic Variation	[1157]
BMP8B	OTJC3AB9	Strong	Biomarker	[1158]
BNIP3L	OTJKOMXE	Strong	Biomarker	[1159]
BRD8	OTIKS3PC	Strong	Biomarker	[602]
BTC	OTW4B2O0	Strong	Genetic Variation	[1160]
BUB1B	OT8KME51	Strong	Biomarker	[441]
C16orf74	OTLLVHH0	Strong	Biomarker	[1161]
C1GALT1C1	OTRTZUF5	Strong	Biomarker	[1162]
C9	OT7I5FDX	Strong	Genetic Variation	[431]
CAST	OTBXZZGF	Strong	Biomarker	[1163]
CBLL2	OTB4AD3V	Strong	Altered Expression	[758]
CCL1	OT23NON8	Strong	Biomarker	[1164]
CCL18	OT7JYSK9	Strong	Biomarker	[1165]
CCL7	OTDIS99H	Strong	Biomarker	[1166]
CCL8	OTCTWYN8	Strong	Biomarker	[1167]
CCN3	OTOW5YL4	Strong	Biomarker	[1168]
CCN6	OTRFHQ2Z	Strong	Biomarker	[538]
CCSER1	OTVLD4J3	Strong	Genetic Variation	[1169]
CD101	OT4QX6BR	Strong	Biomarker	[1170]
CD109	OTDADBM4	Strong	Altered Expression	[1171]
CD82	OTH8MC64	Strong	Biomarker	[1172]
CDK14	OT385ZH1	Strong	Biomarker	[1173]
CDK2AP2	OTR99SJ8	Strong	Genetic Variation	[1174]
CDKAL1	OTA0SGNE	Strong	Genetic Variation	[422]
CDKN3	OTBE3H07	Strong	Altered Expression	[1175]
CDO1	OTLG1P77	Strong	Posttranslational Modification	[1176]
CDX1	OTOHTMJE	Strong	Altered Expression	[1177]
CELA3B	OTGU8BE9	Strong	Biomarker	[1178]
CENPX	OTG1RAKJ	Strong	Biomarker	[1179]
CEP55	OTGSG2PA	Strong	Biomarker	[1180]
CEP70	OTMY5KAE	Strong	Altered Expression	[1181]
CETN1	OTGQ8JOZ	Strong	Biomarker	[1182]
CHD1L	OT7CZK7C	Strong	Altered Expression	[1183]
CHD3	OTDBU4F3	Strong	ModifyingMutation	[1184]
CHD5	OTS5EVHH	Strong	Altered Expression	[1185]
CHSY3	OT8ERGMH	Strong	Biomarker	[1186]
CIAPIN1	OTWS90F9	Strong	Biomarker	[1187]
CIP2A	OTVS2GXA	Strong	Altered Expression	[1188]
CKLF	OTHLPHA0	Strong	Biomarker	[1189]
CLDN5	OTUX60YO	Strong	Biomarker	[1190]
CLDN7	OTNE0XHQ	Strong	Altered Expression	[1191]
CLDN8	OT7IIWXG	Strong	Altered Expression	[1192]
CLEC14A	OT0UJQ4O	Strong	Biomarker	[454]
CMTM5	OTMS7NDP	Strong	Biomarker	[1189]
CNDP2	OTJR9436	Strong	Biomarker	[1193]
CNKSR1	OTSNAEQ9	Strong	Altered Expression	[1194]
COL11A2	OT3BQUBH	Strong	Genetic Variation	[618]
COL6A2	OTQC6PPO	Strong	Biomarker	[1195]
COP1	OT6J2K12	Strong	Altered Expression	[1196]
COX2	OTTMVBJJ	Strong	Biomarker	[1197]
CRISP1	OTDI4B55	Strong	Genetic Variation	[380]
CRKL	OTOYSD1R	Strong	Altered Expression	[1198]
CSMD2	OT541Z3W	Strong	Posttranslational Modification	[716]
CSN2	OT22C0PD	Strong	Biomarker	[1199]
CST1	OTE4I83Q	Strong	Altered Expression	[1200]
CTHRC1	OTV88X2G	Strong	Biomarker	[1201]
CXCL14	OTM189TA	Strong	Biomarker	[1202]
CXCL16	OTD49T9R	Strong	Biomarker	[1203]
CXCL5	OTZOUPCA	Strong	Biomarker	[1204]
DAB2	OTRMQTMZ	Strong	Biomarker	[1205]
DAB2IP	OTF456VC	Strong	Biomarker	[1206]
DACH1	OTMKNAGG	Strong	Altered Expression	[1207]
DAP	OT5YLL7E	Strong	Biomarker	[1208]
DAPK1	OTNCNUCO	Strong	Biomarker	[1209]
DCAF1	OT3ZDVOE	Strong	Biomarker	[1127]
DCD	OTV5PBGJ	Strong	Biomarker	[1210]
DCX	OTISR7K3	Strong	Altered Expression	[317]
DDB2	OTO8HVVB	Strong	Genetic Variation	[606]
DHX40	OTOL02QN	Strong	Genetic Variation	[1211]
DKK4	OTWCCVF6	Strong	Biomarker	[1212]
DMKN	OTRIGZMK	Strong	Biomarker	[1213]
DNAAF3	OT3OHO0O	Strong	Biomarker	[1214]
DNAH5	OTC21RUS	Strong	Biomarker	[1214]
DNAI1	OTF6C65Q	Strong	Biomarker	[1214]
DNER	OT2GH2E5	Strong	Biomarker	[1215]
DOC2A	OT5G9V94	Strong	Altered Expression	[1216]
DPP6	OTWW3H0K	Strong	Genetic Variation	[1156]
DSTN	OTMXO4YB	Strong	Biomarker	[1217]
DUSP6	OT4H6RKW	Strong	Altered Expression	[1218]
DYNC2H1	OTLC8K6B	Strong	Biomarker	[1219]
EBAG9	OTTQLQCP	Strong	Altered Expression	[1220]
EBPL	OT59J1GY	Strong	Biomarker	[1221]
EDIL3	OTDVVNS0	Strong	Biomarker	[1222]
EEF1A1	OT00THXS	Strong	Biomarker	[1223]
EEF1G	OTW7DH2F	Strong	Altered Expression	[1224]
EFNA2	OTEAUKRX	Strong	Biomarker	[1225]
EGR3	OTGPJIRA	Strong	Biomarker	[1226]
EIF3F	OTU20K6L	Strong	Posttranslational Modification	[1227]
EIF4A1	OTMTBX6N	Strong	Biomarker	[487]
EIF4A2	OT08H03R	Strong	Biomarker	[742]
ELAVL2	OT6EJ8MQ	Strong	Biomarker	[1228]
EMD	OTR8ZANE	Strong	Genetic Variation	[1229]
EML2	OTRX2NTA	Strong	Altered Expression	[1128]
EML5	OT0EFCPB	Strong	Altered Expression	[1128]
ENTPD2	OTZ2PKPM	Strong	Biomarker	[491]
ERCC1	OTNPYQHI	Strong	Genetic Variation	[1230]
ERCC4	OTFIOPG1	Strong	Genetic Variation	[1231]
ERO1B	OTHZ25Y8	Strong	Biomarker	[1232]
ETV5	OTE2OBM4	Strong	Biomarker	[1233]
EXOC2	OT5QG1WG	Strong	Altered Expression	[1234]
FANCC	OTTIDM3P	Strong	Genetic Variation	[1019]
FANCD2	OTVEB5LF	Strong	Biomarker	[1235]
FBL	OTRODIE5	Strong	Biomarker	[1236]
FBLN2	OTEHR7N7	Strong	Biomarker	[1237]
FBP1	OTQBANEP	Strong	Altered Expression	[724]
FERMT1	OT626PBA	Strong	Altered Expression	[1238]
FERMT2	OTZNPWWX	Strong	Biomarker	[1239]
FLVCR1	OT9XCFOC	Strong	Genetic Variation	[1240]
FOXA2	OTJOCVOY	Strong	Biomarker	[1241]
FOXO3	OTHXQG4P	Strong	Biomarker	[1242]
FRS2	OTDMD800	Strong	Biomarker	[1243]
FRY	OT74IAG2	Strong	Biomarker	[1244]
FRZB	OTTO3DPY	Strong	Altered Expression	[1245]
FXYD3	OT9PPRHE	Strong	Altered Expression	[1246]
GABBR1	OTU5A52J	Strong	Biomarker	[1247]
GABPA	OT9YB2SA	Strong	Genetic Variation	[1248]
GADD45A	OTDRV63V	Strong	Biomarker	[1249]
GALNT14	OT9BSDDQ	Strong	Biomarker	[1250]
GALNT3	OT7M67WT	Strong	Biomarker	[1251]
GATA5	OTO81B63	Strong	Posttranslational Modification	[1252]
GCKR	OTSIWXGG	Strong	Genetic Variation	[1253]
GCNT1	OTF6OC66	Strong	Biomarker	[1254]
GCNT3	OTQ9ALTR	Strong	Biomarker	[1255]
GDF10	OTEVXGJ7	Strong	Biomarker	[1256]
GEMIN2	OT4L6TLL	Strong	Altered Expression	[1257]
GFPT1	OTQBDO45	Strong	Biomarker	[510]
GFRA1	OT3WBVYB	Strong	Biomarker	[1258]
GIPC1	OTXLVCPJ	Strong	Biomarker	[1259]
GLS2	OT08MSHL	Strong	Altered Expression	[1260]
GNA15	OTFYRZGV	Strong	Biomarker	[423]
GOLM1	OTOZSV6O	Strong	Biomarker	[1261]
GOT2	OT6XBWN0	Strong	Biomarker	[1262]
GP2	OTB6TMGY	Strong	Biomarker	[871]
GPC4	OTUJ14DW	Strong	Biomarker	[1263]
GPR68	OT1NXSMN	Strong	Altered Expression	[1264]
GPX4	OTRAFFX2	Strong	Altered Expression	[1265]
GRB7	OTF8Y9XY	Strong	Altered Expression	[1266]
H1-4	OTQ450A3	Strong	Biomarker	[1267]
H1-5	OTAN7RD9	Strong	Biomarker	[1267]
HAT1	OT307KEN	Strong	Biomarker	[1268]
HINT2	OTW9GS0U	Strong	Altered Expression	[1269]
HLA-DOA	OTZE5Q7R	Strong	Genetic Variation	[1270]
HMMR	OT4M0JTZ	Strong	Biomarker	[1271]
HNRNPU	OTLQN1E2	Strong	Biomarker	[602]
HOPX	OTBSR6C9	Strong	Posttranslational Modification	[1272]
HOXA1	OTMSOJ7D	Strong	Altered Expression	[1273]
HOXB2	OTTD6HMV	Strong	Altered Expression	[1274]
HOXB6	OT3TFQ0U	Strong	Altered Expression	[1274]
HOXB9	OTMVHQOU	Strong	Altered Expression	[1275]
HRNR	OT560QR5	Strong	Biomarker	[1276]
HS3ST3B1	OTK53GUD	Strong	Biomarker	[1277]
HSPB2	OTS01646	Strong	Biomarker	[1278]
HTRA2	OTC7616F	Strong	Altered Expression	[445]
IARS1	OT9WXH5N	Strong	Altered Expression	[1279]
ICAM2	OT3E070F	Strong	Altered Expression	[1280]
IER3	OTZJI5FZ	Strong	Biomarker	[1281]
IFIT3	OTPGHZB9	Strong	Altered Expression	[1282]
IFNA17	OTHXRYG3	Strong	Biomarker	[1035]
IGSF1	OT3XD6U2	Strong	Biomarker	[602]
IL17RB	OT0KDNSF	Strong	Biomarker	[1283]
ING5	OTRNNSFM	Strong	Altered Expression	[1284]
INSIG2	OTX4VY51	Strong	Altered Expression	[1285]
IRF6	OTKJ44EV	Strong	Altered Expression	[695]
KCMF1	OTVTKFAU	Strong	Biomarker	[1286]
KDM2B	OTDMCVW7	Strong	Biomarker	[1287]
KDM6A	OTZM3MJJ	Strong	Biomarker	[1288]
KIF14	OTXHT4JM	Strong	Altered Expression	[1289]
KIF15	OTJRJEXL	Strong	Biomarker	[1290]
KIF20A	OTXOQHE0	Strong	Biomarker	[1291]
KIFAP3	OT450PAO	Strong	Biomarker	[717]
KLF11	OTKVQDJD	Strong	Biomarker	[1292]
KLF2	OTIP1UFX	Strong	Biomarker	[1293]
KLHL1	OTAX6SAD	Strong	Altered Expression	[1294]
KRT18	OTVLQFIP	Strong	Altered Expression	[475]
LAMTOR2	OTHEDISB	Strong	Genetic Variation	[1174]
LBR	OT1HG3HG	Strong	Altered Expression	[1295]
LFNG	OTPSUBN2	Strong	Biomarker	[1296]
LGALS3BP	OT9AGQKH	Strong	Biomarker	[1297]
LIG3	OT48SKET	Strong	Genetic Variation	[1298]
LIG4	OT40DNXU	Strong	Genetic Variation	[1298]
LITAF	OTT5JX1F	Strong	Biomarker	[1299]
LLGL1	OTAIQSXZ	Strong	Altered Expression	[1300]
LMLN	OTQF0JPY	Strong	Posttranslational Modification	[592]
LMNB1	OT100T3P	Strong	Biomarker	[1301]
LMO4	OT5NDCT9	Strong	Altered Expression	[1302]
LRG1	OTLD0KWA	Strong	Biomarker	[1303]
LXN	OTZQ2M6Y	Strong	Biomarker	[1304]
LYPD5	OTGP7UKA	Strong	Biomarker	[1305]
MACC1	OTV3DLX0	Strong	Biomarker	[621]
MAGED1	OT6EOLFC	Strong	Altered Expression	[1306]
MAGEH1	OTVE05K7	Strong	Altered Expression	[1307]
MAL2	OTVPEI80	Strong	Biomarker	[1308]
MAML3	OTZFV53Z	Strong	Biomarker	[648]
MARCHF8	OTH7PNN2	Strong	Genetic Variation	[1309]
MARVELD3	OTFTPOJ4	Strong	Altered Expression	[1310]
MATK	OTVOJJLJ	Strong	Altered Expression	[467]
MBD1	OTD19VO6	Strong	Biomarker	[1311]
MCC	OTQVI1EM	Strong	Biomarker	[1312]
MCIDAS	OTK1JVAH	Strong	Altered Expression	[732]
MCM8	OTC93H3S	Strong	Biomarker	[1313]
MCPH1	OTYT3TT5	Strong	Biomarker	[714]
MCTS1	OT7SAOJP	Strong	Altered Expression	[281]
MDH1	OTJEO4E8	Strong	Posttranslational Modification	[444]
ME2	OTO4LL76	Strong	Genetic Variation	[1314]
ME3	OT3XMLYG	Strong	Biomarker	[1315]
MED1	OTOO24C4	Strong	Genetic Variation	[1316]
MED19	OTT9RT5N	Strong	Biomarker	[1317]
MED29	OTFD4SGK	Strong	Biomarker	[1318]
MEF2D	OT7CEIG0	Strong	Biomarker	[1319]
MICAL3	OTD229X7	Strong	Genetic Variation	[609]
MICB	OTS2DVDW	Strong	Altered Expression	[1320]
MICU1	OTS7N0LE	Strong	Biomarker	[1321]
MLXIP	OT30UNI7	Strong	Genetic Variation	[1309]
MMRN1	OT7ZNYHT	Strong	Altered Expression	[1322]
MMRN2	OT4IRL0U	Strong	Biomarker	[454]
MMS19	OTAXB34N	Strong	Genetic Variation	[1323]
MPRIP	OT5FV5NS	Strong	Altered Expression	[1324]
MRE11	OTGU8TZM	Strong	Genetic Variation	[1325]
MRPS30	OTDXIAGG	Strong	Biomarker	[720]
MRTFA	OTCVXASM	Strong	Biomarker	[963]
MSX2	OT1WDKE1	Strong	Altered Expression	[1326]
MTPAP	OT6HQ02S	Strong	Biomarker	[720]
MUC13	OTWKS9MF	Strong	Biomarker	[1327]
MUC6	OTPVL723	Strong	Altered Expression	[1328]
MUL1	OT2JC9YR	Strong	Altered Expression	[758]
MVP	OTJGHJRB	Strong	Biomarker	[1329]
MYCBPAP	OT3W21WR	Strong	Genetic Variation	[1143]
MYLIP	OTL0PFGV	Strong	Genetic Variation	[1309]
NAA25	OTS3QVF1	Strong	Biomarker	[602]
NAE1	OTMC6F3Y	Strong	Altered Expression	[1330]
NAF1	OTMJKJAK	Strong	Genetic Variation	[1331]
ND2	OTG9OHOX	Strong	Genetic Variation	[1332]
NDRG1	OTVO66BO	Strong	Biomarker	[1333]
NECTIN3	OTS8N7MK	Strong	Altered Expression	[1334]
NEO1	OTGJ1997	Strong	Altered Expression	[1335]
NEUROD1	OTZQ7QJ2	Strong	Altered Expression	[1336]
NEUROG3	OT6DIPWC	Strong	Genetic Variation	[1337]
NFAT5	OTKIE59S	Strong	Altered Expression	[1338]
NFATC2	OTK5T6HZ	Strong	Altered Expression	[288]
NFE2	OTLM94BI	Strong	Altered Expression	[1339]
NKD1	OTY3MO97	Strong	Altered Expression	[1340]
NKRF	OTUVY0P6	Strong	Altered Expression	[1341]
NME5	OTE8OLFN	Strong	Biomarker	[1342]
NOB1	OTW0YNSL	Strong	Altered Expression	[1343]
NOP14	OTKPM0Z5	Strong	Biomarker	[1344]
NOSTRIN	OT0LDSGS	Strong	Biomarker	[1345]
NPC1	OTRIPICX	Strong	Altered Expression	[1346]
NR2C2	OTDZWVOJ	Strong	Altered Expression	[232]
NRTN	OT4PAKUY	Strong	Altered Expression	[1258]
NSUN5	OTBN7RS8	Strong	Biomarker	[602]
NT5C3A	OT67KZJA	Strong	Biomarker	[1347]
NT5DC3	OTRHBVM5	Strong	Biomarker	[1348]
NUP153	OTCAS0AR	Strong	Altered Expression	[1349]
OGDHL	OT1AZK6R	Strong	Altered Expression	[1350]
OGT	OT1Z1ZXE	Strong	Biomarker	[1351]
OIT3	OT20DO1Z	Strong	Biomarker	[1321]
ONECUT1	OTK1QUQT	Strong	Altered Expression	[1352]
OSBP	OT7R0OQQ	Strong	Altered Expression	[921]
OXA1L	OTS0BFRD	Strong	Biomarker	[1353]
PAIP2B	OT7MUY3B	Strong	Biomarker	[546]
PAK3	OT80M3BV	Strong	Biomarker	[1354]
PALD1	OTLGUM8H	Strong	Genetic Variation	[1355]
PALLD	OTZ2MUJZ	Strong	Genetic Variation	[1355]
PAPOLA	OTPHD65D	Strong	Biomarker	[720]
PARPBP	OTPZDGW7	Strong	Biomarker	[1356]
PCBD1	OTDSRUD5	Strong	Biomarker	[1214]
PCBP1	OTHN0TD7	Strong	Biomarker	[1357]
PDAP1	OTJSWMOD	Strong	Biomarker	[720]
PDLIM5	OTLQVV22	Strong	Altered Expression	[1302]
PEAK1	OTVVM637	Strong	Biomarker	[1358]
PEG3	OTHQW98S	Strong	Biomarker	[1359]
PER3	OTVKYVJA	Strong	Genetic Variation	[654]
PES1	OTMZK7XE	Strong	Biomarker	[1360]
PFDN5	OTTKPTUP	Strong	Biomarker	[1361]
PFKFB4	OTQYEXL2	Strong	Altered Expression	[1362]
PGK1	OT6V1ICH	Strong	Altered Expression	[1338]
PIAS4	OTB7SVMZ	Strong	Biomarker	[1363]
PIGR	OT6GLSUL	Strong	Altered Expression	[1364]
PIK3R3	OTXGJ8N1	Strong	Biomarker	[1365]
PIP5K1B	OT8JQ1F7	Strong	Altered Expression	[1366]
PLEK	OTB73XXA	Strong	Genetic Variation	[1367]
PLEKHF1	OT9OL16U	Strong	Biomarker	[1208]
PLXNA1	OTN0BING	Strong	Biomarker	[1168]
PMAIP1	OTXEE550	Strong	Biomarker	[1368]
PNPT1	OTBR2Q0F	Strong	Biomarker	[1369]
PODXL	OTPNQXF3	Strong	Biomarker	[483]
POLQ	OTBHK0E6	Strong	Genetic Variation	[636]
PPFIA4	OTWXG0DO	Strong	Biomarker	[1370]
PPM1H	OTKSVU7S	Strong	Biomarker	[1371]
PPP1R11	OTSHYPPW	Strong	Biomarker	[1372]
PPP1R13L	OTNCPLWE	Strong	Biomarker	[1373]
PPP1R14A	OTQODWZB	Strong	Biomarker	[1374]
PRAP1	OT48QD82	Strong	Biomarker	[1375]
PRDM1	OTQLSVBS	Strong	Biomarker	[1376]
PRELP	OT9EEBUJ	Strong	Biomarker	[1377]
PRIMA1	OT9ITT3P	Strong	Altered Expression	[1378]
PRKN	OTJBN41W	Strong	Altered Expression	[779]
PROX1	OT68R6IO	Strong	Biomarker	[1379]
PRR11	OT2JJ08Z	Strong	Biomarker	[1380]
PRRX1	OTTZK5G8	Strong	Biomarker	[316]
PSRC1	OT7MDJMN	Strong	Biomarker	[1381]
PTGR2	OTYPYOUM	Strong	Biomarker	[1382]
PTPRA	OTZA82J1	Strong	Biomarker	[1329]
PTPRG	OT9N2WOF	Strong	Altered Expression	[1383]
PTTG1	OTIMYS4W	Strong	Posttranslational Modification	[1384]
PVR	OT3N91T7	Strong	Altered Expression	[1385]
QSOX1	OT4ZPK4P	Strong	Altered Expression	[1386]
RAB11A	OTC4FW0J	Strong	Altered Expression	[1387]
RAB11FIP4	OTIGHER7	Strong	Altered Expression	[1388]
RAB23	OTBAKFBR	Strong	Biomarker	[1389]
RAB31	OTMLXQZ0	Strong	Biomarker	[1390]
RABGEF1	OTWC3Z3R	Strong	Altered Expression	[1391]
RABIF	OTEW72FR	Strong	Altered Expression	[1366]
RAD17	OT1I93DT	Strong	Biomarker	[1392]
RAD50	OTYMU9G1	Strong	Genetic Variation	[636]
RAD54L	OTEGMAKG	Strong	Genetic Variation	[1393]
RADIL	OTQTRGMB	Strong	Altered Expression	[1394]
RAG2	OTG9UYTW	Strong	Biomarker	[1395]
RALA	OT734R7X	Strong	Genetic Variation	[1396]
RAP1A	OT5RH6TI	Strong	Altered Expression	[1391]
RAP1B	OTHEIIMM	Strong	Altered Expression	[1391]
RASGRF1	OTNWJ7EN	Strong	Biomarker	[1397]
RASSF2	OT2JHDO4	Strong	Altered Expression	[1398]
RBP1	OTRP1MFC	Strong	Altered Expression	[1399]
RDX	OTNSYUN6	Strong	Biomarker	[1400]
REM1	OTUXL0HC	Strong	Biomarker	[1401]
RERE	OT3G4GBZ	Strong	Genetic Variation	[380]
RGL2	OTJCW5ZD	Strong	Altered Expression	[1397]
RGN	OTD04KB1	Strong	Altered Expression	[1402]
RHBDF1	OTCQ7UDS	Strong	Biomarker	[1403]
RHOC	OTOLE1FT	Strong	Altered Expression	[1404]
RHOF	OTPA3F8Q	Strong	Altered Expression	[1405]
RIOX2	OT2YFPI2	Strong	Biomarker	[1406]
RMC1	OT7K8MTJ	Strong	Biomarker	[1407]
RNASE1	OTKZ7CO9	Strong	Biomarker	[1408]
RNF2	OTFPLOIN	Strong	Altered Expression	[1409]
RPAIN	OTBMXAYK	Strong	Biomarker	[1127]
RPL26	OTFNRC27	Strong	Biomarker	[1410]
RPL29	OTUFIBJL	Strong	Biomarker	[1410]
RPL34	OT0U9VMQ	Strong	Biomarker	[1411]
RPL39	OTL8TZHQ	Strong	Biomarker	[1412]
RPP14	OT4OYFSK	Strong	Genetic Variation	[1174]
RPS8	OTEBS4HZ	Strong	Biomarker	[1377]
RSPO2	OT3HHXU0	Strong	Biomarker	[1413]
RUVBL1	OTWV19L7	Strong	Biomarker	[1414]
S100A1	OT1F2G4J	Strong	Genetic Variation	[1415]
S100PBP	OT6O7Y14	Strong	Genetic Variation	[1416]
SATB2	OT2W80XC	Strong	Altered Expression	[1417]
SBF2	OTBB8NO8	Strong	Genetic Variation	[546]
SCAF11	OTX59D0X	Strong	Altered Expression	[1257]
SCNN1G	OTSJYQVQ	Strong	Genetic Variation	[1353]
SCPEP1	OT43LYEZ	Strong	Biomarker	[473]
SDC3	OT1P0LJM	Strong	Altered Expression	[644]
SEMA3C	OTEGUY7F	Strong	Biomarker	[1418]
SEMA5A	OTUOIOJV	Strong	Genetic Variation	[212]
SEPTIN9	OT1VMRFQ	Strong	Altered Expression	[1419]
SERPINA3	OT9BP2S0	Strong	Biomarker	[699]
SESN2	OT889IXY	Strong	Genetic Variation	[1420]
SF3B6	OTPRKS6S	Strong	Genetic Variation	[1174]
SH3BP4	OTVIRKW7	Strong	Biomarker	[1421]
SIN3B	OTFB59FK	Strong	Biomarker	[1422]
SINHCAF	OTHMZZ0A	Strong	Altered Expression	[1423]
SKI	OT4KJ8F6	Strong	Biomarker	[1424]
SKIL	OTNBXH32	Strong	Biomarker	[1425]
SLURP1	OT89YD2E	Strong	Biomarker	[468]
SMAD2	OTC6VB4K	Strong	Biomarker	[1426]
SMARCC1	OTUOMBE7	Strong	Biomarker	[1427]
SMUG1	OT2YIOCQ	Strong	Biomarker	[1428]
SMURF2	OT3TRVL7	Strong	Altered Expression	[1429]
SOCS6	OT2O5ZBK	Strong	Biomarker	[1430]
SOD3	OTIOZQAB	Strong	Genetic Variation	[1431]
SORBS2	OTJSX44Y	Strong	Biomarker	[1432]
SOX15	OTTB37I1	Strong	Biomarker	[1433]
SPARCL1	OT74DWMV	Strong	Biomarker	[1434]
SPINK7	OTK3VOI3	Strong	Genetic Variation	[1164]
SPP2	OTX254AR	Strong	Altered Expression	[1435]
SRL	OT7IEBWZ	Strong	Altered Expression	[1436]
SSR2	OTQJSL7M	Strong	Biomarker	[1437]
ST3GAL4	OTNENJZQ	Strong	Biomarker	[1438]
ST6GAL1	OT7US3NO	Strong	Biomarker	[1439]
STK24	OTGUHOIL	Strong	Biomarker	[1440]
STUB1	OTSUYI9A	Strong	Posttranslational Modification	[1441]
SUB1	OTK71JYU	Strong	Biomarker	[1442]
SUGCT	OTA8L0TN	Strong	Genetic Variation	[609]
SYCE1L	OTXU44F3	Strong	Altered Expression	[1294]
SYCP1	OTWFV4KA	Strong	Biomarker	[473]
SYT9	OT7S8WU0	Strong	Genetic Variation	[800]
TAFA5	OT2SWBT6	Strong	Genetic Variation	[431]
TAT	OT2CJ91O	Strong	Biomarker	[1443]
TBC1D9	OTSSCTB5	Strong	Biomarker	[1444]
TBX2	OTTOT7A9	Strong	Altered Expression	[1445]
TBX3	OTM64N7K	Strong	Biomarker	[1446]
TCEA1	OTBFO594	Strong	Biomarker	[1447]
TCEA2	OT1OS9TY	Strong	Biomarker	[1447]
TCEA3	OTLTRSK4	Strong	Biomarker	[1447]
TCTN1	OTG5KEV8	Strong	Biomarker	[1448]
TEAD1	OTK6971C	Strong	Biomarker	[427]
TERF2IP	OT3M5P3G	Strong	Altered Expression	[1391]
TEX11	OTJDBGSS	Strong	Biomarker	[768]
TFCP2	OTA246TE	Strong	Altered Expression	[1449]
TFPI2	OTZCRWOR	Strong	Biomarker	[427]
TGFBI	OTR443C5	Strong	Biomarker	[1450]
THY1	OTVONVTB	Strong	Altered Expression	[1451]
TIMP1	OTOXC51H	Strong	Biomarker	[1452]
TM4SF18	OTDES2NC	Strong	Biomarker	[1453]
TM4SF5	OTPAV531	Strong	Biomarker	[1454]
TMEM204	OT7X11D9	Strong	Genetic Variation	[716]
TMEM45B	OTVQCO8N	Strong	Biomarker	[1455]
TMPRSS13	OTMAOAP3	Strong	Posttranslational Modification	[592]
TMPRSS3	OT0GTO1Z	Strong	Altered Expression	[1456]
TMPRSS9	OT7ETD15	Strong	Biomarker	[1457]
TNFAIP1	OT37EWR0	Strong	Biomarker	[1458]
TNFRSF10D	OTOSRDJT	Strong	Altered Expression	[1459]
TNS3	OTPG2D8Z	Strong	Genetic Variation	[609]
TOPBP1	OT6UPZPD	Strong	Genetic Variation	[1460]
TP63	OT0WOOKQ	Strong	Genetic Variation	[609]
TPD52L2	OTTOG0NK	Strong	Altered Expression	[1461]
TRAF2	OT1MEZZN	Strong	Altered Expression	[1462]
TRIB1	OTPEO17G	Strong	Genetic Variation	[1463]
TSPAN1	OTZQPIYK	Strong	Altered Expression	[1464]
TTF2	OT5LJOWM	Strong	Biomarker	[1465]
ACTN4	OTCNZAJ5	Definitive	Altered Expression	[823]
ALPP	OTZU4G9W	Definitive	Biomarker	[541]
BHLHE41	OTY9GJ1Y	Definitive	Biomarker	[1466]
CACYBP	OTJMZD2T	Definitive	Biomarker	[895]
CDX2	OTCG4TSY	Definitive	Altered Expression	[1467]
CFL1	OTT6D5MH	Definitive	Altered Expression	[803]
CIB1	OT4BVCRU	Definitive	Biomarker	[1468]
CUX1	OTU1LCNJ	Definitive	Altered Expression	[1469]
DNM1L	OTXK1Q1G	Definitive	Genetic Variation	[1470]
EHF	OTY6TPWD	Definitive	Biomarker	[1471]
ESRP1	OTNCS4SL	Definitive	Biomarker	[1472]
FASTKD2	OTD635WX	Definitive	Biomarker	[1473]
IL17B	OTS86H50	Definitive	Biomarker	[774]
LGALS4	OTKQCG0H	Definitive	Biomarker	[1474]
LGALS9	OT7MF91K	Definitive	Altered Expression	[565]
LIMS1	OT729S0T	Definitive	Biomarker	[1475]
MAGT1	OTQSAV5C	Definitive	Biomarker	[541]
MOK	OTQK7M9V	Definitive	Biomarker	[322]
MRPL28	OT4LUTZU	Definitive	Biomarker	[1442]
NDRG2	OT5L6KD7	Definitive	Altered Expression	[1054]
NT5C1A	OTS7UF36	Definitive	Altered Expression	[1476]
NUPR1	OT4FU8C0	Definitive	Biomarker	[1477]
NXT1	OT0VO6AY	Definitive	Biomarker	[1442]
PACC1	OTKBS8CC	Definitive	Genetic Variation	[1478]
PDPN	OTBUV19I	Definitive	Biomarker	[1479]
PFN1	OTHTGA1H	Definitive	Biomarker	[1480]
PLAC8	OT3SYRUJ	Definitive	Biomarker	[1481]
PLEC	OTU4XDEG	Definitive	Biomarker	[1482]
PTPA	OTRGFOI7	Definitive	Biomarker	[1483]
RAP1GAP	OTC31ONQ	Definitive	Biomarker	[1484]
RREB1	OT62460U	Definitive	Altered Expression	[130]
SEL1L	OTC0FB7T	Definitive	Biomarker	[1485]
SMARCA1	OT0Y6PTU	Definitive	Genetic Variation	[438]
SNAI1	OTDPYAMC	Definitive	Altered Expression	[1021]
SRPX2	OT6A63TX	Definitive	Biomarker	[1390]
THBS2	OTXET551	Definitive	Biomarker	[1486]
TIMM8A	OTDX9687	Definitive	Biomarker	[824]
TIMP2	OT8S1RRP	Definitive	Biomarker	[1487]
TM4SF1	OTY0ECQN	Definitive	Biomarker	[1488]
TMIGD2	OTWWAHTV	Definitive	Altered Expression	[1489]
TP53INP1	OT2363Z9	Definitive	Biomarker	[1490]
TP73	OT0LUO47	Definitive	Altered Expression	[816]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
• [4] ClinicalTrials.gov (NCT01970371) A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE). U.S. National Institutes of Health.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
• [6] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [7] Sunitinib FDA Label
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7316).
• [9] ClinicalTrials.gov (NCT02110147) Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT01741194) AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT01836432) Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT02923921) Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia). U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT00337389) Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.. U.S. National Institutes of Health.
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004347)
• [15] ClinicalTrials.gov (NCT03504423) Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas. U.S. National Institutes of Health.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] ClinicalTrials.gov (NCT01523808) Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer. U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT01579188) Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer. U.S. National Institutes of Health.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5220).
• [20] ClinicalTrials.gov (NCT01494506) Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
• [21] Clinical pipeline report, company report or official report of Fibrogen.
• [22] ClinicalTrials.gov (NCT01072981) Immunotherapy Study for Surgically Resected Pancreatic Cancer. U.S. National Institutes of Health.
• [23] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [24] Clinical pipeline report, company report or official report of Advantagene.
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018609)
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8087).
• [27] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [28] ClinicalTrials.gov (NCT03816163) A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
• [29] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020300)
• [30] ClinicalTrials.gov (NCT03512756) A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
• [31] ClinicalTrials.gov (NCT01608711) A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002. U.S. National Institutes of Health.
• [32] ClinicalTrials.gov (NCT01413087) Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
• [33] ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
• [34] ClinicalTrials.gov (NCT03801915) Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers. U.S. National Institutes of Health.
• [35] ClinicalTrials.gov (NCT02650804) A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients. U.S.National Institutes of Health.
• [36] ClinicalTrials.gov (NCT00203892) Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
• [37] ClinicalTrials.gov (NCT02640209) Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
• [38] ClinicalTrials.gov (NCT01233375) Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
• [39] Clinical pipeline report, company report or official report of Cornerstone pharmaceuticals.
• [40] ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
• [41] Clinical pipeline report, company report or official report of Cytocom
• [42] ClinicalTrials.gov (NCT04698915) Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer. U.S. National Institutes of Health.
• [43] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [44] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004141)
• [45] ClinicalTrials.gov (NCT01186731) Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
• [46] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7960).
• [47] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022260)
• [48] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031248)
• [49] ClinicalTrials.gov (NCT01020006) Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine. U.S. National Institutes of Health.
• [50] ClinicalTrials.gov (NCT01839487) PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer. U.S. National Institutes of Health.
• [51] A Randomized Phase II Study of PX-12, an Inhibitor of Thioredoxin in Patients With Advanced Cancer of the Pancreas Following Progression After a Gemcitabine-Containing Combination. Cancer Chemother Pharmacol. 2011 Mar;67(3):503-9.
• [52] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026972)
• [53] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8453).
• [54] ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
• [55] ClinicalTrials.gov (NCT01659502) Investigator's Initiated Phase II Study for Pancreatic Cancer Patients. U.S. National Institutes of Health.
• [56] ClinicalTrials.gov (NCT02912949) A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy). U.S.National Institutes of Health.
• [57] ClinicalTrials.gov (NCT04431258) A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic. U.S.National Institutes of Health.
• [58] ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
• [59] ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
• [60] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [61] ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
• [62] ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
• [63] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010209)
• [64] ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
• [65] ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
• [66] ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
• [67] Clinical pipeline report, company report or official report of Northwest BioTherapeutics.
• [68] ClinicalTrials.gov (NCT02705196) Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer. U.S.National Institutes of Health.
• [69] VC-01's Path to the Clinic. Viacyte. 2015.
• [70] ClinicalTrials.gov (NCT02204085) A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
• [71] ClinicalTrials.gov (NCT04060342) GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
• [72] ClinicalTrials.gov (NCT03854110) Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine. U.S. National Institutes of Health.
• [73] ClinicalTrials.gov (NCT03681951) First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors. U.S. National Institutes of Health.
• [74] Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase ... Br J Cancer. 2007 Sep 3;97(5):598-604.
• [75] ClinicalTrials.gov (NCT02346370) A Phase 1b/2, Study of Pegylated Recombinant Human Hyaluronidase Combined With Docetaxel Versus Docetaxel Alone in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC.. U.S. National Institutes of Health.
• [76] ClinicalTrials.gov (NCT04104672) A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies. U.S. National Institutes of Health.
• [77] ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
• [78] ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
• [79] ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
• [80] ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
• [81] ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
• [82] Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004 Dec;15(12):1825-33.
• [83] Clinical pipeline report, company report or official report of Quest PharmaTech.
• [84] 2011 Pipeline of Seattle Genetics.
• [85] ClinicalTrials.gov (NCT01897415) Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer
• [86] ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
• [87] ClinicalTrials.gov (NCT02159716) CART-meso in Mesothelin Expressing Cancers
• [88] ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
• [89] ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer
• [90] ClinicalTrials.gov (NCT03517176) CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
• [91] Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. Int J Oncol. 2014 Mar;44(3):662-8.
• [92] ClinicalTrials.gov (NCT03323944) CAR T Cell Immunotherapy for Pancreatic Cancer
• [93] ClinicalTrials.gov (NCT04327986) Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer. U.S. National Institutes of Health.
• [94] ClinicalTrials.gov (NCT02706782) A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
• [95] ClinicalTrials.gov (NCT01761240) Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC. U.S. National Institutes of Health.
• [96] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [97] ClinicalTrials.gov (NCT03819387) A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer. U.S. National Institutes of Health.
• [98] Clinical pipeline report, company report or official report of Otsuka Pharmaceutical Co Ltd.
• [99] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038879)
• [100] Clinical pipeline report, company report or official report of Statera Biopharma
• [101] ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
• [102] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [103] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010227)
• [104] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6468).
• [105] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026002)
• [106] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 890).
• [107] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2948).
• [108] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000894)
• [109] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010558)
• [110] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035599)
• [111] 2011 Pipeline of Anavex.
• [112] Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
• [113] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017007)
• [114] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [115] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
• [116] Clinical pipeline report, company report or official report of GlobeImmune.
• [117] The ABCC4 gene is a promising target for pancreatic cancer therapy.Gene. 2012 Jan 10;491(2):194-9. doi: 10.1016/j.gene.2011.09.029. Epub 2011 Oct 2.
• [118] Cross-talk among AFAP1-AS1, ACVR1 and microRNA-384 regulates the stemness of pancreatic cancer cells and tumorigenicity in nude mice.J Exp Clin Cancer Res. 2019 Feb 28;38(1):107. doi: 10.1186/s13046-019-1051-0.
• [119] Propofol inhibits pancreatic cancer progress under hypoxia via ADAM8.J Hepatobiliary Pancreat Sci. 2019 Jun;26(6):219-226. doi: 10.1002/jhbp.624. Epub 2019 May 11.
• [120] Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood.Clin Epigenetics. 2019 Apr 5;11(1):59. doi: 10.1186/s13148-019-0650-0.
• [121] Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma.Pancreatology. 2009;9(1-2):89-98. doi: 10.1159/000178879. Epub 2008 Dec 12.
• [122] Regulatory Role of G Protein-coupled Receptors in Pancreatic Cancer Development and Progression.Curr Med Chem. 2018;25(22):2566-2575. doi: 10.2174/0929867324666170303121708.
• [123] Long non-coding RNA LINC01207 silencing suppresses AGR2 expression to facilitate autophagy and apoptosis of pancreatic cancer cells by sponging miR-143-5p.Mol Cell Endocrinol. 2019 Aug 1;493:110424. doi: 10.1016/j.mce.2019.04.004. Epub 2019 Apr 13.
• [124] MicroRNA-410 functions as a tumor suppressor by targeting angiotensin II type 1 receptor in pancreatic cancer.IUBMB Life. 2015 Jan;67(1):42-53. doi: 10.1002/iub.1342. Epub 2015 Feb 3.
• [125] 2-AR regulates the expression of AKR1B1 in human pancreatic cancer cells and promotes their proliferation via the ERK1/2 pathway.Mol Biol Rep. 2018 Dec;45(6):1863-1871. doi: 10.1007/s11033-018-4332-3. Epub 2018 Oct 10.
• [126] Role of miR-489 in the proliferation and apoptosis of pancreatic carcinoma.J BUON. 2019 Jul-Aug;24(4):1574-1580.
• [127] Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
• [128] Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer.Cancer Cell. 2018 Apr 9;33(4):752-769.e8. doi: 10.1016/j.ccell.2018.02.012. Epub 2018 Mar 29.
• [129] Angiogenesis in adenosquamous cancer of pancreas.Oncotarget. 2017 Sep 27;8(56):95773-95779. doi: 10.18632/oncotarget.21319. eCollection 2017 Nov 10.
• [130] RREB1-induced upregulation of the lncRNA AGAP2-AS1 regulates the proliferation and migration of pancreatic cancer partly through suppressing ANKRD1 and ANGPTL4.Cell Death Dis. 2019 Feb 27;10(3):207. doi: 10.1038/s41419-019-1384-9.
• [131] Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer.Invest New Drugs. 2020 Apr;38(2):350-359. doi: 10.1007/s10637-019-00785-5. Epub 2019 May 23.
• [132] Annexin A8 Is a Prognostic Marker and Potential Therapeutic Target for Pancreatic Cancer. Pancreas. 2015 Jan;44(1):122-7.
• [133] CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.Int J Cancer. 2019 Apr 15;144(8):1877-1887. doi: 10.1002/ijc.31900. Epub 2018 Dec 4.
• [134] Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling.Biochem Biophys Res Commun. 2017 May 13;486(4):1097-1102. doi: 10.1016/j.bbrc.2017.03.168. Epub 2017 Apr 1.
• [135] Critical role for arginase 2 in obesity-associated pancreatic cancer.Nat Commun. 2017 Aug 14;8(1):242. doi: 10.1038/s41467-017-00331-y.
• [136] Recent advances in research on aspartate -hydroxylase (ASPH) in pancreatic cancer: A brief update.Bosn J Basic Med Sci. 2018 Nov 5;18(4):297-304. doi: 10.17305/bjbms.2018.3539.
• [137] Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines.Pancreas. 2017 Apr;46(4):575-581. doi: 10.1097/MPA.0000000000000780.
• [138] 3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer.Oncol Lett. 2018 Jun;15(6):8878-8884. doi: 10.3892/ol.2018.8367. Epub 2018 Mar 28.
• [139] BTK signaling drives CD1d(hi)CD5(+) regulatory B-cell differentiation to promote pancreatic carcinogenesis.Oncogene. 2019 Apr;38(17):3316-3324. doi: 10.1038/s41388-018-0668-3. Epub 2019 Jan 11.
• [140] Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.Gastroenterology. 2019 Sep;157(3):823-837. doi: 10.1053/j.gastro.2019.05.004. Epub 2019 May 9.
• [141] Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer.Tumour Biol. 2015 Jul;36(7):5617-26. doi: 10.1007/s13277-015-3233-5. Epub 2015 Mar 1.
• [142] Heterogeneous expression of cholecystokinin and gastrin receptor in stomach and pancreatic cancer: An immunohistochemical study.J Cancer Res Ther. 2016 Jan-Mar;12(1):411-6. doi: 10.4103/0973-1482.168970.
• [143] Gene Expression Profiles in Chemokine (C-C Motif) Ligand 21-Overexpressing Pancreatic Cancer Cells.Pathol Oncol Res. 2020 Jan;26(1):201-208. doi: 10.1007/s12253-018-0390-z. Epub 2018 Apr 23.
• [144] A centralized communication network: Recent insights into the role of the cancer associated fibroblast in the development of drug resistance in tumors.Semin Cell Dev Biol. 2020 May;101:111-114. doi: 10.1016/j.semcdb.2019.10.016. Epub 2019 Nov 7.
• [145] CCL20/CCR6 expression profile in pancreatic cancer.J Transl Med. 2010 May 10;8:45. doi: 10.1186/1479-5876-8-45.
• [146] CCL21/CCR7 Axis Contributed to CD133+ Pancreatic Cancer Stem-Like Cell Metastasis via EMT and Erk/NF-B Pathway.PLoS One. 2016 Aug 9;11(8):e0158529. doi: 10.1371/journal.pone.0158529. eCollection 2016.
• [147] Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.Dis Markers. 2017;2017:3276806. doi: 10.1155/2017/3276806. Epub 2017 Jun 4.
• [148] B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma.Int J Biochem Cell Biol. 2019 Mar;108:84-91. doi: 10.1016/j.biocel.2019.01.011. Epub 2019 Jan 18.
• [149] Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.J Hematol Oncol. 2019 Nov 27;12(1):124. doi: 10.1186/s13045-019-0822-6.
• [150] MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.Cancer Chemother Pharmacol. 2017 Oct;80(4):765-775. doi: 10.1007/s00280-017-3418-2. Epub 2017 Sep 8.
• [151] Inhibition of Cell Survival by Curcumin Is Associated with Downregulation of Cell Division Cycle 20 (Cdc20) in Pancreatic Cancer Cells.Nutrients. 2017 Feb 4;9(2):109. doi: 10.3390/nu9020109.
• [152] Modulation of VDR and Cell Cycle-Related Proteins by Vitamin D in Normal Pancreatic Cells and Poorly Differentiated Metastatic Pancreatic Cancer Cells.Nutr Cancer. 2019;71(5):818-824. doi: 10.1080/01635581.2018.1521445. Epub 2018 Oct 25.
• [153] Pancreatic cancer-associated inflammation drives dynamic regulation of p35 and Ebi3.Cytokine. 2020 Jan;125:154817. doi: 10.1016/j.cyto.2019.154817. Epub 2019 Aug 28.
• [154] CDK8 regulates the angiogenesis of pancreatic cancer cells in part via the CDK8--catenin-KLF2 signal axis.Exp Cell Res. 2018 Aug 15;369(2):304-315. doi: 10.1016/j.yexcr.2018.05.033. Epub 2018 May 29.
• [155] Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.Sci Signal. 2019 Jul 16;12(590):eaav7259. doi: 10.1126/scisignal.aav7259.
• [156] Network-based integration of mRNA and miRNA profiles reveals new target genes involved in pancreatic cancer.Mol Carcinog. 2019 Feb;58(2):206-218. doi: 10.1002/mc.22920. Epub 2018 Oct 29.
• [157] CEACAM6 induces epithelial-mesenchymal transition and mediates invasion and metastasis in pancreatic cancer.Int J Oncol. 2013 Sep;43(3):877-85. doi: 10.3892/ijo.2013.2015. Epub 2013 Jul 12.
• [158] Accuracy of EUS and CEH EUS for the diagnosis of pancreatic tumours.Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1411-1417. doi: 10.1080/00365521.2018.1524023. Epub 2018 Nov 5.
• [159] Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study.Cancer Biomark. 2019;24(3):335-342. doi: 10.3233/CBM-181847.
• [160] Overexpression of carbohydrate sulfotransferase 15 in pancreatic cancer stroma is associated with worse prognosis.Oncol Lett. 2019 Oct;18(4):4100-4105. doi: 10.3892/ol.2019.10764. Epub 2019 Aug 16.
• [161] Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma.BMC Cancer. 2018 Nov 12;18(1):1096. doi: 10.1186/s12885-018-5013-2.
• [162] New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8.Am J Surg Pathol. 2008 Feb;32(2):188-96. doi: 10.1097/PAS.0b013e31815701f3.
• [163] Intracellular Ion Channels in Pancreas Cancer.Cell Physiol Biochem. 2019;53(S1):44-51. doi: 10.33594/000000193.
• [164] A feature-based analysis identifies COL1A2 as a regulator in pancreatic cancer.J Enzyme Inhib Med Chem. 2019 Dec;34(1):420-428. doi: 10.1080/14756366.2018.1484734.
• [165] Research on circadian clock genes in common abdominal malignant tumors.Chronobiol Int. 2019 Jul;36(7):906-918. doi: 10.1080/07420528.2018.1477792. Epub 2019 Apr 24.
• [166] Targeting NAD(P)H:Quinone Oxidoreductase (NQO1) in Pancreatic Cancer.Mol Carcinog. 2017 Jul;56(7):1825-1834. doi: 10.1002/mc.20199. Epub 2006 Mar 27.
• [167] Vitamin D metabolic pathway genes and pancreatic cancer risk.PLoS One. 2015 Mar 23;10(3):e0117574. doi: 10.1371/journal.pone.0117574. eCollection 2015.
• [168] dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.Cell Prolif. 2018 Aug;51(4):e12456. doi: 10.1111/cpr.12456. Epub 2018 Apr 27.
• [169] Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.Cancer Res Treat. 2020 Jan;52(1):149-166. doi: 10.4143/crt.2019.183. Epub 2019 Jun 25.
• [170] Differentiation of pancreatic carcinoma and mass-forming focal pancreatitis: qualitative and quantitative assessment by dynamic contrast-enhanced MRI combined with diffusion-weighted imaging.Oncotarget. 2017 Jan 3;8(1):1744-1759. doi: 10.18632/oncotarget.12120.
• [171] Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer.Oncol Rep. 2019 Jan;41(1):67-76. doi: 10.3892/or.2018.6817. Epub 2018 Oct 24.
• [172] Long non-coding RNA LINC01133 silencing exerts antioncogenic effect in pancreatic cancer through the methylation of DKK1 promoter and the activation of Wnt signaling pathway.Cancer Biol Ther. 2019;20(3):368-380. doi: 10.1080/15384047.2018.1529110. Epub 2018 Dec 22.
• [173] Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924.Cell Death Dis. 2019 Nov 25;10(12):883. doi: 10.1038/s41419-019-2123-y.
• [174] Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.Cancer Res. 2009 Apr 15;69(8):3317-24. doi: 10.1158/0008-5472.CAN-08-2903. Epub 2009 Apr 7.
• [175] MiR-210 knockdown promotes the development of pancreatic cancer via upregulating E2F3 expression.Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8640-8648. doi: 10.26355/eurrev_201812_16628.
• [176] Elongation factor-2 kinase regulates TG2/1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.J Cell Mol Med. 2014 Nov;18(11):2235-51. doi: 10.1111/jcmm.12361. Epub 2014 Sep 12.
• [177] HIF-3 Promotes Metastatic Phenotypes in Pancreatic Cancer by Transcriptional Regulation of the RhoC-ROCK1 Signaling Pathway.Mol Cancer Res. 2018 Jan;16(1):124-134. doi: 10.1158/1541-7786.MCR-17-0256. Epub 2017 Sep 19.
• [178] Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer.J Pharm Pharmacol. 2019 Feb;71(2):196-205. doi: 10.1111/jphp.12941. Epub 2019 Jan 2.
• [179] EphB4 regulates the growth and migration of pancreatic cancer cells.Tumour Biol. 2014 Jul;35(7):6855-9. doi: 10.1007/s13277-014-1937-6. Epub 2014 Apr 15.
• [180] COUP-TFII in pancreatic adenocarcinoma: clinical implication for patient survival and tumor progression.Int J Cancer. 2014 Apr 1;134(7):1648-58. doi: 10.1002/ijc.28502. Epub 2013 Oct 15.
• [181] Ezrin promotes pancreatic cancer cell proliferation and invasion through activating the Akt/mTOR pathway and inducing YAP translocation.Cancer Manag Res. 2019 Jul 12;11:6553-6566. doi: 10.2147/CMAR.S202342. eCollection 2019.
• [182] Fibroblast activation protein -positive pancreatic stellate cells promote the migration and invasion of pancreatic cancer by CXCL1-mediated Akt phosphorylation.Ann Transl Med. 2019 Oct;7(20):532. doi: 10.21037/atm.2019.09.164.
• [183] Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells.J Med Chem. 2019 Dec 12;62(23):10867-10896. doi: 10.1021/acs.jmedchem.9b01405. Epub 2019 Dec 2.
• [184] Fibroblast Growth Factor 10 in Pancreas Development and Pancreatic Cancer.Front Genet. 2018 Oct 29;9:482. doi: 10.3389/fgene.2018.00482. eCollection 2018.
• [185] Outlier kinase expression by RNA sequencing as targets for precision therapy.Cancer Discov. 2013 Mar;3(3):280-93. doi: 10.1158/2159-8290.CD-12-0336. Epub 2013 Feb 5.
• [186] USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling.EMBO J. 2017 May 15;36(10):1434-1446. doi: 10.15252/embj.201695669. Epub 2017 Mar 31.
• [187] Proteomic Identification of FLT3 and PCBP3 as Potential Prognostic Biomarkers for Pancreatic Cancer.Anticancer Res. 2018 Oct;38(10):5759-5765. doi: 10.21873/anticanres.12914.
• [188] Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.Cancer Sci. 2019 Apr;110(4):1408-1419. doi: 10.1111/cas.13929. Epub 2019 Mar 6.
• [189] FOXC1 plays a crucial role in the growth of pancreatic cancer.Oncogenesis. 2018 Jul 6;7(7):52. doi: 10.1038/s41389-018-0061-7.
• [190] GATA4 inhibits cell differentiation and proliferation in pancreatic cancer.PLoS One. 2018 Aug 24;13(8):e0202449. doi: 10.1371/journal.pone.0202449. eCollection 2018.
• [191] Integrated whole genome microarray analysis and immunohistochemical assay identifies COL11A1, GJB2 and CTRL as predictive biomarkers for pancreatic cancer.Cancer Cell Int. 2018 Nov 6;18:174. doi: 10.1186/s12935-018-0669-x. eCollection 2018.
• [192] Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.Diabetes Obes Metab. 2020 Apr;22(4):699-704. doi: 10.1111/dom.13924. Epub 2019 Dec 11.
• [193] A covalent small molecule inhibitor of glutamate-oxaloacetate transaminase 1 impairs pancreatic cancer growth.Biochem Biophys Res Commun. 2020 Feb 12;522(3):633-638. doi: 10.1016/j.bbrc.2019.11.130. Epub 2019 Nov 28.
• [194] Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells.Mol Cancer Res. 2017 Jul;15(7):929-941. doi: 10.1158/1541-7786.MCR-17-0023. Epub 2017 Mar 30.
• [195] Overexpression of grainyhead-like transcription factor 2 is associated with poor prognosis in human pancreatic carcinoma.Oncol Lett. 2019 Feb;17(2):1491-1496. doi: 10.3892/ol.2018.9741. Epub 2018 Nov 21.
• [196] Expression levels of long non-coding RNA HOXA distal transcript antisense RNA and metabotropic glutamate receptor 1 in pancreatic carcinoma, and their prognostic values.Oncol Lett. 2018 Jun;15(6):9464-9470. doi: 10.3892/ol.2018.8519. Epub 2018 Apr 17.
• [197] ARHGEF4 predicts poor prognosis and promotes cell invasion by influencing ERK1/2 and GSK-3/ signaling in pancreatic cancer.Int J Oncol. 2018 Nov;53(5):2224-2240. doi: 10.3892/ijo.2018.4549. Epub 2018 Aug 31.
• [198] Impact of high-mobility-group A2 overexpression on epithelial-mesenchymal transition in pancreatic cancer.Cancer Manag Res. 2019 May 3;11:4075-4084. doi: 10.2147/CMAR.S199289. eCollection 2019.
• [199] Expression of HMGB2 indicates worse survival of patients and is required for the maintenance of Warburg effect in pancreatic cancer.Acta Biochim Biophys Sin (Shanghai). 2017 Feb 6;49(2):119-127. doi: 10.1093/abbs/gmw124.
• [200] HNF1A/CASC2 regulates pancreatic cancer cell proliferation through PTEN/Akt signaling.J Cell Biochem. 2019 Mar;120(3):2816-2827. doi: 10.1002/jcb.26395. Epub 2018 Nov 30.
• [201] Prognostic role of HSF1 overexpression in solid tumors: a pooled analysis of 3,159 patients.Onco Targets Ther. 2018 Jan 17;11:383-393. doi: 10.2147/OTT.S153682. eCollection 2018.
• [202] Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.Int J Cancer. 2019 Sep 15;145(6):1529-1537. doi: 10.1002/ijc.32227. Epub 2019 Mar 19.
• [203] Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in KRAS and BRAF Tumor Cells.Mol Cell Biol. 2017 Aug 28;37(18):e00061-17. doi: 10.1128/MCB.00061-17. Print 2017 Sep 15.
• [204] Indoleamine 2,3-dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma.Cancer Sci. 2019 Oct;110(10):3061-3067. doi: 10.1111/cas.14179. Epub 2019 Sep 25.
• [205] Interleukin-13 receptor 2 is a novel marker and potential therapeutic target for human melanoma.Sci Rep. 2019 Feb 4;9(1):1281. doi: 10.1038/s41598-019-39018-3.
• [206] Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages.Cytokine. 2017 Jan;89:194-200. doi: 10.1016/j.cyto.2015.12.003. Epub 2016 Feb 8.
• [207] Prediction of improved survival in patients with pancreatic cancer via IL-21 enhanced detection of mesothelin epitope-reactive T-cell responses.Oncotarget. 2018 Apr 27;9(32):22451-22459. doi: 10.18632/oncotarget.25121. eCollection 2018 Apr 27.
• [208] Correlation of miR-425-5p and IL-23 with pancreatic cancer.Oncol Lett. 2019 May;17(5):4595-4599. doi: 10.3892/ol.2019.10099. Epub 2019 Mar 4.
• [209] Targeted blockade of interleukin 9 inhibits tumor growth in murine model of pancreatic cancer.Adv Clin Exp Med. 2019 Oct;28(10):1285-1292. doi: 10.17219/acem/104543.
• [210] Coexpression of UCA1 and ITGA2 in pancreatic cancer cells target the expression of miR-107 through focal adhesion pathway.J Cell Physiol. 2019 Aug;234(8):12884-12896. doi: 10.1002/jcp.27953. Epub 2018 Dec 19.
• [211] Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.Sci Transl Med. 2019 Jul 3;11(499):eaau9240. doi: 10.1126/scitranslmed.aau9240.
• [212] Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis.Oncotarget. 2017 Dec 23;9(5):5931-5943. doi: 10.18632/oncotarget.23644. eCollection 2018 Jan 19.
• [213] Integrin 6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).Tumour Biol. 2016 Apr;37(4):5117-31. doi: 10.1007/s13277-015-4353-7. Epub 2015 Nov 7.
• [214] 5-FU resistant EMT-like pancreatic cancer cells are hypersensitive to photochemical internalization of the novel endoglin-targeting immunotoxin CD105-saporin.J Exp Clin Cancer Res. 2017 Dec 19;36(1):187. doi: 10.1186/s13046-017-0662-6.
• [215] Knockdown of KDM1B inhibits cell proliferation and induces apoptosis of pancreatic cancer cells.Pathol Res Pract. 2019 May;215(5):1054-1060. doi: 10.1016/j.prp.2019.02.014. Epub 2019 Feb 27.
• [216] A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism.Oncogene. 2020 Jan;39(5):1140-1151. doi: 10.1038/s41388-019-1051-8. Epub 2019 Oct 22.
• [217] KiSS?mediated suppression of the invasive ability of human pancreatic carcinoma cells is not dependent on the level of KiSS? receptor GPR54.Mol Med Rep. 2016 Jan;13(1):123-9. doi: 10.3892/mmr.2015.4535. Epub 2015 Nov 9.
• [218] -Bisabolol Inhibits Invasiveness and Motility in Pancreatic Cancer Through KISS1R Activation.Anticancer Res. 2016 Feb;36(2):583-9.
• [219] In-silico analysis of kallikrein gene expression in pancreatic and colon cancers.Anticancer Res. 2004 Jan-Feb;24(1):43-51.
• [220] Kallikrein-related peptidase 7 is a potential target for the treatment of pancreatic cancer.Oncotarget. 2018 Jan 10;9(16):12894-12906. doi: 10.18632/oncotarget.24132. eCollection 2018 Feb 27.
• [221] Homozygous KSR1 deletion attenuates morbidity but does not prevent tumor development in a mouse model of RAS-driven pancreatic cancer.PLoS One. 2018 Mar 29;13(3):e0194998. doi: 10.1371/journal.pone.0194998. eCollection 2018.
• [222] L1CAM induces perineural invasion of pancreas cancer cells by upregulation of metalloproteinase expression.Oncogene. 2019 Jan;38(4):596-608. doi: 10.1038/s41388-018-0458-y. Epub 2018 Aug 31.
• [223] ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.J Exp Clin Cancer Res. 2019 Aug 8;38(1):347. doi: 10.1186/s13046-019-1340-7.
• [224] Asparaginyl endopeptidase enhances pancreatic ductal adenocarcinoma cell invasion in an exosome-dependent manner and correlates with poor prognosis.Int J Oncol. 2018 May;52(5):1651-1660. doi: 10.3892/ijo.2018.4318. Epub 2018 Mar 15.
• [225] N-WASP Control of LPAR1 Trafficking Establishes Response to Self-Generated LPA Gradients to Promote Pancreatic Cancer Cell Metastasis.Dev Cell. 2019 Nov 18;51(4):431-445.e7. doi: 10.1016/j.devcel.2019.09.018. Epub 2019 Oct 24.
• [226] Suppression of Gingival NK Cells in Precancerous and Cancerous Stages of Pancreatic Cancer in KC and BLT-Humanized Mice.Front Immunol. 2017 Dec 4;8:1606. doi: 10.3389/fimmu.2017.01606. eCollection 2017.
• [227] Functional and mechanistic studies reveal MAGEA3 as a pro-survival factor in pancreatic cancer cells.J Exp Clin Cancer Res. 2019 Jul 8;38(1):294. doi: 10.1186/s13046-019-1272-2.
• [228] Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer.Int J Cancer. 2020 Mar 15;146(6):1618-1630. doi: 10.1002/ijc.32567. Epub 2019 Jul 25.
• [229] Interaction of tRNA with MEK2 in pancreatic cancer cells.Sci Rep. 2016 Jun 15;6:28260. doi: 10.1038/srep28260.
• [230] The MST4-MOB4 complex disrupts the MST1-MOB1 complex in the Hippo-YAP pathway and plays a pro-oncogenic role in pancreatic cancer.J Biol Chem. 2018 Sep 14;293(37):14455-14469. doi: 10.1074/jbc.RA118.003279. Epub 2018 Aug 2.
• [231] Apoptosis signal-regulating kinase 1 exhibits oncogenic activity in pancreatic cancer.Oncotarget. 2016 Nov 15;7(46):75155-75164. doi: 10.18632/oncotarget.12090.
• [232] Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer.Mol Cancer Ther. 2020 Jan;19(1):247-257. doi: 10.1158/1535-7163.MCT-19-0270. Epub 2019 Sep 27.
• [233] Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704.Cancer. 2018 Feb 1;124(3):491-498. doi: 10.1002/cncr.31058. Epub 2017 Oct 20.
• [234] Identification of Matrix Metalloproteinase 11 as a Prognostic Biomarker in Pancreatic Cancer.Anticancer Res. 2019 Nov;39(11):5963-5971. doi: 10.21873/anticanres.13801.
• [235] LncRNA DANCR promotes proliferation and metastasis in pancreatic cancer by regulating miRNA-33b.FEBS Open Bio. 2020 Jan;10(1):18-27. doi: 10.1002/2211-5463.12732. Epub 2019 Dec 10.
• [236] CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis.J Cancer Res Clin Oncol. 2019 May;145(5):1147-1164. doi: 10.1007/s00432-019-02860-z. Epub 2019 Feb 15.
• [237] Silencing of Astrocyte elevated gene-1 (AEG-1) inhibits proliferation, migration, and invasiveness, and promotes apoptosis in pancreatic cancer cells.Biochem Cell Biol. 2019 Apr;97(2):165-175. doi: 10.1139/bcb-2018-0181. Epub 2018 Oct 25.
• [238] MYB Promotes Desmoplasia in Pancreatic Cancer through Direct Transcriptional Up-regulation and Cooperative Action of Sonic Hedgehog and Adrenomedullin.J Biol Chem. 2016 Jul 29;291(31):16263-70. doi: 10.1074/jbc.M116.732651. Epub 2016 May 31.
• [239] Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer.Oncotarget. 2017 Jun 29;8(49):85054-85067. doi: 10.18632/oncotarget.18841. eCollection 2017 Oct 17.
• [240] Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation.Oncogene. 2019 Mar;38(11):1832-1844. doi: 10.1038/s41388-018-0556-x. Epub 2018 Oct 24.
• [241] SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma.Cancer Lett. 2019 Feb 1;442:310-319. doi: 10.1016/j.canlet.2018.11.012. Epub 2018 Nov 10.
• [242] Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer.Biomolecules. 2018 Dec 10;8(4):169. doi: 10.3390/biom8040169.
• [243] Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents.Gut Liver. 2020 Mar 15;14(2):269-273. doi: 10.5009/gnl18573.
• [244] Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer.Clin Cancer Res. 2019 Aug 1;25(15):4589-4591. doi: 10.1158/1078-0432.CCR-19-1280. Epub 2019 Jun 4.
• [245] The miR-141/neuropilin-1 axis is associated with the clinicopathology and contributes to the growth and metastasis of pancreatic cancer.Cancer Cell Int. 2019 Sep 27;19:248. doi: 10.1186/s12935-019-0963-2. eCollection 2019.
• [246] Netrin-1 suppresses the MEK/ERK pathway and ITGB4 in pancreatic cancer.Oncotarget. 2016 Apr 26;7(17):24719-33. doi: 10.18632/oncotarget.8348.
• [247] AMPK-related kinase 5 (ARK5) enhances gemcitabine resistance in pancreatic carcinoma by inducing epithelial-mesenchymal transition.Am J Transl Res. 2018 Dec 15;10(12):4095-4106. eCollection 2018.
• [248] siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo.Biosci Rep. 2015 Jan 14;35(1):e00170. doi: 10.1042/BSR20140124.
• [249] Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.J Hematol Oncol. 2019 Sep 12;12(1):97. doi: 10.1186/s13045-019-0777-7.
• [250] DNA released from neutrophil extracellular traps (NETs) activates pancreatic stellate cells and enhances pancreatic tumor growth.Oncoimmunology. 2019 Jun 11;8(9):e1605822. doi: 10.1080/2162402X.2019.1605822. eCollection 2019.
• [251] Dual role of Par-4 in abrogation of EMT and switching on Mesenchymal to Epithelial Transition (MET) in metastatic pancreatic cancer cells.Mol Carcinog. 2018 Sep;57(9):1102-1115. doi: 10.1002/mc.22828. Epub 2018 May 15.
• [252] Primate-specific miRNA-637 inhibited tumorigenesis in human pancreatic ductal adenocarcinoma cells by suppressing Akt1 expression.Exp Cell Res. 2018 Feb 15;363(2):310-314. doi: 10.1016/j.yexcr.2018.01.026.
• [253] Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-/STAT3 Pathway.Cell Physiol Biochem. 2018;47(5):1751-1768. doi: 10.1159/000491058. Epub 2018 Jun 28.
• [254] MiR-1271 negatively regulates AKT/MTOR signaling and promotes apoptosis via targeting PDK1 in pancreatic cancer.Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):678-686. doi: 10.26355/eurrev_201802_14293.
• [255] PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation.Oncotarget. 2017 Aug 24;8(42):72893-72909. doi: 10.18632/oncotarget.20552. eCollection 2017 Sep 22.
• [256] RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling.Int J Oncol. 2018 Apr;52(4):1105-1116. doi: 10.3892/ijo.2018.4269. Epub 2018 Feb 7.
• [257] FoxM1 Induced Paclitaxel Resistance via Activation of the FoxM1/PHB1/RAF-MEK-ERK Pathway and Enhancement of the ABCA2 Transporter.Mol Ther Oncolytics. 2019 May 21;14:196-212. doi: 10.1016/j.omto.2019.05.005. eCollection 2019 Sep 27.
• [258] TMEM158 promotes pancreatic cancer aggressiveness by activation of TGF1 and PI3K/AKT signaling pathway.J Cell Physiol. 2020 Mar;235(3):2761-2775. doi: 10.1002/jcp.29181. Epub 2019 Sep 17.
• [259] Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine.Biomed Pharmacother. 2020 Jan;121:109521. doi: 10.1016/j.biopha.2019.109521. Epub 2019 Nov 2.
• [260] Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.Theranostics. 2017 Apr 10;7(6):1689-1704. doi: 10.7150/thno.18125. eCollection 2017.
• [261] PRMT1 promotes pancreatic cancer growth and predicts poor prognosis.Cell Oncol (Dordr). 2020 Feb;43(1):51-62. doi: 10.1007/s13402-019-00435-1. Epub 2019 Sep 13.
• [262] PRMT5 promotes epithelial-mesenchymal transition via EGFR--catenin axis in pancreatic cancer cells.J Cell Mol Med. 2020 Jan;24(2):1969-1979. doi: 10.1111/jcmm.14894. Epub 2019 Dec 18.
• [263] PKR2 and -catenin genes regulates pancreatic cancer chemosensitivity.Eur Rev Med Pharmacol Sci. 2017 Jan;21(1):48-54.
• [264] Identification of Upregulated HNRNPs Associated with Poor Prognosis in Pancreatic Cancer.Biomed Res Int. 2019 Jul 4;2019:5134050. doi: 10.1155/2019/5134050. eCollection 2019.
• [265] PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.Mol Cancer Res. 2015 Aug;13(8):1174-84. doi: 10.1158/1541-7786.MCR-15-0034. Epub 2015 May 26.
• [266] Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway.Cell Death Dis. 2019 Nov 19;10(12):874. doi: 10.1038/s41419-019-2073-4.
• [267] A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer.Cancer Cell. 2017 Oct 9;32(4):460-473.e6. doi: 10.1016/j.ccell.2017.09.007.
• [268] Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer.Int J Cancer. 2015 Mar 1;136(5):1228-33. doi: 10.1002/ijc.29070. Epub 2014 Jul 21.
• [269] Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1.Mol Cancer Res. 2016 Mar;14(3):267-77. doi: 10.1158/1541-7786.MCR-15-0456. Epub 2016 Jan 8.
• [270] Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models.Oncotarget. 2017 Apr 11;8(15):24491-24505. doi: 10.18632/oncotarget.15524.
• [271] MicroRNA-218 inhibits cell invasion and migration of pancreatic cancer via regulating ROBO1.Cancer Biol Ther. 2014 Oct;15(10):1333-9. doi: 10.4161/cbt.29706. Epub 2014 Jul 10.
• [272] Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling.Int J Obes (Lond). 2018 Mar;42(3):334-343. doi: 10.1038/ijo.2017.285. Epub 2017 Nov 20.
• [273] Downregulation of Human Endogenous Retrovirus Type K (HERV-K) Viral env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth.Clin Cancer Res. 2017 Oct 1;23(19):5892-5911. doi: 10.1158/1078-0432.CCR-17-0001. Epub 2017 Jul 5.
• [274] Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.Cancer Chemother Pharmacol. 2014 Apr;73(4):711-9. doi: 10.1007/s00280-014-2397-9. Epub 2014 Feb 12.
• [275] ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways.Exp Cell Res. 2019 Jun 1;379(1):30-47. doi: 10.1016/j.yexcr.2019.03.022. Epub 2019 Mar 17.
• [276] S100 calcium-binding protein A6 promotes epithelial-mesenchymal transition through -catenin in pancreatic cancer cell line.PLoS One. 2015 Mar 23;10(3):e0121319. doi: 10.1371/journal.pone.0121319. eCollection 2015.
• [277] S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes.BMC Cancer. 2018 Dec 17;18(1):1255. doi: 10.1186/s12885-018-5161-4.
• [278] Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer.Cell Death Dis. 2018 Oct 18;9(11):1065. doi: 10.1038/s41419-018-1104-x.
• [279] Targeting Semaphorin 4D in Cancer: A Look from Different Perspectives.Cancer Res. 2019 Oct 15;79(20):5146-5148. doi: 10.1158/0008-5472.CAN-19-2387.
• [280] The Role of PEDF in Pancreatic Cancer.Anticancer Res. 2019 Jul;39(7):3311-3315. doi: 10.21873/anticanres.13473.
• [281] Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma.Pancreas. 2019 Sep;48(8):1102-1110. doi: 10.1097/MPA.0000000000001369.
• [282] Bitter melon juice-intake modulates glucose metabolism and lactate efflux in tumors in its efficacy against pancreatic cancer.Carcinogenesis. 2019 Sep 18;40(9):1164-1176. doi: 10.1093/carcin/bgz114.
• [283] Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma.EBioMedicine. 2019 Feb;40:382-393. doi: 10.1016/j.ebiom.2019.01.003. Epub 2019 Jan 11.
• [284] Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine.Theranostics. 2018 May 23;8(12):3366-3379. doi: 10.7150/thno.23978. eCollection 2018.
• [285] A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells.Mol Pharm. 2013 Jan 7;10(1):406-16. doi: 10.1021/mp3005353. Epub 2012 Dec 24.
• [286] Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.Dig Dis Sci. 2020 Feb;65(2):489-499. doi: 10.1007/s10620-019-05797-y. Epub 2019 Aug 22.
• [287] The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer.Oncogene. 2019 Mar;38(10):1764-1777. doi: 10.1038/s41388-018-0553-0. Epub 2018 Oct 31.
• [288] The active role of the transcription factor Sp1 in NFATc2-mediated gene regulation in pancreatic cancer.BMC Biochem. 2019 Jan 29;20(1):2. doi: 10.1186/s12858-019-0105-4.
• [289] Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer.Mol Biol Cell. 2016 Nov 7;27(22):3659-3672. doi: 10.1091/mbc.E16-06-0427. Epub 2016 Sep 28.
• [290] mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer.World J Surg Oncol. 2015 Feb 13;13:46. doi: 10.1186/s12957-015-0467-z.
• [291] STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1.Cancer Res. 2017 Dec 15;77(24):6851-6862. doi: 10.1158/0008-5472.CAN-17-0067. Epub 2017 Oct 16.
• [292] Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells.Mol Cancer Res. 2013 Mar;11(3):294-302. doi: 10.1158/1541-7786.MCR-12-0609. Epub 2013 Jan 23.
• [293] Gene expression profile analysis of pancreatic cancer based on microarray data.Mol Med Rep. 2016 May;13(5):3913-9. doi: 10.3892/mmr.2016.5021. Epub 2016 Mar 21.
• [294] Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.Neoplasia. 2016 Nov;18(11):689-698. doi: 10.1016/j.neo.2016.09.003. Epub 2016 Oct 25.
• [295] TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia.Brain Behav Immun. 2018 Oct;73:364-374. doi: 10.1016/j.bbi.2018.05.021. Epub 2018 May 28.
• [296] Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status.Immunol Lett. 2019 Dec;216:43-50. doi: 10.1016/j.imlet.2019.10.003. Epub 2019 Oct 3.
• [297] Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer.J Clin Med. 2018 Jul 13;7(7):175. doi: 10.3390/jcm7070175.
• [298] TNIK serves as a novel biomarker associated with poor prognosis in patients with pancreatic cancer.Tumour Biol. 2016 Jan;37(1):1035-40. doi: 10.1007/s13277-015-3881-5. Epub 2015 Aug 14.
• [299] Comparison of UVB and UVC effects on the DNA damage-response protein 53BP1 in human pancreatic cancer.J Cell Biochem. 2014 Oct;115(10):1724-8. doi: 10.1002/jcb.24837.
• [300] MicroRNA-216b-5p Functions as a Tumor-suppressive RNA by Targeting TPT1 in Pancreatic Cancer Cells.J Cancer. 2017 Aug 23;8(14):2854-2865. doi: 10.7150/jca.18931. eCollection 2017.
• [301] Nanoparticle-based hyperthermia distinctly impacts production of ROS, expression of Ki-67, TOP2A, and TPX2, and induction of apoptosis in pancreatic cancer.Int J Nanomedicine. 2017 Feb 7;12:1009-1018. doi: 10.2147/IJN.S108577. eCollection 2017.
• [302] TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer.Clin Exp Med. 2019 May;19(2):211-218. doi: 10.1007/s10238-018-00543-6. Epub 2019 Jan 23.
• [303] TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis.J Cell Biochem. 2020 Feb;121(2):1986-1997. doi: 10.1002/jcb.29433. Epub 2019 Nov 6.
• [304] FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer.Clin Cancer Res. 2016 Aug 1;22(15):3950-60. doi: 10.1158/1078-0432.CCR-15-2380. Epub 2016 Mar 16.
• [305] Hyperglycemia regulates TXNIP/TRX/ROS axis via p38 MAPK and ERK pathways in pancreatic cancer.Curr Cancer Drug Targets. 2014;14(4):348-56. doi: 10.2174/1568009614666140331231658.
• [306] Analysis of the autophagy gene expression profile of pancreatic cancer based on autophagy-related protein microtubule-associated protein 1A/1B-light chain 3.World J Gastroenterol. 2019 May 7;25(17):2086-2098. doi: 10.3748/wjg.v25.i17.2086.
• [307] USP5 promotes tumorigenesis and progression of pancreatic cancer by stabilizing FoxM1 protein.Biochem Biophys Res Commun. 2017 Oct 7;492(1):48-54. doi: 10.1016/j.bbrc.2017.08.040. Epub 2017 Aug 12.
• [308] DRP1 upregulation promotes pancreatic cancer growth and metastasis through increased aerobic glycolysis.J Gastroenterol Hepatol. 2020 May;35(5):885-895. doi: 10.1111/jgh.14912. Epub 2020 Jan 2.
• [309] Downregulation of miR-21 inhibits the malignant phenotype of pancreatic cancer cells by targeting VHL.Onco Targets Ther. 2019 Sep 3;12:7215-7226. doi: 10.2147/OTT.S211535. eCollection 2019.
• [310] The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis.Int J Biol Markers. 2019 Dec;34(4):373-380. doi: 10.1177/1724600819881147. Epub 2019 Oct 14.
• [311] In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5-MYC Axis.Trends Cancer. 2016 Aug;2(8):391-392. doi: 10.1016/j.trecan.2016.07.002. Epub 2016 Jul 19.
• [312] DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma.Cancers (Basel). 2019 Aug 2;11(8):1101. doi: 10.3390/cancers11081101.
• [313] Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.Mol Carcinog. 2019 Oct;58(10):1908-1918. doi: 10.1002/mc.23084. Epub 2019 Jul 16.
• [314] Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.Pancreatology. 2019 Jun;19(4):569-577. doi: 10.1016/j.pan.2019.04.007. Epub 2019 Apr 22.
• [315] Citrate synthase expression affects tumor phenotype and drug resistance in human ovarian carcinoma.PLoS One. 2014 Dec 29;9(12):e115708. doi: 10.1371/journal.pone.0115708. eCollection 2014.
• [316] PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells.Oncogene. 2019 May;38(22):4325-4339. doi: 10.1038/s41388-019-0725-6. Epub 2019 Jan 31.
• [317] The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.Gastroenterology. 2019 Dec;157(6):1646-1659.e11. doi: 10.1053/j.gastro.2019.08.018. Epub 2019 Aug 20.
• [318] Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.PLoS Genet. 2013 Apr;9(4):e1003464. doi: 10.1371/journal.pgen.1003464. Epub 2013 Apr 25.
• [319] Organic anion transporting polypeptides expressed in pancreatic cancer may serve as potential diagnostic markers and therapeutic targets for early stage adenocarcinomas.Pharm Res. 2013 Sep;30(9):2260-9. doi: 10.1007/s11095-012-0962-7. Epub 2013 Jan 11.
• [320] TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer.Exp Cell Res. 2020 Jan 1;386(1):111713. doi: 10.1016/j.yexcr.2019.111713. Epub 2019 Nov 6.
• [321] Photodynamic Therapy Using Photosensitizer-Encapsulated Polymeric Nanoparticle to Overcome ATP-Binding Cassette Transporter Subfamily G2 Function in Pancreatic Cancer.Mol Cancer Ther. 2017 Aug;16(8):1487-1496. doi: 10.1158/1535-7163.MCT-16-0642. Epub 2017 Apr 17.
• [322] The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines.Invest New Drugs. 2019 Apr;37(2):262-270. doi: 10.1007/s10637-018-0635-4. Epub 2018 Jul 12.
• [323] Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients.Oncotarget. 2017 Nov 30;8(67):111333-111345. doi: 10.18632/oncotarget.22794. eCollection 2017 Dec 19.
• [324] ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation.Cell Physiol Biochem. 2018;48(2):838-846. doi: 10.1159/000491915. Epub 2018 Jul 20.
• [325] TMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis.Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):13026-13035. doi: 10.1073/pnas.1900703116. Epub 2019 Jun 10.
• [326] ATAD2 is associated with malignant characteristics of pancreatic cancer cells.Oncol Lett. 2019 Mar;17(3):3489-3494. doi: 10.3892/ol.2019.9960. Epub 2019 Jan 23.
• [327] Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma.Transl Oncol. 2019 Apr;12(4):683-692. doi: 10.1016/j.tranon.2019.01.009. Epub 2019 Mar 4.
• [328] AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF--mediated ERK signaling.Oncogene. 2010 Sep 16;29(37):5146-58. doi: 10.1038/onc.2010.258. Epub 2010 Jun 28.
• [329] Itraconazole inhibits proliferation of pancreatic cancer cells through activation of Bak-1.J Cell Biochem. 2019 Mar;120(3):4333-4341. doi: 10.1002/jcb.27719. Epub 2018 Sep 27.
• [330] Value of anti-plasminogen binding peptide, anti-carbonic anhydrase II, immunoglobulin G4, and other serological markers for the differentiation of autoimmune pancreatitis and pancreatic cancer.Medicine (Baltimore). 2018 Aug;97(31):e11641. doi: 10.1097/MD.0000000000011641.
• [331] An effective computer aided diagnosis model for pancreas cancer on PET/CT images.Comput Methods Programs Biomed. 2018 Oct;165:205-214. doi: 10.1016/j.cmpb.2018.09.001. Epub 2018 Sep 4.
• [332] PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem. 2006 Apr 28;281(17):11923-32. doi: 10.1074/jbc.M508533200. Epub 2006 Jan 30.
• [333] Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.Cancer Immunol Immunother. 2015 Dec;64(12):1553-63. doi: 10.1007/s00262-015-1760-y. Epub 2015 Sep 30.
• [334] Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration.Am J Pathol. 2017 Jan;187(1):146-155. doi: 10.1016/j.ajpath.2016.09.012. Epub 2016 Nov 14.
• [335] Expression of the tumor suppressor ARHI inhibits the growth of pancreatic cancer cells by inducing G1 cell cycle arrest.Oncol Rep. 2009 Sep;22(3):635-40.
• [336] Targeting claudin-4 in human pancreatic cancer.Expert Opin Ther Targets. 2012 Sep;16(9):881-7. doi: 10.1517/14728222.2012.708340. Epub 2012 Jul 16.
• [337] Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer.Oncotarget. 2015 Jul 10;6(19):17391-403. doi: 10.18632/oncotarget.3975.
• [338] EUS-guided celiac ganglion radiofrequency ablation versus celiac plexus neurolysis for palliation of pain in pancreatic cancer: a randomized controlled trial (with videos).Gastrointest Endosc. 2019 Jan;89(1):58-66.e3. doi: 10.1016/j.gie.2018.08.005. Epub 2018 Aug 16.
• [339] Inhibition of interleukin 8/CX-C chemokine receptor1,/2 signaling reduces malignant features in human pancreatic cancer cells.Int J Oncol. 2018 Jul;53(1):349-357. doi: 10.3892/ijo.2018.4389. Epub 2018 Apr 30.
• [340] Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer.Carcinogenesis. 2008 Jun;29(6):1184-91. doi: 10.1093/carcin/bgn085. Epub 2008 May 21.
• [341] Targeting the CYP2B 1/cyclophosphamide suicide system to fibroblast growth factor receptors results in a potent antitumoral response in pancreatic cancer models.Hum Gene Ther. 2006 Dec;17(12):1187-200. doi: 10.1089/hum.2006.17.1187.
• [342] Pancreatic cancer biomarker detection by two support vector strategies for recursive feature elimination.Biomark Med. 2019 Feb;13(2):105-121. doi: 10.2217/bmm-2018-0273. Epub 2019 Feb 15.
• [343] Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.Life Sci. 2020 Jan 15;241:117150. doi: 10.1016/j.lfs.2019.117150. Epub 2019 Dec 11.
• [344] Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer.Mol Ther. 2019 Mar 6;27(3):507-517. doi: 10.1016/j.ymthe.2018.11.012. Epub 2018 Nov 17.
• [345] DEPTOR has growth suppression activity against pancreatic cancer cells.Oncotarget. 2014 Dec 30;5(24):12811-9. doi: 10.18632/oncotarget.2659.
• [346] Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.Neuro Oncol. 2018 Jan 22;20(2):192-202. doi: 10.1093/neuonc/nox119.
• [347] DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.PLoS One. 2012;7(2):e31507. doi: 10.1371/journal.pone.0031507. Epub 2012 Feb 20.
• [348] Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy.Cancer Sci. 2020 Feb;111(2):548-560. doi: 10.1111/cas.14258. Epub 2019 Dec 19.
• [349] Long Non-Coding RNA Differentiation Antagonizing Nonprotein Coding RNA (DANCR) Promotes Proliferation and Invasion of Pancreatic Cancer by Sponging miR-214-5p to Regulate E2F2 Expression.Med Sci Monit. 2019 Jun 19;25:4544-4552. doi: 10.12659/MSM.916960.
• [350] A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.Oncologist. 2020 Jan;25(1):e186-e193. doi: 10.1634/theoncologist.2019-0221. Epub 2019 Sep 6.
• [351] TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1 axis and indicates prognosis in pancreatic cancer.Cell Death Dis. 2018 Feb 23;9(3):321. doi: 10.1038/s41419-018-0367-6.
• [352] Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer.Am J Cancer Res. 2018 Sep 1;8(9):1812-1822. eCollection 2018.
• [353] Therapeutic Targeting Cancer-Initiating Cell Markers by Exosome miRNA: Efficacy and Functional Consequences Exemplified for claudin7 and EpCAM.Transl Oncol. 2019 Feb;12(2):191-199. doi: 10.1016/j.tranon.2018.08.021. Epub 2018 Oct 28.
• [354] Exome-Wide Association Study of Pancreatic Cancer Risk.Gastroenterology. 2018 Feb;154(3):719-722.e3. doi: 10.1053/j.gastro.2017.10.015. Epub 2017 Oct 24.
• [355] EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth.Cancer Sci. 2006 Nov;97(11):1211-6. doi: 10.1111/j.1349-7006.2006.00313.x. Epub 2006 Sep 5.
• [356] Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study.Thromb Res. 2018 Jun;166:54-59. doi: 10.1016/j.thromres.2018.04.009. Epub 2018 Apr 10.
• [357] Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.Gastroenterology. 2019 Nov;157(5):1413-1428.e11. doi: 10.1053/j.gastro.2019.07.030. Epub 2019 Jul 25.
• [358] Keratinocyte growth factor induces matrix metalloproteinase-9 expression and correlates with venous invasion in pancreatic cancer.Int J Oncol. 2012 Apr;40(4):1040-8. doi: 10.3892/ijo.2011.1280. Epub 2011 Dec 6.
• [359] Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients.Med Mol Morphol. 2018 Dec;51(4):237-243. doi: 10.1007/s00795-018-0197-8. Epub 2018 Jun 20.
• [360] Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.Ann Surg. 2017 Apr;265(4):800-805. doi: 10.1097/SLA.0000000000001741.
• [361] Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma.Exp Mol Med. 2014 Oct 10;46(10):e117. doi: 10.1038/emm.2014.61.
• [362] LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.J Exp Clin Cancer Res. 2018 Nov 12;37(1):274. doi: 10.1186/s13046-018-0947-4.
• [363] Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-B signaling pathway.Mol Cancer. 2017 Mar 14;16(1):61. doi: 10.1186/s12943-017-0627-6.
• [364] Integrated phenotypic screening and activity-based protein profiling to reveal potential therapy targets of pancreatic cancer.Chem Commun (Camb). 2019 Jan 31;55(11):1596-1599. doi: 10.1039/c8cc08753a.
• [365] Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer.Cell Prolif. 2019 May;52(3):e12603. doi: 10.1111/cpr.12603. Epub 2019 Apr 1.
• [366] Heparanase expression in blood is sensitive to monitor response to anticancer treatment in pancreatic cancer, a pilot study.Pancreatology. 2018 Jan;18(1):100-105. doi: 10.1016/j.pan.2017.11.004. Epub 2017 Nov 13.
• [367] Silencing of GRP94 expression promotes apoptosis in pancreatic cancer cells.Int J Oncol. 2009 Oct;35(4):823-8. doi: 10.3892/ijo_00000395.
• [368] ER stress sensor, glucose regulatory protein 78 (GRP78) regulates redox status in pancreatic cancer thereby maintaining "stemness".Cell Death Dis. 2019 Feb 12;10(2):132. doi: 10.1038/s41419-019-1408-5.
• [369] Impact of Celiac Plexus Neurolysis on Survival in Patients with Unresectable Pancreatic Cancer: A Retrospective, Propensity Score Matching Analysis.Pain Physician. 2017 Mar;20(3):E357-E365.
• [370] Down-regulation of 5-HT1B and 5-HT1D receptors inhibits proliferation, clonogenicity and invasion of human pancreatic cancer cells.PLoS One. 2014 Aug 29;9(8):e105245. doi: 10.1371/journal.pone.0105245. eCollection 2014.
• [371] HtrA1 suppresses the growth of pancreatic cancer cells by modulating Notch-1 expression.Braz J Med Biol Res. 2018 Nov 23;52(1):e7718. doi: 10.1590/1414-431X20187718.
• [372] IL24 and its Receptors Regulate Growth and Migration of Pancreatic Cancer Cells and Are Potential Biomarkers for IL24 Molecular Therapy.Anticancer Res. 2016 Mar;36(3):1153-63.
• [373] Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.Nat Commun. 2018 Mar 28;9(1):1250. doi: 10.1038/s41467-018-03600-6.
• [374] Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.Oncotarget. 2016 Jan 12;7(2):1477-85. doi: 10.18632/oncotarget.6395.
• [375] Role of ion channels in gastrointestinal cancer.World J Gastroenterol. 2019 Oct 14;25(38):5732-5772. doi: 10.3748/wjg.v25.i38.5732.
• [376] circZMYM2 Competed Endogenously with miR-335-5p to Regulate JMJD2C in Pancreatic Cancer.Cell Physiol Biochem. 2018;51(5):2224-2236. doi: 10.1159/000495868. Epub 2018 Dec 7.
• [377] SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer.J Cell Biol. 2018 Feb 5;217(2):763-777. doi: 10.1083/jcb.201705031. Epub 2017 Dec 11.
• [378] LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target.J Immunother. 2019 Oct;42(8):279-283. doi: 10.1097/CJI.0000000000000283.
• [379] HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway.Carbohydr Polym. 2019 Jan 15;204:111-123. doi: 10.1016/j.carbpol.2018.10.008. Epub 2018 Oct 5.
• [380] Lack of association between UGT1A7, UGT1A9, ARP, SPINK1 and CFTR gene polymorphisms and pancreatic cancer in Italian patients.World J Gastroenterol. 2006 Oct 21;12(39):6343-8. doi: 10.3748/wjg.v12.i39.6343.
• [381] Association of breast cancer susceptibility variants with risk of pancreatic cancer.Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3044-8. doi: 10.1158/1055-9965.EPI-09-0306. Epub 2009 Oct 20.
• [382] MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity.Anticancer Res. 2018 Apr;38(4):1937-1946. doi: 10.21873/anticanres.12431.
• [383] Selective activation of tumor-suppressive MAPKP signaling pathway by triptonide effectively inhibits pancreatic cancer cell tumorigenicity and tumor growth.Biochem Pharmacol. 2019 Aug;166:70-81. doi: 10.1016/j.bcp.2019.05.010. Epub 2019 May 7.
• [384] miR-7 Suppresses Tumor Progression by Directly Targeting MAP3K9 in Pancreatic Cancer.Mol Ther Nucleic Acids. 2018 Dec 7;13:121-132. doi: 10.1016/j.omtn.2018.08.012. Epub 2018 Aug 22.
• [385] Does Axl have potential as a therapeutic target in pancreatic cancer?.Expert Opin Ther Targets. 2018 Nov;22(11):955-966. doi: 10.1080/14728222.2018.1527315. Epub 2018 Oct 3.
• [386] Correlations of Moesin expression with the pathological stage, nerve infiltration, tumor location and pain severity in patients with pancreatic cancer.J BUON. 2019 May-Jun;24(3):1225-1232.
• [387] Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines.J Gastroenterol. 2018 Oct;53(10):1159-1167. doi: 10.1007/s00535-018-1466-y. Epub 2018 Apr 17.
• [388] Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.FASEB J. 2017 Jun;31(6):2429-2438. doi: 10.1096/fj.201601240R. Epub 2017 Feb 21.
• [389] MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages.Oncogene. 2019 Jul;38(28):5599-5611. doi: 10.1038/s41388-019-0811-9. Epub 2019 Apr 9.
• [390] Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer.Cell Cycle. 2018;17(2):191-199. doi: 10.1080/15384101.2017.1405194. Epub 2018 Jan 3.
• [391] Differential expression of metastasis-associated genes in papilla of vater and pancreatic cancer correlates with disease stage.J Clin Oncol. 2001 May 1;19(9):2422-32. doi: 10.1200/JCO.2001.19.9.2422.
• [392] Identification of Prognostic Biomarkers by Combined mRNA and miRNA Expression Microarray Analysis in Pancreatic Cancer.Transl Oncol. 2018 Jun;11(3):700-714. doi: 10.1016/j.tranon.2018.03.003. Epub 2018 Apr 6.
• [393] Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability.Nat Commun. 2018 Sep 7;9(1):3646. doi: 10.1038/s41467-018-05692-6.
• [394] A genetic variant in PIK3R1 is associated with pancreatic cancer survival in the Chinese population.Cancer Med. 2019 Jul;8(7):3575-3582. doi: 10.1002/cam4.2228. Epub 2019 May 6.
• [395] Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.Oncotarget. 2017 Jan 10;8(2):3064-3071. doi: 10.18632/oncotarget.13619.
• [396] Detecting discordance enrichment among a series of two-sample genome-wide expression data sets.BMC Genomics. 2017 Jan 25;18(Suppl 1):1050. doi: 10.1186/s12864-016-3265-2.
• [397] Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine.Int J Oncol. 2007 Jun;30(6):1397-406.
• [398] Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147.Cancer. 2006 May 15;106(10):2284-94. doi: 10.1002/cncr.21862.
• [399] Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer.Scand J Gastroenterol. 2019 Feb;54(2):246-251. doi: 10.1080/00365521.2019.1574360. Epub 2019 Mar 17.
• [400] Gemcitabine Induces Microvesicle Particle Release in a Platelet-Activating Factor-Receptor-Dependent Manner via Modulation of the MAPK Pathway in Pancreatic Cancer Cells.Int J Mol Sci. 2018 Dec 21;20(1):32. doi: 10.3390/ijms20010032.
• [401] Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras(G12D/+) mice.Immunology. 2017 Sep;152(1):36-51. doi: 10.1111/imm.12746. Epub 2017 May 29.
• [402] Discovery and characterization of small molecule Rac1 inhibitors.Oncotarget. 2017 May 23;8(21):34586-34600. doi: 10.18632/oncotarget.16656.
• [403] A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.PLoS One. 2018 Jun 1;13(6):e0198038. doi: 10.1371/journal.pone.0198038. eCollection 2018.
• [404] Measurement of serum PODXL concentration for detection of pancreatic cancer.Onco Targets Ther. 2018 Mar 15;11:1433-1445. doi: 10.2147/OTT.S155367. eCollection 2018.
• [405] Synergistic antitumor effects of CDK inhibitor SNS?32 and an oncolytic adenovirus coexpressing TRAIL and Smac in pancreatic cancer.Mol Med Rep. 2017 Jun;15(6):3521-3528. doi: 10.3892/mmr.2017.6472. Epub 2017 Apr 12.
• [406] Upregulation of C1-inhibitor in pancreatic cancer.Oncotarget. 2019 Oct 1;10(55):5703-5712. doi: 10.18632/oncotarget.27191. eCollection 2019 Oct 1.
• [407] SLC5A1 promotes growth and proliferation of pancreatic carcinoma via glucose-dependent AMPK/mTOR signaling.Cancer Manag Res. 2019 Apr 12;11:3171-3185. doi: 10.2147/CMAR.S195424. eCollection 2019.
• [408] Feasibility of 2D-conformal radiotherapy for pancreatic carcinoma.Oncol Lett. 2018 Nov;16(5):5939-5945. doi: 10.3892/ol.2018.9389. Epub 2018 Sep 4.
• [409] SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1.Pancreas. 2018 May/Jun;47(5):637-642. doi: 10.1097/MPA.0000000000001052.
• [410] Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer.Cancer Res. 2004 May 15;64(10):3599-606. doi: 10.1158/0008-5472.CAN-03-2999.
• [411] LncRNA SNHG16 induces the SREBP2 to promote lipogenesis and enhance the progression of pancreatic cancer.Future Oncol. 2019 Nov;15(33):3831-3844. doi: 10.2217/fon-2019-0321. Epub 2019 Oct 30.
• [412] Long non-coding RNA lnc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3.Int J Cancer. 2018 Dec 15;143(12):3143-3154. doi: 10.1002/ijc.31657. Epub 2018 Nov 15.
• [413] RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples.Cancers (Basel). 2019 Sep 5;11(9):1309. doi: 10.3390/cancers11091309.
• [414] Expression and prognostic significance of TRPV6 in the development and progression of pancreatic cancer.Oncol Rep. 2018 Mar;39(3):1432-1440. doi: 10.3892/or.2018.6216. Epub 2018 Jan 15.
• [415] Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.Cancer J. 2007 Jul-Aug;13(4):247-56. doi: 10.1097/PPO.0b013e31813c12b8.
• [416] UCHL3 promotes pancreatic cancer progression and chemo-resistance through FOXM1 stabilization.Am J Cancer Res. 2019 Sep 1;9(9):1970-1981. eCollection 2019.
• [417] Dynamic quantitative detection of ABC transporter family promoter methylation by MS-HRM for predicting MDR in pancreatic cancer.Oncol Lett. 2018 Apr;15(4):5602-5610. doi: 10.3892/ol.2018.8041. Epub 2018 Feb 13.
• [418] Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.Gastroenterology. 2016 Jan;150(1):218-228.e12. doi: 10.1053/j.gastro.2015.09.013. Epub 2015 Sep 25.
• [419] Antitumor activity of ALK1 in pancreatic carcinoma cells.Int J Cancer. 2007 Apr 15;120(8):1641-51. doi: 10.1002/ijc.22393.
• [420] Adiponectin Suppresses Human Pancreatic Cancer Growth through Attenuating the -Catenin Signaling Pathway.Int J Biol Sci. 2019 Jan 1;15(2):253-264. doi: 10.7150/ijbs.27420. eCollection 2019.
• [421] Can pancreatic cancer be detected by adrenomedullin in patients with new-onset diabetes? The PaCANOD cohort study protocol.Tumori. 2018 Aug;104(4):312-314. doi: 10.5301/tj.5000693. Epub 2018 May 8.
• [422] Case-control study of diabetes-related genetic variants and pancreatic cancer risk in Japan.World J Gastroenterol. 2014 Dec 14;20(46):17456-62. doi: 10.3748/wjg.v20.i46.17456.
• [423] Ectopic expression of the heterotrimeric G15 protein in pancreatic carcinoma and its potential in cancer signal transduction.Cell Signal. 2013 Mar;25(3):651-9. doi: 10.1016/j.cellsig.2012.11.018. Epub 2012 Nov 29.
• [424] MicroRNA?96 targets AKT2 in pancreatic cancer and functions as a potential tumor suppressor.Mol Med Rep. 2017 Jul;16(1):466-472. doi: 10.3892/mmr.2017.6602. Epub 2017 May 18.
• [425] Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.PLoS One. 2017 Apr 3;12(4):e0175039. doi: 10.1371/journal.pone.0175039. eCollection 2017.
• [426] High Co-expression of Large Tenascin C Splice Variants in Stromal Tissue and Annexin A2 in Cancer Cell Membranes is Associated with Poor Prognosis in Pancreatic Cancer.Ann Surg Oncol. 2020 Mar;27(3):924-930. doi: 10.1245/s10434-019-07708-x. Epub 2019 Aug 28.
• [427] Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival.Sci Rep. 2018 Sep 13;8(1):13759. doi: 10.1038/s41598-018-32034-9.
• [428] A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline.Br J Cancer. 2017 Dec 5;117(12):1846-1854. doi: 10.1038/bjc.2017.365. Epub 2017 Nov 9.
• [429] Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci. 2010 Nov;101(11):2351-60. doi: 10.1111/j.1349-7006.2010.01671.x.
• [430] Pancreatic cancer genetics.Pancreatology. 2001;1(6):571-5. doi: 10.1159/000055865.
• [431] Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations.Nat Genet. 2011 Dec 11;44(1):62-6. doi: 10.1038/ng.1020.
• [432] Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-B signaling pathway in human pancreatic ductal adenocarcinoma.Int J Mol Sci. 2012;13(1):1186-1208. doi: 10.3390/ijms13011186. Epub 2012 Jan 20.
• [433] Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines.Gastroenterology. 2001 Sep;121(3):657-67. doi: 10.1053/gast.2001.27222.
• [434] Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer.J Clin Pathol. 2007 Aug;60(8):885-95. doi: 10.1136/jcp.2006.038257. Epub 2006 Jun 14.
• [435] High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway.J Exp Clin Cancer Res. 2019 May 14;38(1):192. doi: 10.1186/s13046-019-1209-9.
• [436] Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.Cancer Res. 2019 Sep 1;79(17):4491-4502. doi: 10.1158/0008-5472.CAN-18-3645. Epub 2019 Jul 4.
• [437] LncRNA BANCR Promotes Pancreatic Cancer Tumorigenesis via Modulating MiR-195-5p/Wnt/-Catenin Signaling Pathway.Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819887962. doi: 10.1177/1533033819887962.
• [438] Genetic variants in the SWI/SNF complex and smoking collaborate to modify the risk of pancreatic cancer in a Chinese population.Mol Carcinog. 2015 Sep;54(9):761-8. doi: 10.1002/mc.22140. Epub 2014 Feb 28.
• [439] BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity.Oncotarget. 2017 Jul 4;8(27):44669-44681. doi: 10.18632/oncotarget.17965.
• [440] Therapeutic anti-CD147 antibody sensitizes cells to chemoradiotherapy via targeting pancreatic cancer stem cells.Am J Transl Res. 2019 Jun 15;11(6):3543-3554. eCollection 2019.
• [441] A double missense variation of the BUB1 gene and a defective mitotic spindle checkpoint in the pancreatic cancer cell line Hs766T.Hum Mutat. 2003 Apr;21(4):445. doi: 10.1002/humu.9120.
• [442] Complement component 1, q subcomponent binding protein (C1QBP) in lipid rafts mediates hepatic metastasis of pancreatic cancer by regulating IGF-1/IGF-1R signaling.Int J Cancer. 2017 Oct 1;141(7):1389-1401. doi: 10.1002/ijc.30831. Epub 2017 Jun 24.
• [443] High calpain-1 expression predicts a poor clinical outcome and contributes to tumor progression in pancreatic cancer patients.Clin Transl Oncol. 2019 Jul;21(7):924-932. doi: 10.1007/s12094-018-02006-6. Epub 2018 Dec 18.
• [444] Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer.Mol Cell. 2016 Nov 17;64(4):673-687. doi: 10.1016/j.molcel.2016.09.028. Epub 2016 Nov 10.
• [445] Induction of apoptosis by Galectin-9 in liver metastatic cancer cells: In vitro study.Int J Oncol. 2017 Aug;51(2):607-614. doi: 10.3892/ijo.2017.4053. Epub 2017 Jun 23.
• [446] Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.Clin Cancer Res. 2015 Jan 1;21(1):157-65. doi: 10.1158/1078-0432.CCR-14-0610. Epub 2014 Oct 27.
• [447] Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1 from activated macrophages leads to poor prognosis in pancreatic cancer.Cancer Sci. 2018 Feb;109(2):462-470. doi: 10.1111/cas.13467. Epub 2018 Jan 27.
• [448] CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.Oncotarget. 2017 Jan 31;8(5):8010-8021. doi: 10.18632/oncotarget.14037.
• [449] PRPF40A as a potential diagnostic and prognostic marker is upregulated in pancreatic cancer tissues and cell lines: an integrated bioinformatics data analysis.Onco Targets Ther. 2019 Jun 28;12:5037-5051. doi: 10.2147/OTT.S206039. eCollection 2019.
• [450] Detection of CCN1 and CCN5 mRNA in Human Cancer Samples Using a Modified In Situ Hybridization Technique.Methods Mol Biol. 2017;1489:495-504. doi: 10.1007/978-1-4939-6430-7_41.
• [451] Screening for genes and subnetworks associated with pancreatic cancer based on the gene expression profile.Mol Med Rep. 2016 May;13(5):3779-86. doi: 10.3892/mmr.2016.5007. Epub 2016 Mar 18.
• [452] Induction and expression of cyclin D3 in human pancreatic cancer.J Cancer Res Clin Oncol. 2001 Jul;127(7):449-54. doi: 10.1007/s004320100235.
• [453] The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival.PLoS One. 2013 Oct 8;8(10):e76450. doi: 10.1371/journal.pone.0076450. eCollection 2013.
• [454] Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.Oncogene. 2017 Nov 2;36(44):6097-6108. doi: 10.1038/onc.2017.214. Epub 2017 Jul 3.
• [455] Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer.Clin Cancer Res. 2006 Apr 15;12(8):2419-26. doi: 10.1158/1078-0432.CCR-05-1852.
• [456] Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells.Hum Mol Genet. 2012 Nov 1;21(21):4615-27. doi: 10.1093/hmg/dds303. Epub 2012 Jul 25.
• [457] A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.Clin Cancer Res. 2015 Apr 1;21(7):1665-74. doi: 10.1158/1078-0432.CCR-14-2316. Epub 2015 Jan 8.
• [458] Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair.Clin Cancer Res. 2013 Aug 15;19(16):4422-32. doi: 10.1158/1078-0432.CCR-13-0788. Epub 2013 Jun 18.
• [459] Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.Oncotarget. 2016 Apr 5;7(14):18495-507. doi: 10.18632/oncotarget.7611.
• [460] Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.Clin Cancer Res. 2008 Oct 15;14(20):6487-95. doi: 10.1158/1078-0432.CCR-08-1086.
• [461] HIF-2 promotes the formation of vasculogenic mimicry in pancreatic cancer by regulating the binding of Twist1 to the VE-cadherin promoter.Oncotarget. 2017 Jul 18;8(29):47801-47815. doi: 10.18632/oncotarget.17999.
• [462] Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.Clin Cancer Res. 2011 Oct 1;17(19):6140-50. doi: 10.1158/1078-0432.CCR-10-2288. Epub 2011 Aug 8.
• [463] Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data.Mol Med Rep. 2016 Dec;14(6):5451-5460. doi: 10.3892/mmr.2016.5928. Epub 2016 Nov 7.
• [464] THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.Oncogene. 2019 May;38(20):3932-3945. doi: 10.1038/s41388-019-0701-1. Epub 2019 Jan 28.
• [465] Preoperative neutrophili-to-lymphocyte ratio is useful for stratifying the prognosis of tumor markers-negative pancreatic cancer patients.Am J Surg. 2020 Jan;219(1):93-98. doi: 10.1016/j.amjsurg.2019.04.014. Epub 2019 Apr 21.
• [466] Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.Clin Cancer Res. 2019 Apr 1;25(7):2290-2304. doi: 10.1158/1078-0432.CCR-18-1620. Epub 2018 Dec 11.
• [467] CHK negatively regulates Lyn kinase and suppresses pancreatic cancer cell invasion.Int J Oncol. 2006 Dec;29(6):1453-8.
• [468] Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer.Oncotarget. 2018 Jan 24;9(14):11734-11751. doi: 10.18632/oncotarget.24312. eCollection 2018 Feb 20.
• [469] Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer.Surgery. 2011 Aug;150(2):306-15. doi: 10.1016/j.surg.2011.05.011. Epub 2011 Jun 30.
• [470] Downregulation of CPE regulates cell proliferation and chemosensitivity in pancreatic cancer.Tumour Biol. 2014 Dec;35(12):12459-65. doi: 10.1007/s13277-014-2564-y. Epub 2014 Nov 6.
• [471] SIRT1 and circadian gene expression in pancreatic ductal adenocarcinoma: Effect of starvation.Chronobiol Int. 2015 May;32(4):497-512. doi: 10.3109/07420528.2014.1003351. Epub 2015 Mar 23.
• [472] Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.BMC Cancer. 2010 Aug 19;10:440. doi: 10.1186/1471-2407-10-440.
• [473] Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.Int J Cancer. 2004 Apr 20;109(4):568-75. doi: 10.1002/ijc.20006.
• [474] MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.Cancer Cell. 2017 Jul 10;32(1):71-87.e7. doi: 10.1016/j.ccell.2017.06.004.
• [475] Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using subtractive hybridization.FEBS Lett. 1996 Apr 29;385(1-2):72-6. doi: 10.1016/0014-5793(96)00352-3.
• [476] The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver.Cancer Res. 2006 Oct 1;66(19):9576-82. doi: 10.1158/0008-5472.CAN-06-1507.
• [477] Contribution of environment and genetics to pancreatic cancer susceptibility.PLoS One. 2014 Mar 20;9(3):e90052. doi: 10.1371/journal.pone.0090052. eCollection 2014.
• [478] A recombinantly tailored -defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.Oncotarget. 2016 Sep 6;7(36):58418-58434. doi: 10.18632/oncotarget.11170.
• [479] Dickkopf-1 is overexpressed in human pancreatic ductal adenocarcinoma cells and is involved in invasive growth.Int J Cancer. 2010 Apr 1;126(7):1611-20. doi: 10.1002/ijc.24865.
• [480] A Phase I/Ib trial of Ad-REIC in liver cancer: study protocol.Future Oncol. 2019 Nov;15(31):3547-3554. doi: 10.2217/fon-2019-0115. Epub 2019 Oct 30.
• [481] Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma.Exp Ther Med. 2018 Jul;16(1):53-60. doi: 10.3892/etm.2018.6172. Epub 2018 May 16.
• [482] Hypoxia induces upregulation of the deoxyribonuclease I gene in the human pancreatic cancer cell line QGP-1.Biochim Biophys Acta. 2007 Nov;1770(11):1567-75. doi: 10.1016/j.bbagen.2007.08.012. Epub 2007 Aug 29.
• [483] A Direct Podocalyxin-Dynamin-2 Interaction Regulates Cytoskeletal Dynamics to Promote Migration and Metastasis in Pancreatic Cancer Cells.Cancer Res. 2019 Jun 1;79(11):2878-2891. doi: 10.1158/0008-5472.CAN-18-3369. Epub 2019 Apr 11.
• [484] Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A. Chem Biol Interact. 2020 Jan 25;316:108913. doi: 10.1016/j.cbi.2019.108913. Epub 2019 Dec 12.
• [485] Epidermal growth factor-like domain 7 promotes cell invasion and angiogenesis in pancreatic carcinoma.Biomed Pharmacother. 2016 Feb;77:167-75. doi: 10.1016/j.biopha.2015.12.009. Epub 2015 Dec 30.
• [486] Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.Diabet Med. 2019 Apr;36(4):491-498. doi: 10.1111/dme.13835. Epub 2018 Oct 25.
• [487] Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.J Exp Clin Cancer Res. 2019 Feb 11;38(1):66. doi: 10.1186/s13046-019-1053-y.
• [488] EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway.J Cell Mol Med. 2019 Apr;23(4):2678-2688. doi: 10.1111/jcmm.14167. Epub 2019 Feb 14.
• [489] Sonic Hedgehog-GLI Family Zinc Finger 1 Signaling Pathway Promotes the Growth and Migration of Pancreatic Cancer Cells by Regulating the Transcription of Eukaryotic Translation Initiation Factor 5A2.Pancreas. 2015 Nov;44(8):1252-8. doi: 10.1097/MPA.0000000000000532.
• [490] HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.Expert Rev Anticancer Ther. 2009 Oct;9(10):1439-41. doi: 10.1586/era.09.119.
• [491] Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease.Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G223-30. doi: 10.1152/ajpgi.00259.2006. Epub 2006 Aug 17.
• [492] Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4.
• [493] Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs.J Exp Clin Cancer Res. 2019 Apr 8;38(1):150. doi: 10.1186/s13046-019-1160-9.
• [494] Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth.Biochem Biophys Res Commun. 2000 Jul 14;273(3):1019-24. doi: 10.1006/bbrc.2000.3033.
• [495] Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma.Oncotarget. 2016 Jun 7;7(23):33887-900. doi: 10.18632/oncotarget.8432.
• [496] Novel mutations of PRSS1 gene in patients with pancreatic cancer among Han population.Chin Med J (Engl). 2011 Jul 5;124(13):2065-7.
• [497] Antitissue factor antibodymediated immunoSPECT imaging of tissue factor expression in mouse models of pancreatic cancer.Oncol Rep. 2019 Apr;41(4):2371-2378. doi: 10.3892/or.2019.7017. Epub 2019 Feb 14.
• [498] Inhibition of Pancreatic Carcinoma Growth Through Enhancing -3 Epoxy Polyunsaturated Fatty Acid Profile by Inhibition of Soluble Epoxide Hydrolase.Anticancer Res. 2019 Jul;39(7):3651-3660. doi: 10.21873/anticanres.13513.
• [499] PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.Cell Commun Signal. 2019 Mar 29;17(1):30. doi: 10.1186/s12964-019-0344-4.
• [500] YY1 inhibits the migration and invasion of pancreatic ductal adenocarcinoma by downregulating the FER/STAT3/MMP2 signaling pathway.Cancer Lett. 2019 Oct 28;463:37-49. doi: 10.1016/j.canlet.2019.07.019. Epub 2019 Aug 9.
• [501] Tumor-Induced Myeloid Cells Are Reduced by Gemcitabine-Loaded PAMAM Dendrimers Decorated with Anti-Flt1 Antibody.Mol Pharm. 2018 Apr 2;15(4):1526-1533. doi: 10.1021/acs.molpharmaceut.7b01075. Epub 2018 Mar 6.
• [502] FoxQ1 is a Novel Molecular Target for Pancreatic Cancer and is Associated with Poor Prognosis.Curr Mol Med. 2015;15(5):469-77. doi: 10.2174/1566524015666150630125247.
• [503] Knockdown of the (1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis.Int J Cancer. 2011 Dec 15;129(12):2905-15. doi: 10.1002/ijc.25942. Epub 2011 Apr 13.
• [504] Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.Br J Cancer. 1991 Nov;64(5):899-902. doi: 10.1038/bjc.1991.422.
• [505] The N-terminal domain of G3BP enhances cell motility and invasion by posttranscriptional regulation of BART.Mol Cancer Res. 2011 Jul;9(7):856-66. doi: 10.1158/1541-7786.MCR-10-0574. Epub 2011 Jun 10.
• [506] miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer.Mol Cancer. 2017 Oct 27;16(1):167. doi: 10.1186/s12943-017-0723-7.
• [507] GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca(2+) signalling in a GABA-independent manner.Gut. 2019 Nov;68(11):1994-2006. doi: 10.1136/gutjnl-2018-317479. Epub 2019 Mar 2.
• [508] Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention.Carcinogenesis. 2012 Jan;33(1):191-6. doi: 10.1093/carcin/bgr251. Epub 2011 Nov 9.
• [509] Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment.Cancer Immunol Immunother. 2019 Oct;68(10):1635-1648. doi: 10.1007/s00262-019-02398-6. Epub 2019 Sep 24.
• [510] Glucose metabolism gene variants modulate the risk of pancreatic cancer.Cancer Prev Res (Phila). 2011 May;4(5):758-66. doi: 10.1158/1940-6207.CAPR-10-0247. Epub 2011 Mar 16.
• [511] BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo.J Cell Sci. 2010 May 15;123(Pt 10):1684-92. doi: 10.1242/jcs.061556. Epub 2010 Apr 20.
• [512] Artemin regulates CXCR4 expression to induce migration and invasion in pancreatic cancer cells through activation of NF-B signaling.Exp Cell Res. 2018 Apr 1;365(1):12-23. doi: 10.1016/j.yexcr.2018.02.008. Epub 2018 Feb 14.
• [513] Pooling-based genome-wide association study implicates gamma-glutamyltransferase 1 (GGT1) gene in pancreatic carcinogenesis.Pancreatology. 2010;10(2-3):194-200. doi: 10.1159/000236023. Epub 2010 May 17.
• [514] High expression of GLO1 indicates unfavorable clinical outcomes in glioma patients.J Neurosurg Sci. 2022 Jun;66(3):228-233. doi: 10.23736/S0390-5616.19.04805-7. Epub 2019 Nov 13.
• [515] Geminin is overexpressed in human pancreatic cancer and downregulated by the bioflavanoid apigenin in pancreatic cancer cell lines.Mol Carcinog. 2008 Nov;47(11):835-44. doi: 10.1002/mc.20441.
• [516] Loss of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) induces apoptotic processes in pancreatic carcinoma cells.FASEB J. 2012 Feb;26(2):938-46. doi: 10.1096/fj.11-186700. Epub 2011 Nov 2.
• [517] The potential role of the glycoprotein osteoactivin/glycoprotein nonmetastatic melanoma protein B in pancreatic cancer.Pancreas. 2015 Mar;44(2):302-10. doi: 10.1097/MPA.0000000000000250.
• [518] Knockdown of GPR137 by RNAi inhibits pancreatic cancer cell growth and induces apoptosis.Biotechnol Appl Biochem. 2015 Nov-Dec;62(6):861-7. doi: 10.1002/bab.1326. Epub 2015 Aug 24.
• [519] Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR.Cancer Res. 2007 Mar 15;67(6):2666-75. doi: 10.1158/0008-5472.CAN-06-3362.
• [520] mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer.Oncotarget. 2016 Apr 19;7(16):21441-53. doi: 10.18632/oncotarget.7375.
• [521] Glutamate receptor GRIA3--target of CUX1 and mediator of tumor progression in pancreatic cancer.Neoplasia. 2010 Aug;12(8):659-67. doi: 10.1593/neo.10486.
• [522] Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells.J Proteomics. 2008 Dec 2;71(5):561-71. doi: 10.1016/j.jprot.2008.09.002. Epub 2008 Sep 25.
• [523] Identification of stable housekeeping genes in response to ionizing radiation in cancer research.Sci Rep. 2017 Mar 6;7:43763. doi: 10.1038/srep43763.
• [524] Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer.Biochem Biophys Res Commun. 1994 Aug 15;202(3):1705-9. doi: 10.1006/bbrc.1994.2131.
• [525] Cell surface lactate receptor GPR81 is crucial for cancer cell survival.Cancer Res. 2014 Sep 15;74(18):5301-10. doi: 10.1158/0008-5472.CAN-14-0319. Epub 2014 Jun 13.
• [526] The Orexin-A-Regulated Akt/mTOR Pathway Promotes Cell Proliferation Through Inhibiting Apoptosis in Pancreatic Cancer Cells.Front Endocrinol (Lausanne). 2018 Oct 31;9:647. doi: 10.3389/fendo.2018.00647. eCollection 2018.
• [527] Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine.Sci Rep. 2018 Jan 26;8(1):1621. doi: 10.1038/s41598-018-20004-0.
• [528] HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.Oncogene. 2017 Mar 30;36(13):1804-1815. doi: 10.1038/onc.2016.344. Epub 2016 Oct 10.
• [529] HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.Pancreatology. 2019 Mar;19(2):383-389. doi: 10.1016/j.pan.2019.01.011. Epub 2019 Jan 16.
• [530] Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.Invest New Drugs. 2019 Feb;37(1):109-117. doi: 10.1007/s10637-018-0634-5. Epub 2018 Jul 11.
• [531] Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer.Mol Cancer. 2005 Apr 7;4(1):14. doi: 10.1186/1476-4598-4-14.
• [532] Analysis of gene expression profiles in pancreatic carcinoma by using cDNA microarray.Hepatobiliary Pancreat Dis Int. 2003 Aug;2(3):467-70.
• [533] Hepatocyte Growth Factor and Macrophage-stimulating Protein "Hinge" Analogs to Treat Pancreatic Cancer.Curr Cancer Drug Targets. 2019;19(10):782-795. doi: 10.2174/1568009619666190326130008.
• [534] Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer.Cancer Sci. 2008 Jul;99(7):1341-7. doi: 10.1111/j.1349-7006.2008.00828.x. Epub 2008 Apr 16.
• [535] Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma. Oncogene. 2015 Jan 8;34(2):263-8.
• [536] HMGA1 expression levels are elevated in pancreatic intraepithelial neoplasia cells in the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer.Br J Cancer. 2017 Aug 22;117(5):639-647. doi: 10.1038/bjc.2017.216. Epub 2017 Jul 11.
• [537] HNRNPA2B1 regulates the epithelial-mesenchymal transition in pancreatic cancer cells through the ERK/snail signalling pathway.Cancer Cell Int. 2017 Jan 10;17:12. doi: 10.1186/s12935-016-0368-4. eCollection 2017.
• [538] Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action.Cancer Lett. 2009 Jun 18;278(2):241-248. doi: 10.1016/j.canlet.2009.01.005. Epub 2009 Feb 8.
• [539] Enzyme-treated Asparagus Extract Down-regulates Heat Shock Protein 27 of Pancreatic Cancer Cells.In Vivo. 2018 Jul-Aug;32(4):759-763. doi: 10.21873/invivo.11305.
• [540] Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.Int J Cancer. 2014 Mar 15;134(6):1369-78. doi: 10.1002/ijc.28471. Epub 2013 Oct 3.
• [541] Omega-3-polyunsaturated fatty acids suppress pancreatic cancer cell growth in vitro and in vivo via downregulation of Wnt/Beta-catenin signaling.Pancreatology. 2011;11(6):574-84. doi: 10.1159/000334468. Epub 2011 Dec 31.
• [542] The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer.Cancer Res. 1998 Sep 1;58(17):3769-72.
• [543] Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors.Ann Surg. 2007 Aug;246(2):259-68. doi: 10.1097/01.sla.0000261460.07110.f2.
• [544] Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer.Cancer Epidemiol. 2012 Apr;36(2):206-11. doi: 10.1016/j.canep.2011.05.013. Epub 2011 Aug 17.
• [545] Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk.Carcinogenesis. 2016 Nov 1;37(11):1052-1061. doi: 10.1093/carcin/bgw096.
• [546] Genetic polymorphisms associated with pancreatic cancer survival: a genome-wide association study.Int J Cancer. 2017 Aug 15;141(4):678-686. doi: 10.1002/ijc.30762. Epub 2017 May 15.
• [547] mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.Mol Ther. 2005 May;11(5):724-33. doi: 10.1016/j.ymthe.2004.12.021.
• [548] Interleukin 21 Receptor/Ligand Interaction Is Linked to Disease Progression in Pancreatic Cancer.Cells. 2019 Sep 18;8(9):1104. doi: 10.3390/cells8091104.
• [549] ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling.Clin Transl Oncol. 2020 Apr;22(4):563-575. doi: 10.1007/s12094-019-02160-5. Epub 2019 Jun 15.
• [550] Interleukin-32 expression in the pancreas.J Biol Chem. 2009 Jun 26;284(26):17868-76. doi: 10.1074/jbc.M900368200. Epub 2009 Apr 21.
• [551] Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells.Oncogene. 2016 Jul 28;35(30):3897-908. doi: 10.1038/onc.2015.458. Epub 2015 Nov 30.
• [552] Tumor-Stroma IL1-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer.Cancer Res. 2018 Apr 1;78(7):1700-1712. doi: 10.1158/0008-5472.CAN-17-1366. Epub 2018 Jan 23.
• [553] Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer.Cancer Res. 1998 Oct 1;58(19):4250-4.
• [554] ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.Sci Rep. 2017 Aug 30;7(1):10060. doi: 10.1038/s41598-017-09946-z.
• [555] Integrin 11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer.FASEB J. 2019 May;33(5):6609-6621. doi: 10.1096/fj.201802336R. Epub 2019 Feb 26.
• [556] Suppression of CD51 in pancreatic stellate cells inhibits tumor growth by reducing stroma and altering tumor-stromal interaction in pancreatic cancer.Int J Oncol. 2016 Apr;48(4):1499-508. doi: 10.3892/ijo.2016.3374. Epub 2016 Feb 3.
• [557] The NOTCH ligand JAGGED2 promotes pancreatic cancer metastasis independent of NOTCH signaling activation.Mol Cancer Ther. 2015 Jan;14(1):289-97. doi: 10.1158/1535-7163.MCT-14-0501. Epub 2014 Oct 28.
• [558] Jumonji AT-rich interactive domain 1B promotes the growth of pancreatic tumors via the phosphatase and tensin homolog/protein kinase B signaling pathway.Oncol Lett. 2018 Jul;16(1):267-275. doi: 10.3892/ol.2018.8618. Epub 2018 May 2.
• [559] Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBP.Carcinogenesis. 2014 Nov;35(11):2404-14. doi: 10.1093/carcin/bgu136. Epub 2014 Jun 19.
• [560] A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.Oncoimmunology. 2018 Jan 16;7(4):e1303584. doi: 10.1080/2162402X.2017.1303584. eCollection 2018.
• [561] Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer.Sci Rep. 2019 Aug 2;9(1):11239. doi: 10.1038/s41598-019-47519-4.
• [562] LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.Cell Death Dis. 2019 Mar 8;10(3):230. doi: 10.1038/s41419-019-1320-z.
• [563] UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.J Exp Clin Cancer Res. 2019 Jul 9;38(1):297. doi: 10.1186/s13046-019-1278-9.
• [564] Association of lysosomal protein transmembrane 4 beta gene polymorphism with pancreatic carcinoma susceptibility in the Chinese population.Tumour Biol. 2017 Jun;39(6):1010428317705518. doi: 10.1177/1010428317705518.
• [565] Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis.Cancer Cell Int. 2019 Nov 21;19:309. doi: 10.1186/s12935-019-1025-5. eCollection 2019.
• [566] Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.Nat Commun. 2019 Jul 11;10(1):3055. doi: 10.1038/s41467-019-11044-9.
• [567] Leukemia inhibitory factor receptor negatively regulates the metastasis of pancreatic cancer cells in vitro and in vivo.Oncol Rep. 2016 Aug;36(2):827-36. doi: 10.3892/or.2016.4865. Epub 2016 Jun 9.
• [568] LIMK1 and LIMK2 are important for metastatic behavior and tumor cell-induced angiogenesis of pancreatic cancer cells.Zebrafish. 2009 Dec;6(4):433-9. doi: 10.1089/zeb.2009.0602.
• [569] MeCP2 suppresses LIN28A expression via binding to its methylated-CpG islands in pancreatic cancer cells. Oncotarget. 2016 Mar 22;7(12):14476-85. doi: 10.18632/oncotarget.7507.
• [570] Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice.BMC Cancer. 2018 Aug 7;18(1):797. doi: 10.1186/s12885-018-4713-y.
• [571] LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer.Neoplasia. 2009 Jul;11(7):712-9. doi: 10.1593/neo.09418.
• [572] Inhibition of LONP1 Suppresses Pancreatic Cancer Progression Via c-Jun N-Terminal Kinase Pathway-Meditated Epithelial-Mesenchymal Transition. Pancreas. 2019 May/Jun;48(5):629-635.
• [573] miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2.Mol Cancer Res. 2020 Feb;18(2):311-323. doi: 10.1158/1541-7786.MCR-19-0594. Epub 2019 Oct 29.
• [574] Modulation of post-translational modifications in -catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer.Cancer Lett. 2017 Mar 1;388:64-72. doi: 10.1016/j.canlet.2016.11.026. Epub 2016 Dec 3.
• [575] CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer.Anticancer Res. 2003 May-Jun;23(3A):2007-13.
• [576] Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene Ahydrolase.Cancer Res. 2010 Dec 1;70(23):9755-64. doi: 10.1158/0008-5472.CAN-10-2858. Epub 2010 Oct 15.
• [577] BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation.Br J Cancer. 2008 Oct 7;99(7):1064-73. doi: 10.1038/sj.bjc.6604655. Epub 2008 Sep 9.
• [578] Integrin beta 4 (ITGB4) and its tyrosine-1510 phosphorylation promote pancreatic tumorigenesis and regulate the MEK1-ERK1/2 signaling pathway.Bosn J Basic Med Sci. 2020 Feb 5;20(1):106-116. doi: 10.17305/bjbms.2019.4255.
• [579] The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.Mol Cancer Ther. 2012 Sep;11(9):1999-2009. doi: 10.1158/1535-7163.MCT-12-0017. Epub 2012 Jul 2.
• [580] Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation.J Biol Chem. 2019 Jun 7;294(23):9029-9036. doi: 10.1074/jbc.AC119.007466. Epub 2019 Apr 24.
• [581] miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4.Mol Cancer Ther. 2013 Nov;12(11):2569-80. doi: 10.1158/1535-7163.MCT-13-0296. Epub 2013 Sep 6.
• [582] High Glucose-Induced ROS Production Stimulates Proliferation of Pancreatic Cancer via Inactivating the JNK Pathway.Oxid Med Cell Longev. 2018 Nov 21;2018:6917206. doi: 10.1155/2018/6917206. eCollection 2018.
• [583] High-mobility Group Box 1 and Mitogen-activated Protein Kinase activated Protein Kinase-2 Are Up-regulated in Gemcitabine-resistant Pancreatic Cancer Cells.Anticancer Res. 2015 Jul;35(7):3861-5.
• [584] Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.Neoplasia. 2010 Oct;12(10):797-806. doi: 10.1593/neo.10418.
• [585] Co-Delivery of Gemcitabine and Mcl-1 SiRNA via Cationic Liposome-Based System Enhances the Efficacy of Chemotherapy in Pancreatic Cancer.J Biomed Nanotechnol. 2019 May 1;15(5):966-978. doi: 10.1166/jbn.2019.2762.
• [586] Expression of p53 synergistically augments caspases-mediated apoptosis induced by replication-competent adenoviruses in pancreatic carcinoma cells.Cancer Gene Ther. 2015 Sep;22(9):445-53. doi: 10.1038/cgt.2015.33. Epub 2015 Aug 7.
• [587] Inhibiting -Catenin by -Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy.Front Pharmacol. 2018 Jan 17;9:5. doi: 10.3389/fphar.2018.00005. eCollection 2018.
• [588] Self-assembled dual-drug loaded core-shell nanoparticles based on metal-free fully alternating polyester for cancer theranostics.Mater Sci Eng C Mater Biol Appl. 2019 Aug;101:448-463. doi: 10.1016/j.msec.2019.03.041. Epub 2019 Mar 12.
• [589] MicroRNA hsa-miR-623 directly suppresses MMP1 and attenuates IL-8-induced metastasis in pancreatic cancer.Int J Oncol. 2019 Jul;55(1):142-156. doi: 10.3892/ijo.2019.4803. Epub 2019 May 17.
• [590] Therapeutic effects and anti-metastasis effects of cationic liposomes against pancreatic cancer metastasis invitro and invivo.Biochem Biophys Res Commun. 2019 Apr 9;511(3):504-509. doi: 10.1016/j.bbrc.2019.02.116. Epub 2019 Feb 23.
• [591] Clinical implications of mismatched repair gene promoter methylation in pancreatic cancer.Med Oncol. 2012 Jun;29(2):970-6. doi: 10.1007/s12032-011-9968-y. Epub 2011 Jun 10.
• [592] Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer.PLoS One. 2011;6(11):e27684. doi: 10.1371/journal.pone.0027684. Epub 2011 Nov 14.
• [593] Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer.Clin Cancer Res. 2004 Nov 1;10(21):7290-6. doi: 10.1158/1078-0432.CCR-04-0972.
• [594] Addition of analysis of KRAS mutation or immunohistochemistry with MUC1 and carcinoembryonic antigen improves the diagnostic performance of fine needle aspiration cytology for the diagnosis of pancreatic carcinoma.Cytopathology. 2019 Sep;30(5):485-491. doi: 10.1111/cyt.12697. Epub 2019 Apr 23.
• [595] Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis.J Cancer. 2019 Jun 9;10(16):3746-3756. doi: 10.7150/jca.32052. eCollection 2019.
• [596] Expression of MUC17 is regulated by HIF1-mediated hypoxic responses and requires a methylation-free hypoxia responsible element in pancreatic cancer.PLoS One. 2012;7(9):e44108. doi: 10.1371/journal.pone.0044108. Epub 2012 Sep 10.
• [597] Usefulness of immunohistochemical staining for MUC5AC in differentiating primary pancreatic cancer from pancreatic metastasis of breast cancer.Diagn Cytopathol. 2019 Oct;47(10):1037-1041. doi: 10.1002/dc.24249. Epub 2019 Jun 6.
• [598] Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer.J Exp Clin Cancer Res. 2015 Mar 28;34(1):30. doi: 10.1186/s13046-015-0144-7.
• [599] Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer.Cancer Sci. 2016 Sep;107(9):1315-20. doi: 10.1111/cas.12993. Epub 2016 Aug 12.
• [600] ZIP4 upregulates the expression of neuropilin-1, vascular endothelial growth factor, and matrix metalloproteases in pancreatic cancer cell lines and xenografts.Cancer Biol Ther. 2010 Feb;9(3):236-42. doi: 10.4161/cbt.9.3.10749. Epub 2010 Feb 25.
• [601] Sonic hedgehog signaling pathway promotes pancreatic cancer pain via nerve growth factor.Reg Anesth Pain Med. 2020 Feb;45(2):137-144. doi: 10.1136/rapm-2019-100991. Epub 2019 Dec 1.
• [602] Up-regulation, nuclear import, and tumor growth stimulation of the adhesion protein p120 in pancreatic cancer.Gastroenterology. 2003 Apr;124(4):949-60. doi: 10.1053/gast.2003.50142.
• [603] NOX4, a new genetic target for anti-cancer therapy in digestive system cancer.J Dig Dis. 2018 Oct;19(10):578-585. doi: 10.1111/1751-2980.12651. Epub 2018 Oct 15.
• [604] NPTX2 hypermethylation in pure pancreatic juice predicts pancreatic neoplasms.Am J Med Sci. 2013 Sep;346(3):175-80. doi: 10.1097/MAJ.0b013e31827b94b6.
• [605] Peptide tyrosine-tyrosine combined with its receptors exhibits an anti-cancer potential in pancreatic cancer MiaPaCa-2 cell.Chin Med J (Engl). 2014;127(24):4235-42.
• [606] Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer.Int J Clin Exp Pathol. 2015 Sep 1;8(9):11579-86. eCollection 2015.
• [607] Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice.Mol Med. 2017 Mar;23:13-23. doi: 10.2119/molmed.2016.00214. Epub 2017 Feb 6.
• [608] Inactivation of the orphan nuclear receptor NR4A1 contributes to apoptosis induction by fangchinoline in pancreatic cancer cells.Toxicol Appl Pharmacol. 2017 Oct 1;332:32-39. doi: 10.1016/j.taap.2017.07.017. Epub 2017 Jul 25.
• [609] Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer.Nat Commun. 2018 Feb 8;9(1):556. doi: 10.1038/s41467-018-02942-5.
• [610] Development of [(18)F]AlF-NOTA-NT as PET Agents of Neurotensin Receptor-1 Positive Pancreatic Cancer.Mol Pharm. 2018 Aug 6;15(8):3093-3100. doi: 10.1021/acs.molpharmaceut.8b00192. Epub 2018 Jun 26.
• [611] Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor.Int J Oncol. 2008 Aug;33(2):317-23.
• [612] Olfactomedin-4 in digestive diseases: A mini-review.World J Gastroenterol. 2018 May 7;24(17):1881-1887. doi: 10.3748/wjg.v24.i17.1881.
• [613] Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.Mol Cancer. 2015 Dec 16;14:210. doi: 10.1186/s12943-015-0479-x.
• [614] Activating P2X7 Receptors Increases Proliferation of Human Pancreatic Cancer Cells via ERK1/2 and JNK.Pancreas. 2018 May/Jun;47(5):643-651. doi: 10.1097/MPA.0000000000001055.
• [615] Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?.Oncotarget. 2017 Feb 21;8(8):14173-14191. doi: 10.18632/oncotarget.13309.
• [616] P21 activated kinase 2 promotes pancreatic cancer growth and metastasis.Oncol Lett. 2019 Apr;17(4):3709-3718. doi: 10.3892/ol.2019.10040. Epub 2019 Feb 14.
• [617] P21-activated kinase 4 in pancreatic acinar cells is activated by numerous gastrointestinal hormones/neurotransmitters and growth factors by novel signaling, and its activation stimulates secretory/growth cascades.Am J Physiol Gastrointest Liver Physiol. 2018 Aug 1;315(2):G302-G317. doi: 10.1152/ajpgi.00005.2018. Epub 2018 Apr 19.
• [618] Maintenance Rucaparib Controls Some Pancreatic Cancers.Cancer Discov. 2019 Jun;9(6):OF4. doi: 10.1158/2159-8290.CD-NB2019-043. Epub 2019 Apr 2.
• [619] The clinical significance of SWI/SNF complex in pancreatic cancer.Int J Oncol. 2013 Feb;42(2):403-10. doi: 10.3892/ijo.2012.1723. Epub 2012 Nov 30.
• [620] PACE4 regulates apoptosis in human pancreatic cancer Panc? cells via the mitochondrial signaling pathway.Mol Med Rep. 2016 Dec;14(6):5205-5210. doi: 10.3892/mmr.2016.5885. Epub 2016 Oct 25.
• [621] Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer.Cancer Lett. 2018 Sep 28;432:237-250. doi: 10.1016/j.canlet.2018.04.035. Epub 2018 Apr 28.
• [622] High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF.Neoplasia. 2008 Jul;10(7):674-9. doi: 10.1593/neo.08292.
• [623] p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA.Mol Cell Biol. 1998 Dec;18(12):6962-70. doi: 10.1128/MCB.18.12.6962.
• [624] Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting.Mol Ther Oncolytics. 2019 May 17;14:149-158. doi: 10.1016/j.omto.2019.04.006. eCollection 2019 Sep 27.
• [625] ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer.ACS Appl Mater Interfaces. 2019 Apr 24;11(16):14647-14659. doi: 10.1021/acsami.9b02756. Epub 2019 Apr 12.
• [626] Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility.Cancer Lett. 2016 Mar 28;372(2):210-8. doi: 10.1016/j.canlet.2016.01.016. Epub 2016 Jan 19.
• [627] Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis.Int J Cancer. 2005 Oct 10;116(6):925-33. doi: 10.1002/ijc.21118.
• [628] Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer.J Natl Cancer Inst. 2019 Jun 1;111(6):557-567. doi: 10.1093/jnci/djy155.
• [629] Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis.J Cell Biochem. 2019 Dec;120(12):19496-19508. doi: 10.1002/jcb.29253. Epub 2019 Jul 11.
• [630] Cyclophilin B promotes cell proliferation, migration, invasion and angiogenesis via regulating the STAT3 pathway in non-small cell lung cancer.Pathol Res Pract. 2019 Jun;215(6):152417. doi: 10.1016/j.prp.2019.04.009. Epub 2019 Apr 17.
• [631] Gemcitabine-induced pancreatic cancer cell death is associated with MST1/cyclophilin D mitochondrial complexation.Biochimie. 2014 Aug;103:71-9. doi: 10.1016/j.biochi.2014.04.004. Epub 2014 Apr 13.
• [632] Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells in vitro.Oncol Lett. 2018 Jun;15(6):8761-8769. doi: 10.3892/ol.2018.8363. Epub 2018 Mar 28.
• [633] Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells.Oncotarget. 2017 May 9;8(19):30992-31002. doi: 10.18632/oncotarget.16047.
• [634] Protein kinase C zeta regulates human pancreatic cancer cell transformed growth and invasion through a STAT3-dependent mechanism.PLoS One. 2013 Aug 28;8(8):e72061. doi: 10.1371/journal.pone.0072061. eCollection 2013.
• [635] Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1.Br J Cancer. 2020 Jan;122(1):121-131. doi: 10.1038/s41416-019-0629-9. Epub 2019 Dec 10.
• [636] Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers.Cancer Res. 2008 Feb 15;68(4):971-5. doi: 10.1158/0008-5472.CAN-07-6272.
• [637] Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer.J Hematol Oncol. 2019 Jul 19;12(1):79. doi: 10.1186/s13045-019-0769-7.
• [638] Expression of prion protein is closely associated with pathological and clinical progression and abnormalities of p53 in head and neck squamous cell carcinomas.Oncol Rep. 2016 Feb;35(2):817-24. doi: 10.3892/or.2015.4425. Epub 2015 Nov 16.
• [639] Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer.Med Mol Morphol. 2019 Dec;52(4):198-208. doi: 10.1007/s00795-019-00218-5. Epub 2019 Feb 25.
• [640] Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.J Nucl Med. 2018 Sep;59(9):1398-1405. doi: 10.2967/jnumed.117.207332. Epub 2018 Mar 30.
• [641] Gankyrin promotes the proliferation of human pancreatic cancer.Cancer Lett. 2010 Nov 1;297(1):9-17. doi: 10.1016/j.canlet.2010.04.019. Epub 2010 May 18.
• [642] Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth.Pancreas. 2008 May;36(4):353-62. doi: 10.1097/MPA.0b013e31815ccc44.
• [643] Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines.Bioorg Chem. 2020 Jan;94:103408. doi: 10.1016/j.bioorg.2019.103408. Epub 2019 Oct 30.
• [644] Pleiotrophin and N-syndecan promote perineural invasion and tumor progression in an orthotopic mouse model of pancreatic cancer.World J Gastroenterol. 2017 Jun 7;23(21):3907-3914. doi: 10.3748/wjg.v23.i21.3907.
• [645] FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis.J Cell Sci. 2001 Aug;114(Pt 15):2735-46. doi: 10.1242/jcs.114.15.2735.
• [646] Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation.J Cancer. 2018 Sep 8;9(18):3394-3399. doi: 10.7150/jca.26068. eCollection 2018.
• [647] Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862.
• [648] RBPJ and MAML3: Potential Therapeutic Targets for Small Cell Lung Cancer. Anticancer Res. 2018 Aug;38(8):4543-4547.
• [649] Eckol inhibits Reg3A-induced proliferation of human SW1990 pancreatic cancer cells.Exp Ther Med. 2019 Oct;18(4):2825-2832. doi: 10.3892/etm.2019.7889. Epub 2019 Aug 14.
• [650] The pancreatic cancer secreted REG4 promotes macrophage polarization to M2 through EGFR/AKT/CREB pathway.Oncol Rep. 2016 Jan;35(1):189-96. doi: 10.3892/or.2015.4357. Epub 2015 Oct 29.
• [651] RGS16 and FosB underexpressed in pancreatic cancer with lymph node metastasis promote tumor progression.Tumour Biol. 2010 Oct;31(5):541-8. doi: 10.1007/s13277-010-0067-z. Epub 2010 Jun 23.
• [652] RNASEL germline variants are associated with pancreatic cancer.Int J Cancer. 2005 Dec 10;117(5):718-22. doi: 10.1002/ijc.21254.
• [653] ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1.Cancers (Basel). 2019 Nov 27;11(12):1881. doi: 10.3390/cancers11121881.
• [654] Genetic variation of clock genes and cancer risk: a field synopsis and meta-analysis.Oncotarget. 2017 Apr 4;8(14):23978-23995. doi: 10.18632/oncotarget.15074.
• [655] Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.J Clin Pharm Ther. 2018 Apr;43(2):163-169. doi: 10.1111/jcpt.12655. Epub 2017 Dec 6.
• [656] Inhibition of LINC00994 represses malignant behaviors of pancreatic cancer cells: interacting with miR-765-3p/RUNX2 axis.Cancer Biol Ther. 2019;20(6):799-811. doi: 10.1080/15384047.2018.1564566. Epub 2019 Feb 11.
• [657] NO(? /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer.Int J Cancer. 2020 Jun 1;146(11):3160-3169. doi: 10.1002/ijc.32733. Epub 2019 Nov 19.
• [658] Genetic variants in vitamin d pathway genes and risk of pancreas cancer; results from a population-based case-control study in ontario, Canada.PLoS One. 2013 Jun 24;8(6):e66768. doi: 10.1371/journal.pone.0066768. Print 2013.
• [659] Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance.World J Surg Oncol. 2019 Sep 16;17(1):163. doi: 10.1186/s12957-019-1707-4.
• [660] Triptolide and celastrol loaded silk fibroin nanoparticles show synergistic effect against human pancreatic cancer cells.Nanoscale. 2017 Aug 17;9(32):11739-11753. doi: 10.1039/c7nr03016a.
• [661] Using an endoscopic distal cap to collect pancreatic fluid fromthe ampulla (with video).Gastrointest Endosc. 2017 Dec;86(6):1152-1156.e2. doi: 10.1016/j.gie.2017.02.026. Epub 2017 Mar 1.
• [662] Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.Nature. 2019 Apr;568(7752):410-414. doi: 10.1038/s41586-019-1062-1. Epub 2019 Mar 27.
• [663] Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47.Am J Clin Pathol. 2002 Jul;118(1):52-9. doi: 10.1309/3PAM-P5WL-2LV0-R4EG.
• [664] SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma.Am J Cancer Res. 2019 Feb 1;9(2):363-377. eCollection 2019.
• [665] Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer.Front Oncol. 2019 Jul 9;9:542. doi: 10.3389/fonc.2019.00542. eCollection 2019.
• [666] miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer.Oncol Rep. 2016 Mar;35(3):1365-74. doi: 10.3892/or.2015.4534. Epub 2015 Dec 29.
• [667] Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis.Lancet Oncol. 2018 Jun;19(6):758-767. doi: 10.1016/S1470-2045(18)30188-8. Epub 2018 Apr 26.
• [668] MiR-708-5p inhibits the progression of pancreatic ductal adenocarcinoma by targeting Sirt3.Pathol Res Pract. 2019 Apr;215(4):794-800. doi: 10.1016/j.prp.2019.01.026. Epub 2019 Jan 18.
• [669] Skp2 Expression Is Inhibited by Arsenic Trioxide through the Upregulation of miRNA-330-5p in Pancreatic Cancer Cells.Mol Ther Oncolytics. 2019 Feb 5;12:214-223. doi: 10.1016/j.omto.2019.01.006. eCollection 2019 Mar 29.
• [670] Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Br J Pharmacol. 2016 Dec;173(23):3292-3306.
• [671] The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.Mol Cancer Ther. 2016 Nov;15(11):2679-2687. doi: 10.1158/1535-7163.MCT-16-0225. Epub 2016 Aug 22.
• [672] A Novel Approach for Image-Guided (131)I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery.Mol Cancer Res. 2019 Jan;17(1):310-320. doi: 10.1158/1541-7786.MCR-18-0185. Epub 2018 Sep 17.
• [673] c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells.Oncol Rep. 2012 Sep;28(3):862-6. doi: 10.3892/or.2012.1878. Epub 2012 Jun 20.
• [674] Activation of Na+/H+ exchanger 1 by neurotensin signaling in pancreatic cancer cell lines.Biochem Biophys Res Commun. 2010 Mar 12;393(3):414-9. doi: 10.1016/j.bbrc.2010.02.009. Epub 2010 Feb 6.
• [675] Expression of OATP family members in hormone-related cancers: potential markers of progression.PLoS One. 2011;6(5):e20372. doi: 10.1371/journal.pone.0020372. Epub 2011 May 19.
• [676] Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling.Cell Death Dis. 2015 Jan 15;6(1):e1592. doi: 10.1038/cddis.2014.557.
• [677] Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2.Carcinogenesis. 2009 Feb;30(2):238-48. doi: 10.1093/carcin/bgn274. Epub 2008 Dec 4.
• [678] Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer.Biochem Biophys Res Commun. 1999 Feb 16;255(2):268-73. doi: 10.1006/bbrc.1999.0171.
• [679] Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer.Carcinogenesis. 2019 Jun 10;40(4):521-528. doi: 10.1093/carcin/bgz029.
• [680] Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.Genes Dev. 2016 Apr 1;30(7):772-85. doi: 10.1101/gad.275529.115. Epub 2016 Mar 17.
• [681] Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer.Clin Cancer Res. 2009 Apr 15;15(8):2864-71. doi: 10.1158/1078-0432.CCR-08-2946. Epub 2009 Apr 7.
• [682] Association between methylation of tumor suppressor gene SOCS1 and acute myeloid leukemia.Oncol Rep. 2018 Aug;40(2):1008-1016. doi: 10.3892/or.2018.6508. Epub 2018 Jun 19.
• [683] MiR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3.Eur Rev Med Pharmacol Sci. 2019 Aug;23(16):6906-6913. doi: 10.26355/eurrev_201908_18730.
• [684] Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer.Oncotarget. 2015 Oct 13;6(31):31119-33. doi: 10.18632/oncotarget.5045.
• [685] Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.Clin Cancer Res. 2017 Sep 1;23(17):5066-5073. doi: 10.1158/1078-0432.CCR-17-0492. Epub 2017 Jun 13.
• [686] Pancreatic stellate cells derived from human pancreatic cancer demonstrate aberrant SPARC-dependent ECM remodeling in 3D engineered fibrotic tissue of clinically relevant thickness.Biomaterials. 2019 Feb;192:355-367. doi: 10.1016/j.biomaterials.2018.11.023. Epub 2018 Nov 17.
• [687] Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.Oncotarget. 2016 Sep 13;7(37):60181-60192. doi: 10.18632/oncotarget.11112.
• [688] Stromal SPOCK1 supports invasive pancreatic cancer growth.Mol Oncol. 2017 Aug;11(8):1050-1064. doi: 10.1002/1878-0261.12073. Epub 2017 Jun 5.
• [689] Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells.Cancer Biol Ther. 2019;20(6):855-865. doi: 10.1080/15384047.2019.1579956. Epub 2019 Mar 13.
• [690] Serine/arginine protein-specific kinase 2 promotes the development and progression of pancreatic cancer by downregulating Numb and p53.FEBS J. 2019 May;286(9):1668-1682. doi: 10.1111/febs.14778. Epub 2019 Mar 1.
• [691] New somatostatin-drug conjugates for effective targeting pancreatic cancer.Bioorg Med Chem. 2018 Jul 30;26(13):3825-3836. doi: 10.1016/j.bmc.2018.06.032. Epub 2018 Jun 30.
• [692] Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer.Cancer Sci. 2008 Nov;99(11):2218-23. doi: 10.1111/j.1349-7006.2008.00940.x. Epub 2008 Sep 22.
• [693] STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines.Oncotarget. 2017 Sep 11;8(45):78556-78572. doi: 10.18632/oncotarget.20833. eCollection 2017 Oct 3.
• [694] High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Clinical Patients with Pancreatic Cancer.Anticancer Res. 2018 Feb;38(2):939-944. doi: 10.21873/anticanres.12307.
• [695] Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody.Cancer Med. 2019 Dec;8(18):7781-7792. doi: 10.1002/cam4.2658. Epub 2019 Nov 1.
• [696] Upregulation of transgelin is an independent factor predictive of poor prognosis in patients with advanced pancreatic cancer.Cancer Sci. 2013 Apr;104(4):423-30. doi: 10.1111/cas.12107. Epub 2013 Feb 27.
• [697] Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer. J Exp Clin Cancer Res. 2018 Jul 24;37(1):166.
• [698] Oncogenic Ras suppresses ING4-TDG-Fas axis to promote apoptosis resistance.Oncotarget. 2015 Dec 8;6(39):41997-2007. doi: 10.18632/oncotarget.6015.
• [699] Quantitative analysis of single amino acid variant peptides associated with pancreatic cancer in serum by an isobaric labeling quantitative method.J Proteome Res. 2014 Dec 5;13(12):6058-66. doi: 10.1021/pr500934u. Epub 2014 Nov 24.
• [700] Aberrant expressions of AP-2 splice variants in pancreatic cancer.Pancreas. 2011 Jul;40(5):695-700. doi: 10.1097/MPA.0b013e31821f2715.
• [701] Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.EBioMedicine. 2019 Apr;42:375-385. doi: 10.1016/j.ebiom.2019.03.056. Epub 2019 Apr 5.
• [702] Mesothelin and TGF- predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib.PLoS One. 2019 Mar 28;14(3):e0213294. doi: 10.1371/journal.pone.0213294. eCollection 2019.
• [703] Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis.Cell Prolif. 2018 Jun;51(3):e12428. doi: 10.1111/cpr.12428. Epub 2017 Dec 20.
• [704] Association between Variants in Atopy-Related Immunologic Candidate Genes and Pancreatic Cancer Risk.PLoS One. 2015 May 6;10(5):e0125273. doi: 10.1371/journal.pone.0125273. eCollection 2015.
• [705] Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model.Cancer Immunol Res. 2019 Oct;7(10):1714-1726. doi: 10.1158/2326-6066.CIR-19-0101. Epub 2019 Aug 13.
• [706] TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer.Int J Oncol. 2015 Sep;47(3):857-66. doi: 10.3892/ijo.2015.3069. Epub 2015 Jul 2.
• [707] Anti-tumor Efficacy Assessment of the Sigma Receptor Pan Modulator RC-106. A Promising Therapeutic Tool for Pancreatic Cancer.Front Pharmacol. 2019 May 14;10:490. doi: 10.3389/fphar.2019.00490. eCollection 2019.
• [708] Thymosin Beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation.Cancer Biol Ther. 2008 Mar;7(3):419-23. doi: 10.4161/cbt.7.3.5415. Epub 2007 Dec 13.
• [709] HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.Mol Cancer Res. 2016 Jul;14(7):599-611. doi: 10.1158/1541-7786.MCR-15-0448. Epub 2016 Apr 6.
• [710] The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection.Cancers (Basel). 2019 May 29;11(6):745. doi: 10.3390/cancers11060745.
• [711] MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma.Theranostics. 2019 Jan 1;9(2):436-448. doi: 10.7150/thno.27576. eCollection 2019.
• [712] High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.Mol Cancer Res. 2011 Jun;9(6):724-32. doi: 10.1158/1541-7786.MCR-10-0436. Epub 2011 May 2.
• [713] TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas.Scand J Gastroenterol. 2015 Apr;50(4):485-94. doi: 10.3109/00365521.2014.980318. Epub 2015 Jan 23.
• [714] Mast Cell Tryptase Contributes to Pancreatic Cancer Growth through Promoting Angiogenesis via Activation of Angiopoietin-1.Int J Mol Sci. 2016 May 27;17(6):834. doi: 10.3390/ijms17060834.
• [715] Novel TREM-1 Inhibitors Attenuate Tumor Growth and Prolong Survival in Experimental Pancreatic Cancer.Mol Pharm. 2017 Dec 4;14(12):4572-4582. doi: 10.1021/acs.molpharmaceut.7b00711. Epub 2017 Nov 13.
• [716] Identification of epigenetically silenced genes in human pancreatic cancer by a novel method "microarray coupled with methyl-CpG targeted transcriptional activation" (MeTA-array). Biochem Biophys Res Commun. 2011 Jul 22;411(1):162-7.
• [717] KAP-1 is overexpressed and correlates with increased metastatic ability and tumorigenicity in pancreatic cancer.Med Oncol. 2014 Jul;31(7):25. doi: 10.1007/s12032-014-0025-5. Epub 2014 May 27.
• [718] TRIM37 promoted the growth and migration of the pancreatic cancer cells.Tumour Biol. 2016 Feb;37(2):2629-34. doi: 10.1007/s13277-015-4078-7. Epub 2015 Sep 22.
• [719] Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.PLoS One. 2017 Apr 5;12(4):e0174863. doi: 10.1371/journal.pone.0174863. eCollection 2017.
• [720] PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker.Cell Mol Life Sci. 2017 Nov;74(22):4231-4243. doi: 10.1007/s00018-017-2579-9. Epub 2017 Jun 27.
• [721] Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy.Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):490-497. doi: 10.1016/j.ijrobp.2017.10.030. Epub 2017 Oct 28.
• [722] Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer.Cancer Lett. 2020 Feb 1;470:149-160. doi: 10.1016/j.canlet.2019.11.028. Epub 2019 Nov 23.
• [723] Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma.Pathol Oncol Res. 2007;13(2):105-13. doi: 10.1007/BF02893485. Epub 2007 Jul 3.
• [724] USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1.Am J Cancer Res. 2019 Aug 1;9(8):1722-1733. eCollection 2019.
• [725] Strabismus (STB)/Vang-like (VANGL) gene family (Review).Int J Mol Med. 2002 Jul;10(1):11-5.
• [726] Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.Int J Oncol. 2005 Sep;27(3):669-79.
• [727] WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells.Hepatobiliary Pancreat Dis Int. 2014 Oct;13(5):529-38. doi: 10.1016/s1499-3872(14)60277-0.
• [728] Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy.Oncotarget. 2016 Jan 26;7(4):3984-92. doi: 10.18632/oncotarget.6766.
• [729] UV light killing efficacy of fluorescent protein-expressing cancer cells in vitro and in vivo.J Cell Biochem. 2010 Aug 15;110(6):1439-46. doi: 10.1002/jcb.22693.
• [730] Linc-RoR promotes proliferation, migration, and invasion via the Hippo/YAP pathway in pancreatic cancer cells.J Cell Biochem. 2020 Jan;121(1):632-641. doi: 10.1002/jcb.29308. Epub 2019 Aug 26.
• [731] The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion.Pancreas. 2014 Jul;43(5):768-76. doi: 10.1097/MPA.0000000000000103.
• [732] Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.J Exp Clin Cancer Res. 2019 Aug 5;38(1):312. doi: 10.1186/s13046-019-1308-7.
• [733] Polymorphisms and pancreatic cancer risk: a meta-analysis.Eur J Cancer Prev. 2011 May;20(3):169-83. doi: 10.1097/CEJ.0b013e328344743a.
• [734] Role of CCL20 mediated immune cell recruitment in NF-B mediated TRAIL resistance of pancreatic cancer.Biochim Biophys Acta Mol Cell Res. 2017 May;1864(5):782-796. doi: 10.1016/j.bbamcr.2017.02.005. Epub 2017 Feb 8.
• [735] CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer.Cancer Immunol Immunother. 2017 Dec;66(12):1609-1617. doi: 10.1007/s00262-017-2053-4. Epub 2017 Aug 30.
• [736] Menin Coordinates C/EBP-Mediated TGF- Signaling for Epithelial-Mesenchymal Transition and Growth Inhibition in Pancreatic Cancer.Mol Ther Nucleic Acids. 2019 Dec 6;18:155-165. doi: 10.1016/j.omtn.2019.08.013. Epub 2019 Aug 16.
• [737] Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells.Gut. 2011 Feb;60(2):225-37. doi: 10.1136/gut.2009.202325. Epub 2010 Sep 28.
• [738] CSN5 promotes the invasion and metastasis of pancreatic cancer by stabilization of FOXM1.Exp Cell Res. 2019 Jan 15;374(2):274-281. doi: 10.1016/j.yexcr.2018.10.012. Epub 2018 Oct 21.
• [739] Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer.Pancreatology. 2019 Oct;19(7):951-956. doi: 10.1016/j.pan.2019.09.009. Epub 2019 Sep 20.
• [740] Oncolytic Ad co-expressing decorin and Wnt decoy receptor overcomes chemoresistance of desmoplastic tumor through degradation of ECM and inhibition of EMT.Cancer Lett. 2019 Sep 10;459:15-29. doi: 10.1016/j.canlet.2019.05.033. Epub 2019 May 29.
• [741] Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis.J Cancer. 2019 Jan 29;10(4):911-917. doi: 10.7150/jca.27405. eCollection 2019.
• [742] eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer.JCI Insight. 2019 Nov 1;4(21):e121951. doi: 10.1172/jci.insight.121951.
• [743] Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth.Oncotarget. 2014 May 15;5(9):2575-87. doi: 10.18632/oncotarget.1842.
• [744] Tenascin-C Modulates Cell Cycle Progression to Enhance Tumour Cell Proliferation through AKT/FOXO1 Signalling in Pancreatic Cancer.J Cancer. 2018 Oct 31;9(23):4449-4462. doi: 10.7150/jca.25926. eCollection 2018.
• [745] Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes.Gastroenterology. 2014 May;146(5):1386-96.e1-17. doi: 10.1053/j.gastro.2014.01.046. Epub 2014 Jan 23.
• [746] Cucurbitacin B Induces Hypoglycemic Effect in Diabetic Mice by Regulation of AMP-Activated Protein Kinase Alpha and Glucagon-Like Peptide-1 via Bitter Taste Receptor Signaling.Front Pharmacol. 2018 Sep 21;9:1071. doi: 10.3389/fphar.2018.01071. eCollection 2018.
• [747] Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan.J Clin Med. 2019 Aug 4;8(8):1170. doi: 10.3390/jcm8081170.
• [748] Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.Cancer Med. 2019 Oct;8(13):5903-5915. doi: 10.1002/cam4.2463. Epub 2019 Aug 19.
• [749] Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.Br J Cancer. 2017 May 23;116(11):1462-1469. doi: 10.1038/bjc.2017.115. Epub 2017 Apr 27.
• [750] Endogenously Expressed IL-4R Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo.Int J Mol Sci. 2017 Mar 28;18(4):716. doi: 10.3390/ijms18040716.
• [751] ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression.Cancer Immunol Immunother. 2019 Dec;68(12):2029-2039. doi: 10.1007/s00262-019-02422-9. Epub 2019 Nov 11.
• [752] Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-1/smad2/3 axis in pancreatic cancer.Cancer Lett. 2019 Sep 10;459:204-215. doi: 10.1016/j.canlet.2019.06.005. Epub 2019 Jun 12.
• [753] The effect of JDP2 and ATF2 on the epithelial-mesenchymal transition of human pancreatic cancer cell lines.Pathol Oncol Res. 2012 Jul;18(3):571-7. doi: 10.1007/s12253-011-9476-6. Epub 2011 Nov 23.
• [754] Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review.Cell Commun Signal. 2019 Sep 11;17(1):121. doi: 10.1186/s12964-019-0435-2.
• [755] The TALE homeodomain transcription factor MEIS1 activates the pro-metastatic melanoma cell adhesion molecule Mcam to promote migration of pancreatic cancer cells.Mol Carcinog. 2017 Mar;56(3):936-944. doi: 10.1002/mc.22547. Epub 2016 Sep 21.
• [756] Transcriptional upregulation of MT2-MMP in response to hypoxia is promoted by HIF-1 in cancer cells.Mol Carcinog. 2011 Oct;50(10):770-80. doi: 10.1002/mc.20678. Epub 2011 Jul 12.
• [757] The Immunohistochemical Expression MTA 1 Protein and its Prognostic Value in Pancreatic Cancer.J Invest Surg. 2018 Apr;31(2):142-150. doi: 10.1080/08941939.2017.1280565. Epub 2017 Feb 10.
• [758] The E3 ubiquitin ligase NEDD4 is translationally upregulated and facilitates pancreatic cancer.Oncotarget. 2017 Mar 21;8(12):20288-20296. doi: 10.18632/oncotarget.15446.
• [759] Regulation of pancreatic stellate cell activation by Notch3.BMC Cancer. 2018 Jan 5;18(1):36. doi: 10.1186/s12885-017-3957-2.
• [760] MiR-429 suppresses neurotrophin-3 to alleviate perineural invasion of pancreatic cancer.Biochem Biophys Res Commun. 2018 Nov 10;505(4):1077-1083. doi: 10.1016/j.bbrc.2018.09.147. Epub 2018 Oct 9.
• [761] Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.J Exp Clin Cancer Res. 2019 May 14;38(1):191. doi: 10.1186/s13046-019-1191-2.
• [762] Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis.Onco Targets Ther. 2019 Feb 1;12:1007-1020. doi: 10.2147/OTT.S176101. eCollection 2019.
• [763] The association of changes in RAD51 and survivin expression levels with the proton beam sensitivity of Capan? and Panc? human pancreatic cancer cells.Int J Oncol. 2019 Feb;54(2):744-752. doi: 10.3892/ijo.2018.4642. Epub 2018 Nov 22.
• [764] MicroRNA-216b reduces growth, migration and invasion of pancreatic ductal adenocarcinoma cells by directly targeting -associated coiled-coil containing protein kinase 1.Oncol Lett. 2018 May;15(5):6745-6751. doi: 10.3892/ol.2018.8109. Epub 2018 Feb 23.
• [765] MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.Biosci Rep. 2019 May 7;39(5):BSR20181374. doi: 10.1042/BSR20181374. Print 2019 May 31.
• [766] The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway.Int J Oncol. 2018 Jun;52(6):2101-2109. doi: 10.3892/ijo.2018.4363. Epub 2018 Apr 5.
• [767] Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells.Bioelectrochemistry. 2018 Aug;122:84-92. doi: 10.1016/j.bioelechem.2018.03.009. Epub 2018 Mar 15.
• [768] ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin 31 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.Gastroenterology. 2020 Feb;158(3):679-692.e1. doi: 10.1053/j.gastro.2019.10.038. Epub 2019 Nov 9.
• [769] Elevated expression of Tiam1 is associated with poor prognosis and promotes tumor progression in pancreatic cancer.Onco Targets Ther. 2018 Jul 26;11:4367-4375. doi: 10.2147/OTT.S171425. eCollection 2018.
• [770] Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.J Immunother Cancer. 2018 Nov 13;6(1):118. doi: 10.1186/s40425-018-0435-6.
• [771] Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer.Oncol Lett. 2018 Feb;15(2):1771-1776. doi: 10.3892/ol.2017.7512. Epub 2017 Dec 5.
• [772] Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697. doi: 10.1073/pnas.1811067116. Epub 2019 Jan 11.
• [773] MicroRNA-215 functions as a tumor suppressor and directly targets ZEB2 in human pancreatic cancer.Genet Mol Res. 2015 Dec 8;14(4):16133-45. doi: 10.4238/2015.December.8.2.
• [774] A novel plectin/integrin-targeted bispecific molecular probe for magnetic resonance/near-infrared imaging of pancreatic cancer.Biomaterials. 2018 Nov;183:173-184. doi: 10.1016/j.biomaterials.2018.08.048. Epub 2018 Aug 26.
• [775] Blockage of SLC31A1-dependent copper absorption increases pancreatic cancer cell autophagy to resist cell death.Cell Prolif. 2019 Mar;52(2):e12568. doi: 10.1111/cpr.12568. Epub 2019 Jan 31.
• [776] The cytotoxic role of RREB1, ZIP3 zinc transporter, and zinc in human pancreatic adenocarcinoma.Cancer Biol Ther. 2014 Oct;15(10):1431-7. doi: 10.4161/cbt.29927. Epub 2014 Jul 22.
• [777] Characterization and proteomic profiling of pancreatic cancer-derived serum exosomes.J Cell Biochem. 2019 Jan;120(1):988-999. doi: 10.1002/jcb.27465. Epub 2018 Aug 30.
• [778] PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.Colloids Surf B Biointerfaces. 2019 Feb 1;174:126-135. doi: 10.1016/j.colsurfb.2018.10.069. Epub 2018 Oct 28.
• [779] PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism.Dev Cell. 2018 Aug 20;46(4):441-455.e8. doi: 10.1016/j.devcel.2018.07.012. Epub 2018 Aug 9.
• [780] pH-sensitive K(+) channel TREK-1 is a novel target in pancreatic cancer.Biochim Biophys Acta. 2016 Oct;1862(10):1994-2003. doi: 10.1016/j.bbadis.2016.07.009. Epub 2016 Jul 19.
• [781] Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of the key molecules involved in pancreatic carcinogenesis.Cancer Sci. 2009 Mar;100(3):457-64. doi: 10.1111/j.1349-7006.2008.01058.x. Epub 2008 Dec 16.
• [782] A small interfering RNA targeting proteinase-activated receptor-2 is effective in suppression of tumor growth in a Panc1 xenograft model.Int J Cancer. 2008 Feb 1;122(3):658-63. doi: 10.1002/ijc.23123.
• [783] Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer.Pancreas. 2008 May;36(4):e32-9. doi: 10.1097/MPA.0b013e3181630ffe.
• [784] Time and concentration dependency of P-gp, MRP1 and MRP5 induction in response to gemcitabine uptake in Capan-2 pancreatic cancer cells.Xenobiotica. 2015;45(7):642-52. doi: 10.3109/00498254.2014.1001809. Epub 2015 Jan 7.
• [785] Distinct prognostic values of alcohol dehydrogenase mRNA expression in pancreatic adenocarcinoma.Onco Targets Ther. 2017 Jul 24;10:3719-3732. doi: 10.2147/OTT.S140221. eCollection 2017.
• [786] Aldh1b1 expression defines progenitor cells in the adult pancreas and is required for Kras-induced pancreatic cancer.Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20679-20688. doi: 10.1073/pnas.1901075116. Epub 2019 Sep 23.
• [787] Measuring human carboxylesterase 2 activity in pancreatic cancer patient-derived xenografts using a ratiometric fluorescent chemosensor.Chem Sci. 2019 Jul 29;10(36):8428-8437. doi: 10.1039/c9sc00283a. eCollection 2019 Sep 28.
• [788] Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1.Onco Targets Ther. 2018 Nov 29;11:8507-8515. doi: 10.2147/OTT.S187615. eCollection 2018.
• [789] Effects of nicotinamide N-methyltransferase on PANC-1 cells proliferation, metastatic potential and survival under metabolic stress.Cell Physiol Biochem. 2015;35(2):710-21. doi: 10.1159/000369731. Epub 2015 Jan 28.
• [790] CYP2A13, ADH1B, and ADH1C gene polymorphisms and pancreatic cancer risk.Pancreas. 2010 Mar;39(2):144-8. doi: 10.1097/MPA.0b013e3181bab6c2.
• [791] Dihomo--linolenic acid inhibits growth of xenograft tumors in mice bearing human pancreatic cancer cells (BxPC-3) transfected with delta-5-desaturase shRNA.Redox Biol. 2019 Jan;20:236-246. doi: 10.1016/j.redox.2018.10.001. Epub 2018 Oct 15.
• [792] [ARTICLE WITHDRAWN] Upregulation of MicroRNA-935 Promotes the Malignant Behaviors of Pancreatic Carcinoma PANC-1 Cells via Targeting Inositol Polyphosphate 4-Phosphatase Type I Gene (INPP4A).Oncol Res. 2017 Apr 14;25(4):559-569. doi: 10.3727/096504016X14759554689565. Epub 2016 Oct 11.
• [793] Split-bolus pancreas CTA protocol for local staging of pancreatic cancer and detection and characterization of liver lesions.Abdom Radiol (NY). 2018 Feb;43(2):340-350. doi: 10.1007/s00261-017-1350-x.
• [794] Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer.Anticancer Res. 2019 Jul;39(7):3609-3614. doi: 10.21873/anticanres.13508.
• [795] Suicide gene therapy with the yeast fusion gene cytosine deaminase/uracil phosphoribosyltransferase is not enough for pancreatic cancer.Pancreas. 2007 Oct;35(3):224-31. doi: 10.1097/mpa.0b013e3180622519.
• [796] Phosphorylation-dependent regulation of ALDH1A1 by Aurora kinase A: insights on their synergistic relationship in pancreatic cancer. BMC Biol. 2017 Feb 13;15(1):10.
• [797] Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res. 2007 Apr 1;67(7):3345-55. doi: 10.1158/0008-5472.CAN-06-2519.
• [798] Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.Neoplasia. 2009 Jul;11(7):637-50. doi: 10.1593/neo.81686.
• [799] RNA-seq SSRs and small RNA-seq SSRs: new approaches in cancer biomarker discovery.Gene. 2015 Apr 10;560(1):34-43. doi: 10.1016/j.gene.2015.01.027. Epub 2015 Jan 30.
• [800] Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4.Cancer Causes Control. 2013 Mar;24(3):595-602. doi: 10.1007/s10552-012-0138-0. Epub 2013 Jan 19.
• [801] Alcohol drinking and one-carbon metabolism-related gene polymorphisms on pancreatic cancer risk.Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2742-7. doi: 10.1158/1055-9965.EPI-08-0470.
• [802] Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport.Mol Cell. 2017 Aug 17;67(4):685-701.e6. doi: 10.1016/j.molcel.2017.07.014. Epub 2017 Aug 10.
• [803] Expression of UGP2 and CFL1 expression levels in benign and malignant pancreatic lesions and their clinicopathological significance.World J Surg Oncol. 2018 Jan 18;16(1):11. doi: 10.1186/s12957-018-1316-7.
• [804] Increased UGT1A3 and UGT1A7 expression is associated with pancreatic cancer.Asian Pac J Cancer Prev. 2015;16(4):1651-5. doi: 10.7314/apjcp.2015.16.4.1651.
• [805] Hypoxia signature of splice forms of tryptophanyl-tRNA synthetase marks pancreatic cancer cells with distinct metastatic abilities.Pancreas. 2011 Oct;40(7):1043-56. doi: 10.1097/MPA.0b013e318222e635.
• [806] Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.Mod Pathol. 2012 May;25(5):758-66. doi: 10.1038/modpathol.2011.191. Epub 2012 Jan 6.
• [807] Nutrient Stress-Dysregulated Antisense lncRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression.Cancer Res. 2019 Apr 1;79(7):1398-1412. doi: 10.1158/0008-5472.CAN-18-0419. Epub 2018 Dec 18.
• [808] Association between N-acetyltransferase 2 polymorphisms and pancreatic cancer risk: a meta-analysis.Genet Mol Res. 2015 Dec 17;14(4):17219-27. doi: 10.4238/2015.December.16.21.
• [809] Genetic polymorphisms in human UDP-glucuronosyltransferases 1A7 and the risk of gastrointestinal carcinomas: A systematic review and network meta-analysis.Oncotarget. 2017 Jun 27;8(39):66371-66381. doi: 10.18632/oncotarget.18675. eCollection 2017 Sep 12.
• [810] Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies.Clin Transl Oncol. 2017 Jul;19(7):834-843. doi: 10.1007/s12094-016-1609-7. Epub 2017 Jan 19.
• [811] Contrast-Enhanced Endoscopic Ultrasound for Differentially Diagnosing Autoimmune Pancreatitis and Pancreatic Cancer.Gut Liver. 2018 Sep 15;12(5):591-596. doi: 10.5009/gnl17391.
• [812] Long noncoding RNA DIO3OS interacts with miR-122 to promote proliferation and invasion of pancreatic cancer cells through upregulating ALDOA.Cancer Cell Int. 2019 Jul 30;19:202. doi: 10.1186/s12935-019-0922-y. eCollection 2019.
• [813] Angiopoietin-like Protein 2 is a Useful Biomarker for Pancreatic Cancer that is Associated with Type 2 Diabetes Mellitus and Inflammation.J Cancer. 2018 Nov 25;9(24):4736-4741. doi: 10.7150/jca.25404. eCollection 2018.
• [814] An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer.Cancers (Basel). 2019 Jan 29;11(2):155. doi: 10.3390/cancers11020155.
• [815] Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer.Mol Oncol. 2019 Feb;13(2):212-227. doi: 10.1002/1878-0261.12398. Epub 2018 Nov 15.
• [816] The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer.Biochem Pharmacol. 2017 Sep 15;140:28-40. doi: 10.1016/j.bcp.2017.05.014. Epub 2017 May 20.
• [817] ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/-catenin signaling pathway.Carcinogenesis. 2019 Nov 25;40(11):1405-1414. doi: 10.1093/carcin/bgz067.
• [818] ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.Mol Cancer. 2016 May 4;15(1):32. doi: 10.1186/s12943-016-0516-4.
• [819] A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.Cancer. 2017 Dec 1;123(23):4556-4565. doi: 10.1002/cncr.30897. Epub 2017 Aug 18.
• [820] Significance of MUC2 gene methylation detection in pancreatic cancer diagnosis.Pancreatology. 2019 Dec;19(8):1049-1053. doi: 10.1016/j.pan.2019.09.012. Epub 2019 Sep 27.
• [821] Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.Sci Rep. 2019 Nov 8;9(1):16735. doi: 10.1038/s41598-019-53130-4.
• [822] Unexpected distribution of CA19.9 and other type 1 chain Lewis antigens in normal and cancer tissues of colon and pancreas: Importance of the detection method and role of glycosyltransferase regulation.Biochim Biophys Acta Gen Subj. 2017 Jan;1861(1 Pt A):3210-3220. doi: 10.1016/j.bbagen.2016.08.005. Epub 2016 Aug 14.
• [823] Targeting Mechanoresponsive Proteins in Pancreatic Cancer: 4-Hydroxyacetophenone Blocks Dissemination and Invasion by Activating MYH14.Cancer Res. 2019 Sep 15;79(18):4665-4678. doi: 10.1158/0008-5472.CAN-18-3131. Epub 2019 Jul 29.
• [824] Therapeutic efficacy of a novel III/IV-tubulin inhibitor (VERU-111) in pancreatic cancer.J Exp Clin Cancer Res. 2019 Jan 23;38(1):29. doi: 10.1186/s13046-018-1009-7.
• [825] Inhibition of Isoprenylcysteine Carboxylmethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer.Mol Cancer Ther. 2017 May;16(5):914-923. doi: 10.1158/1535-7163.MCT-16-0703. Epub 2017 Feb 6.
• [826] Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer.Br J Cancer. 2020 Feb;122(3):293-294. doi: 10.1038/s41416-019-0645-9. Epub 2019 Dec 2.
• [827] Basic transcription factor 3 (BTF3) regulates transcription of tumor-associated genes in pancreatic cancer cells.Cancer Biol Ther. 2007 Mar;6(3):367-76. doi: 10.4161/cbt.6.3.3704. Epub 2007 Mar 13.
• [828] Pancreatic cancer cell-derived exosomal microRNA-27a promotes angiogenesis of human microvascular endothelial cells in pancreatic cancer via BTG2.J Cell Mol Med. 2020 Jan;24(1):588-604. doi: 10.1111/jcmm.14766. Epub 2019 Nov 13.
• [829] Correction to: c-Src confers resistance to mitotic stress through inhibition of DMAP1/Bub3 complex formation in pancreatic cancer.Mol Cancer. 2019 Nov 29;18(1):172. doi: 10.1186/s12943-019-1067-2.
• [830] Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model.Front Pharmacol. 2017 Jul 7;8:319. doi: 10.3389/fphar.2017.00319. eCollection 2017.
• [831] Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma.Lab Invest. 2017 Mar;97(3):302-317. doi: 10.1038/labinvest.2016.146. Epub 2017 Jan 16.
• [832] A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.Mol Ther Oncolytics. 2018 Dec 14;12:56-67. doi: 10.1016/j.omto.2018.12.005. eCollection 2019 Mar 29.
• [833] Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma.Gastroenterology. 2018 Nov;155(5):1625-1639.e2. doi: 10.1053/j.gastro.2018.08.009. Epub 2018 Aug 6.
• [834] Integrin 1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110 signaling.Biochem Biophys Res Commun. 2018 Oct 20;505(1):215-221. doi: 10.1016/j.bbrc.2018.09.061. Epub 2018 Sep 20.
• [835] CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells.Anticancer Res. 2018 Nov;38(11):6107-6111. doi: 10.21873/anticanres.12961.
• [836] Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death.Cancer Lett. 2019 Jul 10;454:204-214. doi: 10.1016/j.canlet.2019.04.022. Epub 2019 Apr 17.
• [837] A functional variant rs1537373 in 9p21.3 region is associated with pancreatic cancer risk.Mol Carcinog. 2019 May;58(5):760-766. doi: 10.1002/mc.22968. Epub 2019 Jan 17.
• [838] Upregulation of cugbp2 increases response of pancreatic cancer cells to chemotherapy.Langenbecks Arch Surg. 2016 Feb;401(1):99-111. doi: 10.1007/s00423-015-1364-1. Epub 2015 Dec 21.
• [839] Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer.Sci Rep. 2018 Feb 21;8(1):3383. doi: 10.1038/s41598-018-21823-x.
• [840] Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):176-184. doi: 10.1158/1055-9965.EPI-19-0672. Epub 2019 Nov 4.
• [841] Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic cancer cell lines and patient-derived xenografts.Cancer Lett. 2019 Nov 28;465:36-44. doi: 10.1016/j.canlet.2019.08.019. Epub 2019 Aug 31.
• [842] Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways.Oxid Med Cell Longev. 2018 Mar 22;2018:9482018. doi: 10.1155/2018/9482018. eCollection 2018.
• [843] Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance.Nat Med. 2017 May;23(5):556-567. doi: 10.1038/nm.4314. Epub 2017 Apr 10.
• [844] Association of chloride intracellular channel 4 and Indian hedgehog proteins with survival of patients with pancreatic ductal adenocarcinoma.Int J Exp Pathol. 2016 Dec;97(6):422-429. doi: 10.1111/iep.12213. Epub 2017 Feb 16.
• [845] Research progress on circadian clock genes in common abdominal malignant tumors.Oncol Lett. 2017 Nov;14(5):5091-5098. doi: 10.3892/ol.2017.6856. Epub 2017 Aug 31.
• [846] COMP is selectively up-regulated in degenerating acinar cells in chronic pancreatitis and in chronic-pancreatitis-like lesions in pancreatic cancer.Scand J Gastroenterol. 2003 Feb;38(2):207-15. doi: 10.1080/00365520310000717.
• [847] CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis.Cancer Biol Ther. 2019;20(9):1290-1299. doi: 10.1080/15384047.2019.1632143. Epub 2019 Jul 16.
• [848] MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/-catenin signaling pathway by targeting CUL4B in pancreatic cancer cells.J Cell Biochem. 2018 Jan;119(1):1027-1040. doi: 10.1002/jcb.26270. Epub 2017 Aug 23.
• [849] Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway.Pathol Oncol Res. 2019 Apr;25(2):635-646. doi: 10.1007/s12253-018-0487-4. Epub 2018 Nov 8.
• [850] Caerulein-induced pancreatitis augments the expression and phosphorylation of collapsin response mediator protein 4.J Hepatobiliary Pancreat Sci. 2016 Jul;23(7):422-31. doi: 10.1002/jhbp.361. Epub 2016 Jun 12.
• [851] Scattered DUSP28 is a novel biomarker responsible for aggravating malignancy via the autocrine and paracrine signaling in metastatic pancreatic cancer.Cancer Lett. 2019 Aug 1;456:1-12. doi: 10.1016/j.canlet.2019.03.006. Epub 2019 Mar 19.
• [852] miR-663 attenuates tumor growth and invasiveness by targeting eEF1A2 in pancreatic cancer.Mol Cancer. 2015 Feb 13;14:37. doi: 10.1186/s12943-015-0315-3.
• [853] Fibulin-3 negatively regulates ALDH1 via c-MET suppression and increases -radiation-induced sensitivity in some pancreatic cancer cell lines.Biochem Biophys Res Commun. 2014 Nov 21;454(3):369-75. doi: 10.1016/j.bbrc.2014.10.084. Epub 2014 Oct 24.
• [854] EI24 Suppresses Tumorigenesis in Pancreatic Cancer via Regulating c-Myc.Gastroenterol Res Pract. 2018 Oct 2;2018:2626545. doi: 10.1155/2018/2626545. eCollection 2018.
• [855] Eukaryotic Translation Initiation Factor 3a (eIF3a) Promotes Cell Proliferation and Motility in Pancreatic Cancer.J Korean Med Sci. 2016 Oct;31(10):1586-94. doi: 10.3346/jkms.2016.31.10.1586.
• [856] Embigin is overexpressed in pancreatic ductal adenocarcinoma and regulates cell motility through epithelial to mesenchymal transition via the TGF- pathway.Mol Carcinog. 2016 May;55(5):633-45. doi: 10.1002/mc.22309. Epub 2015 Mar 14.
• [857] ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance.Gastroenterol Res Pract. 2018 Feb 1;2018:3842198. doi: 10.1155/2018/3842198. eCollection 2018.
• [858] Comparative proteomic analysis identifies exosomal Eps8 protein as a potential metastatic biomarker for pancreatic cancer.Oncol Rep. 2019 Feb;41(2):1019-1034. doi: 10.3892/or.2018.6869. Epub 2018 Nov 15.
• [859] ERO1 promotes hypoxic tumor progression and is associated with poor prognosis in pancreatic cancer.Oncotarget. 2019 Oct 15;10(57):5970-5982. doi: 10.18632/oncotarget.27235. eCollection 2019 Oct 15.
• [860] Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma.Sci Rep. 2018 Jul 23;8(1):11088. doi: 10.1038/s41598-018-29445-z.
• [861] High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.Br J Cancer. 2019 Jan;120(1):79-87. doi: 10.1038/s41416-018-0341-1. Epub 2018 Nov 15.
• [862] Increased fibrosis and impaired intratumoral accumulation of macromolecules in a murine model of pancreatic cancer co-administered with FGF-2.J Control Release. 2016 May 28;230:109-15. doi: 10.1016/j.jconrel.2016.04.007. Epub 2016 Apr 12.
• [863] Krppel-like factor 8 induces epithelial-to-mesenchymal transition and promotes invasion of pancreatic cancer cells through transcriptional activation of four and a half LIM-only protein 2.Oncol Lett. 2017 Oct;14(4):4883-4889. doi: 10.3892/ol.2017.6734. Epub 2017 Aug 9.
• [864] Reprogramming Enhancers to Drive Metastasis.Cell. 2017 Aug 24;170(5):823-825. doi: 10.1016/j.cell.2017.08.010.
• [865] A holistic approach to dissecting SPARC family protein complexity reveals FSTL-1 as an inhibitor of pancreatic cancer cell growth.Sci Rep. 2016 Nov 25;6:37839. doi: 10.1038/srep37839.
• [866] GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway.J Oncol. 2019 Apr 10;2019:9474273. doi: 10.1155/2019/9474273. eCollection 2019.
• [867] GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.Gut. 2017 Sep;66(9):1665-1676. doi: 10.1136/gutjnl-2015-311256. Epub 2016 Jun 20.
• [868] Interaction of Serum microRNAs and Serum Folate With the Susceptibility to Pancreatic Cancer.Pancreas. 2015 Jan;44(1):23-30. doi: 10.1097/MPA.0000000000000204.
• [869] GFR2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer.Cancer Lett. 2016 Oct 1;380(2):434-441. doi: 10.1016/j.canlet.2016.06.016. Epub 2016 Jul 8.
• [870] LncRNA XLOC_006390 promotes pancreatic carcinogenesis and glutamate metabolism by stabilizing c-Myc.Cancer Lett. 2020 Jan 28;469:419-428. doi: 10.1016/j.canlet.2019.11.021. Epub 2019 Nov 14.
• [871] Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases.Oncotarget. 2019 Feb 1;10(10):1045-1055. doi: 10.18632/oncotarget.26620. eCollection 2019 Feb 1.
• [872] The Effect of GPRC5a on the Proliferation, Migration Ability, Chemotherapy Resistance, and Phosphorylation of GSK-3 in Pancreatic Cancer.Int J Mol Sci. 2018 Jun 26;19(7):1870. doi: 10.3390/ijms19071870.
• [873] Hormophysa triquerta polyphenol, an elixir that deters CXCR4- and COX2-dependent dissemination destiny of treatment-resistant pancreatic cancer cells.Oncotarget. 2017 Jan 24;8(4):5717-5734. doi: 10.18632/oncotarget.13900.
• [874] Expression and Localization of Huntingtin-Associated Protein 1 (HAP1) in the Human Digestive System.Dig Dis Sci. 2019 Jun;64(6):1486-1492. doi: 10.1007/s10620-018-5425-5. Epub 2018 Dec 17.
• [875] Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.J Exp Clin Cancer Res. 2017 Feb 28;36(1):36. doi: 10.1186/s13046-017-0509-1.
• [876] HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling.Redox Biol. 2020 Jan;29:101390. doi: 10.1016/j.redox.2019.101390. Epub 2019 Nov 20.
• [877] HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.Cancer Lett. 2019 Feb 1;442:333-340. doi: 10.1016/j.canlet.2018.11.007. Epub 2018 Nov 14.
• [878] HIC1 attenuates invasion and metastasis by inhibiting the IL-6/STAT3 signalling pathway in human pancreatic cancer.Cancer Lett. 2016 Jul 1;376(2):387-98. doi: 10.1016/j.canlet.2016.04.013. Epub 2016 Apr 13.
• [879] Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.Int J Cancer. 2010 Jan 15;126(2):395-404. doi: 10.1002/ijc.24744.
• [880] Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer.Oncoimmunology. 2017 Mar 31;6(5):e1310358. doi: 10.1080/2162402X.2017.1310358. eCollection 2017.
• [881] Oncogenic HSP60 regulates mitochondrial oxidative phosphorylation to support Erk1/2 activation during pancreatic cancer cell growth.Cell Death Dis. 2018 Feb 7;9(2):161. doi: 10.1038/s41419-017-0196-z.
• [882] MicroRNA-634 functions as a tumor suppressor in pancreatic cancer via directly targeting heat shock-related 70-kDa protein 2.Exp Ther Med. 2019 May;17(5):3949-3956. doi: 10.3892/etm.2019.7433. Epub 2019 Mar 22.
• [883] The Insulin-Like Growth Factor 2 mRNA Binding Protein IMP2/IGF2BP2 is Overexpressed and Correlates with Poor Survival in Pancreatic Cancer.Int J Mol Sci. 2019 Jun 29;20(13):3204. doi: 10.3390/ijms20133204.
• [884] Expression and clinical significance of IMP3 in microdissected premalignant and malignant pancreatic lesions.Clin Transl Oncol. 2015 Mar;17(3):215-22. doi: 10.1007/s12094-014-1216-4. Epub 2014 Sep 3.
• [885] Bioinformatics method to analyze the mechanism of pancreatic cancer disorder.J Comput Biol. 2013 Jun;20(6):444-52. doi: 10.1089/cmb.2012.0281. Epub 2013 Apr 24.
• [886] Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.Curr Cancer Drug Targets. 2019;19(5):417-427. doi: 10.2174/1568009618666180430123939.
• [887] Synergistic antitumor effect of adenovirus-mediated hING4 gene therapy and (125)I radiation therapy on pancreatic cancer.Cancer Lett. 2012 Mar 28;316(2):211-8. doi: 10.1016/j.canlet.2011.11.003. Epub 2011 Nov 7.
• [888] INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT.Onco Targets Ther. 2019 Oct 9;12:8287-8299. doi: 10.2147/OTT.S223221. eCollection 2019.
• [889] IQGAP1 promotes pancreatic cancer progression and epithelial-mesenchymal transition (EMT) through Wnt/-catenin signaling.Sci Rep. 2019 May 17;9(1):7539. doi: 10.1038/s41598-019-44048-y.
• [890] Downregulation of GEP100 Improved the Growth Inhibition Effect of Erlotinib Through Modulating Mesenchymal Epithelial Transition Process in Pancreatic Cancer.Pancreas. 2018 Jul;47(6):732-737. doi: 10.1097/MPA.0000000000001076.
• [891] The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer.Pancreas. 2014 Aug;43(6):909-16. doi: 10.1097/MPA.0000000000000116.
• [892] Knockdown of ISOC1 suppresses cell proliferation in pancreatic cancer in vitro.Oncol Lett. 2019 May;17(5):4263-4270. doi: 10.3892/ol.2019.10082. Epub 2019 Feb 28.
• [893] Blockade of integrin 3 attenuates human pancreatic cancer via inhibition of EGFR signalling.Sci Rep. 2019 Feb 26;9(1):2793. doi: 10.1038/s41598-019-39628-x.
• [894] ITIH5 induces a shift in TGF- superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death.Mol Carcinog. 2018 Feb;57(2):167-181. doi: 10.1002/mc.22742. Epub 2017 Oct 30.
• [895] CacyBP/SIP enhances multidrug resistance of pancreatic cancer cells by regulation of P-gp and Bcl-2.Apoptosis. 2013 Jul;18(7):861-9. doi: 10.1007/s10495-013-0831-9.
• [896] KLF10 as a Tumor Suppressor Gene and Its TGF- Signaling.Cancers (Basel). 2018 May 25;10(6):161. doi: 10.3390/cancers10060161.
• [897] Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer.Aging (Albany NY). 2019 Jul 21;11(14):5035-5057. doi: 10.18632/aging.102096.
• [898] Downregulation of circular RNA circ-LDLRAD3 suppresses pancreatic cancer progression through miR-137-3p/PTN axis.Life Sci. 2019 Dec 15;239:116871. doi: 10.1016/j.lfs.2019.116871. Epub 2019 Sep 12.
• [899] Latent Transforming Growth Factor Binding Protein 2 (LTBP2) as a Novel Biomarker for the Diagnosis and Prognosis of Pancreatic Carcinoma.Med Sci Monit. 2017 Jul 3;23:3232-3239. doi: 10.12659/msm.905284.
• [900] Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma.Cell Death Differ. 2019 Jan;26(2):382-393. doi: 10.1038/s41418-018-0207-3. Epub 2018 Oct 3.
• [901] Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer.PLoS One. 2016 Mar 29;11(3):e0152300. doi: 10.1371/journal.pone.0152300. eCollection 2016.
• [902] SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.Oncogene. 2018 Feb 15;37(7):912-923. doi: 10.1038/onc.2017.393. Epub 2017 Oct 23.
• [903] RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):27-38. doi: 10.1093/abbs/gmv090. Epub 2015 Sep 7.
• [904] The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion.Pathol Res Pract. 2019 Nov;215(11):152666. doi: 10.1016/j.prp.2019.152666. Epub 2019 Sep 24.
• [905] miR-125a induces apoptosis, metabolism disorder and migrationimpairment in pancreatic cancer cells by targeting Mfn2-related mitochondrial fission.Int J Oncol. 2018 Jul;53(1):124-136. doi: 10.3892/ijo.2018.4380. Epub 2018 Apr 26.
• [906] Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.Clin Exp Med. 2017 Feb;17(1):19-31. doi: 10.1007/s10238-015-0394-x. Epub 2015 Oct 8.
• [907] The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer.Fam Cancer. 2012 Jun;11(2):243-7. doi: 10.1007/s10689-011-9507-1.
• [908] LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1.Theranostics. 2019 Jul 9;9(18):5298-5314. doi: 10.7150/thno.34559. eCollection 2019.
• [909] Loss of MTSS1 results in increased metastatic potential in pancreatic cancer.Oncotarget. 2017 Mar 7;8(10):16473-16487. doi: 10.18632/oncotarget.14869.
• [910] DUSP28 links regulation of Mucin 5B and Mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells.Tumour Biol. 2016 Sep;37(9):12193-12202. doi: 10.1007/s13277-016-5079-x. Epub 2016 May 26.
• [911] Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.J Med Chem. 2019 May 23;62(10):4949-4966. doi: 10.1021/acs.jmedchem.9b00059. Epub 2019 May 8.
• [912] Long Non-coding RNA LINC01420 Contributes to Pancreatic Cancer Progression Through Targeting KRAS Proto-oncogene.Dig Dis Sci. 2020 Apr;65(4):1042-1052. doi: 10.1007/s10620-019-05829-7. Epub 2019 Sep 27.
• [913] Synthesis and Preliminary Cytotoxicity Studies of 1-[1-(4,5-Dihydrooxazol- 2-yl)-1H-indazol-3-yl]-3-phenylurea and 3-phenylthiourea Derivatives.Med Chem. 2017;13(7):616-624. doi: 10.2174/1573406413666170306114401.
• [914] Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?.Int J Cancer. 2016 Aug 1;139(3):601-6. doi: 10.1002/ijc.30116. Epub 2016 Apr 18.
• [915] Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells.Cell Death Dis. 2018 Feb 12;9(2):210. doi: 10.1038/s41419-017-0191-4.
• [916] NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas.Gastroenterology. 2015 May;148(5):1024-1034.e9. doi: 10.1053/j.gastro.2015.01.033. Epub 2015 Jan 23.
• [917] Polydopamine-tailored paclitaxel-loaded polymeric microspheres with adhered NIR-controllable gold nanoparticles for chemo-phototherapy of pancreatic cancer.Drug Deliv. 2019 Dec;26(1):629-640. doi: 10.1080/10717544.2019.1628118.
• [918] New neurotensin analogue radiolabeled by 99m-technetium as a potential agent for tumor identification.Chem Biol Drug Des. 2018 Jan;91(1):304-313. doi: 10.1111/cbdd.13082. Epub 2017 Sep 12.
• [919] OCIAD1 promoted pancreatic ductal adenocarcinoma migration by regulating ATM.Pancreatology. 2019 Jul;19(5):751-759. doi: 10.1016/j.pan.2019.01.009. Epub 2019 Jan 31.
• [920] Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis.Transl Res. 2019 Oct;212:67-79. doi: 10.1016/j.trsl.2019.06.003. Epub 2019 Jun 29.
• [921] The role of oxysterol binding protein-related protein 5 in pancreatic cancer.Cancer Sci. 2010 Apr;101(4):898-905. doi: 10.1111/j.1349-7006.2009.01475.x. Epub 2009 Dec 16.
• [922] Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.PLoS One. 2011;6(10):e26926. doi: 10.1371/journal.pone.0026926. Epub 2011 Oct 27.
• [923] PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.Biochem Biophys Res Commun. 2018 Jun 27;501(3):654-660. doi: 10.1016/j.bbrc.2018.05.039. Epub 2018 May 16.
• [924] Silencing of long noncoding RNA LINC00958 prevents tumor initiation of pancreatic cancer by acting as a sponge of microRNA-330-5p to down-regulate PAX8.Cancer Lett. 2019 Apr 1;446:49-61. doi: 10.1016/j.canlet.2018.12.017. Epub 2019 Jan 9.
• [925] MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4.Am J Transl Res. 2017 Nov 15;9(11):5048-5055. eCollection 2017.
• [926] PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer.J Exp Clin Cancer Res. 2017 Feb 13;36(1):30. doi: 10.1186/s13046-017-0500-x.
• [927] Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer.PLoS One. 2019 Jan 29;14(1):e0211291. doi: 10.1371/journal.pone.0211291. eCollection 2019.
• [928] PRDM14 is overexpressed in chronic pancreatitis prior to pancreatic cancer.FEBS Open Bio. 2018 Sep 17;8(10):1733-1741. doi: 10.1002/2211-5463.12519. eCollection 2018 Oct.
• [929] Peroxiredoxin 1 silencing inhibited the growth and promoted apoptosis of pancreatic cancer cells via targeting FOXO3 gene.Cancer Manag Res. 2018 Oct 26;10:5019-5026. doi: 10.2147/CMAR.S177243. eCollection 2018.
• [930] Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progression.Biomed Pharmacother. 2019 Apr;112:108685. doi: 10.1016/j.biopha.2019.108685. Epub 2019 Feb 23.
• [931] Protein kinase C isoforms in the normal pancreas and in pancreatic disease.Cell Signal. 2017 Dec;40:1-9. doi: 10.1016/j.cellsig.2017.08.005. Epub 2017 Aug 18.
• [932] Bioinformatics Tools and Workflow to Select Blood Biomarkers for Early Cancer Diagnosis: An Application to Pancreatic Cancer.Proteomics. 2019 Nov;19(21-22):e1800489. doi: 10.1002/pmic.201800489. Epub 2019 Oct 10.
• [933] PSME3 Promotes TGFB1 Secretion by Pancreatic Cancer Cells to Induce Pancreatic Stellate Cell Proliferation.J Cancer. 2019 May 16;10(9):2128-2138. doi: 10.7150/jca.30235. eCollection 2019.
• [934] Effects of Rab27A and Rab27B on Invasion, Proliferation, Apoptosis, and Chemoresistance in Human Pancreatic Cancer Cells.Pancreas. 2017 Oct;46(9):1173-1179. doi: 10.1097/MPA.0000000000000910.
• [935] Expression of Rab5a correlates with tumor progression in pancreatic carcinoma.Virchows Arch. 2017 May;470(5):527-536. doi: 10.1007/s00428-017-2098-y. Epub 2017 Feb 27.
• [936] Sulforaphane Induces miR135b-5p and Its Target Gene, RASAL2, thereby Inhibiting the Progression of Pancreatic Cancer.Mol Ther Oncolytics. 2019 Apr 6;14:74-81. doi: 10.1016/j.omto.2019.03.011. eCollection 2019 Sep 27.
• [937] Long noncoding RNA PCAT-1 accelerates the metastasis of pancreatic cancer by repressing RBM5.Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7350-7355. doi: 10.26355/eurrev_201909_18841.
• [938] Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression.Cell Death Dis. 2017 Sep 7;8(9):e3033. doi: 10.1038/cddis.2017.424.
• [939] RGC-32 induces transition of pancreatic cancer to epithelial mesenchyme invivo.Pancreatology. 2018 Jul;18(5):572-576. doi: 10.1016/j.pan.2018.05.480. Epub 2018 May 18.
• [940] Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mice.Gastroenterology. 2017 May;152(6):1492-1506.e24. doi: 10.1053/j.gastro.2017.01.010. Epub 2017 Jan 23.
• [941] Ribosomal protein L10 in mitochondria serves as a regulator for ROS level in pancreatic cancer cells.Redox Biol. 2018 Oct;19:158-165. doi: 10.1016/j.redox.2018.08.016. Epub 2018 Aug 24.
• [942] Overexpression of microRNA-519d-3p suppressed the growth of pancreatic cancer cells by inhibiting ribosomal protein S15A-mediated Wnt/-catenin signaling.Chem Biol Interact. 2019 May 1;304:1-9. doi: 10.1016/j.cbi.2019.02.026. Epub 2019 Mar 1.
• [943] S100A10, a novel biomarker in pancreatic ductal adenocarcinoma.Mol Oncol. 2018 Nov;12(11):1895-1916. doi: 10.1002/1878-0261.12356. Epub 2018 Sep 21.
• [944] Correlation between S100A11 and the TGF-(1)/SMAD4 pathway and its effects on the proliferation and apoptosis of pancreatic cancer cell line PANC-1.Mol Cell Biochem. 2019 Jan;450(1-2):53-64. doi: 10.1007/s11010-018-3372-2. Epub 2018 Jun 19.
• [945] Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.Gastroenterology. 2009 Aug;137(2):558-68, 568.e1-11. doi: 10.1053/j.gastro.2009.04.009. Epub 2009 Apr 16.
• [946] Alteration of the tumor suppressor SARDH in sporadic colorectal cancer: A functional and transcriptome profiling-based study.Mol Carcinog. 2019 Jun;58(6):957-966. doi: 10.1002/mc.22984. Epub 2019 Mar 5.
• [947] Protein salvador homolog 1 acts as a tumor suppressor and is modulated by hypermethylation in pancreatic ductal adenocarcinoma.Oncotarget. 2017 May 18;8(38):62953-62961. doi: 10.18632/oncotarget.17972. eCollection 2017 Sep 8.
• [948] Inhibition of SCAMP1 suppresses cell migration and invasion in human pancreatic and gallbladder cancer cells.Tumour Biol. 2013 Oct;34(5):2731-9. doi: 10.1007/s13277-013-0825-9. Epub 2013 May 8.
• [949] Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer.Sci Signal. 2015 Aug 4;8(388):ra77. doi: 10.1126/scisignal.aaa5823.
• [950] LncRNA LOXL1-AS1/miR-28-5p/SEMA7A axis facilitates pancreatic cancer progression.Cell Biochem Funct. 2020 Jan;38(1):58-65. doi: 10.1002/cbf.3449. Epub 2019 Nov 15.
• [951] SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer.Oncogene. 2017 Jul 27;36(30):4288-4298. doi: 10.1038/onc.2017.63. Epub 2017 Mar 27.
• [952] SET contributes to the epithelial-mesenchymal transition of pancreatic cancer.Oncotarget. 2017 Jul 7;8(40):67966-67979. doi: 10.18632/oncotarget.19067. eCollection 2017 Sep 15.
• [953] Over-expression of microRNA-940 promotes cell proliferation by targeting GSK3 and sFRP1 in human pancreatic carcinoma.Biomed Pharmacother. 2016 Oct;83:593-601. doi: 10.1016/j.biopha.2016.06.057. Epub 2016 Jul 25.
• [954] Reverting chemoresistance of targeted agents by a ultrasoluble dendritic nanocapsule.J Control Release. 2020 Jan 10;317:67-77. doi: 10.1016/j.jconrel.2019.11.020. Epub 2019 Nov 19.
• [955] Up-regulation of N-cadherin by Collagen I-activated Discoidin Domain Receptor 1 in Pancreatic Cancer Requires the Adaptor Molecule Shc1.J Biol Chem. 2016 Oct 28;291(44):23208-23223. doi: 10.1074/jbc.M116.740605. Epub 2016 Sep 7.
• [956] Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer.BMC Cancer. 2017 Apr 7;17(1):249. doi: 10.1186/s12885-017-3225-5.
• [957] TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.Autophagy. 2020 Mar;16(3):486-500. doi: 10.1080/15548627.2019.1628540. Epub 2019 Jun 17.
• [958] BRM/SMARCA2 promotes the proliferation and chemoresistance ofpancreatic cancer cells by targeting JAK2/STAT3 signaling.Cancer Lett. 2017 Aug 28;402:213-224. doi: 10.1016/j.canlet.2017.05.006. Epub 2017 Jun 7.
• [959] A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene.PLoS Genet. 2019 Aug 30;15(8):e1008344. doi: 10.1371/journal.pgen.1008344. eCollection 2019 Aug.
• [960] SMURF1 amplification promotes invasiveness in pancreatic cancer.PLoS One. 2011;6(8):e23924. doi: 10.1371/journal.pone.0023924. Epub 2011 Aug 22.
• [961] Transcriptome-wide association study identifies multiple genes and pathways associated with pancreatic cancer.Cancer Med. 2018 Nov;7(11):5727-5732. doi: 10.1002/cam4.1836. Epub 2018 Oct 18.
• [962] Conserved expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin in human colorectal carcinomas.Cancer Lett. 2000 Feb 1;148(2):127-34. doi: 10.1016/s0304-3835(99)00322-5.
• [963] The MRTF-A/B function as oncogenes in pancreatic cancer.Oncol Rep. 2016 Jan;35(1):127-38. doi: 10.3892/or.2015.4329. Epub 2015 Oct 15.
• [964] Sex Determining Region Y Box 9 Induces Chemoresistance in Pancreatic Cancer Cells by Induction of Putative Cancer Stem Cell Characteristics and Its High Expression Predicts Poor Prognosis.Pancreas. 2017 Nov/Dec;46(10):1296-1304. doi: 10.1097/MPA.0000000000000945.
• [965] STING (or SRC) Like an ICB: Priming the Immune Response in Pancreatic Cancer.Cancer Res. 2019 Aug 1;79(15):3815-3817. doi: 10.1158/0008-5472.CAN-19-1700.
• [966] Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk.Mol Carcinog. 2019 Aug;58(8):1338-1348. doi: 10.1002/mc.23018. Epub 2019 Apr 17.
• [967] Sulfatase 1 expression in pancreatic cancer and its correlation with clinicopathological features and postoperative prognosis.Cancer Biomark. 2018;22(4):701-707. doi: 10.3233/CBM-181210.
• [968] Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10.J Cancer. 2018 Feb 1;9(4):711-725. doi: 10.7150/jca.21803. eCollection 2018.
• [969] Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.Amino Acids. 2017 Aug;49(8):1325-1335. doi: 10.1007/s00726-017-2430-5. Epub 2017 May 23.
• [970] Hic-5 in pancreatic stellate cells affects proliferation, apoptosis, migration, invasion of pancreatic cancer cells and postoperative survival time of pancreatic cancer.Biomed Pharmacother. 2020 Jan;121:109355. doi: 10.1016/j.biopha.2019.109355. Epub 2019 Nov 1.
• [971] Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.Mol Cancer. 2019 May 20;18(1):96. doi: 10.1186/s12943-019-1023-1.
• [972] JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells.Oncotarget. 2016 Mar 1;7(9):9890-906. doi: 10.18632/oncotarget.7066.
• [973] Silencing of TPD52 inhibits proliferation, migration, invasion but induces apoptosis of pancreatic cancer cells by deactivating Akt pathway.Neoplasma. 2020 Mar;67(2):277-285. doi: 10.4149/neo_2019_190404N295. Epub 2019 Dec 17.
• [974] Research on the establishment of a TPM3 monoclonal stable transfected PANC-1 cell line and the experiment of the EMT occurrence in human pancreatic cancer.Onco Targets Ther. 2019 Jul 11;12:5577-5587. doi: 10.2147/OTT.S212689. eCollection 2019.
• [975] The Pancreatic Cancer-Initiating Cell Marker CD44v6 Affects Transcription, Translation, and Signaling: Consequences for Exosome Composition and Delivery.J Oncol. 2019 Aug 7;2019:3516973. doi: 10.1155/2019/3516973. eCollection 2019.
• [976] ALPPL2 Is a Potential Diagnostic Biomarker for Pancreatic Cancer-Derived Extracellular Vesicles.Mol Ther Methods Clin Dev. 2019 Sep 12;15:204-210. doi: 10.1016/j.omtm.2019.08.016. eCollection 2019 Dec 13.
• [977] Forkhead box B2 inhibits the malignant characteristics of the pancreatic cancer cell line Panc-1 in vitro.Genes Cells. 2019 Oct;24(10):674-681. doi: 10.1111/gtc.12717. Epub 2019 Oct 7.
• [978] Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score).Radiother Oncol. 2018 Nov;129(2):313-318. doi: 10.1016/j.radonc.2018.08.012. Epub 2018 Sep 11.
• [979] An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.Oncotarget. 2017 Jan 17;8(3):4484-4500. doi: 10.18632/oncotarget.13152.
• [980] BART inhibits pancreatic cancer cell invasion by PKC inactivation through binding to ANX7.PLoS One. 2012;7(4):e35674. doi: 10.1371/journal.pone.0035674. Epub 2012 Apr 19.
• [981] Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms.Cancer Lett. 2017 Jul 10;398:24-36. doi: 10.1016/j.canlet.2017.04.001. Epub 2017 Apr 9.
• [982] Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.Oncotarget. 2018 Jan 4;9(10):8972-8984. doi: 10.18632/oncotarget.23944. eCollection 2018 Feb 6.
• [983] Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation.Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):E10505-E10514. doi: 10.1073/pnas.1804897115. Epub 2018 Oct 11.
• [984] Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue.EBioMedicine. 2019 May;43:282-294. doi: 10.1016/j.ebiom.2019.04.008. Epub 2019 Apr 11.
• [985] Overexpression of MIST1 reverses the epithelial-mesenchymal transition and reduces the tumorigenicity of pancreatic cancer cells via the Snail/E-cadherin pathway.Cancer Lett. 2018 Sep 1;431:96-104. doi: 10.1016/j.canlet.2018.05.043. Epub 2018 May 31.
• [986] WITHDRAWN: MicroRNA-340 suppresses pancreatic cancer growth by targeting BICD2.Pancreatology. 2019 May 9:S1424-3903(19)30556-3. doi: 10.1016/j.pan.2019.05.453. Online ahead of print.
• [987] MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer.Digestion. 2020;101(6):794-806. doi: 10.1159/000503225. Epub 2019 Sep 27.
• [988] MiR-451 Promotes Cell Proliferation and Metastasis in Pancreatic Cancer through Targeting CAB39.Biomed Res Int. 2017;2017:2381482. doi: 10.1155/2017/2381482. Epub 2017 Jan 19.
• [989] Phosphorylation Regulates CAP1 (Cyclase-Associated Protein 1) Functions in the Motility and Invasion of Pancreatic Cancer Cells.Sci Rep. 2019 Mar 20;9(1):4925. doi: 10.1038/s41598-019-41346-3.
• [990] MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125.Int J Cancer. 2018 Dec 1;143(11):2919-2931. doi: 10.1002/ijc.31654. Epub 2018 Sep 29.
• [991] CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer.Biochem Biophys Res Commun. 2018 Jun 7;500(3):691-697. doi: 10.1016/j.bbrc.2018.04.137. Epub 2018 Apr 22.
• [992] Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer.Pancreas. 2014 Oct;43(7):1093-100. doi: 10.1097/MPA.0000000000000168.
• [993] Synthesis of novel tetrazole containing hybrid ciprofloxacin and pipemidic acid analogues and preliminary biological evaluation of their antibacterial and antiproliferative activity.Mol Divers. 2018 Feb;22(1):83-93. doi: 10.1007/s11030-017-9795-y. Epub 2017 Nov 14.
• [994] Differential secretome of pancreatic cancer cells in serum-containing conditioned medium reveals CCT8 as a new biomarker of pancreatic cancer invasion and metastasis.Cancer Cell Int. 2019 Oct 11;19:262. doi: 10.1186/s12935-019-0980-1. eCollection 2019.
• [995] Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth.Mol Ther Nucleic Acids. 2017 Mar 17;6:80-88. doi: 10.1016/j.omtn.2016.11.008. Epub 2016 Dec 10.
• [996] High-molecular-weight hyaluronan produced by activated pancreatic stellate cells promotes pancreatic cancer cell migration via paracrine signaling.Biochem Biophys Res Commun. 2019 Jul 30;515(3):493-498. doi: 10.1016/j.bbrc.2019.05.167. Epub 2019 Jun 3.
• [997] ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism.Clin Cancer Res. 2018 Jul 1;24(13):3186-3196. doi: 10.1158/1078-0432.CCR-18-0263. Epub 2018 Apr 3.
• [998] CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells.Int J Cancer. 2019 Mar 15;144(6):1367-1378. doi: 10.1002/ijc.32012. Epub 2019 Jan 3.
• [999] Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma. Oncol Rep. 2018 Apr;39(4):1919-1929.
• [1000] Key genes associated with pancreatic cancer and their association with outcomes: A bioinformatics analysis.Mol Med Rep. 2019 Aug;20(2):1343-1352. doi: 10.3892/mmr.2019.10321. Epub 2019 Jun 3.
• [1001] E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.Cancer Lett. 2009 Nov 18;285(1):89-98. doi: 10.1016/j.canlet.2009.05.006. Epub 2009 May 28.
• [1002] Integrated transcriptomic analysis reveals hub genes involved in diagnosis and prognosis of pancreatic cancer.Mol Med. 2019 Nov 9;25(1):47. doi: 10.1186/s10020-019-0113-2.
• [1003] COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer.Int J Oncol. 2019 Aug;55(2):391-404. doi: 10.3892/ijo.2019.4825. Epub 2019 Jun 14.
• [1004] A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.Mol Pharm. 2018 Jun 4;15(6):2403-2412. doi: 10.1021/acs.molpharmaceut.8b00234. Epub 2018 May 23.
• [1005] A functional variant in the boundary of a topological association domain is associated with pancreatic cancer risk.Mol Carcinog. 2019 Oct;58(10):1855-1862. doi: 10.1002/mc.23077. Epub 2019 Jun 24.
• [1006] Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer.Dev Cell. 2018 Jun 18;45(6):696-711.e8. doi: 10.1016/j.devcel.2018.05.025.
• [1007] Molecular biology of pancreatic cancer: potential clinical implications.BioDrugs. 2001;15(7):439-52. doi: 10.2165/00063030-200115070-00003.
• [1008] Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group.Lancet. 1999 Dec 18-25;354(9196):2125-9. doi: 10.1016/s0140-6736(99)04232-4.
• [1009] Identification of lncRNAs and Their Functional Network Associated with Chemoresistance in SW1990/GZ Pancreatic Cancer Cells by RNA Sequencing.DNA Cell Biol. 2018 Oct;37(10):839-849. doi: 10.1089/dna.2018.4312. Epub 2018 Aug 16.
• [1010] Upregulation of DLC-1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model.Oncol Lett. 2019 Nov;18(5):5600-5606. doi: 10.3892/ol.2019.10871. Epub 2019 Sep 16.
• [1011] New 1-phthalazinone Scaffold based Compounds: Design, Synthesis, Cytotoxicity and Protein Kinase Inhibition Activity.Mini Rev Med Chem. 2018;18(20):1759-1774. doi: 10.2174/1389557518666180903153254.
• [1012] Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer.Surg Today. 2019 Dec;49(12):1035-1043. doi: 10.1007/s00595-019-01842-5. Epub 2019 Jul 2.
• [1013] MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12.J Exp Clin Cancer Res. 2019 Mar 12;38(1):126. doi: 10.1186/s13046-019-1105-3.
• [1014] Integrated microRNA-mRNA analysis of pancreatic ductal adenocarcinoma.Genet Mol Res. 2015 Aug 28;14(3):10288-97. doi: 10.4238/2015.August.28.14.
• [1015] Identification of ENTPD8 and cytidine in pancreatic cancer by metabolomic and transcriptomic conjoint analysis.Cancer Sci. 2018 Sep;109(9):2811-2821. doi: 10.1111/cas.13733. Epub 2018 Sep 3.
• [1016] ETV4 Facilitates Cell-Cycle Progression in Pancreatic Cells through Transcriptional Regulation of Cyclin D1.Mol Cancer Res. 2018 Feb;16(2):187-196. doi: 10.1158/1541-7786.MCR-17-0219. Epub 2017 Nov 8.
• [1017] Mutations in Known and Novel cancer Susceptibility Genes in Young Patients with Pancreatic Cancer.Arch Iran Med. 2018 Jun 1;21(6):228-233.
• [1018] FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer.Oncogenesis. 2017 Mar 13;6(3):e300. doi: 10.1038/oncsis.2017.3.
• [1019] Germ line Fanconi anemia complementation group C mutations and pancreatic cancer.Cancer Res. 2005 Jan 15;65(2):383-6.
• [1020] Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis.Gut. 2019 Nov;68(11):2007-2018. doi: 10.1136/gutjnl-2018-317208. Epub 2019 Apr 6.
• [1021] LKB1 obliterates Snail stability and inhibits pancreatic cancer metastasis in response to metformin treatment.Cancer Sci. 2018 May;109(5):1382-1392. doi: 10.1111/cas.13591.
• [1022] Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism.Oncol Rep. 2017 Apr;37(4):1971-1979. doi: 10.3892/or.2017.5479. Epub 2017 Feb 28.
• [1023] Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma.J Cancer. 2019 Aug 28;10(21):5031-5040. doi: 10.7150/jca.31191. eCollection 2019.
• [1024] Long non-coding RNA MCM3AP-AS1 promotes growth and migration through modulating FOXK1 by sponging miR-138-5p in pancreatic cancer.Mol Med. 2019 Dec 12;25(1):55. doi: 10.1186/s10020-019-0121-2.
• [1025] FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.Cancer Res. 2013 Sep 1;73(17):5416-25. doi: 10.1158/0008-5472.CAN-13-0362. Epub 2013 Jun 25.
• [1026] Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1.Biochem Biophys Res Commun. 2018 Nov 2;505(3):830-836. doi: 10.1016/j.bbrc.2018.10.009. Epub 2018 Oct 6.
• [1027] Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating miR-497-5p/FZD4/FZD6/Wnt/-catenin pathway in pancreatic cancer.Cancer Manag Res. 2019 May 7;11:4209-4221. doi: 10.2147/CMAR.S194453. eCollection 2019.
• [1028] The glycoprotein mucin-1 negatively regulates GalNAc transferase 5 expression in pancreatic cancer.FEBS Lett. 2019 Oct;593(19):2751-2761. doi: 10.1002/1873-3468.13532. Epub 2019 Jul 21.
• [1029] GDF11 restrains tumor growth by promoting apoptosis in pancreatic cancer.Onco Targets Ther. 2018 Nov 27;11:8371-8379. doi: 10.2147/OTT.S181792. eCollection 2018.
• [1030] Genome-wide association study using diversity outcross mice identified candidate genes of pancreatic cancer.Genomics. 2019 Dec;111(6):1882-1888. doi: 10.1016/j.ygeno.2018.12.011. Epub 2018 Dec 20.
• [1031] GPX2 silencing relieves epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer by downregulating Wnt pathway.J Cell Physiol. 2020 Nov;235(11):7780-7790. doi: 10.1002/jcp.29391. Epub 2019 Nov 27.
• [1032] Ras-ERK1/2 signalling promotes the development of osteosarcoma through regulation of H4K12ac through HAT1.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1207-1215. doi: 10.1080/21691401.2019.1593857.
• [1033] Haspin knockdown can inhibit progression and development of pancreatic cancer in vitro and vivo.Exp Cell Res. 2019 Dec 1;385(1):111605. doi: 10.1016/j.yexcr.2019.111605. Epub 2019 Sep 4.
• [1034] LINC01006 promotes cell proliferation and metastasis in pancreatic cancer via miR-2682-5p/HOXB8 axis.Cancer Cell Int. 2019 Dec 2;19:320. doi: 10.1186/s12935-019-1036-2. eCollection 2019.
• [1035] Pancreatic adenocarcinoma upregulated factor (PAUF) confers resistance to pancreatic cancer cells against oncolytic parvovirus H-1 infection through IFNA receptor-mediated signaling.Biochem Biophys Res Commun. 2015 Apr 3;459(2):313-318. doi: 10.1016/j.bbrc.2015.02.107. Epub 2015 Feb 26.
• [1036] Significance of IL28RA in diagnosis of early pancreatic cancer and its regulation to pancreatic cancer cells by JAK/STAT signaling pathway - effects of IL28RA on pancreatic cancer.Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9863-9870. doi: 10.26355/eurrev_201911_19550.
• [1037] Insulin-like growth factor 2 mRNA-binding protein 1 promotes cell proliferation via activation of AKT and is directly targeted by microRNA-494 in pancreatic cancer.World J Gastroenterol. 2019 Oct 28;25(40):6063-6076. doi: 10.3748/wjg.v25.i40.6063.
• [1038] Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway.Oncotarget. 2017 Dec 7;9(19):14803-14814. doi: 10.18632/oncotarget.22976. eCollection 2018 Mar 13.
• [1039] IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer.Cancer Res. 2018 Jun 15;78(12):3293-3305. doi: 10.1158/0008-5472.CAN-17-3131. Epub 2018 Mar 23.
• [1040] MicroRNA-7 functions as a tumor-suppressor gene by regulating ILF2 in pancreatic carcinoma.Int J Mol Med. 2017 Apr;39(4):900-906. doi: 10.3892/ijmm.2017.2894. Epub 2017 Feb 17.
• [1041] Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.Target Oncol. 2019 Feb;14(1):93-105. doi: 10.1007/s11523-018-0616-8.
• [1042] Expression of KLF9 in pancreatic cancer and its effects on the invasion, migration, apoptosis, cell cycle distribution, and proliferation of pancreatic cancer cell lines.Oncol Rep. 2018 Dec;40(6):3852-3860. doi: 10.3892/or.2018.6760. Epub 2018 Oct 2.
• [1043] Leukemia-related protein 16 (LRP16) promotes tumor growth and metastasis in pancreatic cancer.Onco Targets Ther. 2018 Mar 5;11:1215-1222. doi: 10.2147/OTT.S157914. eCollection 2018.
• [1044] Methyl-CpG-binding domain 3 inhibits epithelial-mesenchymal transition in pancreatic cancer cells via TGF-/Smad signalling.Br J Cancer. 2017 Jan 3;116(1):91-99. doi: 10.1038/bjc.2016.397. Epub 2016 Nov 29.
• [1045] Distribution bias analysis of germline and somatic single-nucleotide variations that impact protein functional site and neighboring amino acids.Sci Rep. 2017 Feb 8;7:42169. doi: 10.1038/srep42169.
• [1046] Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer.Clin Cancer Res. 2019 Nov 1;25(21):6417-6428. doi: 10.1158/1078-0432.CCR-19-0187. Epub 2019 Jul 22.
• [1047] MiRNA-646-mediated reciprocal repression between HIF-1 and MIIP contributes to tumorigenesis of pancreatic cancer.Oncogene. 2018 Mar;37(13):1743-1758. doi: 10.1038/s41388-017-0082-2. Epub 2018 Jan 18.
• [1048] MiR-137 functions as a tumor suppressor in pancreatic cancer by targeting MRGBP.J Cell Biochem. 2018 Jun;119(6):4799-4807. doi: 10.1002/jcb.26676. Epub 2018 Mar 1.
• [1049] Orchestrating a biomarker panel with lncRNAs and mRNAs for predicting survival in pancreatic ductal adenocarcinoma.J Cell Biochem. 2018 Sep;119(9):7696-7706. doi: 10.1002/jcb.27119. Epub 2018 Jun 20.
• [1050] SPOP suppresses pancreatic cancer progression by promoting the degradation of NANOG.Cell Death Dis. 2019 Oct 17;10(11):794. doi: 10.1038/s41419-019-2017-z.
• [1051] Non-SMC condensin I complex subunit H mediates mature chromosome condensation and DNA damage in pancreatic cancer cells.Sci Rep. 2019 Nov 29;9(1):17889. doi: 10.1038/s41598-019-54478-3.
• [1052] Evaluation of the prognostic significances of -secretase genes in pancreatic cancer.Oncol Lett. 2019 May;17(5):4614-4620. doi: 10.3892/ol.2019.10113. Epub 2019 Mar 5.
• [1053] Upregulation of LASP2 inhibits pancreatic cancer cell migration and invasion through suppressing TGF--induced EMT.J Cell Biochem. 2019 Aug;120(8):13651-13657. doi: 10.1002/jcb.28638. Epub 2019 Apr 4.
• [1054] NELFE promoted pancreatic cancer metastasis and the epithelialtomesenchymal transition by decreasing the stabilization of NDRG2 mRNA.Int J Oncol. 2019 Dec;55(6):1313-1323. doi: 10.3892/ijo.2019.4890. Epub 2019 Oct 2.
• [1055] NETO2 promotes pancreatic cancer cell proliferation, invasion and migration via activation of the STAT3 signaling pathway.Cancer Manag Res. 2019 Jun 6;11:5147-5156. doi: 10.2147/CMAR.S204260. eCollection 2019.
• [1056] lncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity.Biomed Pharmacother. 2017 May;89:1269-1276. doi: 10.1016/j.biopha.2017.02.041. Epub 2017 Mar 17.
• [1057] Downregulation of microRNA-181d had suppressive effect on pancreatic cancer development through inverse regulation of KNAIN2.Tumour Biol. 2017 Apr;39(4):1010428317698364. doi: 10.1177/1010428317698364.
• [1058] Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway.Cancer Lett. 2009 May 8;277(1):72-81. doi: 10.1016/j.canlet.2008.11.028. Epub 2008 Dec 31.
• [1059] Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein.Oncotarget. 2017 Feb 28;8(9):14359-14373. doi: 10.18632/oncotarget.8736. Epub 2016 Apr 15.
• [1060] Long noncoding RNA 00976 promotes pancreatic cancer progression through OTUD7B by sponging miR-137 involving EGFR/MAPK pathway.J Exp Clin Cancer Res. 2019 Nov 20;38(1):470. doi: 10.1186/s13046-019-1388-4.
• [1061] PARP10 (ARTD10) modulates mitochondrial function.PLoS One. 2018 Jan 2;13(1):e0187789. doi: 10.1371/journal.pone.0187789. eCollection 2018.
• [1062] PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-B pathway.Mol Carcinog. 2019 Jul;58(7):1291-1302. doi: 10.1002/mc.23011. Epub 2019 Apr 10.
• [1063] miR-129-5p suppresses proliferation, migration, and induces apoptosis in pancreatic cancer cells by targeting PBX3.Acta Biochim Biophys Sin (Shanghai). 2019 Sep 6;51(10):997-1007. doi: 10.1093/abbs/gmz096.
• [1064] Antitumor activity of potent pyruvate dehydrogenase kinase 4 inhibitors from plants in pancreatic cancer.Mol Carcinog. 2019 Oct;58(10):1726-1737. doi: 10.1002/mc.23045. Epub 2019 May 20.
• [1065] PDS5B regulates cell proliferation and motility via upregulation of Ptch2 in pancreatic cancer cells.Cancer Lett. 2019 Sep 28;460:65-74. doi: 10.1016/j.canlet.2019.06.014. Epub 2019 Jun 22.
• [1066] Preproenkephalin hypermethylation in the pure pancreatic juice compared with p53 mutation in the diagnosis of pancreatic carcinoma.J Gastroenterol. 2006 Aug;41(8):791-7. doi: 10.1007/s00535-006-1857-3.
• [1067] MiR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1.Nat Commun. 2019 Feb 18;10(1):809. doi: 10.1038/s41467-019-08759-0.
• [1068] Small-molecule screening yields a compound that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone.J Biol Chem. 2018 May 25;293(21):8285-8294. doi: 10.1074/jbc.RA118.002316. Epub 2018 Mar 9.
• [1069] PINK1/Parkin-Mediated Mitophagy Regulation by Reactive Oxygen Species Alleviates Rocaglamide A-Induced Apoptosis in Pancreatic Cancer Cells.Front Pharmacol. 2019 Sep 3;10:968. doi: 10.3389/fphar.2019.00968. eCollection 2019.
• [1070] Long non-coding RNA PXN-AS1 suppresses pancreatic cancer progression by acting as a competing endogenous RNA of miR-3064 to upregulate PIP4K2B expression.J Exp Clin Cancer Res. 2019 Sep 5;38(1):390. doi: 10.1186/s13046-019-1379-5.
• [1071] The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer.J Clin Med. 2019 Aug 22;8(9):1275. doi: 10.3390/jcm8091275.
• [1072] POLE gene hotspot mutations in advanced pancreatic cancer.J Cancer Res Clin Oncol. 2018 Nov;144(11):2161-2166. doi: 10.1007/s00432-018-2746-x. Epub 2018 Sep 7.
• [1073] Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.Mol Pharm. 2018 Feb 5;15(2):369-376. doi: 10.1021/acs.molpharmaceut.7b00718. Epub 2018 Jan 4.
• [1074] Magnetic mesoporous nanospheres anchored with LyP-1 as an efficient pancreatic cancer probe.Biomaterials. 2017 Jan;115:9-18. doi: 10.1016/j.biomaterials.2016.11.006. Epub 2016 Nov 11.
• [1075] EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.Biomed Pharmacother. 2019 Jan;109:762-769. doi: 10.1016/j.biopha.2018.10.125. Epub 2018 Nov 5.
• [1076] SF3A1 and pancreatic cancer: new evidence for the association of the spliceosome and cancer.Oncotarget. 2015 Nov 10;6(35):37750-7. doi: 10.18632/oncotarget.5647.
• [1077] NFB-Mediated Invasiveness in CD133(+) Pancreatic TICs Is Regulated by Autocrine and Paracrine Activation of IL1 Signaling.Mol Cancer Res. 2018 Jan;16(1):162-172. doi: 10.1158/1541-7786.MCR-17-0221. Epub 2017 Sep 28.
• [1078] Effects of RNA binding protein QKI on pancreatic cancer ductal epithelial cells and surrounding activation fibroblasts.J Cell Biochem. 2019 Jul;120(7):11551-11561. doi: 10.1002/jcb.28435. Epub 2019 Apr 10.
• [1079] Rab14 overexpression regulates gemcitabine sensitivity through regulation of Bcl-2 and mitochondrial function in pancreatic cancer.Virchows Arch. 2019 Jan;474(1):59-69. doi: 10.1007/s00428-018-2455-5. Epub 2018 Sep 29.
• [1080] Characterization of human Rab20 overexpressed in exocrine pancreatic carcinoma.Hum Pathol. 2006 Mar;37(3):256-63. doi: 10.1016/j.humpath.2005.10.017.
• [1081] miR?48 targets Rab2B and is pivotal in the suppression of pancreatic cancer.Oncol Rep. 2018 Sep;40(3):1379-1389. doi: 10.3892/or.2018.6562. Epub 2018 Jul 12.
• [1082] High expression of RAB38 promotes malignant progression of pancreatic cancer.Mol Med Rep. 2019 Feb;19(2):909-918. doi: 10.3892/mmr.2018.9732. Epub 2018 Dec 10.
• [1083] Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification.Oncotarget. 2017 Dec 15;9(5):6188-6200. doi: 10.18632/oncotarget.23486. eCollection 2018 Jan 19.
• [1084] RNA-Binding Motif Protein 6 is a Candidate Serum Biomarker for Pancreatic Cancer.Proteomics Clin Appl. 2019 Sep;13(5):e1900048. doi: 10.1002/prca.201900048. Epub 2019 Jul 3.
• [1085] RER1 enhances carcinogenesis and stemness of pancreatic cancer under hypoxic environment.J Exp Clin Cancer Res. 2019 Jan 10;38(1):15. doi: 10.1186/s13046-018-0986-x.
• [1086] Identification of RE1-Silencing Transcription Factor as a Promoter of Metastasis in Pancreatic Cancer.Front Oncol. 2019 Apr 16;9:291. doi: 10.3389/fonc.2019.00291. eCollection 2019.
• [1087] Psoriasin promotes invasion, aggregation and survival of pancreatic cancer cells; association with disease progression.Int J Oncol. 2017 May;50(5):1491-1500. doi: 10.3892/ijo.2017.3953. Epub 2017 Apr 5.
• [1088] Dual-SERS biosensor for one-step detection of microRNAs in exosome and residual plasma of blood samples for diagnosing pancreatic cancer.Biosens Bioelectron. 2019 Apr 1;130:204-213. doi: 10.1016/j.bios.2019.01.039. Epub 2019 Jan 25.
• [1089] A novel secretin receptor splice variant potentially useful for early diagnosis of pancreatic carcinoma.Gastroenterology. 2007 Sep;133(3):853-61. doi: 10.1053/j.gastro.2007.06.013. Epub 2007 Jun 20.
• [1090] LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448.J Cell Physiol. 2018 May;233(5):4044-4055. doi: 10.1002/jcp.26072. Epub 2017 Nov 30.
• [1091] SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells.Tumour Biol. 2017 Mar;39(3):1010428317695913. doi: 10.1177/1010428317695913.
• [1092] A genome-scale CRISPR/Cas9 knockout screening reveals SH3D21 as a sensitizer for gemcitabine.Sci Rep. 2019 Dec 16;9(1):19188. doi: 10.1038/s41598-019-55893-2.
• [1093] The HIF1alpha-inducible pro-cell death gene BNIP3 is a novel target of SIM2s repression through cross-talk on the hypoxia response element.Oncogene. 2009 Oct 15;28(41):3671-80. doi: 10.1038/onc.2009.228. Epub 2009 Aug 10.
• [1094] UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer.Cancer Lett. 2019 Jun 28;452:226-236. doi: 10.1016/j.canlet.2019.03.024. Epub 2019 Mar 22.
• [1095] Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia.Cancer Res. 2001 Dec 15;61(24):8830-7.
• [1096] Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer.Front Oncol. 2019 Sep 27;9:996. doi: 10.3389/fonc.2019.00996. eCollection 2019.
• [1097] Silenced ZNF154 Is Associated with Longer Survival in Resectable Pancreatic Cancer.Int J Mol Sci. 2019 Oct 31;20(21):5437. doi: 10.3390/ijms20215437.
• [1098] SMARCAD1 Promotes Pancreatic Cancer Cell Growth and Metastasis through Wnt/-catenin-Mediated EMT.Int J Biol Sci. 2019 Jan 1;15(3):636-646. doi: 10.7150/ijbs.29562. eCollection 2019.
• [1099] SNX6 predicts poor prognosis and contributes to the metastasis of pancreatic cancer cells via activating epithelial-mesenchymal transition.Acta Biochim Biophys Sin (Shanghai). 2018 Nov 1;50(11):1075-1084. doi: 10.1093/abbs/gmy110.
• [1100] A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors.Oncologist. 2019 Jan;24(1):14-e10. doi: 10.1634/theoncologist.2017-0665. Epub 2018 Aug 16.
• [1101] BRM transcriptionally regulates miR-302a-3p to target SOCS5/STAT3 signaling axis to potentiate pancreatic cancer metastasis.Cancer Lett. 2019 May 1;449:215-225. doi: 10.1016/j.canlet.2019.02.031. Epub 2019 Feb 18.
• [1102] MiR-29b suppresses proliferation and mobility by targeting SOX12 and DNMT3b in pancreatic cancer.Anticancer Drugs. 2019 Mar;30(3):281-288. doi: 10.1097/CAD.0000000000000719.
• [1103] Identification of Sox6 as a regulator of pancreatic cancer development.J Cell Mol Med. 2018 Mar;22(3):1864-1872. doi: 10.1111/jcmm.13470. Epub 2018 Jan 25.
• [1104] Clinical signicance and prognostic value of SOX7 expression in liver and pancreatic carcinoma.Mol Med Rep. 2017 Jul;16(1):499-506. doi: 10.3892/mmr.2017.6660. Epub 2017 May 31.
• [1105] MicroRNA-374a promotes pancreatic cancer cell proliferation and epithelial to mesenchymal transition by targeting SRCIN1.Pathol Res Pract. 2019 Jun;215(6):152382. doi: 10.1016/j.prp.2019.03.011. Epub 2019 Mar 5.
• [1106] miR-331-3p functions as an oncogene by targeting ST7L in pancreatic cancer.Carcinogenesis. 2018 Jul 30;39(8):1006-1015. doi: 10.1093/carcin/bgy074.
• [1107] Several genes involved in the JAK-STAT pathway may act as prognostic markers in pancreatic cancer identified by microarray data analysis.Medicine (Baltimore). 2018 Dec;97(50):e13297. doi: 10.1097/MD.0000000000013297.
• [1108] Stress-induced phosphoprotein 1 promotes pancreatic cancer progression through activation of the FAK/AKT/MMP signaling axis.Pathol Res Pract. 2019 Nov;215(11):152564. doi: 10.1016/j.prp.2019.152564. Epub 2019 Jul 25.
• [1109] The clinical value, regulatory mechanisms, and gene network of the cancer-testis gene STK31 in pancreatic cancer.Oncotarget. 2017 May 23;8(21):35154-35164. doi: 10.18632/oncotarget.16814.
• [1110] Silencing of STRN4 suppresses the malignant characteristics of cancer cells.Cancer Sci. 2014 Dec;105(12):1526-32. doi: 10.1111/cas.12541. Epub 2014 Oct 23.
• [1111] TLE1 function and therapeutic potential in cancer.Oncotarget. 2017 Feb 28;8(9):15971-15976. doi: 10.18632/oncotarget.13278.
• [1112] Expression of TMEFF2 in Human Pancreatic Cancer Tissue and the Effects of TMEFF2 Knockdown on Cell, Proliferation, and Apoptosis in Human Pancreatic Cell Lines.Med Sci Monit. 2019 May 2;25:3238-3246. doi: 10.12659/MSM.913974.
• [1113] Thymosin beta-10 is aberrantly expressed in pancreatic cancer and induces JNK activation.Cancer Invest. 2009 Mar;27(3):251-6. doi: 10.1080/07357900802254016.
• [1114] A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer.Proteomics Clin Appl. 2019 Sep;13(5):e1800195. doi: 10.1002/prca.201800195. Epub 2019 May 7.
• [1115] TRIM21 is a novel regulator of Par-4 in colon and pancreatic cancer cells.Cancer Biol Ther. 2017 Jan 2;18(1):16-25. doi: 10.1080/15384047.2016.1252880. Epub 2016 Nov 10.
• [1116] TRIM29 as a novel biomarker in pancreatic adenocarcinoma.Dis Markers. 2014;2014:317817. doi: 10.1155/2014/317817. Epub 2014 Apr 22.
• [1117] Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-B signaling pathway.Theranostics. 2018 May 11;8(12):3224-3236. doi: 10.7150/thno.23259. eCollection 2018.
• [1118] Involvement of the tubulin tyrosine ligase-like family member 4 polyglutamylase in PELP1 polyglutamylation and chromatin remodeling in pancreatic cancer cells.Cancer Res. 2010 May 15;70(10):4024-33. doi: 10.1158/0008-5472.CAN-09-4444. Epub 2010 May 4.
• [1119] Clinical utility of quantitative RT-PCR targeted to alpha1,4-N-acetylglucosaminyltransferase mRNA for detection of pancreatic cancer.Cancer Sci. 2006 Feb;97(2):119-26. doi: 10.1111/j.1349-7006.2006.00148.x.
• [1120] Circulating Metabolites and Survival Among Patients With Pancreatic Cancer.J Natl Cancer Inst. 2016 Jan 11;108(6):djv409. doi: 10.1093/jnci/djv409. Print 2016 Jun.
• [1121] Silencing of the ARP2/3 complex disturbs pancreatic cancer cell migration.Anticancer Res. 2013 Jan;33(1):45-52.
• [1122] ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9.
• [1123] Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer.Anticancer Res. 2007 Mar-Apr;27(2):793-9.
• [1124] Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.World J Gastroenterol. 2019 Oct 7;25(37):5590-5603. doi: 10.3748/wjg.v25.i37.5590.
• [1125] Expression of METH-1 and METH-2 in pancreatic cancer.Clin Cancer Res. 2001 Nov;7(11):3437-43.
• [1126] Expression of orphan GPR56 correlates with tumor progression in human epithelial ovarian cancer.Neoplasma. 2017;64(1):32-39. doi: 10.4149/neo_2017_104.
• [1127] Effective ablation of pancreatic cancer cells in SCID mice using systemic adenoviral RIP-TK/GCV gene therapy.J Surg Res. 2007 Jul;141(1):45-52. doi: 10.1016/j.jss.2007.02.041. Epub 2007 May 18.
• [1128] Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.Cancer Chemother Pharmacol. 2011 Sep;68(3):571-82. doi: 10.1007/s00280-010-1514-7. Epub 2010 Nov 26.
• [1129] An integrated transcriptome and epigenome analysis identifies a novel candidate gene for pancreatic cancer.BMC Med Genomics. 2013 Sep 22;6:33. doi: 10.1186/1755-8794-6-33.
• [1130] PCA-1/ALKBH3 contributes to pancreatic cancer by supporting apoptotic resistance and angiogenesis.Cancer Res. 2012 Sep 15;72(18):4829-39. doi: 10.1158/0008-5472.CAN-12-0328. Epub 2012 Jul 23.
• [1131] ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer.Br J Cancer. 2017 Dec 5;117(12):1798-1809. doi: 10.1038/bjc.2017.355. Epub 2017 Oct 12.
• [1132] pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.PLoS One. 2010 Nov 29;5(11):e15455. doi: 10.1371/journal.pone.0015455.
• [1133] A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.Br J Cancer. 2017 Oct 24;117(9):1326-1335. doi: 10.1038/bjc.2017.306. Epub 2017 Sep 7.
• [1134] Effect of Adenomatous Polyposis Coli Loss on Tumorigenic Potential in Pancreatic Ductal Adenocarcinoma.Cells. 2019 Sep 14;8(9):1084. doi: 10.3390/cells8091084.
• [1135] Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.Pharmacogenomics J. 2012 Oct;12(5):395-403. doi: 10.1038/tpj.2011.22. Epub 2011 May 31.
• [1136] Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype.Cancer Biol Ther. 2005 Mar;4(3):302-7. doi: 10.4161/cbt.4.3.1501. Epub 2005 Mar 23.
• [1137] Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma.Int J Mol Med. 2014 Jul;34(1):205-12. doi: 10.3892/ijmm.2014.1765. Epub 2014 Apr 30.
• [1138] Intracellular annexin A2 regulates NF-B signaling by binding to the p50 subunit: implications for gemcitabine resistance in pancreatic cancer.Cell Death Dis. 2015 Jan 22;6(1):e1606. doi: 10.1038/cddis.2014.558.
• [1139] ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines.Br J Cancer. 2013 May 28;108(10):2056-62. doi: 10.1038/bjc.2013.200. Epub 2013 May 9.
• [1140] Characterization of the 7q21-q22 amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion in pancreatic cancer.Genes Chromosomes Cancer. 2009 Apr;48(4):330-9. doi: 10.1002/gcc.20643.
• [1141] Alu-polymerase chain reaction genomic fingerprinting technique identifies multiple genetic loci associated with pancreatic tumourigenesis.Genes Chromosomes Cancer. 1997 Jan;18(1):30-41. doi: 10.1002/(sici)1098-2264(199701)18:1<30::aid-gcc4>3.0.co;2-2.
• [1142] Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells.Cancer Chemother Pharmacol. 2013 Mar;71(3):635-45. doi: 10.1007/s00280-012-2050-4. Epub 2012 Dec 21.
• [1143] ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer.Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17450-17459. doi: 10.1073/pnas.1901765116. Epub 2019 Aug 9.
• [1144] Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase.Int J Cancer. 1977 Jan;19(1):128-35. doi: 10.1002/ijc.2910190118.
• [1145] Elucidating the roles of ASPM isoforms reveals a novel prognostic marker for pancreatic cancer.J Pathol. 2020 Feb;250(2):123-125. doi: 10.1002/path.5355. Epub 2019 Dec 2.
• [1146] The activating transcription factor 2: an influencer of cancer progression.Mutagenesis. 2019 Dec 19;34(5-6):375-389. doi: 10.1093/mutage/gez041.
• [1147] MicroRNA targets autophagy in pancreatic cancer cells during cancer therapy.Autophagy. 2013 Dec;9(12):2171-2. doi: 10.4161/auto.26463. Epub 2013 Oct 8.
• [1148] Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer.FASEB J. 2019 Jan;33(1):873-884. doi: 10.1096/fj.201800617R. Epub 2018 Aug 9.
• [1149] Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis.Int J Cancer. 2013 Dec 15;133(12):2824-33. doi: 10.1002/ijc.28322. Epub 2013 Aug 5.
• [1150] Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer.Mol Oncol. 2019 Jun;13(6):1388-1399. doi: 10.1002/1878-0261.12492. Epub 2019 May 17.
• [1151] MicroRNA-127 is aberrantly downregulated and acted as a functional tumor suppressor in human pancreatic cancer.Tumour Biol. 2016 Oct;37(10):14249-14257. doi: 10.1007/s13277-016-5270-0. Epub 2016 Aug 29.
• [1152] Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region.Cancer Gene Ther. 2006 Mar;13(3):242-52. doi: 10.1038/sj.cgt.7700902.
• [1153] CBP-mediated FOXO-1 acetylation inhibits pancreatic tumor growth by targeting SirT.Mol Cancer Ther. 2014 Mar;13(3):687-98. doi: 10.1158/1535-7163.MCT-13-0863. Epub 2014 Jan 13.
• [1154] Role of BCL9L in transforming growth factor- (TGF-)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.Oncotarget. 2016 Nov 8;7(45):73725-73738. doi: 10.18632/oncotarget.12455.
• [1155] Effect of differences in cancer cells and tumor growth sites on recruiting bone marrow-derived endothelial cells and myofibroblasts in cancer-induced stroma.Int J Cancer. 2005 Jul 20;115(6):885-92. doi: 10.1002/ijc.20969.
• [1156] Genome-wide association study of pancreatic cancer in Japanese population.PLoS One. 2010 Jul 29;5(7):e11824. doi: 10.1371/journal.pone.0011824.
• [1157] Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates.Cancer. 2012 May 15;118(10):2623-31. doi: 10.1002/cncr.26558. Epub 2011 Sep 22.
• [1158] BMP8B mediates the survival of pancreatic cancer cells and regulates the progression of pancreatic cancer.Oncol Rep. 2014 Nov;32(5):1861-6. doi: 10.3892/or.2014.3413. Epub 2014 Aug 18.
• [1159] Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.Cancer Discov. 2019 Sep;9(9):1268-1287. doi: 10.1158/2159-8290.CD-18-1409. Epub 2019 Jul 1.
• [1160] Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.Oncotarget. 2017 Aug 24;8(44):77415-77423. doi: 10.18632/oncotarget.20492. eCollection 2017 Sep 29.
• [1161] Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target.Mol Cancer Ther. 2020 Jan;19(1):187-198. doi: 10.1158/1535-7163.MCT-19-0491. Epub 2019 Oct 9.
• [1162] COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.Mol Cancer. 2015 May 29;14:109. doi: 10.1186/s12943-015-0386-1.
• [1163] Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model.Cancer Sci. 2016 Oct;107(10):1443-1452. doi: 10.1111/cas.13024. Epub 2016 Sep 24.
• [1164] Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis.Anticancer Res. 2007 Jan-Feb;27(1A):69-73.
• [1165] Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma.Cell Death Dis. 2018 May 1;9(5):453. doi: 10.1038/s41419-018-0486-0.
• [1166] Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.Cancer Immunol Immunother. 2012 Nov;61(11):2113-23. doi: 10.1007/s00262-012-1279-4. Epub 2012 May 11.
• [1167] MiR-345-5p functions as a tumor suppressor in pancreatic cancer by directly targeting CCL8.Biomed Pharmacother. 2019 Mar;111:891-900. doi: 10.1016/j.biopha.2018.12.121. Epub 2019 Jan 7.
• [1168] NOV promoted the growth and migration of pancreatic cancer cells.Tumour Biol. 2014 Apr;35(4):3195-201. doi: 10.1007/s13277-013-1418-3. Epub 2013 Nov 21.
• [1169] FAM190A deficiency creates a cell division defect.Am J Pathol. 2013 Jul;183(1):296-303. doi: 10.1016/j.ajpath.2013.03.020. Epub 2013 May 10.
• [1170] Inflammation-related gene variants as risk factors for pancreatic cancer.Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1251-4. doi: 10.1158/1055-9965.EPI-11-0264. Epub 2011 Apr 5.
• [1171] Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer.Oncotarget. 2018 Apr 13;9(28):19994-20007. doi: 10.18632/oncotarget.25017. eCollection 2018 Apr 13.
• [1172] Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer.Mol Cancer Res. 2020 Feb;18(2):300-310. doi: 10.1158/1541-7786.MCR-19-0588. Epub 2019 Oct 29.
• [1173] The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.Cancer Biol Ther. 2019;20(6):729-739. doi: 10.1080/15384047.2018.1529121. Epub 2019 Mar 27.
• [1174] CDKN2A germline mutations in familial pancreatic cancer.Ann Surg. 2002 Dec;236(6):730-7. doi: 10.1097/00000658-200212000-00005.
• [1175] YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway.Int J Cancer. 2018 Apr 1;142(7):1392-1404. doi: 10.1002/ijc.31173. Epub 2017 Dec 4.
• [1176] Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.Cancer Sci. 2019 Sep;110(9):2846-2855. doi: 10.1111/cas.14134. Epub 2019 Aug 10.
• [1177] Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells.Cancer Res. 2005 Mar 1;65(5):1619-26. doi: 10.1158/0008-5472.CAN-04-1413.
• [1178] Identification of pancreatic juice proteins as biomarkers of pancreatic cancer.Oncol Rep. 2010 Jun;23(6):1683-92. doi: 10.3892/or_00000812.
• [1179] Identification of genes differentially induced by hypoxia in pancreatic cancer cells.Biochem Biophys Res Commun. 2001 Nov 9;288(4):882-6. doi: 10.1006/bbrc.2001.5867.
• [1180] Centrosomal protein 55 activates NF-B signalling and promotes pancreatic cancer cells aggressiveness.Sci Rep. 2017 Jul 19;7(1):5925. doi: 10.1038/s41598-017-06132-z.
• [1181] Cep70 overexpression stimulates pancreatic cancer by inducing centrosome abnormality and microtubule disorganization.Sci Rep. 2016 Feb 19;6:21263. doi: 10.1038/srep21263.
• [1182] Evaluation of novel highly specific antibodies to cancer testis antigen Centrin-1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer.Cancer Med. 2019 Sep;8(11):5289-5300. doi: 10.1002/cam4.2379. Epub 2019 Jul 16.
• [1183] CHD1L Expression Increases Tumor Progression and Acts as a Predictive Biomarker for Poor Prognosis in Pancreatic Cancer.Dig Dis Sci. 2017 Sep;62(9):2376-2385. doi: 10.1007/s10620-017-4641-8. Epub 2017 Jun 23.
• [1184] Proteomic analysis of pancreatic intraepithelial neoplasia and pancreatic carcinoma in rat models.World J Gastroenterol. 2011 Mar 21;17(11):1434-41. doi: 10.3748/wjg.v17.i11.1434.
• [1185] Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.Oncogene. 2014 Nov 20;33(47):5450-6. doi: 10.1038/onc.2013.488. Epub 2013 Nov 25.
• [1186] Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation.Br J Cancer. 2016 Jun 14;114(12):1376-86. doi: 10.1038/bjc.2016.116. Epub 2016 May 17.
• [1187] Overexpression of CIAPIN1 inhibited pancreatic cancer cell proliferation and was associated with good prognosis in pancreatic cancer.Cancer Gene Ther. 2012 Aug;19(8):538-44. doi: 10.1038/cgt.2012.28. Epub 2012 Jun 8.
• [1188] CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.Oncotarget. 2016 Mar 22;7(12):14831-40. doi: 10.18632/oncotarget.7447.
• [1189] CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha.Biochem Biophys Res Commun. 2009 Sep 11;387(1):139-42. doi: 10.1016/j.bbrc.2009.06.148. Epub 2009 Jul 3.
• [1190] Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays.Cancer Res. 2003 Jul 1;63(13):3735-42.
• [1191] Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer.Pancreatology. 2019 Jan;19(1):88-96. doi: 10.1016/j.pan.2018.10.009. Epub 2018 Nov 2.
• [1192] Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy.Cancer Immunol Immunother. 2005 May;54(5):431-45. doi: 10.1007/s00262-004-0613-x. Epub 2004 Oct 16.
• [1193] Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer.Clin Cancer Res. 2012 Jan 15;18(2):524-33. doi: 10.1158/1078-0432.CCR-11-1903. Epub 2011 Nov 29.
• [1194] Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer.BMC Cancer. 2017 Jul 21;17(1):495. doi: 10.1186/s12885-017-3481-4.
• [1195] Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study.Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1185-91. doi: 10.1158/1055-9965.EPI-15-1217. Epub 2016 May 16.
• [1196] 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability.Cancer Res. 2011 Feb 1;71(3):884-94. doi: 10.1158/0008-5472.CAN-10-2518. Epub 2010 Dec 6.
• [1197] Breaking barriers for T cells by targeting the EPHA2/TGF-/COX-2 axis in pancreatic cancer.J Clin Invest. 2019 Jul 29;129(9):3521-3523. doi: 10.1172/JCI130316. eCollection 2019 Jul 29.
• [1198] CRKL protein overexpression enhances cell proliferation and invasion in pancreatic cancer.Tumour Biol. 2015 Feb;36(2):1015-22. doi: 10.1007/s13277-014-2706-2. Epub 2014 Oct 16.
• [1199] Identification of a novel type of CA19-9 carrier in human bile and sera of cancer patients: an implication of the involvement in nonsecretory exocytosis.J Proteome Res. 2010 Dec 3;9(12):6345-53. doi: 10.1021/pr100600u. Epub 2010 Nov 10.
• [1200] Identification of cystatin SN as a novel biomarker for pancreatic cancer.Tumour Biol. 2015 May;36(5):3903-10. doi: 10.1007/s13277-014-3033-3. Epub 2015 Jan 12.
• [1201] Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells.Carcinogenesis. 2013 Mar;34(3):694-702. doi: 10.1093/carcin/bgs378. Epub 2012 Dec 7.
• [1202] CXCL14 expression and potential function in pancreatic cancer.Cancer Lett. 2008 Feb 8;259(2):209-17. doi: 10.1016/j.canlet.2007.10.021. Epub 2007 Nov 28.
• [1203] The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation.Cancer Res. 2008 Jun 15;68(12):4701-8. doi: 10.1158/0008-5472.CAN-08-0482.
• [1204] Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer.Am J Pathol. 2011 Mar;178(3):1340-9. doi: 10.1016/j.ajpath.2010.11.058.
• [1205] Loss of Disabled-2 Expression in Pancreatic Cancer Progression.Sci Rep. 2019 May 17;9(1):7532. doi: 10.1038/s41598-019-43992-z.
• [1206] Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):204-9. doi: 10.1016/s1499-3872(13)60032-6.
• [1207] Inhibition of DACH1 activity by short hairpin RNA represses cell proliferation and tumor invasion in pancreatic cancer.Oncol Rep. 2016 Aug;36(2):745-54. doi: 10.3892/or.2016.4843. Epub 2016 Jun 2.
• [1208] Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.Tumori. 2009 Nov-Dec;95(6):796-803. doi: 10.1177/030089160909500624.
• [1209] Effect of DAPK1 gene on proliferation, migration, and invasion of carcinoma of pancreas BxPC-3 cell line.Int J Clin Exp Pathol. 2014 Oct 15;7(11):7536-44. eCollection 2014.
• [1210] Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3.FASEB J. 2001 Mar;15(3):562-4. doi: 10.1096/fj.00-0534fje. Epub 2001 Jan 19.
• [1211] Oral bacteria in pancreatic cancer: mutagenesis of the p53 tumour suppressor gene.Int J Clin Exp Pathol. 2015 Sep 1;8(9):11835-6. eCollection 2015.
• [1212] Transcriptomic changes associated with DKK4 overexpression in pancreatic cancer cells detected by RNA-Seq.Tumour Biol. 2016 Aug;37(8):10827-38. doi: 10.1007/s13277-015-4379-x. Epub 2016 Feb 15.
• [1213] Dermokine contributes to epithelial-mesenchymal transition through increased activation of signal transducer and activator of transcription 3 in pancreatic cancer.Cancer Sci. 2017 Nov;108(11):2130-2141. doi: 10.1111/cas.13347. Epub 2017 Sep 15.
• [1214] Pancreatic Cancer Database: an integrative resource for pancreatic cancer.Cancer Biol Ther. 2014 Aug;15(8):963-7. doi: 10.4161/cbt.29188. Epub 2014 May 19.
• [1215] Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.Cancer Cell. 2018 Mar 12;33(3):512-526.e8. doi: 10.1016/j.ccell.2018.02.003.
• [1216] Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis.Lab Invest. 2001 Jun;81(6):863-73. doi: 10.1038/labinvest.3780295.
• [1217] The actin binding protein destrin is associated with growth and perineural invasion of pancreatic cancer.Pancreatology. 2012 Jul-Aug;12(4):350-7. doi: 10.1016/j.pan.2012.05.012. Epub 2012 Jun 15.
• [1218] Haloperidol induces demethylation and expression of the dual specificity phosphatase 6 gene in MIA PaCa-2 human pancreatic cancer cells.Life Sci. 2012 Dec 17;91(25-26):1317-22. doi: 10.1016/j.lfs.2012.10.002. Epub 2012 Oct 12.
• [1219] Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells.Cell Death Dis. 2017 Jul 13;8(7):e2924. doi: 10.1038/cddis.2017.311.
• [1220] Receptor-binding cancer antigen expressed on SiSo cells can be detected in metastatic lymph nodes from gastrointestinal cancers.World J Gastroenterol. 2005 Oct 14;11(38):6014-7. doi: 10.3748/wjg.v11.i38.6014.
• [1221] Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience.World J Gastroenterol. 2004 Feb 15;10(4):471-5. doi: 10.3748/wjg.v10.i4.471.
• [1222] Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.Oncotarget. 2016 Jan 26;7(4):4226-40. doi: 10.18632/oncotarget.6772.
• [1223] Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity.Cancer Res. 1999 Nov 1;59(21):5565-71.
• [1224] Expression of elongation factor-1 gamma-related sequence in human pancreatic cancer.Pancreas. 1992;7(2):144-52. doi: 10.1097/00006676-199203000-00003.
• [1225] Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo.World J Gastroenterol. 2009 Jun 14;15(22):2754-62. doi: 10.3748/wjg.15.2754.
• [1226] Induction, modulation and potential targets of miR-210 in pancreatic cancer cells.Hepatobiliary Pancreat Dis Int. 2012 Jun;11(3):319-24. doi: 10.1016/s1499-3872(12)60168-4.
• [1227] Loss of the eukaryotic initiation factor 3f in pancreatic cancer.Mol Carcinog. 2008 Mar;47(3):235-44. doi: 10.1002/mc.20379.
• [1228] Identification of Acute Pancreatitis-Related Genes and Pathways by Integrated Bioinformatics Analysis.Dig Dis Sci. 2020 Jun;65(6):1720-1732. doi: 10.1007/s10620-019-05928-5. Epub 2019 Nov 13.
• [1229] Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.Oncotarget. 2017 Jan 17;8(3):4399-4409. doi: 10.18632/oncotarget.12642.
• [1230] Genetic polymorphisms and pancreatic cancer risk: A PRISMA-compliant systematic review and meta-analysis.Medicine (Baltimore). 2019 Aug;98(32):e16541. doi: 10.1097/MD.0000000000016541.
• [1231] Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk.Cancer Res. 2008 Jun 15;68(12):4928-35. doi: 10.1158/0008-5472.CAN-07-5539. Epub 2008 Jun 10.
• [1232] Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer.Oncotarget. 2017 Mar 28;8(13):21281-21289. doi: 10.18632/oncotarget.15068.
• [1233] Synthetic 8-hydroxydeoxyguanosine inhibited metastasis of pancreatic cancer through concerted inhibitions of ERM and Rho-GTPase.Free Radic Biol Med. 2017 Sep;110:151-161. doi: 10.1016/j.freeradbiomed.2017.06.003. Epub 2017 Jun 8.
• [1234] Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation.Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):205-12. doi: 10.1016/j.ijrobp.2010.03.023. Epub 2010 Jul 7.
• [1235] Functional defects in the fanconi anemia pathway in pancreatic cancer cells.Am J Pathol. 2004 Aug;165(2):651-7. doi: 10.1016/S0002-9440(10)63329-9.
• [1236] Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance.Curr Med Chem. 2019;26(33):6020-6032. doi: 10.2174/0929867326666181203133332.
• [1237] Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells.Oncogene. 2012 Jul 12;31(28):3346-56. doi: 10.1038/onc.2011.505. Epub 2011 Nov 21.
• [1238] Kindlin-1 expression is involved in migration and invasion of pancreatic cancer.Int J Oncol. 2013 Apr;42(4):1360-6. doi: 10.3892/ijo.2013.1838. Epub 2013 Feb 22.
• [1239] Kindlin-2 in pancreatic stellate cells promotes the progression of pancreatic cancer.Cancer Lett. 2017 Apr 1;390:103-114. doi: 10.1016/j.canlet.2017.01.008. Epub 2017 Jan 16.
• [1240] Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions.Br J Cancer. 2003 Jan 27;88(2):217-22. doi: 10.1038/sj.bjc.6600734.
• [1241] FOXA2 controls the cis-regulatory networks of pancreatic cancer cells in a differentiation grade-specific manner.EMBO J. 2019 Oct 15;38(20):e102161. doi: 10.15252/embj.2019102161. Epub 2019 Sep 17.
• [1242] Expression of the PTEN/FOXO3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression.Invest New Drugs. 2020 Apr;38(2):321-328. doi: 10.1007/s10637-019-00791-7. Epub 2019 May 14.
• [1243] Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models.Br J Cancer. 2014 Jan 21;110(2):320-9. doi: 10.1038/bjc.2013.754. Epub 2013 Dec 10.
• [1244] Identification of Pancreatic Cancer in Biliary Obstruction Patients by FRY Site-specific Methylation.Asian Pac J Cancer Prev. 2016;17(9):4487-4490.
• [1245] Hypermethylation and aberrant expression of secreted frizzled-related protein genes in pancreatic cancer.World J Gastroenterol. 2008 Jun 7;14(21):3421-4. doi: 10.3748/wjg.14.3421.
• [1246] Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers.J Biol Chem. 2011 Apr 8;286(14):11960-9. doi: 10.1074/jbc.M110.193458. Epub 2011 Feb 2.
• [1247] GABA B receptor is a novel drug target for pancreatic cancer.Cancer. 2008 Feb 15;112(4):767-78. doi: 10.1002/cncr.23231.
• [1248] Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk.Cancer Sci. 2019 Jun;110(6):2022-2032. doi: 10.1111/cas.14017. Epub 2019 May 6.
• [1249] Adenoviral-mediated gene transfer of Gadd45a results in suppression by inducing apoptosis and cell cycle arrest in pancreatic cancer cell. J Gene Med. 2009 Jan;11(1):3-13. doi: 10.1002/jgm.1270.
• [1250] Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.Nat Med. 2007 Sep;13(9):1070-7. doi: 10.1038/nm1627. Epub 2007 Sep 2.
• [1251] Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth.Oncogene. 2011 Dec 8;30(49):4843-54. doi: 10.1038/onc.2011.194. Epub 2011 May 30.
• [1252] Evaluation of GATA-4 and GATA-5 methylation profiles in human pancreatic cancers indicate promoter methylation patterns distinct from other human tumor types.Cancer Biol Ther. 2007 Oct;6(10):1546-52. doi: 10.4161/cbt.6.10.4708. Epub 2007 Jul 7.
• [1253] Genes related to diabetes may be associated with pancreatic cancer in a population-based case-control study in Minnesota.Pancreas. 2012 Jan;41(1):50-3. doi: 10.1097/MPA.0b013e3182247625.
• [1254] Pancreas carcinoma antigen fused to invariant chain elicits T-cell response and tumor growth inhibition.Pancreas. 2008 Oct;37(3):321-7. doi: 10.1097/MPA.0b013e318166722e7.
• [1255] Expression of microRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of Rosemary diterpenes in colon and pancreatic cancer.PLoS One. 2014 Jun 3;9(6):e98556. doi: 10.1371/journal.pone.0098556. eCollection 2014.
• [1256] Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.Oncotarget. 2017 Sep 12;8(47):81776-81793. doi: 10.18632/oncotarget.20819. eCollection 2017 Oct 10.
• [1257] Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels.Cancer Res. 2010 Jul 1;70(13):5226-37. doi: 10.1158/0008-5472.CAN-09-4227. Epub 2010 Jun 15.
• [1258] The neurotrophic factor neurturin contributes toward an aggressive cancer cell phenotype, neuropathic pain and neuronal plasticity in pancreatic cancer.Carcinogenesis. 2014 Jan;35(1):103-13. doi: 10.1093/carcin/bgt312. Epub 2013 Sep 25.
• [1259] Therapeutic implications of GIPC1 silencing in cancer.PLoS One. 2010 Dec 30;5(12):e15581. doi: 10.1371/journal.pone.0015581.
• [1260] Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer.Proteomics. 2019 Nov;19(21-22):e1800451. doi: 10.1002/pmic.201800451. Epub 2019 Aug 1.
• [1261] GOLPH2, a gene downstream of ras signaling, promotes the progression of pancreatic ductal adenocarcinoma.Mol Med Rep. 2018 Mar;17(3):4187-4194. doi: 10.3892/mmr.2018.8430. Epub 2018 Jan 15.
• [1262] Mitochondrial glutamine metabolism via GOT2 supports pancreatic cancer growth through senescence inhibition.Cell Death Dis. 2018 Jan 19;9(2):55. doi: 10.1038/s41419-017-0089-1.
• [1263] Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/-catenin pathway in pancreatic cancer cells.J Cell Biochem. 2018 Nov;119(11):9498-9512. doi: 10.1002/jcb.27266. Epub 2018 Jul 16.
• [1264] GPR68: An Emerging Drug Target in Cancer.Int J Mol Sci. 2019 Jan 28;20(3):559. doi: 10.3390/ijms20030559.
• [1265] Suppression of the malignant phenotype in pancreatic cancer by overexpression of phospholipid hydroperoxide glutathione peroxidase.Hum Gene Ther. 2006 Jan;17(1):105-16. doi: 10.1089/hum.2006.17.105.
• [1266] Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.J Natl Cancer Inst. 2006 Apr 5;98(7):491-8. doi: 10.1093/jnci/djj105.
• [1267] Purification and partial sequencing of inhibitory factor on renal membrane adenylate cyclase in pancreatic cancer extract: identity with histones H1b or H1d.Biochem Biophys Res Commun. 1991 Apr 15;176(1):255-61. doi: 10.1016/0006-291x(91)90917-v.
• [1268] Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.J Exp Clin Cancer Res. 2019 Feb 1;38(1):47. doi: 10.1186/s13046-019-1044-z.
• [1269] HINT2 triggers mitochondrial Ca(2+) influx by regulating the mitochondrial Ca(2+) uniporter (MCU) complex and enhances gemcitabine apoptotic effect in pancreatic cancer.Cancer Lett. 2017 Dec 28;411:106-116. doi: 10.1016/j.canlet.2017.09.020. Epub 2017 Sep 23.
• [1270] Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism and susceptibility to pancreatic cancer.DNA Cell Biol. 2012 May;31(5):683-7. doi: 10.1089/dna.2011.1417. Epub 2011 Oct 19.
• [1271] Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells.Clin Cancer Res. 1996 Sep;2(9):1607-18.
• [1272] Cancer specific promoter CpG Islands hypermethylation of HOP homeobox (HOPX) gene and its potential tumor suppressive role in pancreatic carcinogenesis.BMC Cancer. 2012 Sep 7;12:397. doi: 10.1186/1471-2407-12-397.
• [1273] MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene.Ann Surg Oncol. 2012 Jul;19(7):2394-402. doi: 10.1245/s10434-012-2252-3. Epub 2012 Mar 10.
• [1274] Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia.Clin Cancer Res. 2005 May 1;11(9):3587-96. doi: 10.1158/1078-0432.CCR-04-1813.
• [1275] Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.Clin Cancer Res. 2017 Aug 1;23(15):4312-4322. doi: 10.1158/1078-0432.CCR-16-3153. Epub 2017 Mar 15.
• [1276] Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity.Nat Commun. 2017 Sep 15;8(1):552. doi: 10.1038/s41467-017-00488-6.
• [1277] Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1, a novel epithelial-mesenchymal transition inducer in pancreatic cancer.Cancer Biol Ther. 2011 Sep 1;12(5):388-98. doi: 10.4161/cbt.12.5.15957. Epub 2011 Sep 1.
• [1278] Molecular chaperone HspB2 inhibited pancreatic cancer cell proliferation via activating p53 downstream gene RPRM, BAI1, and TSAP6.J Cell Biochem. 2020 Mar;121(3):2318-2329. doi: 10.1002/jcb.29455. Epub 2019 Nov 6.
• [1279] Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells.J Biol Chem. 2004 Feb 6;279(6):3941-8. doi: 10.1074/jbc.M303975200. Epub 2003 Nov 6.
• [1280] Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.J Gastroenterol Hepatol. 2009 May;24(5):900-11. doi: 10.1111/j.1440-1746.2008.05668.x. Epub 2008 Nov 3.
• [1281] IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation.J Clin Invest. 2014 Nov;124(11):4709-22. doi: 10.1172/JCI76037. Epub 2014 Sep 24.
• [1282] Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.J Cancer Res Clin Oncol. 2017 Jun;143(6):1061-1068. doi: 10.1007/s00432-017-2351-4. Epub 2017 Feb 17.
• [1283] Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines.J Exp Med. 2015 Mar 9;212(3):333-49. doi: 10.1084/jem.20141702. Epub 2015 Mar 2.
• [1284] Expression pattern and level of ING5 protein in normal and cancer tissues.Oncol Lett. 2019 Jan;17(1):63-68. doi: 10.3892/ol.2018.9581. Epub 2018 Oct 16.
• [1285] Insig2 is overexpressed in pancreatic cancer and its expression is induced by hypoxia.Cancer Sci. 2011 Jun;102(6):1137-43. doi: 10.1111/j.1349-7006.2011.01936.x. Epub 2011 Apr 27.
• [1286] The zinc-finger protein KCMF1 is overexpressed during pancreatic cancer development and downregulation of KCMF1 inhibits pancreatic cancer development in mice.Oncogene. 2010 Jul 15;29(28):4058-67. doi: 10.1038/onc.2010.156. Epub 2010 May 17.
• [1287] KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.J Clin Invest. 2013 Feb;123(2):727-39. doi: 10.1172/JCI64535. Epub 2013 Jan 16.
• [1288] Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.Int J Cancer. 2019 Jul 1;145(1):192-205. doi: 10.1002/ijc.32072. Epub 2018 Dec 30.
• [1289] Consensus transcriptome signature of perineural invasion in pancreatic carcinoma.Mol Cancer Ther. 2009 Jun;8(6):1494-504. doi: 10.1158/1535-7163.MCT-08-0755. Epub 2009 Jun 9.
• [1290] KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway.Br J Cancer. 2017 Jul 11;117(2):245-255. doi: 10.1038/bjc.2017.165. Epub 2017 Jun 8.
• [1291] Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.Cancer Sci. 2017 Jan;108(1):73-80. doi: 10.1111/cas.13113. Epub 2016 Dec 19.
• [1292] The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.Mol Cancer Res. 2006 Nov;4(11):861-72. doi: 10.1158/1541-7786.MCR-06-0081.
• [1293] Long non-coding RNA IRAIN suppresses apoptosis and promotes proliferation by binding to LSD1 and EZH2 in pancreatic cancer.Tumour Biol. 2016 Nov;37(11):14929-14937. doi: 10.1007/s13277-016-5380-8. Epub 2016 Sep 19.
• [1294] Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.Int J Oncol. 2008 Dec;33(6):1187-94.
• [1295] Phytohemagglutinin-L (PHA-L) lectin surface binding of N-linked beta 1-6 carbohydrate and its relationship to activated mutant ras in human pancreatic cancer cell lines.Cancer Lett. 1996 Oct 22;107(2):285-91. doi: 10.1016/0304-3835(96)04386-8.
• [1296] Quantitative secretomic analysis of pancreatic cancer cells in serum-containing conditioned medium.Sci Rep. 2016 Nov 21;6:37606. doi: 10.1038/srep37606.
• [1297] Spectral library-based glycopeptide analysis-detection of circulating galectin-3 binding protein in pancreatic cancer.Proteomics Clin Appl. 2017 Sep;11(9-10):10.1002/prca.201700064. doi: 10.1002/prca.201700064. Epub 2017 Jul 10.
• [1298] DNA repair gene polymorphisms and risk of pancreatic cancer.Clin Cancer Res. 2009 Jan 15;15(2):740-6. doi: 10.1158/1078-0432.CCR-08-1607.
• [1299] LITAF Enhances Radiosensitivity of Human Glioma Cells via the FoxO1 Pathway.Cell Mol Neurobiol. 2019 Aug;39(6):871-882. doi: 10.1007/s10571-019-00686-4. Epub 2019 May 16.
• [1300] Preservation of HUGL-1 expression as a favourable prognostic factor in pancreatic carcinoma.Anticancer Res. 2012 Aug;32(8):3153-9.
• [1301] Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer.Clin Cancer Res. 2013 Sep 1;19(17):4651-61. doi: 10.1158/1078-0432.CCR-12-3630. Epub 2013 Jul 15.
• [1302] LIM only 4 is overexpressed in late stage pancreas cancer.Mol Cancer. 2008 Dec 22;7:93. doi: 10.1186/1476-4598-7-93.
• [1303] LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling.J Exp Clin Cancer Res. 2019 Feb 13;38(1):75. doi: 10.1186/s13046-019-1088-0.
• [1304] Latexin inhibits the proliferation of CD133+ miapaca-2 pancreatic cancer stem-like cells.World J Surg Oncol. 2014 Dec 30;12:404. doi: 10.1186/1477-7819-12-404.
• [1305] AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D.Cancer Res. 2011 Nov 15;71(22):7091-102. doi: 10.1158/0008-5472.CAN-11-1367. Epub 2011 Sep 26.
• [1306] NRAGE suppresses metastasis of melanoma and pancreatic cancer in vitro and in vivo.Cancer Lett. 2007 Jun 8;250(2):268-75. doi: 10.1016/j.canlet.2006.10.020. Epub 2006 Nov 30.
• [1307] Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme.Br J Cancer. 1994 Aug;70(2):239-43. doi: 10.1038/bjc.1994.286.
• [1308] MAL2 expression predicts distant metastasis and short survival in pancreatic cancer.Surgery. 2013 Sep;154(3):573-82. doi: 10.1016/j.surg.2013.03.010. Epub 2013 Jul 19.
• [1309] Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures.Mol Nutr Food Res. 2013 Feb;57(2):235-48. doi: 10.1002/mnfr.201200297. Epub 2013 Jan 7.
• [1310] Downregulation of tight junction-associated MARVEL protein marvelD3 during epithelial-mesenchymal transition in human pancreatic cancer cells.Exp Cell Res. 2011 Oct 1;317(16):2288-98. doi: 10.1016/j.yexcr.2011.06.020. Epub 2011 Jul 8.
• [1311] Zinc finger E-box-binding homeobox 1 mediates aerobic glycolysis via suppression of sirtuin 3 in pancreatic cancer.World J Gastroenterol. 2018 Nov 21;24(43):4893-4905. doi: 10.3748/wjg.v24.i43.4893.
• [1312] A peroxisome proliferator-activated receptor ligand MCC-555 imparts anti-proliferative response in pancreatic cancer cells by PPARgamma-independent up-regulation of KLF4. Toxicol Appl Pharmacol. 2012 Sep 1;263(2):225-32. doi: 10.1016/j.taap.2012.06.014. Epub 2012 Jun 30.
• [1313] The Expression and Prognostic Roles of MCMs in Pancreatic Cancer.PLoS One. 2016 Oct 3;11(10):e0164150. doi: 10.1371/journal.pone.0164150. eCollection 2016.
• [1314] Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer.Nature. 2017 Feb 2;542(7639):119-123. doi: 10.1038/nature21052. Epub 2017 Jan 18.
• [1315] Effects of ME3 on the proliferation, invasion and metastasis of pancreatic cancer cells through epithelial-mesenchymal transition.Neoplasma. 2019 Nov;66(6):896-907. doi: 10.4149/neo_2019_190119N59. Epub 2019 Oct 8.
• [1316] Role of MED1 (MBD4) Gene in DNA repair and human cancer.J Cell Physiol. 2001 May;187(2):137-44. doi: 10.1002/jcp.1064.
• [1317] Knockdown of MED19 by short hairpin RNA-mediated gene silencing inhibits pancreatic cancer cell proliferation.Cancer Biother Radiopharm. 2011 Aug;26(4):495-501. doi: 10.1089/cbr.2010.0863.
• [1318] MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer.Int J Cancer. 2011 Dec 1;129(11):2553-65. doi: 10.1002/ijc.25924. Epub 2011 Mar 25.
• [1319] Overexpression and biological function of MEF2D in human pancreatic cancer.Am J Transl Res. 2017 Nov 15;9(11):4836-4847. eCollection 2017.
• [1320] Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.BMC Cancer. 2014 May 25;14:370. doi: 10.1186/1471-2407-14-370.
• [1321] Loss of heterozygosity at the calcium regulation gene locus on chromosome 10q in human pancreatic cancer.Asian Pac J Cancer Prev. 2015;16(6):2489-93. doi: 10.7314/apjcp.2015.16.6.2489.
• [1322] Typing of pancreatic cancer-associated fibroblasts identifies different subpopulations.World J Gastroenterol. 2018 Nov 7;24(41):4663-4678. doi: 10.3748/wjg.v24.i41.4663.
• [1323] Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L.Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1295-302. doi: 10.1158/1055-9965.EPI-08-1109. Epub 2009 Mar 24.
• [1324] Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1/RIP3 and synergizes the activity of gemcitabine.Am J Transl Res. 2017 Dec 15;9(12):5507-5517. eCollection 2017.
• [1325] Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers.BMC Genet. 2006 Jan 17;7:3. doi: 10.1186/1471-2156-7-3.
• [1326] Analysis of circulating blood and tissue biopsy PDX1 and MSX2 gene expression in patients with pancreatic cancer: A case-control experimental study.Medicine (Baltimore). 2019 Jun;98(26):e15954. doi: 10.1097/MD.0000000000015954.
• [1327] MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer.Oncogenesis. 2018 Feb 22;7(2):19. doi: 10.1038/s41389-018-0031-0.
• [1328] Gastric gland mucin-specific O-glycan expression decreases with tumor progression from precursor lesions to pancreatic cancer.Cancer Sci. 2017 Sep;108(9):1897-1902. doi: 10.1111/cas.13317. Epub 2017 Aug 8.
• [1329] Knockdown of LRP/LR induces apoptosis in pancreatic cancer and neuroblastoma cells through activation of caspases.Exp Cell Res. 2017 Nov 15;360(2):264-272. doi: 10.1016/j.yexcr.2017.09.016. Epub 2017 Sep 10.
• [1330] An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cisplatin in pancreatic cancer.Oncol Lett. 2019 Sep;18(3):2724-2732. doi: 10.3892/ol.2019.10596. Epub 2019 Jul 9.
• [1331] Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study.Int J Cancer. 2019 Mar 15;144(6):1275-1283. doi: 10.1002/ijc.31928. Epub 2018 Nov 12.
• [1332] Mitochondrial DNA sequence variation and risk of pancreatic cancer.Cancer Res. 2012 Feb 1;72(3):686-95. doi: 10.1158/0008-5472.CAN-11-1682. Epub 2011 Dec 15.
• [1333] Role of metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) in pancreatic cancer.PLoS One. 2018 Feb 1;13(2):e0192264. doi: 10.1371/journal.pone.0192264. eCollection 2018.
• [1334] Nectin expression in pancreatic adenocarcinoma: nectin-3 is associated with a poor prognosis.Surg Today. 2015 Apr;45(4):487-94. doi: 10.1007/s00595-015-1126-2. Epub 2015 Feb 19.
• [1335] Identification and characterization of neogenin, a DCC-related gene.Oncogene. 1997 Mar 13;14(10):1129-36. doi: 10.1038/sj.onc.1200935.
• [1336] Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of Twist expression in pancreatic juice.Int J Cancer. 2007 Apr 15;120(8):1634-40. doi: 10.1002/ijc.22295.
• [1337] Neurogenin 3-directed cre deletion of Tsc1 gene causes pancreatic acinar carcinoma.Neoplasia. 2014 Nov 20;16(11):909-17. doi: 10.1016/j.neo.2014.08.010. eCollection 2014 Nov.
• [1338] Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1.Cell Death Dis. 2019 Dec 11;10(12):948. doi: 10.1038/s41419-019-2072-5.
• [1339] MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer.Curr Mol Med. 2016;16(4):404-11. doi: 10.2174/1566524016666160316154150.
• [1340] Molecular cloning, gene structure, and expression analyses of NKD1 and NKD2.Int J Oncol. 2001 Nov;19(5):963-9.
• [1341] miR-301a as an NF-B activator in pancreatic cancer cells.EMBO J. 2011 Jan 5;30(1):57-67. doi: 10.1038/emboj.2010.296. Epub 2010 Nov 26.
• [1342] Transactivation of the human NME5 gene by Sp1 in pancreatic cancer cells.Gene. 2012 Jul 25;503(2):200-7. doi: 10.1016/j.gene.2012.04.088. Epub 2012 May 4.
• [1343] NOB1: A Potential Biomarker or Target in Cancer.Curr Drug Targets. 2019;20(10):1081-1089. doi: 10.2174/1389450120666190308145346.
• [1344] NOP14 promotes proliferation and metastasis of pancreatic cancer cells.Cancer Lett. 2012 Sep 28;322(2):195-203. doi: 10.1016/j.canlet.2012.03.010. Epub 2012 Mar 14.
• [1345] Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.Clin Cancer Res. 2016 Dec 15;22(24):5992-6001. doi: 10.1158/1078-0432.CCR-16-0511. Epub 2016 Jul 8.
• [1346] A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.Cancer Chemother Pharmacol. 2016 Sep;78(3):577-84. doi: 10.1007/s00280-016-3108-5. Epub 2016 Jul 23.
• [1347] Labdane diterpenoids from Curcuma amada rhizomes collected in Myanmar and their antiproliferative activities.Fitoterapia. 2017 Oct;122:34-39. doi: 10.1016/j.fitote.2017.08.006. Epub 2017 Aug 18.
• [1348] TU12B1-TY, a novel gene in the region at 12q22-q23.1 frequently deleted in pancreatic cancer, shows reduced expression in pancreatic cancer cells.Oncol Rep. 2004 Dec;12(6):1263-8.
• [1349] Integrative genomic and functional profiling of the pancreatic cancer genome.BMC Genomics. 2013 Sep 16;14:624. doi: 10.1186/1471-2164-14-624.
• [1350] A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis.Clin Cancer Res. 2019 Sep 1;25(17):5407-5421. doi: 10.1158/1078-0432.CCR-18-4113. Epub 2019 Jun 7.
• [1351] Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1.J Biol Chem. 2013 Nov 22;288(47):33927-33938. doi: 10.1074/jbc.M113.500983. Epub 2013 Oct 15.
• [1352] Loss of HNF6 expression correlates with human pancreatic cancer progression.Lab Invest. 2014 May;94(5):517-27. doi: 10.1038/labinvest.2014.47. Epub 2014 Mar 17.
• [1353] Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.J Bone Miner Res. 1998 Sep;13(9):1378-83. doi: 10.1359/jbmr.1998.13.9.1378.
• [1354] p21-Activated kinase 3 promotes cancer stem cell phenotypes through activating the Akt-GSK3--catenin signaling pathway in pancreatic cancer cells.Cancer Lett. 2019 Aug 1;456:13-22. doi: 10.1016/j.canlet.2019.04.026. Epub 2019 Apr 30.
• [1355] Screening of high-risk families for pancreatic cancer.Pancreatology. 2009;9(3):215-22. doi: 10.1159/000210262. Epub 2009 Apr 7.
• [1356] Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.Dig Dis Sci. 2019 Oct;64(10):2878-2892. doi: 10.1007/s10620-019-05608-4. Epub 2019 Apr 4.
• [1357] Fyn/heterogeneous nuclear ribonucleoprotein E1 signaling regulates pancreatic cancer metastasis by affecting the alternative splicing of integrin 1.Int J Oncol. 2017 Jul;51(1):169-183. doi: 10.3892/ijo.2017.4018. Epub 2017 May 24.
• [1358] eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.Cancer Res. 2017 Apr 15;77(8):1997-2007. doi: 10.1158/0008-5472.CAN-16-2594. Epub 2017 Apr 5.
• [1359] Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice.Cancer Res. 2005 Oct 1;65(19):9056-63. doi: 10.1158/0008-5472.CAN-05-1261.
• [1360] PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer.J Exp Clin Cancer Res. 2019 Nov 12;38(1):463. doi: 10.1186/s13046-019-1466-7.
• [1361] Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer.Pancreatology. 2005;5(4-5):370-9. doi: 10.1159/000086537. Epub 2005 Jun 23.
• [1362] Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.Acta Biochim Pol. 2006;53(4):789-99. Epub 2006 Dec 4.
• [1363] PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells.Br J Cancer. 2013 Oct 1;109(7):1795-804. doi: 10.1038/bjc.2013.531. Epub 2013 Sep 3.
• [1364] Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes.J Pathol. 2013 May;230(1):107-17. doi: 10.1002/path.4172. Epub 2013 Mar 21.
• [1365] PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition.Cell Physiol Biochem. 2018;46(5):1930-1938. doi: 10.1159/000489382. Epub 2018 Apr 28.
• [1366] Cloning of novel transcripts of the human guanine-nucleotide-exchange factor Mss4: in situ chromosomal mapping and expression in pancreatic cancer.Genomics. 1997 Dec 15;46(3):389-96. doi: 10.1006/geno.1997.5049.
• [1367] AKT1 (E17K) mutation in pancreatic cancer.Technol Cancer Res Treat. 2008 Oct;7(5):407-8. doi: 10.1177/153303460800700509.
• [1368] The PMAIP1 gene on chromosome 18 is a candidate tumor suppressor gene in human pancreatic cancer.Dig Dis Sci. 2008 Sep;53(9):2576-82. doi: 10.1007/s10620-007-0154-1. Epub 2008 Jan 31.
• [1369] Progression elevated gene-3 promoter (PEG-Prom) confers cancer cell selectivity to human polynucleotide phosphorylase (hPNPase(old-35))-mediated growth suppression.J Cell Physiol. 2008 May;215(2):401-9. doi: 10.1002/jcp.21320.
• [1370] Liprin-4 as a Possible New Therapeutic Target for Pancreatic Cancer.Anticancer Res. 2017 Dec;37(12):6649-6654. doi: 10.21873/anticanres.12122.
• [1371] Effect of PPM1H on malignant phenotype of human pancreatic cancer cells.Oncol Rep. 2016 Nov;36(5):2926-2934. doi: 10.3892/or.2016.5065. Epub 2016 Sep 5.
• [1372] MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer.Clin Cancer Res. 2017 Oct 1;23(19):5881-5891. doi: 10.1158/1078-0432.CCR-17-1151. Epub 2017 Jul 18.
• [1373] The lncRNA XIST interacts with miR-140/miR-124/iASPP axis to promote pancreatic carcinoma growth.Oncotarget. 2017 Nov 20;8(69):113701-113718. doi: 10.18632/oncotarget.22555. eCollection 2017 Dec 26.
• [1374] Nuclear localization of CPI-17, a protein phosphatase-1 inhibitor protein, affects histone H3 phosphorylation and corresponds to proliferation of cancer and smooth muscle cells.Biochem Biophys Res Commun. 2013 Apr 26;434(1):137-42. doi: 10.1016/j.bbrc.2013.03.055. Epub 2013 Mar 26.
• [1375] miR-193b directly targets STMN1 and uPA genes and suppresses tumor growth and metastasis in pancreatic cancer.Mol Med Rep. 2014 Nov;10(5):2613-20. doi: 10.3892/mmr.2014.2558. Epub 2014 Sep 11.
• [1376] BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer.Cancer Discov. 2017 Oct;7(10):1184-1199. doi: 10.1158/2159-8290.CD-17-0250. Epub 2017 Aug 8.
• [1377] Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma.Lab Invest. 2015 Jan;95(1):43-55. doi: 10.1038/labinvest.2014.128. Epub 2014 Oct 27.
• [1378] PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.Invest New Drugs. 2014 Oct;32(5):783-94. doi: 10.1007/s10637-014-0090-9. Epub 2014 May 20.
• [1379] Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread.Int J Oncol. 2006 Apr;28(4):883-90.
• [1380] Expression of PRR11 protein and its correlation with pancreatic cancer and effect on survival.Oncol Lett. 2017 Jun;13(6):4117-4122. doi: 10.3892/ol.2017.5974. Epub 2017 Apr 3.
• [1381] Integrated regulatory network involving differently expressed genes and protein-protein interaction on pancreatic cancer.Eur Rev Med Pharmacol Sci. 2015 Jul;19(13):2423-8.
• [1382] Inhibition of Prostaglandin Reductase 2, a Putative Oncogene Overexpressed in Human Pancreatic Adenocarcinoma, Induces Oxidative Stress-Mediated Cell Death Involving xCT and CTH Gene Expressions through 15-Keto-PGE2.PLoS One. 2016 Jan 28;11(1):e0147390. doi: 10.1371/journal.pone.0147390. eCollection 2016.
• [1383] Receptor-type protein tyrosine phosphatase gamma (PTPgamma), a new identifier for myeloid dendritic cells and specialized macrophages.Blood. 2006 Dec 15;108(13):4223-31. doi: 10.1182/blood-2006-05-024257. Epub 2006 Aug 8.
• [1384] Epigenetic changes of pituitary tumor-derived transforming gene 1 in pancreatic cancer.Hepatobiliary Pancreat Dis Int. 2008 Jun;7(3):313-7.
• [1385] Clinical significance of CD155 expression in human pancreatic cancer.Anticancer Res. 2015 Apr;35(4):2287-97.
• [1386] HIF1 contributes to hypoxia-induced pancreatic cancer cells invasion via promoting QSOX1 expression.Cell Physiol Biochem. 2013;32(3):561-8. doi: 10.1159/000354460. Epub 2013 Aug 30.
• [1387] Rab11a sustains GSK3/Wnt/-catenin signaling to enhance cancer progression in pancreatic cancer.Tumour Biol. 2016 Oct;37(10):13821-13829. doi: 10.1007/s13277-016-5172-1. Epub 2016 Aug 1.
• [1388] High Rab11-FIP4 expression predicts poor prognosis and exhibits tumor promotion in pancreatic cancer.Int J Oncol. 2017 Feb;50(2):396-404. doi: 10.3892/ijo.2016.3828. Epub 2016 Dec 30.
• [1389] Inactivation of Rab23 inhibits the invasion and motility of pancreatic duct adenocarcinoma.Genet Mol Res. 2015 Mar 30;14(1):2707-15. doi: 10.4238/2015.March.30.31.
• [1390] SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer.J Cancer. 2019 Jun 2;10(12):2670-2678. doi: 10.7150/jca.32072. eCollection 2019.
• [1391] An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering.Sci Signal. 2013 May 28;6(277):ra39. doi: 10.1126/scisignal.2003374.
• [1392] Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine.J Cell Sci. 2013 Aug 1;126(Pt 15):3380-9. doi: 10.1242/jcs.124768. Epub 2013 May 17.
• [1393] Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.J Clin Oncol. 2006 Apr 10;24(11):1720-8. doi: 10.1200/JCO.2005.04.4206. Epub 2006 Mar 6.
• [1394] Rap GTPase Interactor: A Potential Marker for Cancer Prognosis Following Kidney Transplantation.Front Oncol. 2019 Aug 7;9:737. doi: 10.3389/fonc.2019.00737. eCollection 2019.
• [1395] Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung.BMC Cancer. 2010 Jun 16;10:295. doi: 10.1186/1471-2407-10-295.
• [1396] The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.Acta Pharmacol Sin. 2015 Mar;36(3):291-7. doi: 10.1038/aps.2014.129. Epub 2015 Jan 5.
• [1397] Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms.J Biol Chem. 2010 Nov 5;285(45):34729-40. doi: 10.1074/jbc.M110.116756. Epub 2010 Aug 27.
• [1398] Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.Pancreas. 2012 Mar;41(2):206-11. doi: 10.1097/MPA.0b013e318223d1a5.
• [1399] Retinoid signaling in pancreatic cancer, injury and regeneration.PLoS One. 2011;6(12):e29075. doi: 10.1371/journal.pone.0029075. Epub 2011 Dec 29.
• [1400] Knockdown of radixin by RNA interference suppresses the growth of human pancreatic cancer cells in vitro and in vivo.Asian Pac J Cancer Prev. 2012;13(3):753-9. doi: 10.7314/apjcp.2012.13.3.753.
• [1401] Brucein D, a Naturally Occurring Tetracyclic Triterpene Quassinoid, Induces Apoptosis in Pancreatic Cancer through ROS-Associated PI3K/Akt Signaling Pathway.Front Pharmacol. 2017 Dec 22;8:936. doi: 10.3389/fphar.2017.00936. eCollection 2017.
• [1402] Prolonged survival of patients with colorectal cancer is associated with a higher regucalcin gene expression: Overexpression of regucalcin suppresses the growth of human colorectal carcinoma cells invitro.Int J Oncol. 2018 Sep;53(3):1313-1322. doi: 10.3892/ijo.2018.4458. Epub 2018 Jun 28.
• [1403] Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer.Cancer Res. 2006 Aug 1;66(15):7653-60. doi: 10.1158/0008-5472.CAN-06-1019.
• [1404] Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas.Br J Cancer. 1998;77(1):147-52. doi: 10.1038/bjc.1998.23.
• [1405] miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis.Cell Death Dis. 2017 Oct 19;8(10):e3129. doi: 10.1038/cddis.2017.530.
• [1406] Potential effects of Mina53 on tumor growth in human pancreatic cancer.Cell Biochem Biophys. 2014 Jul;69(3):619-25. doi: 10.1007/s12013-014-9841-7.
• [1407] Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies.Medicine (Baltimore). 2018 Mar;97(9):e9994. doi: 10.1097/MD.0000000000009994.
• [1408] Increased N-glycosylation of Asn in serum pancreatic ribonuclease 1 is a novel diagnostic marker for pancreatic cancer.Sci Rep. 2014 Oct 22;4:6715. doi: 10.1038/srep06715.
• [1409] Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells invitro and in nude mice.Cancer Lett. 2016 Dec 1;383(1):73-84. doi: 10.1016/j.canlet.2016.09.027. Epub 2016 Sep 28.
• [1410] Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells.Mol Cell Biochem. 2012 Nov;370(1-2):127-39. doi: 10.1007/s11010-012-1404-x. Epub 2012 Aug 7.
• [1411] Ribosomal protein L34 promotes the proliferation, invasion and metastasis of pancreatic cancer cells.Oncotarget. 2016 Dec 20;7(51):85259-85272. doi: 10.18632/oncotarget.13269.
• [1412] Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo.Biotechnol J. 2014 May;9(5):652-63. doi: 10.1002/biot.201300321. Epub 2014 Apr 10.
• [1413] RSPO2 Enhances Canonical Wnt Signaling to Confer Stemness-Associated Traits to Susceptible Pancreatic Cancer Cells.Cancer Res. 2015 May 1;75(9):1883-96. doi: 10.1158/0008-5472.CAN-14-1327. Epub 2015 Mar 13.
• [1414] RUVBL1 directly binds actin filaments and induces formation of cell protrusions to promote pancreatic cancer cell invasion.Int J Oncol. 2014 Jun;44(6):1945-54. doi: 10.3892/ijo.2014.2380. Epub 2014 Apr 10.
• [1415] The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D.Cancer Res. 2007 Sep 15;67(18):8633-42. doi: 10.1158/0008-5472.CAN-07-0545.
• [1416] Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.Am J Pathol. 2005 Jan;166(1):81-92. doi: 10.1016/S0002-9440(10)62234-1.
• [1417] Role of SATB2 in human pancreatic cancer: Implications in transformation and a promising biomarker.Oncotarget. 2016 Sep 6;7(36):57783-57797. doi: 10.18632/oncotarget.10860.
• [1418] Semaphorin 3C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cells.Sci Rep. 2017 Sep 13;7(1):11501. doi: 10.1038/s41598-017-11914-6.
• [1419] Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue.Biol Chem. 2014 Feb;395(2):157-67. doi: 10.1515/hsz-2013-0247.
• [1420] Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner.Mol Cancer. 2013 Jun 20;12:66. doi: 10.1186/1476-4598-12-66.
• [1421] Low tristetraprolin expression promotes cell proliferation and predicts poor patients outcome in pancreatic cancer.Oncotarget. 2016 Apr 5;7(14):17737-50. doi: 10.18632/oncotarget.7397.
• [1422] Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression.J Clin Invest. 2014 May;124(5):2125-35. doi: 10.1172/JCI72619. Epub 2014 Apr 1.
• [1423] FAM60A, increased by Helicobacter pylori, promotes proliferation and suppresses apoptosis of gastric cancer cells by targeting the PI3K/AKT pathway.Biochem Biophys Res Commun. 2020 Jan 22;521(4):1003-1009. doi: 10.1016/j.bbrc.2019.11.029. Epub 2019 Nov 12.
• [1424] Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.Mol Cancer Ther. 2009 Jun;8(6):1484-93. doi: 10.1158/1535-7163.MCT-09-0075. Epub 2009 Jun 9.
• [1425] The influence of SnoN gene silencing by siRNA on the cell proliferation and apoptosis of human pancreatic cancer cells.Diagn Pathol. 2015 Apr 18;10:30. doi: 10.1186/s13000-015-0267-3.
• [1426] Silencing of DLEU2 suppresses pancreatic cancer cell proliferation and invasion by upregulating microRNA-455.Cancer Sci. 2019 May;110(5):1676-1685. doi: 10.1111/cas.13987. Epub 2019 Mar 25.
• [1427] miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.Br J Cancer. 2013 Jul 23;109(2):502-11. doi: 10.1038/bjc.2013.320. Epub 2013 Jun 25.
• [1428] Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2.Crit Rev Oncol Hematol. 2019 Jul;139:117-124. doi: 10.1016/j.critrevonc.2019.03.008. Epub 2019 Mar 20.
• [1429] miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer.Int J Oncol. 2015 Sep;47(3):1043-53. doi: 10.3892/ijo.2015.3076. Epub 2015 Jul 9.
• [1430] MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer.Pathol Oncol Res. 2013 Oct;19(4):739-48. doi: 10.1007/s12253-013-9637-x. Epub 2013 May 9.
• [1431] Superoxide dismutase and nicotinamide adenine dinucleotide phosphate: quinone oxidoreductase polymorphisms and pancreatic cancer risk.Pancreas. 2011 Jan;40(1):72-8. doi: 10.1097/MPA.0b013e3181f74ad7.
• [1432] CIP4 is a new ArgBP2 interacting protein that modulates the ArgBP2 mediated control of WAVE1 phosphorylation and cancer cell migration.Cancer Lett. 2010 Feb 1;288(1):116-23. doi: 10.1016/j.canlet.2009.06.030. Epub 2009 Jul 23.
• [1433] SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/-catenin signaling.Oncogene. 2014 Jan 16;33(3):279-88. doi: 10.1038/onc.2012.595. Epub 2013 Jan 14.
• [1434] Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.Neoplasia. 2007 Jan;9(1):8-17. doi: 10.1593/neo.06646.
• [1435] Association between the expression of secreted phosphoprotein - related genes and prognosis of human cancer.BMC Cancer. 2019 Dec 18;19(1):1230. doi: 10.1186/s12885-019-6441-3.
• [1436] Novel synthetic chalcones induce apoptosis in the A549 non-small cell lung cancer cells harboring a KRAS mutation.Bioorg Med Chem Lett. 2016 Dec 1;26(23):5703-5706. doi: 10.1016/j.bmcl.2016.10.063. Epub 2016 Oct 24.
• [1437] Somatostatin receptor subtype 2 gene therapy inhibits pancreatic cancer in vitro.J Surg Res. 2002 Jun 1;105(1):58-64. doi: 10.1006/jsre.2002.6450.
• [1438] Elucidation of Molecular Mechanisms of Streptozotocin-Induced Oxidative Stress, Apoptosis, and Mitochondrial Dysfunction in Rin-5F Pancreatic -Cells.Oxid Med Cell Longev. 2017;2017:7054272. doi: 10.1155/2017/7054272. Epub 2017 Aug 6.
• [1439] Elevation of -galactoside 2,6-sialyltransferase 1 in a fructoseresponsive manner promotes pancreatic cancer metastasis.Oncotarget. 2017 Jan 31;8(5):7691-7709. doi: 10.18632/oncotarget.13845.
• [1440] The CUL7/F-box and WD repeat domain containing 8 (CUL7/Fbxw8) ubiquitin ligase promotes degradation of hematopoietic progenitor kinase 1.J Biol Chem. 2014 Feb 14;289(7):4009-17. doi: 10.1074/jbc.M113.520106. Epub 2013 Dec 20.
• [1441] The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF.Oncogene. 2010 Oct 21;29(42):5667-77. doi: 10.1038/onc.2010.327. Epub 2010 Aug 9.
• [1442] Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis.Mol Cancer Res. 2017 Jul;15(7):811-820. doi: 10.1158/1541-7786.MCR-16-0462. Epub 2017 Apr 10.
• [1443] (89)Zr-anti-H2AX-TAT but not (18)F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma.Clin Cancer Res. 2017 Nov 1;23(21):6498-6504. doi: 10.1158/1078-0432.CCR-17-0664. Epub 2017 Aug 3.
• [1444] Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer.Int J Cancer. 2014 Jun 1;134(11):2656-62. doi: 10.1002/ijc.28593. Epub 2013 Nov 29.
• [1445] Expression and clinical significance of tbx2 in pancreatic cancer.Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):118-22.
• [1446] Tbx3 fosters pancreatic cancer growth by increased angiogenesis and activin/nodal-dependent induction of stemness.Stem Cell Res. 2016 Sep;17(2):367-378. doi: 10.1016/j.scr.2016.08.007. Epub 2016 Aug 10.
• [1447] Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis.BMC Cancer. 2008 May 12;8:133. doi: 10.1186/1471-2407-8-133.
• [1448] Silencing of TCTN1 inhibits proliferation, induces cell cycle arrest and apoptosis in human thyroid cancer.Exp Ther Med. 2017 Oct;14(4):3720-3726. doi: 10.3892/etm.2017.4940. Epub 2017 Aug 16.
• [1449] TFCP2 activates beta-catenin/TCF signaling in the progression of pancreatic cancer.Oncotarget. 2017 Jul 31;8(41):70538-70549. doi: 10.18632/oncotarget.19741. eCollection 2017 Sep 19.
• [1450] Stromal protein ig-h3 reprogrammes tumour microenvironment in pancreatic cancer.Gut. 2019 Apr;68(4):693-707. doi: 10.1136/gutjnl-2018-317570. Epub 2018 Nov 10.
• [1451] CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer.Cancer Lett. 2019 Jul 1;453:158-169. doi: 10.1016/j.canlet.2019.03.051. Epub 2019 Apr 4.
• [1452] Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.BMC Cancer. 2018 Feb 2;18(1):128. doi: 10.1186/s12885-018-4055-9.
• [1453] TM4SF18 is aberrantly expressed in pancreatic cancer and regulates cell growth.PLoS One. 2019 Mar 21;14(3):e0211711. doi: 10.1371/journal.pone.0211711. eCollection 2019.
• [1454] A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model.Onco Targets Ther. 2018 Dec 3;11:8655-8672. doi: 10.2147/OTT.S186606. eCollection 2018.
• [1455] TMEM45B promotes proliferation, invasion and migration and inhibits apoptosis in pancreatic cancer cells.Mol Biosyst. 2016 May 24;12(6):1860-70. doi: 10.1039/c6mb00203j.
• [1456] A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer.Cancer Res. 2000 May 15;60(10):2602-6.
• [1457] Polyserase-1/TMPRSS9 induces pro-tumor effects in pancreatic cancer cells by activation of pro-uPA.Oncol Rep. 2014 Jun;31(6):2792-6. doi: 10.3892/or.2014.3146. Epub 2014 Apr 23.
• [1458] Interaction between microRNA-181a and TNFAIP1 regulates pancreatic cancer proliferation and migration.Tumour Biol. 2015 Dec;36(12):9693-701. doi: 10.1007/s13277-015-3704-8. Epub 2015 Jul 8.
• [1459] Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005 Mar 15;65(6):2344-52. doi: 10.1158/0008-5472.CAN-04-3502.
• [1460] Interaction of polymorphisms in mitotic regulator genes with cigarette smoking and pancreatic cancer risk.Mol Carcinog. 2013 Nov;52 Suppl 1(0 1):E103-9. doi: 10.1002/mc.22037. Epub 2013 Jun 12.
• [1461] MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma.Oncol Rep. 2017 Dec;38(6):3567-3573. doi: 10.3892/or.2017.6036. Epub 2017 Oct 16.
• [1462] TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):94-8. doi: 10.1016/s1499-3872(13)60012-0.
• [1463] A case-control study indicates that the TRIB1 gene is associated with pancreatic cancer.Genet Mol Res. 2014 Aug 7;13(3):6142-7. doi: 10.4238/2014.August.7.30.
• [1464] TSPAN1 upregulates MMP2 to promote pancreatic cancer cell migration and invasion via PLC.Oncol Rep. 2019 Apr;41(4):2117-2125. doi: 10.3892/or.2019.6989. Epub 2019 Jan 30.
• [1465] EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.Br J Cancer. 2013 Feb 5;108(2):469-76. doi: 10.1038/bjc.2012.495. Epub 2012 Nov 20.
• [1466] GLI1 interferes with the DNA mismatch repair system in pancreatic cancer through BHLHE41-mediated suppression of MLH1.Cancer Res. 2013 Dec 15;73(24):7313-23. doi: 10.1158/0008-5472.CAN-13-2008. Epub 2013 Oct 28.
• [1467] CDX2 inhibits pancreatic adenocarcinoma cell proliferation via promoting tumor suppressor miR-615-5p.Tumour Biol. 2016 Jan;37(1):1041-9. doi: 10.1007/s13277-015-3900-6. Epub 2015 Aug 14.
• [1468] Vitamin E -tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism.PLoS One. 2013;8(2):e52526. doi: 10.1371/journal.pone.0052526. Epub 2013 Feb 5.
• [1469] WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer.Neoplasia. 2013 Jan;15(1):11-22. doi: 10.1593/neo.121312.
• [1470] Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth.Cell Rep. 2019 Aug 13;28(7):1845-1859.e5. doi: 10.1016/j.celrep.2019.07.031.
• [1471] ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin.Cancer Res. 2017 Feb 15;77(4):874-885. doi: 10.1158/0008-5472.CAN-16-2170. Epub 2016 Dec 6.
• [1472] MicroRNA-23a promotes pancreatic cancer metastasis by targeting epithelial splicing regulator protein 1.Oncotarget. 2017 Aug 24;8(47):82854-82871. doi: 10.18632/oncotarget.20692. eCollection 2017 Oct 10.
• [1473] FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma.J Cell Biochem. 2020 Mar;121(3):2458-2466. doi: 10.1002/jcb.29468. Epub 2019 Nov 6.
• [1474] Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma.Scand J Gastroenterol. 2019 Jan;54(1):95-100. doi: 10.1080/00365521.2018.1561937. Epub 2019 Jan 20.
• [1475] LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation.Clin Cancer Res. 2019 Jul 1;25(13):4091-4103. doi: 10.1158/1078-0432.CCR-18-3533. Epub 2019 Jan 24.
• [1476] Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.EBioMedicine. 2019 Feb;40:394-405. doi: 10.1016/j.ebiom.2019.01.037. Epub 2019 Jan 30.
• [1477] Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis.J Clin Invest. 2019 Mar 28;129(6):2500-2513. doi: 10.1172/JCI127223.
• [1478] Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes.Gastroenterology. 2018 Sep;155(3):730-739.e3. doi: 10.1053/j.gastro.2018.05.023. Epub 2018 Jun 11.
• [1479] Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma.Anticancer Res. 2019 Oct;39(10):5565-5572. doi: 10.21873/anticanres.13750.
• [1480] Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1 axis.Mol Cancer. 2014 Aug 7;13:187. doi: 10.1186/1476-4598-13-187.
• [1481] PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulatory Pathways.Cancer Res. 2016 Jan 1;76(1):96-107. doi: 10.1158/0008-5472.CAN-15-0216. Epub 2015 Dec 15.
• [1482] Plectin-1 Targeted Dual-modality Nanoparticles for Pancreatic Cancer Imaging.EBioMedicine. 2018 Apr;30:129-137. doi: 10.1016/j.ebiom.2018.03.008. Epub 2018 Mar 15.
• [1483] PR55 Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signaling.Cancer Res. 2016 Apr 15;76(8):2243-2253. doi: 10.1158/0008-5472.CAN-15-2119. Epub 2016 Feb 18.
• [1484] Rap1GAP alters leukemia cell differentiation, apoptosis and invasion invitro.Oncol Rep. 2012 Aug;28(2):622-8. doi: 10.3892/or.2012.1825. Epub 2012 May 18.
• [1485] SEL1L and squamous cell carcinoma of the esophagus.Clin Cancer Res. 2004 Sep 1;10(17):5857-61. doi: 10.1158/1078-0432.CCR-04-0075.
• [1486] Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.Ann Surg Oncol. 2019 Mar;26(3):807-814. doi: 10.1245/s10434-018-07109-6. Epub 2018 Dec 19.
• [1487] Matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor 2 (TIMP-2) in pancreatic cancer (PC).Oncotarget. 2019 Jan 8;10(3):395-403. doi: 10.18632/oncotarget.26571. eCollection 2019 Jan 8.
• [1488] TM4SF1 Promotes Metastasis of Pancreatic Cancer via Regulating the Expression of DDR1.Sci Rep. 2017 Apr 3;7:45895. doi: 10.1038/srep45895.
• [1489] B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma.Cancer Sci. 2019 Feb;110(2):530-539. doi: 10.1111/cas.13914. Epub 2019 Jan 16.
• [1490] A positive feedback loop of p53/miR-19/TP53INP1 modulates pancreatic cancer cell proliferation and apoptosis.Oncol Rep. 2016 Jan;35(1):518-23. doi: 10.3892/or.2015.4361. Epub 2015 Oct 30.